0001104659-21-133085.txt : 20211102 0001104659-21-133085.hdr.sgml : 20211102 20211102164618 ACCESSION NUMBER: 0001104659-21-133085 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38804 FILM NUMBER: 211372113 BUSINESS ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (800)-495-6670 MAIL ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 10-Q 1 zyxi-20210930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2021


	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-38804

Zynex, Inc.

(Exact name of registrant as specified in its charter)

NEVADA		90-0275169
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

9655 Maroon Cir.
Englewood, CO		80112
(Address of principal executive offices)		(Zip Code)

(303) 703-4906

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ZYXI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Shares Outstanding as of October 27, 2021
Common Stock, par value $0.001		34,779,691

Table of Contents

ZYNEX, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q


		Page
PART I—FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3

	Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020	3

	Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020	4

	Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020	5

	Unaudited Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020	6

	Unaudited Notes to Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II—OTHER INFORMATION		22

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities And Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

SIGNATURES		24

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ZYNEX, INC.

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES)

(unaudited)


	September 30,		December 31,
	2021		2020
ASSETS
Current assets:
Cash	$	35,368	$	39,173
Accounts receivable, net		24,234		13,837
Inventory, net		9,154		8,635
Prepaid expenses and other		1,102		1,378
Total current assets		69,858		63,023

Property and equipment, net		2,253		1,925
Operating lease asset		17,234		5,993
Finance lease asset		418		321
Deposits		584		347
Deferred income taxes		376		566
Total assets	$	90,723	$	72,175

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses		2,669		4,717
Operating lease liability		2,416		2,051
Finance lease liability		115		77
Income taxes payable		1,577		280
Accrued payroll and related taxes		3,515		2,992
Total current liabilities		10,292		10,117
Long-term liabilities:
Operating lease liability		16,701		4,920
Finance lease liability		347		283
Total liabilities		27,340		15,320

Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020		—		—
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,436,593 issued and 34,774,723 outstanding as of September 30, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020		37		36
Additional paid-in capital		38,220		37,235
Treasury stock 1,246,399 shares, at September 30, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost		(6,513)		(3,846)
Retained earnings		31,639		23,430
Total stockholders' equity		63,383		56,855
Total liabilities and stockholders' equity	$	90,723	$	72,175

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
NET REVENUE
Devices	$	9,071	$	5,301	$	23,264	$	13,026
Supplies		25,715		14,725		66,671		41,491
Total net revenue		34,786		20,026		89,935		54,517

COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies		6,837		4,296		19,990		11,758
Sales and marketing		13,083		9,425		40,662		21,817
General and administrative		6,820		4,896		18,503		12,990
Total costs of revenue and operating expenses		26,740		18,617		79,155		46,565

Income from operations		8,046		1,409		10,780		7,952

Other expense
Interest expense		(18)		(5)		(72)		(14)
Other expense, net		(18)		(5)		(72)		(14)

Income from operations before income taxes		8,028		1,404		10,708		7,938
Income tax expense		1,921		71		2,499		651
Net income	$	6,107	$	1,333	$	8,209	$	7,287

Net income per share:
Basic	$	0.18	$	0.04	$	0.24	$	0.22
Diluted	$	0.17	$	0.04	$	0.23	$	0.21

Weighted average basic shares outstanding		34,768		34,486		34,805		33,564
Weighted average diluted shares outstanding		35,493		35,476		35,583		34,715

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN THOUSANDS)

(unaudited)


	For the Nine Months Ended September 30,
	2021		2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	8,209	$	7,287
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Depreciation		1,689		1,042
Non-cash recoveries		(83)		(296)
Stock-based compensation		1,042		1,806
Non-cash lease expense		905		27
Provision for deferred income taxes		190		(473)
Change in operating assets and liabilities:
Accounts receivable		(10,397)		(3,532)
Prepaid and other assets		276		(745)
Accounts payable and other accrued expenses		(284)		1,625
Inventory		(1,898)		(4,274)
Deposits		(238)		47
Net cash (used in)/provided by operating activities		(589)		2,514

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(420)		(759)
Net cash (used in) investing activities		(420)		(759)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations		(73)		(42)
Purchase of treasury stock		(2,667)		—
Proceeds from issuance of common stock under equity offering		—		25,240
Proceeds from the issuance of common stock on stock-based awards		127		236
Taxes withheld and paid on employees' equity awards		(183)		—
Net cash (used in)/provided by financing activities		(2,796)		25,434
Net (decrease)/increase in cash		(3,805)		27,189
Cash at beginning of period		39,173		14,040
Cash at end of period	$	35,368	$	41,229

Supplemental disclosure of cash flow information:
Cash paid for interest	$	(72)	$	(14)
Cash paid for rent	$	(1,510)	$	(1,182)
Cash paid for income taxes	$	(1,019)	$	(750)
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities	$	13,240	$	1,433
Right-of-use assets obtained in exchange for new finance lease liabilities	$	175	$	72
Inventory transferred to property and equipment under lease	$	1,254	$	641
Inventory transferred to property and equipment as demo devices	$	125	$	377
Capital expenditures not yet paid	$	56	$	—

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)

(unaudited)


				Additional								Total
	Common Stock			Paid-in		Treasury		Retained		Non-Controlling		Stockholders’
	Shares	Amount		Capital		Stock		Earnings		Interest		Equity
Balance, December 31, 2019	32,791,665	$	34	$	9,198	$	(3,846)	$	14,356	$	(89)	$	19,653
Exercised and vested stock-based awards	385,917		—		221		—		—		—		221
Stock-based compensation expense	—		—		497		—		—		—		497
Net income	—		—		—		—		2,937		—		2,937
Balance at March 31, 2020	33,177,582	$	34	$	9,916	$	(3,846)	$	17,293	$	(89)	$	23,308
Exercised and vested stock-based awards, net of tax	157,414		—		53		—		—		—		53
Stock-based compensation expense	—		—		579		—		—		—		579
Net income	—		—		—		—		3,017		—		3,017
Balance at June 30, 2020	33,334,996		34		10,548		(3,846)		20,310		(89)		26,957
Stock issued for public offering	1,250,000		1		25,239		—		—		—		25,240
Exercised and vested stock-based awards, net of tax	152,269		—		(38)		—		—		—		(38)
Stock-based compensation expense	—		—		730		—		—		—		730
Net income	—		—		—		—		1,333		—		1,333
Balance at September 30, 2020	34,737,265	$	35	$	36,479	$	(3,846)	$	21,643	$	(89)	$	54,222


				Additional								Total
	Common Stock			Paid-in		Treasury		Retained		Non-Controlling		Stockholders’
	Shares	Amount		Capital		Stock		Earnings		Interest		Equity
Balance, December 31, 2020	34,791,931	$	36	$	37,235	$	(3,846)	$	23,430	$	—	$	56,855
Exercised and vested stock-based awards	57,769		1		29		—		—		—		30
Stock-based compensation expense	—		—		108		—		—		—		108
Shares of common stock withheld to pay taxes on employees' equity awards	(3,758)		—		(59)		—		—		—		(59)
Warrants exercised	8,848		—		—		—		—		—		—
Treasury stock	(5,000)		—		—		(75)		—		—		(75)
Net income	—		—		—		—		(706)		—		(706)
Balance at March 31, 2021	34,849,790	$	37	$	37,313	$	(3,921)	$	22,724	$	—	$	56,153
Exercised and vested stock-based awards, net of tax	85,190		—		59		—		—		—		59
Stock-based compensation expense	—		—		401		—		—		—		401
Shares of common stock withheld to pay taxes on employees' equity awards	(31,902)		—		(76)		—		—		—		(76)
Treasury stock	(135,179)				—		(2,045)		—		—		(2,045)
Net income	—		—		—		—		2,808		—		2,808
Balance at June 30, 2021	34,767,899	$	37	$	37,697	$	(5,966)	$	25,532	$	—	$	57,300
Exercised and vested stock-based awards, net of tax	45,165		—		38		—		—		—		38
Stock-based compensation expense	—		—		533		—		—		—		533
Shares of common stock withheld to pay taxes on employees' equity awards	(3,341)		—		(48)		—		—		—		(48)
Treasury stock	(35,000)		—		—		(547)		—		—		(547)
Net income	—		—		—		—		6,107		—		6,107
Balance at September 30, 2021	34,774,723	$	37	$	38,220	$	(6,513)	$	31,639	$	—	$	63,383

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(1) BASIS OF PRESENTATION

Organization

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries. The Company operates in one primary business segment, medical devices which include electrotherapy and pain management products. As of September 30, 2021, the Company’s only active subsidiaries are Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations, and Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation). ZMS has developed a blood volume monitoring device which received approval by the U.S. Food and Drug Administration (“FDA”) during 2020 and is still awaiting CE Marking in Europe. ZMS has achieved no revenues to date. The Company’s inactive subsidiaries include Zynex Europe, Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly-owned Colorado corporation) and Pharmazy, Inc. (“Pharmazy”, a wholly-owned Colorado Corporation), which was incorporated in June 2015. The Company’s compounding pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

Nature of Business

The Company designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). All of our medical devices are designed to be patient friendly and designed for home use. Our devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a physician’s prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.

During the three and nine months ended September 30, 2021 and 2020, the Company generated substantially all of its revenue in the United States from sales of its devices and related supplies to patients and health care providers.

Unaudited Consolidated Financial Statements

The unaudited consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Amounts as of December 31, 2020, are derived from those audited consolidated financial statements. These interim consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of September 30, 2021 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.

Leases

The Company recognizes finance and operating lease right-of-use assets and liabilities at the lease commencement date based on the estimated present value of the lease payments over the lease term. For our finance leases, the Company uses the implicit rate to determine the present value of future lease payments. For our operating leases that do not provide an implicit rate, the Company uses incremental borrowing rates to determine the present value of future lease payments. The Company includes options to extend or terminate a lease in the lease term when it is reasonably certain to exercise such options. The Company recognizes leases with an initial term of 12 months or less as lease expense over the lease term and those leases are not recorded on our Consolidated Balance Sheets. For additional information on our leases where the Company is the lessee, see Note 7- Leases.

A significant portion of our device revenue is derived from patients who obtain our devices under month-to-month lease arrangements. Revenue related to devices on lease is recognized in accordance with ASC 842, Leases. Using the guidance in ASC 842, we concluded these transactions should be accounted for as operating leases based on the criteria below:

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term;

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise;

●

The lease term is month-to-month, which does not meet the major part of the remaining economic life of the underlying asset; however, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease;

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset; and

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Accounts Receivable, Net

The Company’s accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the Company’s devices, related supplies or complimentary products. In conjunction with fulfilling the Company’s obligation to deliver a product, the Company invoices the patient’s third-party payor or the patient. Billing adjustments represent the difference between the list price and the reimbursement rates set by third-party payors, including Medicare, commercial payors and amounts billed directly to the patient. Specific amounts, if uncollected over a period of time, may be written-off after several appeals, which in some cases may take longer than twelve months. Substantially all of the Company’s receivables are due from patients with commercial or government health plans and workers compensation claims with a small portion related to private pay individuals, attorney and auto claims.

Revenue Recognition

Revenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to our patient.

Sales of our devices and supplies are primarily made with and shipped directly to the patient with a small amount of revenue generated from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Device revenue
Purchased	$	2,076	$	1,618	$	6,734	$	4,121
Leased		6,995		3,683		16,530		8,905
Total Device revenue	$	9,071	$	5,301	$	23,264	$	13,026

Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which the difference is identified. Historically these differences have been immaterial, and the Company has not had a significant reversal of revenue from prior periods.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

Stock-based Compensation

The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved over the respective performance period.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, accounts receivable, accounts payable, and accrued liabilities, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also include capitalized leases, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.

Inventory, Net

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory (in thousands):


	September 30, 2021		December 31, 2020
Raw Materials	$	4,102	$	3,213
Work-in-process		466		1,455
Finished Goods		4,738		4,119
	$	9,306	$	8,787
Less: reserve		(152)		(152)
	$	9,154	$	8,635

The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

Segment Information

We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer as our chief operating decision-makers (“CODM”).

We currently operate our business as one operating segment that includes two revenue types: Devices and Supplies.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Income Taxes

We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

We recognize tax benefits from uncertain tax positions if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position.

Recent Accounting Pronouncements

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2022, and interim periods therein for smaller reporting companies. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

(2) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):


	September 30, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,232	$	2,362
Assembly equipment		100		143
Vehicles		203		198
Leasehold improvements		1,033		559
Sales rep demo units		122		361
Leased devices		1,223		809
		4,913		4,432
Less accumulated depreciation		(2,660)		(2,507)
	$	2,253	$	1,925

Total depreciation expense related to our property and equipment, exclusive of leased devices, was $0.2 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively. Depreciation expense for the nine months ended September 30, 2021 and 2020 was $0.7 million and $0.5 million, respectively.

Total depreciation expense related to devices out on lease was $0.4 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively. Depreciation expense related to devices out on lease was $1.0 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively. Depreciation on leased units is reflected on the income statement as cost of revenue.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The Company monitors devices out on lease for potential loss and places an estimated reserve on the net book value based on an analysis of the number of units which are still with patients for which the Company cannot determine the current status.

The Company monitors demo devices for potential losses and places an estimated reserve on the net book value based on an analysis of terminated territory managers that have not yet returned their units.

(3) EARNINGS PER SHARE

Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method for outstanding stock options.

The calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Basic earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Basic weighted-average shares outstanding		34,768		34,486		34,805		33,564

Basic earnings per share	$	0.18	$	0.04	$	0.24	$	0.22

Diluted earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Weighted-average shares outstanding		34,768		34,486		34,805		33,564
Effect of dilutive securities - options and restricted stock		725		990		778		1,151
Diluted weighted-average shares outstanding		35,493		35,476		35,583		34,715

Diluted earnings per share	$	0.17	$	0.04	$	0.23	$	0.21

For both the three and nine months ended September 30, 2021, options to purchase 0.2 million shares of common stock were excluded from the dilutive stock calculation because their effect would have been anti-dilutive.

For both the three and nine months ended September 30, 2020, options to purchase 0.1 million shares of common stock were excluded from the dilutive stock calculation because their effect would have been anti-dilutive.

(4) STOCK-BASED COMPENSATION PLANS

In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5 million shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon grant and are not included in outstanding shares until such vesting and issuance occurs.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

During the three and nine months ended September 30, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended September 30, 2020, no stock option awards were granted under the 2017 Stock Plan. During the nine months ended September 30, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At September 30, 2021, the company had 0.7 million stock options outstanding and 0.6 million exercisable under the following plans:


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	295		295
Equity Compensation Plans not approved by Shareholders	25		25
2017 Stock Option Plan	388		268
Total	708		588

During the three and nine months ended September 30, 2021, 0.2 million and 0.3 million shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. During the three and nine months ended September 30, 2020, 0.1 million and 0.3 million shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock Awards typically occurs quarterly over three years for the Board of Directors and quarterly or annually over two to four years for management.

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Cost of revenue	$	12	$	13	$	42	$	22
Sales and marketing expense		48		13		78		45
General, and administrative		473		704		922		1,739
Total stock based compensation expense	$	533	$	730	$	1,042	$	1,806

The Company received minimal cash proceeds related to option exercises during the three months ended September 30, 2021. The Company received cash proceeds of $0.1 million related to option exercises during the nine months ended September 30, 2021. The Company received cash proceeds of $0.1 million and $0.6 million related to option exercises during the three and nine months ended September 30, 2020, respectively.

The Company did not grant any stock options during the three and nine months ended September 30, 2021, nor during the three months ended September 30, 2020. The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the nine months ended September 30, 2020:


Expected term (years)	6.79
Risk-free interest rate	1.59	%
Expected volatility	116.76	%
Expected dividend yield	—	%

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

A summary of stock option activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Forfeited	(198)	$	7.22
Exercised	(100)	$	5.31
Outstanding at September 30, 2021	708	$	1.55	4.97	$	6,963

Exercisable at September 30, 2021	588	$	1.04	4.52	$	6,088

A summary of restricted stock award activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		317
Forfeited		(83)
Vested		(87)
Granted but not vested at September 30, 2021		415

As of September 30, 2021, the Company had approximately $5.9 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.9 years.

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

On March 8, 2021, our Board of Directors approved a program to repurchase up to $10.0 million of our common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 8, 2021. From the inception of the plan through September 8, 2021, the Company purchased 175,179 shares of our common stock for $2.7 million or an average price of $15.22 per share.

Warrants

A summary of stock warrant activity for the nine months ended September 30, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.02	$	192
Forfeited	—	$	—
Outstanding and Exercisable at September 30, 2021	90	$	2.64		3.02	$	788

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(6) INCOME TAXES

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, primarily related to excess tax benefits on stock option exercises. For the three and nine months ended September 30, 2021 discrete items adjusted were $0.3 million and $0.8 million, respectively. At September 30, 2021 the Company is currently estimating an annual effective tax rate of approximately 25%. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to various factors.

Income taxes of $1.0 million and $0.7 million were paid during the nine months ended September 30, 2021 and 2020, respectively.

(7) LEASES

The Company categorize leases at their inception as either operating or financing leases. Leases include various office and warehouse facilities which have been categorized as operating leases while certain equipment is leased under financing leases.

The Company entered into a sublease agreement on April 9, 2021 with Cognizant Trizetto Software Group, Inc. for up to approximately 110,754 square feet of office space as its new corporate headquarters. The term of the sublease began on May 1, 2021 and will run through April 29, 2028. The Company is entitled to rent credits equal to twenty-one months of base rent at the initial rate. During the first thirty-three months of the sublease, the rent per square foot is $26.50. The price per square foot increases by an additional $0.50 during each subsequent twelve-month period of the sublease. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $13.4 million each. The remaining lease term was 6.5 years at September 30, 2021.

The Company’s operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s weighted average borrowing rate was determined to be 4.12% for its operating lease liabilities. The Company’s equipment lease agreements have a weighted average rate of 9.37% which was used to measure its finance lease liability.

As of September 30, 2021, the maturities of the Company’s future minimum lease payments were as follows:


	Operating lease liability		Finance lease liability
	(in thousands)		(in thousands)
October 1, 2021 through December 31, 2021	$	599	$	38
2022		3,569		154
2023		2,982		143
2024		3,496		80
2025		3,567		76
2026 and thereafter		7,576		15
Total undiscounted future minimum lease payments	$	21,789	$	506
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(2,672)		(44)
Total lease liabilities	$	19,117	$	462

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The components of lease expenses were as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Lease cost:
Operating lease cost:
Total operating lease expense	$	1,072	$	419	$	2,415	$	1,181
Finance lease cost:
Total amortization of leased assets		29		16		78		44
Interest on lease liabilities		11		5		31		14
Total net lease cost	$	1,112	$	440	$	2,524	$	1,239

Operating lease costs related to our manufacturing and warehouse facility, which we began operating out of at the beginning of 2021, were included in cost of sales while all other operating lease costs were included in general and administrative expenses on the consolidated statement of operations.

(8) CONCENTRATIONS

For the three months ended September 30, 2021, the Company sourced approximately 51% of the supplies for its electrotherapy products from three significant vendors (defined as supplying at least 10%). For the same period in 2020, the Company sourced approximately 64% of the supplies from five significant vendors.

For the nine months ended September 30, 2021, the Company sourced approximately 36% of supplies for its electrotherapy products from two significant vendors. For the same period in 2020, the Company sourced approximately 31% of supplies from one significant vendor.

Management believes that its relationships with suppliers are good; however, if the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred.

The Company had receivables from two third-party payers at September 30, 2021 that made up approximately 37% of the net accounts receivable balance. The Company had receivables from one third-party payer at December 31, 2020, that made up approximately 26% of the net accounts receivable balance.

(9) LITIGATION

From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would accrue the estimated exposure for such events when losses are determined to be both probable and estimable.

The Company is currently not a party to any material pending legal proceedings.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Notice Regarding Forward-Looking Statements

This quarterly report contains statements that are forward-looking, such as statements relating to plans for future organic growth and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the ability to engage effective sales representatives, the need to obtain U.S. Food and Drug Administration (“FDA”) clearance and Certificate European (“CE”) marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from third-party payors for products sold or leased to our patients, acceptance of our products by health third-party payors for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on our business, and other risks described herein and in our Annual Report on Form 10-K for the year ended December 31, 2020.

These interim financial statements and the information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the annual audited consolidated financial statements, and notes to consolidated financial statements, included in the Company’s 2020 Annual Report on Form 10-K and subsequently filed reports, which have previously been filed with the Securities and Exchange Commission.

General

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate one primary business segment: medical devices which include electrotherapy and pain management products. As of September 30, 2021, the Company’s only active subsidiaries are Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations and Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation). ZMS has developed a blood volume monitoring device, which was approved by the U.S. Food and Drug Administration (“FDA”) during 2020 and is awaiting CE Marking approval in Europe. ZMS has achieved no revenues to date. One other subsidiary, Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation), did not generate material revenues during the three or nine months ended September 30, 2021 and 2020 from international sales and marketing.

RESULTS OF OPERATIONS

Summary

Net revenue was $34.8 million and $20.0 million for the three months ended September 30, 2021 and 2020, respectively, and $89.9 million and $54.5 million for the nine months ended September 30, 2021 and 2020, respectively. Net revenue increased 74% and 65% for the three and nine months ended September 30, 2021, respectively. Net income was $6.1 million for the three months ended September 30, 2021 compared with $1.3 million during the same period in 2020. Net income was $8.2 million for the nine months ended September 30, 2021 compared with $7.3 million during the same period in 2020. Cash used in operating activities was $0.6 million during the nine months ended September 30, 2021. Working capital at September 30, 2021 was $59.6 million, an increase of 13% from $52.9 million as of December 31, 2020.

Net Revenue

Net revenues are comprised of device and supplies sales, constrained by estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Product device revenue is primarily comprised of sales and rentals of our electrotherapy products and other complimentary products.

Supplies revenue is primarily comprised of sales of our consumable supplies to patients using our electrotherapy products, consisting primarily of surface electrodes and batteries.

Table of Contents

Revenue related to both devices and supplies is reported net, after adjustments for estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Estimates for third-party payor reimbursement deductions and uncollectible accounts are adjusted on an ongoing basis in conjunction with the processing of third-party payor insurance claims and other customer collection history. Billing allowance adjustments are common in our industry whereby third-party payors unilaterally reduce the amount they reimburse for our products as compared to the sales price charged by us. These deductions from gross revenue take into account the estimated denials, net of resubmitted billings of claims for products placed with patients which may affect collectability. See our Significant Accounting Policies in Note 1 to the Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.

We occasionally receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims that have been resubmitted or where we are pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid.

Net revenue increased $14.8 million or 74% to $34.8 million for the three months ended September 30, 2021, from $20.0 million for the same period in 2020. Net revenue increased $35.4 million or 65% to $89.9 million for the nine months ended September 30, 2021, from $54.5 million for the same period in 2020. For the three and nine months ended September 30, 2021, the growth in net revenue from the same periods in 2020 is primarily related to a 70% and 134% growth in device orders, respectively, which led to an increased customer base and drove higher sales of consumable supplies.

Device Revenue

Device revenue is related to the sale or lease of our electrotherapy and complimentary products. Device revenue increased $3.8 million or 71% to $9.1 million for the three months ended September 30, 2021, from $5.3 million for the same period in 2020.

Device revenue increased $10.3 million or 79% to $23.3 million for the nine months ended September 30, 2020, from $13.0 million for the same period in 2020.

The increase in device revenue is primarily related to increased orders which are attributable to the growth of our sales force as well as an increase in the amount of revenue provided by each sales representative.

Supplies Revenue

Supplies revenue is related to the sale of supplies, primarily electrodes and batteries, for our electrotherapy products. Supplies revenue increased $11.0 million or 75% to $25.7 million for the three months ended September 30, 2021, from $14.7 million for the same period in 2020.

Supplies revenue increased $25.2 million or 61% to $66.7 million for the nine months ended September 30, 2021, from $41.5 million for the same period in 2020.

The increase in supplies revenue is primarily related to a larger customer base from increased device sales in 2020 and 2021.

Operating Expenses

Cost of Revenue – Device and Supply

Cost of Revenue – device and supply consist primarily of device and supply costs, facilities, operations labor and overhead, shipping and depreciation. Cost of revenue for the three months ended September 30, 2021 increased 59% to $6.8 million from $4.3 million for the same period in 2020. As a percentage of revenue, cost of revenue – device and supply decreased to 20% for the three months ended September 30, 2020 from 21% for the same period in 2020.

Table of Contents

Cost of revenue for the nine months ended September 30, 2021 increased 70% to $20.0 million from $11.8 million for the same period in 2020. As a percentage of revenue, cost of revenue – device and supply remained at 22% for the nine months ended September 30, 2021 compared to the same period in 2020.

The increase in cost of revenue is primarily due to an increase in overhead costs related to our new manufacturing and warehouse facility and freight costs, as well as an increase of 70% and 134% in device orders in the three and nine months ended September 30, 2021, respectively.

Sales and Marketing Expense

Sales and marketing expenses primarily consist of employee related costs, including commissions and other direct costs associated with these personnel including travel expenses and marketing campaign and related expenses.

Sales and marketing expense for the three months ended September 30, 2021 increased 39% to $13.1 million from $9.4 million for the same period in 2020. Sales and marketing expense for the nine months ended September 30, 2021 increased 86% to $40.7 million from $21.8 million for the same period in 2020. The increase in sales and marketing expense is primarily due to the expansion of our sales force and the related costs associated with increased headcount.

As a percentage of revenue, sales and marketing expense decreased to 38% for the three months ended September 30, 2021 from 47% for the same period in 2020 primarily due to decelerating our sales force expansion compared to the same period in 2020 during which we hired over 100 sales representatives. As a percentage of revenue, sales and marketing expense increased to 45% for the nine months ended September 30, 2021 from 40% for the same period in 2020. The increase as a percentage of revenue is primarily due to the related costs associated with increased headcount.

General and Administrative Expense

General and administrative expenses primarily consist of employee-related costs, and other direct costs associated with these personnel including facilities and travel expenses and professional fees, depreciation and amortization. General and administrative expense for the three months ended September 30, 2021 increased 39% to $6.8 million from $4.9 million for the same period in 2020. The increase in general and administrative expense for the three months is primarily due to increased compensation and benefit expense related to headcount growth and increased occupancy expense as a result of our corporate headquarters expansion. As a percentage of revenue, general and administrative expense decreased to 20% for the three months ended September 30, 2021 from 24% for the same period in 2020. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period, partially offset by costs associated with increased headcount from the prior year.

General and administrative expense for the nine months ended September 30, 2021 increased 42% to $18.5 million from $13.0 million for the same period in 2020. The increase in general and administrative expense for the nine months is primarily due to increased compensation and benefit expense related to headcount growth. As a percentage of revenue, general and administrative expense decreased to 21% for the nine months ended September 30, 2021 from 24% for the same period in 2020. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period, partially offset by costs associated with increased headcount from prior year.

Income Taxes

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 24% and 23% for the three and nine months ended September 30, 2021, respectively. Discrete items, primarily related to excess tax benefits related to stock option exercises, of $0.3 million and $0.8 million for the three and nine months ended September 30, 2021, respectively, are recognized as a benefit against income tax expense. For the three and nine months ended September 30, 2021 the Company had an income tax expense of approximately $1.9 million and $2.5 million, respectively. The Company recorded income tax expense of $0.1 million and $0.7 million for the three and nine months ended September 30, 2020.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

We have historically financed operations through cash flows from operations, debt and equity transactions. At September 30, 2021, our principal source of liquidity was $35.4 million in cash and $24.2 million in accounts receivable.

Net cash used in operating activities for the nine months ended September 30, 2021 was $0.6 million compared with net cash provided by operating activities of $2.5 million for the nine months ended September 30, 2020. The decrease in cash provided by operating activities for the nine months ended September 30, 2021 was primarily due to an increase in inventory in 2021 as well as an increase in receivables balances. The increase in inventory is related to our order growth plus increased stockpiles in anticipation of possible supply chain shortages related to the COVID-19 virus. The increase in receivables is related to increased revenue and slightly longer collection cycles.

Net cash used in investing activities for the nine months ended September 30, 2021 and 2020 was $0.4 million and $0.8 million, respectively. Cash used in investing activities for the nine months ended September 30, 2021 was primarily related to leasehold improvements at our new manufacturing and warehouse facilities. Cash used in investing activities for the nine months ended September 30, 2020 was primarily related to the purchase of office equipment, IT infrastructure, and leasehold improvements related to our expansion into the second floor at our prior corporate headquarters.

Net cash used in financing activities for the nine months ended September 30, 2021 was $2.8 million compared with net cash provided by financing activities of $25.4 million for the same period in 2020. Net cash used in financing activities for the nine months ended September 30, 2021 was primarily due to purchases of treasury stock. Net cash provided by financing activities for the nine months ended September 30, 2020 was primarily due to proceeds of $25.2 million from our equity offering, which closed on July 17, 2020.

We believe our cash and cash equivalents, together with anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the following:

●

Our cash and cash equivalents balance at September 30, 2021 of $35.4 million;

●

Our working capital balance of $59.6 million;

●

Our projected income and cash flows for the next 12 months.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and Note 2 to the Consolidated Financial Statements located within our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021.

OFF BALANCE SHEET ARRANGEMENTS

The Company had no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

RISKS AND UNCERTAINTIES

In December 2019, a novel Coronavirus disease (“COVID-19”) was reported and on March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. While the Company did not incur significant disruptions to its operations during the three and nine months ended September 30, 2021 from COVID-19, it is unable at this time to predict the impact that COVID-19 will have on its

Table of Contents

business, financial position and operating results in future periods due to numerous uncertainties. The Company has been and continues to closely monitor the impact of the pandemic on all aspects of its business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are exposed to certain market risks, including changes in interest rates. Uncertainties that are either non-financial or non-quantifiable such as political, economic, tax, other regulatory, or credit risks, including healthcare reimbursement practices, are not included in the following assessment of market risks.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of September 30, 2021, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control Over Financial Reporting

During the three months ended September 30, 2021, there were no changes that materially affected or are reasonably likely to affect our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not a party to any material pending legal proceedings.

ITEM 1A. RISK FACTORS

There have been no material changes in the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Items 2(a) and 2(b) are not applicable.

Issuer Purchases of Equity Securities


	(a)
	Total	(b)		(c)	(d)
	Number of	Average		Total Number of	Approximate Dollar
	Shares	Price Paid		Shares Purchased as Part of	Value (in thousands) of Shares that may
	Purchased	per Share		Publicly Announced Program	yet be Purchased under the Program
March 8 to September 8, 2021	175,179	$	15.22	175,179	$	—

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

N/A

ITEM 5. OTHER INFORMATION

None.

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number		Description

31.1*		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

32.1**		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Calculation Linkbase Document

101.LAB *		XBRL Taxonomy Label Linkbase Document

101.PRE *		XBRL Presentation Linkbase Document

101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith

**Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ZYNEX, INC.

	/s/ Daniel J. Moorhead
Dated: November 2, 2021	Daniel J. Moorhead
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 zyxi-20210930xex31d1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Thomas Sandgaard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2021

/s/ Thomas Sandgaard
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

EX-31.2 3 zyxi-20210930xex31d2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Daniel J. Moorhead, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2021

/s/ Daniel J. Moorhead
Daniel J. Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer

EX-32.1 4 zyxi-20210930xex32d1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his knowledge:

This Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of November 2, 2021.


/s/ Thomas Sandgaard
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Zynex, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-32.2 5 zyxi-20210930xex32d2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of November 2, 2021.

/s/ Daniel J. Moorhead
Daniel J. Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer

EX-101.SCH 6 zyxi-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - BASIS OF PRESENTATION - Breakdown of net revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - BASIS OF PRESENTATION - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 407010 - Disclosure - LEASES - Calc 2 (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - LEASES - Components of lease expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - PROPERTY AND EQUIPMENT - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - EARNINGS PER SHARE - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - STOCK-BASED COMPENSATION PLANS - Stock options granted (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) link:presentationLink link:calculationLink link:definitionLink 40406 - Disclosure - STOCK-BASED COMPENSATION PLANS - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - INCOME TAXES - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - LEASES - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - STOCK-BASED COMPENSATION PLANS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - LITIGATION link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 zyxi-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 zyxi-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 zyxi-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document Type Document Period End Date Document Quarterly Report Document Transition Report Entity Registrant Name Entity Current Reporting Status Security Exchange Name Title of 12(b) Security Entity Interactive Data Current Entity Small Business Entity Emerging Growth Company Entity Filer Category Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Trading Symbol Entity File Number Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash at end of period Cash at beginning of period Cash Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventory, net Inventory, net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and Equipment, Net Operating Lease, Right-of-Use Asset Operating lease asset Operating lease asset Finance Lease, Right-of-Use Asset Finance lease asset Deposits Assets, Noncurrent Deposits Deferred Tax Assets, Net, Noncurrent Deferred income taxes Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Operating Lease, Liability, Current Operating lease liability Finance Lease, Liability, Current Finance lease liability Accrued Income Taxes, Current Income taxes payable Employee-related Liabilities, Current Accrued payroll and related taxes Liabilities, Current Total current liabilities Liabilities, Other than Long-term Debt, Noncurrent [Abstract] Long-term liabilities: Operating Lease, Liability, Noncurrent Operating lease liability Finance Lease, Liability, Noncurrent Finance lease liability Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common Stock, Value, Issued Common stock, $0.001 par value; 100,000,000 shares authorized; 36,436,593 issued and 34,774,723 outstanding as of September 30, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020 Additional Paid in Capital, Common Stock Additional paid-in capital Treasury Stock, Value Treasury stock 1,246,399 shares, at September 30, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Treasury Stock, Shares CONSOLIDATED STATEMENTS OF OPERATIONS Product and Service [Axis] Product and Service [Domain] Represent the devices. Devices [Member] Supplies [Member] Revenues [Abstract] NET REVENUE Revenues Total Device revenue Total net revenue Operating Expenses [Abstract] COSTS OF REVENUE AND OPERATING EXPENSES Cost of Goods and Services Sold Costs of revenue - devices and supplies Selling and Marketing Expense Sales and marketing General and Administrative Expense General and administrative Costs and Expenses Total costs of revenue and operating expenses Operating Income (Loss) Income from operations Nonoperating Income (Expense) [Abstract] Other expense Interest Income (Expense), Net Interest expense Nonoperating Income (Expense) Other expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income from operations before income taxes Income Tax Expense (Benefit) Income tax benefit Income tax expense Net income available to common stockholders Net Income (Loss) Attributable to Parent Net income available to common stockholders Net Income Net income Earnings Per Share, Basic and Diluted [Abstract] Net income per share: Earnings Per Share, Basic Basic Basic earnings per share Earnings Per Share, Diluted Diluted earnings per share Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Basic Basic weighted-average shares outstanding Weighted average basic shares outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted average diluted shares outstanding Diluted weighted-average shares outstanding CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash (used in)/provided by operating activities: Depreciation Depreciation Amount of non-cash reserve charges. Non-Cash Reserve Charges Non-cash recoveries Share-based Compensation Stock-based compensation Amount of Non-cash lease expense. Increase Decrease In Non Cash Lease Expense Non-cash lease expense Deferred Income Tax Expense (Benefit) Provision for deferred income taxes Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and other accrued expenses Increase (Decrease) in Inventories Inventory Increase (Decrease) in Deposit Assets Deposits Net Cash Provided by (Used in) Operating Activities Net cash (used in)/ provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Finance Lease, Principal Payments Payments on finance lease obligations Payments for Repurchase of Common Stock Purchase of treasury stock Proceeds from Issuance of Common Stock Proceeds from issuance of common stock under equity offering Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Proceeds from the issuance of common stock on stock-based awards Payment, Tax Withholding, Share-based Payment Arrangement Taxes withheld and paid on employees' equity awards Net Cash Provided by (Used in) Financing Activities Net cash (used in)/provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease)/ increase in cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash paid for interest Amount paid for rent. Rent Paid Cash paid for rent Income Taxes Paid, Net Cash paid for income taxes Noncash Investing and Financing Items [Abstract] Supplemental disclosure of non-cash investing and financing activities: Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-use assets obtained in exchange for new finance lease liabilities The amount of inventory transferred to property and equipment under lease in in noncash investing or financing activities. Inventory Transferred To Property and Equipment Under Lease Inventory transferred to property and equipment under lease Amount of inventory transferred to sales rep demos. Inventory Transferred to Sales Rep Demos Inventory transferred to property and equipment as demo devices Capital expenditures not yet paid. Capital Expenditures Not Yet Paid Capital expenditures not yet paid CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Retained Earnings Non-Controlling Interest [Member] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Shares, Outstanding Balance (in shares) Balance (in shares) stock issued during public offering . Stock issued for public offering Stock issued for public offering Stock issued for public offering shares . Stock issued for public offering [shares ] Stock issued for public offering ( shares) Value of stock issued as a result of the exercise and vest of stock-based awards. Stock Issued During Period, Value, Stock Based Awards Exercised and Vested Exercised and vested stock-based awards Number of stock-based awards exercised or vested during the current period. Share-based Compensation Arrangement by Share-based Payment Award, Stock Based Awards, Exercises and Vested in Period Exercised and vested stock-based awards (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation expense Value of shares withheld to pay tax withholding for share based compensation. Shares With held To Pay Tax Withholding For Share Based Compensation Shares of common stock withheld to pay taxes on employees' equity awards Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares of common stock withheld to pay taxes on employees' equity awards (in shares) Stock Issued During Period Shares Stock Warrants Exercised. Stock Issued During Period, Shares, Stock Warrants Exercised Warrants exercised (in shares) Stock Repurchased During Period, Value Treasury stock Stock Repurchased During Period, Value Stock Repurchased During Period, Shares Treasury stock (in shares) Stock Repurchased During Period, Shares Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] BASIS OF PRESENTATION PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT EARNINGS PER SHARE Earnings Per Share [Text Block] EARNINGS PER SHARE STOCK-BASED COMPENSATION PLANS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION PLANS STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES LEASES Lessee, Operating Leases [Text Block] LEASES CONCENTRATIONS Concentration Risk Disclosure [Text Block] CONCENTRATIONS LITIGATION Commitments and Contingencies Disclosure [Text Block] LITIGATION Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Lessee, Leases [Policy Text Block] Leases Accounts Receivable [Policy Text Block] Accounts Receivable, Net Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Compensation Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Inventory, Policy [Policy Text Block] Inventory, Net Segment Reporting, Policy [Policy Text Block] Segment Information Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue Inventory Disclosure [Text Block] Schedule of components of inventory Property, Plant and Equipment [Table Text Block] Schedule of components of property and equipment Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Calculation of Basic and Diluted earnings per share Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Tabular disclosure for outstanding and exercisable number of stock options. Schedule Of Outstanding And Exercisable Number Of Stock Options [Table Text Block] Schedule of outstanding and exercisable number of options EX-101.PRE 10 zyxi-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 zyxi-20210930x10q_htm.xml IDEA: XBRL DOCUMENT 0000846475 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000846475 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-01 2024-01-31 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-07-01 2021-09-30 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-09-30 0000846475 us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-07-01 2020-09-30 0000846475 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-09-30 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 2021-04-09 0000846475 2021-04-09 2021-04-09 0000846475 us-gaap:CommonStockMember 2021-03-08 0000846475 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000846475 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000846475 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2021-09-30 0000846475 us-gaap:RetainedEarningsMember 2021-09-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000846475 us-gaap:TreasuryStockMember 2021-06-30 0000846475 us-gaap:RetainedEarningsMember 2021-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000846475 2021-06-30 0000846475 us-gaap:TreasuryStockMember 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000846475 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2020-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000846475 us-gaap:TreasuryStockMember 2020-09-30 0000846475 us-gaap:RetainedEarningsMember 2020-09-30 0000846475 us-gaap:NoncontrollingInterestMember 2020-09-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000846475 us-gaap:TreasuryStockMember 2020-06-30 0000846475 us-gaap:RetainedEarningsMember 2020-06-30 0000846475 us-gaap:NoncontrollingInterestMember 2020-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000846475 2020-06-30 0000846475 us-gaap:TreasuryStockMember 2020-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-03-31 0000846475 us-gaap:NoncontrollingInterestMember 2020-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000846475 2020-03-31 0000846475 us-gaap:TreasuryStockMember 2019-12-31 0000846475 us-gaap:RetainedEarningsMember 2019-12-31 0000846475 us-gaap:NoncontrollingInterestMember 2019-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000846475 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:CommonStockMember 2021-09-30 0000846475 us-gaap:CommonStockMember 2021-06-30 0000846475 us-gaap:CommonStockMember 2021-03-31 0000846475 us-gaap:CommonStockMember 2020-12-31 0000846475 us-gaap:CommonStockMember 2020-09-30 0000846475 us-gaap:CommonStockMember 2020-06-30 0000846475 us-gaap:CommonStockMember 2020-03-31 0000846475 us-gaap:CommonStockMember 2019-12-31 0000846475 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000846475 us-gaap:WarrantMember 2021-09-30 0000846475 us-gaap:WarrantMember 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-12-31 0000846475 zyxi:StockIncentivePlan2017Member 2021-07-01 2021-09-30 0000846475 zyxi:StockIncentivePlan2017Member 2021-01-01 2021-09-30 0000846475 zyxi:StockIncentivePlan2017Member 2020-07-01 2020-09-30 0000846475 zyxi:StockIncentivePlan2017Member 2020-01-01 2020-09-30 0000846475 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000846475 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000846475 zyxi:TwoThousandAndFiveStockOptionPlanMember 2021-09-30 0000846475 zyxi:StockIncentivePlan2017Member 2021-09-30 0000846475 zyxi:EquityCompensationPlansNotApprovedByShareholdersMember 2021-09-30 0000846475 us-gaap:EmployeeStockOptionMember 2021-09-30 0000846475 zyxi:StockIncentivePlan2017Member 2017-06-30 0000846475 us-gaap:RestrictedStockMember 2021-09-30 0000846475 us-gaap:RestrictedStockMember 2020-12-31 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2021-07-01 2021-09-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2021-01-01 2021-09-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2020-07-01 2020-09-30 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2020-01-01 2020-09-30 0000846475 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0000846475 zyxi:DevicesMember 2021-07-01 2021-09-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2021-07-01 2021-09-30 0000846475 zyxi:DevicesMember 2021-01-01 2021-09-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2021-01-01 2021-09-30 0000846475 zyxi:DevicesMember 2020-07-01 2020-09-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2020-07-01 2020-09-30 0000846475 zyxi:DevicesMember 2020-01-01 2020-09-30 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2020-01-01 2020-09-30 0000846475 zyxi:SalesRepDemoUnitsMember 2021-09-30 0000846475 zyxi:LeasedDevicesMember 2021-09-30 0000846475 us-gaap:VehiclesMember 2021-09-30 0000846475 us-gaap:LeaseholdImprovementsMember 2021-09-30 0000846475 us-gaap:FurnitureAndFixturesMember 2021-09-30 0000846475 us-gaap:EquipmentMember 2021-09-30 0000846475 zyxi:SalesRepDemoUnitsMember 2020-12-31 0000846475 zyxi:LeasedDevicesMember 2020-12-31 0000846475 us-gaap:VehiclesMember 2020-12-31 0000846475 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000846475 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000846475 us-gaap:EquipmentMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000846475 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000846475 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000846475 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000846475 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000846475 zyxi:OperatingLeasesFiveMember 2021-09-30 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 0000846475 zyxi:EstimatedRateOneMember 2021-01-01 2021-09-30 0000846475 zyxi:LeasedDevices1Member 2021-07-01 2021-09-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2021-07-01 2021-09-30 0000846475 zyxi:LeasedDevices1Member 2021-01-01 2021-09-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-09-30 0000846475 zyxi:LeasedDevices1Member 2020-07-01 2020-09-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2020-07-01 2020-09-30 0000846475 zyxi:LeasedDevices1Member 2020-01-01 2020-09-30 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2020-01-01 2020-09-30 0000846475 2020-09-30 0000846475 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000846475 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000846475 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000846475 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0000846475 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0000846475 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0000846475 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0000846475 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000846475 2020-01-01 2020-09-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000846475 2021-07-01 2021-09-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000846475 2021-04-01 2021-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000846475 2021-01-01 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000846475 2020-07-01 2020-09-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000846475 2020-04-01 2020-06-30 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000846475 2020-01-01 2020-03-31 0000846475 2021-09-30 0000846475 2020-12-31 0000846475 2021-10-27 0000846475 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure utr:sqft zyxi:segment iso4217:USD utr:sqft zyxi:item

0000846475 --12-31 2021 Q3 false ZYNEX INC NV

10-Q true 2021-09-30 false 001-38804 90-0275169 9655 Maroon Cir. Englewood CO 80112 303 703-4906 Common Stock, $0.001 par value per share ZYXI NASDAQ Yes Yes Non-accelerated Filer true false false 34779691

35368000

39173000

24234000

13837000

9154000

8635000

1102000

1378000

69858000

63023000

2253000

1925000

17234000

5993000

418000

321000

584000

347000

376000

566000

90723000

72175000

2669000

4717000

2416000

2051000

115000

77000

1577000

280000

3515000

2992000

10292000

10117000

16701000

4920000

347000

283000

27340000

15320000

0.001

10000000

0.001

100000000

36436593

34774723

36126698

34791931

37000

36000

38220000

37235000

1246399

1071220

6513000

3846000

31639000

23430000

63383000

56855000

90723000

72175000

9071000

5301000

23264000

13026000

25715000

14725000

66671000

41491000

34786000

20026000

89935000

54517000

6837000

4296000

19990000

11758000

13083000

9425000

40662000

21817000

6820000

4896000

18503000

12990000

26740000

18617000

79155000

46565000

8046000

1409000

10780000

7952000

-18000

-5000

-72000

-14000

-18000

-5000

-72000

-14000

8028000

1404000

10708000

7938000

1921000

71000

2499000

651000

6107000

1333000

8209000

7287000

0.18

0.04

0.24

0.22

0.17

0.04

0.23

0.21

34768000

34486000

34805000

33564000

35493000

35476000

35583000

34715000

8209000

7287000

1689000

1042000

-83000 -296000

1042000

1806000

905000 27000

190000

-473000

10397000

3532000

-276000

745000

-284000

1625000

1898000

4274000

238000

-47000

-589000

2514000

420000

759000

-420000

-759000

73000

42000

2667000

25240000

127000

236000

183000

-2796000

25434000

-3805000

27189000

39173000

14040000

35368000

41229000

72000

14000

1510000 1182000

-1019000

-750000

13240000

1433000

175000

72000

1254000 641000 125000 377000 56000 0

32791665

34000

9198000

-3846000

14356000

-89000

19653000

385917 221000 221000

497000

2937000

33177582

34000

9916000

-3846000

17293000

-89000

23308000

157414 53000 53000

579000

3017000

33334996

34000

10548000

-3846000

20310000

-89000

26957000

-1250000 -1000 -25239000 -25240000 152269 -38000 -38000

730000

1333000

34737265

35000

36479000

-3846000

21643000

-89000

54222000

34791931

36000

37235000

-3846000

23430000

56855000

57769 1000 29000 30000

108000

3758

59000 59000 8848

5000

75000

-706000

34849790

37000

37313000

-3921000

22724000

56153000

85190 59000 59000

401000

31902

76000 76000

135179

2045000

2808000

34767899

37000

37697000

-5966000

25532000

57300000

45165 38000 38000

533000

3341

48000 48000

35000

547000

6107000

34774723

37000

38220000

-6513000

31639000

63383000

Revenue RecognitionRevenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to our patient.Sales of our devices and supplies are primarily made with and shipped directly to the patient with a small amount of revenue generated from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Device revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Purchased</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 2,076</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"> 1,618</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> 6,734</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> 4,121</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Leased</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,995</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,683</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,530</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,905</td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Total Device revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,071</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,301</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,264</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,026</td></tr></table>Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which the difference is identified. Historically these differences have been immaterial, and the Company has not had a significant reversal of revenue from prior periods.A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Device revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Purchased</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;margin:0pt;padding:0pt;"> 2,076</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"> 1,618</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> 6,734</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"> 4,121</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Leased</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,995</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,683</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,530</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,905</td></tr><tr><td style="vertical-align:bottom;width:26.49%;margin:0pt;padding:0pt;">Total Device revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,071</td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,301</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,264</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,026</td></tr></table>

2076000 1618000 6734000 4121000 6995000 3683000 16530000 8905000

9071000

5301000

23264000

13026000

Inventory, NetInventories are stated at the lower of cost or net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Raw Materials</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 4,102</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 3,213</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Work-in-process</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 466</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 1,455</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Finished Goods</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,738</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,119</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 9,306</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 8,787</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Less: reserve</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,154</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,635</td></tr></table>The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Raw Materials</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 4,102</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 3,213</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Work-in-process</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 466</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 1,455</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Finished Goods</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,738</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,119</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 9,306</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 8,787</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Less: reserve</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,154</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,635</td></tr></table>

4102000

3213000

466000

1455000

4738000

4119000

9306000

8787000

152000

9154000

8635000

The components of property and equipment are as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Property and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Office furniture and equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 2,232</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 2,362</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Assembly equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 100</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 143</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Vehicles</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 203</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 198</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 1,033</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 559</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Sales rep demo units</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 361</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Leased devices</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,223</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 809</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> 4,913</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"> 4,432</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;">Less accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,660)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,507)</td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,253</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,925</td></tr></table>

2232000

2362000

100000

143000

203000

198000

1033000

559000

122000

361000

1223000

809000

4913000

4432000

2660000

2507000

2253000

1925000

200000

300000

700000

500000

400000

200000

1000000.0

600000

The calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands, except per share data):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Basic earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Net income available to common stockholders</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 6,107</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 1,333</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 8,209</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 7,287</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Basic weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,768</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,486</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,805</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 33,564</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Basic earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.24</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.22</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Diluted earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Net income available to common stockholders</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 6,107</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 1,333</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 8,209</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 7,287</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 34,768</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 34,486</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 34,805</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 33,564</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Effect of dilutive securities - options and restricted stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 725</td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 990</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 778</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,151</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Diluted weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 35,493</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 35,476</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 35,583</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 34,715</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Diluted earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.17</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.23</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.21</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr></table>

6107000

1333000

8209000

7287000

34768000

34486000

34805000

33564000

0.18

0.04

0.24

0.22

6107000

1333000

8209000

7287000

34768000

34486000

34805000

33564000

725000

990000

778000

1151000

35493000

35476000

35583000

34715000

0.17

0.04

0.23

0.21

200000

100000

(4) STOCK-BASED COMPENSATION PLANSIn June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5 million shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon grant and are not included in outstanding shares until such vesting and issuance occurs.During the three and nine months ended September 30, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended September 30, 2020, no stock option awards were granted under the 2017 Stock Plan. During the nine months ended September 30, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At September 30, 2021, the company had 0.7 million stock options outstanding and 0.6 million exercisable under the following plans:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;">Number of Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;">Number of Options</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Plan Category</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">2005 Stock Option Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 295</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 295</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Equity Compensation Plans not approved by Shareholders</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 25</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 25</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">2017 Stock Option Plan</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 388</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 708</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 588</td></tr></table>During the three and nine months ended September 30, 2021, 0.2 million and 0.3 million shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. During the three and nine months ended September 30, 2020, 0.1 million and 0.3 million shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan, respectively. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock Awards typically occurs quarterly over three years for the Board of Directors and quarterly or annually over two to four years for management.The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Cost of revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 42</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 22</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 78</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 45</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">General, and administrative</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 473</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 704</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 922</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,739</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Total stock based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 533</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 730</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,042</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,806</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr></table>The Company received minimal cash proceeds related to option exercises during the three months ended September 30, 2021. The Company received cash proceeds of $0.1 million related to option exercises during the nine months ended September 30, 2021. The Company received cash proceeds of $0.1 million and $0.6 million related to option exercises during the three and nine months ended September 30, 2020, respectively.The Company did not grant any stock options during the three and nine months ended September 30, 2021, nor during the three months ended September 30, 2020. The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the nine months ended September 30, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected term (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 6.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 1.59</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected volatility</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 116.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr></table>A summary of stock option activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;">Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> 1,006</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 3.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 6.47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 10,483</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> (198)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 7.22</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (100)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5.31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Outstanding at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 708</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.55</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,963</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Exercisable at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 588</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.04</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.52</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,088</td></tr></table>A summary of restricted stock award activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Number of</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Shares</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 317</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> (83)</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (87)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at September 30, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 415</td></tr></table>As of September 30, 2021, the Company had approximately $5.9 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.9 years.

5000000

14000

700000

600000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;">Number of Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;">Number of Options</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Plan Category</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">2005 Stock Option Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 295</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 295</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Equity Compensation Plans not approved by Shareholders</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 25</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"> 25</td></tr><tr><td style="vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">2017 Stock Option Plan</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 388</td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.54%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 708</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 588</td></tr></table>

295000

25000

388000

268000

708000

588000

200000

300000

100000

300000

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Cost of revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 42</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 22</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"> 78</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"> 45</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">General, and administrative</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 473</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 704</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 922</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,739</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:41.13%;margin:0pt;padding:0pt;">Total stock based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 533</td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 730</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,042</td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,806</td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td></tr></table>

12000

13000

42000

22000

48000

13000

78000

45000

473000

704000

922000

1739000

533000

730000

1042000

1806000

100000

600000

The Company did not grant any stock options during the three and nine months ended September 30, 2021, nor during the three months ended September 30, 2020. The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the nine months ended September 30, 2020:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected term (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 6.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 1.59</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected volatility</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 116.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:top;width:84.15%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;">%</td></tr></table>

P6Y9M14D

0.0159

1.1676

A summary of stock option activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;">Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> 1,006</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 3.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 6.47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 10,483</td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> (198)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 7.22</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (100)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5.31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Outstanding at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 708</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.55</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,963</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;">Exercisable at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 588</td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.04</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.52</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,088</td></tr></table>

1006000

3.04

P6Y5M19D

10483000

198000

7.22

100000

5.31

708000

1.55

P4Y11M19D

6963000

588000

1.04

P4Y6M7D

6088000

A summary of restricted stock award activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Number of</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Shares</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 317</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> (83)</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (87)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at September 30, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 415</td></tr></table>

268000

317000

83000

87000

415000

5900000

P2Y10M24D

10000000.0

175179

2700000

15.22

A summary of stock warrant activity for the nine months ended September 30, 2021 is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;">Warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"> 100</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> 2.63</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 3.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,084</td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"> (10)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> 2.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 3.02</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 192</td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;">Outstanding and Exercisable at September 30, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 90</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.64</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3.02</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 788</td></tr></table>

100000

2.63

P3Y9M3D

1084000

10000

2.50

P3Y7D

192000

90000

2.64

P3Y7D

788000

300000

800000

0.25

0.23

1900000

2500000

100000

700000

1000000.0

700000

110754

26.50 0.50 0.50

13400000

P6Y6M

0.0412

0.0937

As of September 30, 2021, the maturities of the Company’s future minimum lease payments were as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.36%;margin:0pt;padding:0pt;">Operating lease liability</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;margin:0pt;padding:0pt;">Finance lease liability</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">October 1, 2021 through December 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 599</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"> 38</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 3,569</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"> 154</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 2,982</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"> 143</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 3,496</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"> 80</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2025</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 3,567</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"> 76</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2026 and thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,576</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total undiscounted future minimum lease payments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,789</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 506</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Less: Difference between undiscounted lease payments and discounted lease liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,672)</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (44)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,117</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 462</td></tr></table>

599000

38000

3569000

154000

2982000

143000

3496000

80000

3567000

76000

7576000 15000

21789000

506000

2672000

44000

19117000

462000

The components of lease expenses were as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.85%;margin:0pt;padding:0pt;">Three Months Ended</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;margin:0pt;padding:0pt;">Nine Months Ended</td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30,</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30,</td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Lease cost:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Operating lease cost:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Total operating lease expense</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 1,072</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 419</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 2,415</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 1,181</td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Finance lease cost:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Total amortization of leased assets</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 29</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 16</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 78</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 44</td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Interest on lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;">Total net lease cost</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,112</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 440</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,524</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,239</td></tr></table>

1072000

419000

2415000

1181000

29000

16000

78000

44000

11000

5000

31000

14000

1112000

440000

2524000

1239000

0.51 3 0.64 5 0.36 2 0.31 1 2 0.37 1 0.26

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Oct. 27, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	ZYNEX INC
Entity Current Reporting Status	Yes
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, $0.001 par value per share
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,779,691
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000846475
Amendment Flag	false
Trading Symbol	ZYXI
Entity File Number	001-38804
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	90-0275169
Entity Address, Address Line One	9655 Maroon Cir.
Entity Address, City or Town	Englewood
Entity Address, Country	CO
Entity Address, Postal Zip Code	80112
City Area Code	303
Local Phone Number	703-4906

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 35,368	$ 39,173
Accounts receivable, net	24,234	13,837
Inventory, net	9,154	8,635
Prepaid expenses and other	1,102	1,378
Total current assets	69,858	63,023
Property and equipment, net	2,253	1,925
Operating lease asset	17,234	5,993
Finance lease asset	418	321
Deposits	584	347
Deferred income taxes	376	566
Total assets	90,723	72,175
Current liabilities:
Accounts payable and accrued expenses	2,669	4,717
Operating lease liability	2,416	2,051
Finance lease liability	115	77
Income taxes payable	1,577	280
Accrued payroll and related taxes	3,515	2,992
Total current liabilities	10,292	10,117
Long-term liabilities:
Operating lease liability	16,701	4,920
Finance lease liability	347	283
Total liabilities	27,340	15,320
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,436,593 issued and 34,774,723 outstanding as of September 30, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020	37	36
Additional paid-in capital	38,220	37,235
Treasury stock 1,246,399 shares, at September 30, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost	(6,513)	(3,846)
Retained earnings	31,639	23,430
Total stockholders' equity	63,383	56,855
Total liabilities and stockholders' equity	$ 90,723	$ 72,175

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	36,436,593	36,126,698
Common Stock, Shares, Outstanding	34,774,723	34,791,931
Treasury Stock, Shares	1,246,399	1,071,220

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
NET REVENUE
Total net revenue	$ 34,786	$ 20,026	$ 89,935	$ 54,517
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies	6,837	4,296	19,990	11,758
Sales and marketing	13,083	9,425	40,662	21,817
General and administrative	6,820	4,896	18,503	12,990
Total costs of revenue and operating expenses	26,740	18,617	79,155	46,565
Income from operations	8,046	1,409	10,780	7,952
Other expense
Interest expense	(18)	(5)	(72)	(14)
Other expense, net	(18)	(5)	(72)	(14)
Income from operations before income taxes	8,028	1,404	10,708	7,938
Income tax expense	1,921	71	2,499	651
Net Income	$ 6,107	$ 1,333	$ 8,209	$ 7,287
Net income per share:
Basic	$ 0.18	$ 0.04	$ 0.24	$ 0.22
Diluted	$ 0.17	$ 0.04	$ 0.23	$ 0.21
Weighted average basic shares outstanding	34,768	34,486	34,805	33,564
Weighted average diluted shares outstanding	35,493	35,476	35,583	34,715
Devices [Member]
NET REVENUE
Total net revenue	$ 9,071	$ 5,301	$ 23,264	$ 13,026
Supplies [Member]
NET REVENUE
Total net revenue	$ 25,715	$ 14,725	$ 66,671	$ 41,491

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 8,209	$ 7,287
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Depreciation	1,689	1,042
Non-cash recoveries	(83)	(296)
Stock-based compensation	1,042	1,806
Non-cash lease expense	905	27
Provision for deferred income taxes	190	(473)
Change in operating assets and liabilities:
Accounts receivable	(10,397)	(3,532)
Prepaid and other assets	276	(745)
Accounts payable and other accrued expenses	(284)	1,625
Inventory	(1,898)	(4,274)
Deposits	(238)	47
Net cash (used in)/ provided by operating activities	(589)	2,514
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(420)	(759)
Net cash (used in) investing activities	(420)	(759)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations	(73)	(42)
Purchase of treasury stock	(2,667)	0
Proceeds from issuance of common stock under equity offering	0	25,240
Proceeds from the issuance of common stock on stock-based awards	127	236
Taxes withheld and paid on employees' equity awards	(183)	0
Net cash (used in)/provided by financing activities	(2,796)	25,434
Net (decrease)/ increase in cash	(3,805)	27,189
Cash at beginning of period	39,173	14,040
Cash at end of period	35,368	41,229
Supplemental disclosure of cash flow information:
Cash paid for interest	(72)	(14)
Cash paid for rent	(1,510)	(1,182)
Cash paid for income taxes	(1,019)	(750)
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities	13,240	1,433
Right-of-use assets obtained in exchange for new finance lease liabilities	175	72
Inventory transferred to property and equipment under lease	1,254	641
Inventory transferred to property and equipment as demo devices	125	377
Capital expenditures not yet paid	$ 56	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 34	$ 9,198	$ (3,846)	$ 14,356	$ (89)	$ 19,653
Balance (in shares) at Dec. 31, 2019	32,791,665
Exercised and vested stock-based awards		221				221
Exercised and vested stock-based awards (in shares)	385,917
Stock-based compensation expense		497				497
Net income				2,937		2,937
Balance at Mar. 31, 2020	$ 34	9,916	(3,846)	17,293	(89)	23,308
Balance (in shares) at Mar. 31, 2020	33,177,582
Exercised and vested stock-based awards		53				53
Exercised and vested stock-based awards (in shares)	157,414
Stock-based compensation expense		579				579
Net income				3,017		3,017
Balance at Jun. 30, 2020	$ 34	10,548	(3,846)	20,310	(89)	26,957
Balance (in shares) at Jun. 30, 2020	33,334,996
Stock issued for public offering	$ 1	25,239				25,240
Stock issued for public offering ( shares)	1,250,000
Exercised and vested stock-based awards		(38)				(38)
Exercised and vested stock-based awards (in shares)	152,269
Stock-based compensation expense		730				730
Net income				1,333		1,333
Balance at Sep. 30, 2020	$ 35	36,479	(3,846)	21,643	$ (89)	54,222
Balance (in shares) at Sep. 30, 2020	34,737,265
Balance at Dec. 31, 2020	$ 36	37,235	(3,846)	23,430		56,855
Balance (in shares) at Dec. 31, 2020	34,791,931
Exercised and vested stock-based awards	$ 1	29				30
Exercised and vested stock-based awards (in shares)	57,769
Stock-based compensation expense		108				108
Shares of common stock withheld to pay taxes on employees' equity awards		(59)				(59)
Shares of common stock withheld to pay taxes on employees' equity awards (in shares)	(3,758)
Warrants exercised (in shares)	8,848
Treasury stock			(75)			(75)
Treasury stock (in shares)	(5,000)
Net income				(706)		(706)
Balance at Mar. 31, 2021	$ 37	37,313	(3,921)	22,724		56,153
Balance (in shares) at Mar. 31, 2021	34,849,790
Balance at Dec. 31, 2020	$ 36	37,235	(3,846)	23,430		56,855
Balance (in shares) at Dec. 31, 2020	34,791,931
Treasury stock	$ (2,700)
Treasury stock (in shares)	(175,179)
Balance at Sep. 30, 2021	$ 37	38,220	(6,513)	31,639		63,383
Balance (in shares) at Sep. 30, 2021	34,774,723
Balance at Mar. 31, 2021	$ 37	37,313	(3,921)	22,724		56,153
Balance (in shares) at Mar. 31, 2021	34,849,790
Exercised and vested stock-based awards		59				59
Exercised and vested stock-based awards (in shares)	85,190
Stock-based compensation expense		401				401
Shares of common stock withheld to pay taxes on employees' equity awards		(76)				(76)
Shares of common stock withheld to pay taxes on employees' equity awards (in shares)	(31,902)
Treasury stock			(2,045)			(2,045)
Treasury stock (in shares)	(135,179)
Net income				2,808		2,808
Balance at Jun. 30, 2021	$ 37	37,697	(5,966)	25,532		57,300
Balance (in shares) at Jun. 30, 2021	34,767,899
Exercised and vested stock-based awards		38				38
Exercised and vested stock-based awards (in shares)	45,165
Stock-based compensation expense		533				533
Shares of common stock withheld to pay taxes on employees' equity awards		(48)				(48)
Shares of common stock withheld to pay taxes on employees' equity awards (in shares)	(3,341)
Treasury stock			(547)			(547)
Treasury stock (in shares)	(35,000)
Net income				6,107		6,107
Balance at Sep. 30, 2021	$ 37	$ 38,220	$ (6,513)	$ 31,639		$ 63,383
Balance (in shares) at Sep. 30, 2021	34,774,723

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2021

BASIS OF PRESENTATION

BASIS OF PRESENTATION

(1) BASIS OF PRESENTATION

Organization

Nature of Business

Unaudited Consolidated Financial Statements

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Leases

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term;

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise;

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset; and

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Accounts Receivable, Net

Revenue Recognition

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Device revenue
Purchased	$	2,076	$	1,618	$	6,734	$	4,121
Leased		6,995		3,683		16,530		8,905
Total Device revenue	$	9,071	$	5,301	$	23,264	$	13,026

Stock-based Compensation

Fair Value of Financial Instruments

Inventory, Net


	September 30, 2021		December 31, 2020
Raw Materials	$	4,102	$	3,213
Work-in-process		466		1,455
Finished Goods		4,738		4,119
	$	9,306	$	8,787
Less: reserve		(152)		(152)
	$	9,154	$	8,635

Segment Information

We currently operate our business as one operating segment that includes two revenue types: Devices and Supplies.

Income Taxes

Recent Accounting Pronouncements

XML 19 R8.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

9 Months Ended

Sep. 30, 2021

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

(2) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):


	September 30, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,232	$	2,362
Assembly equipment		100		143
Vehicles		203		198
Leasehold improvements		1,033		559
Sales rep demo units		122		361
Leased devices		1,223		809
		4,913		4,432
Less accumulated depreciation		(2,660)		(2,507)
	$	2,253	$	1,925

XML 20 R9.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2021

EARNINGS PER SHARE

EARNINGS PER SHARE

(3) EARNINGS PER SHARE

The calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Basic earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Basic weighted-average shares outstanding		34,768		34,486		34,805		33,564

Basic earnings per share	$	0.18	$	0.04	$	0.24	$	0.22

Diluted earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Weighted-average shares outstanding		34,768		34,486		34,805		33,564
Effect of dilutive securities - options and restricted stock		725		990		778		1,151
Diluted weighted-average shares outstanding		35,493		35,476		35,583		34,715

Diluted earnings per share	$	0.17	$	0.04	$	0.23	$	0.21

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS

9 Months Ended

Sep. 30, 2021

STOCK-BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS

(4) STOCK-BASED COMPENSATION PLANS


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	295		295
Equity Compensation Plans not approved by Shareholders	25		25
2017 Stock Option Plan	388		268
Total	708		588

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Cost of revenue	$	12	$	13	$	42	$	22
Sales and marketing expense		48		13		78		45
General, and administrative		473		704		922		1,739
Total stock based compensation expense	$	533	$	730	$	1,042	$	1,806


Expected term (years)	6.79
Risk-free interest rate	1.59	%
Expected volatility	116.76	%
Expected dividend yield	—	%

A summary of stock option activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Forfeited	(198)	$	7.22
Exercised	(100)	$	5.31
Outstanding at September 30, 2021	708	$	1.55	4.97	$	6,963

Exercisable at September 30, 2021	588	$	1.04	4.52	$	6,088

A summary of restricted stock award activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		317
Forfeited		(83)
Vested		(87)
Granted but not vested at September 30, 2021		415

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2021

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

Warrants

A summary of stock warrant activity for the nine months ended September 30, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.02	$	192
Forfeited	—	$	—
Outstanding and Exercisable at September 30, 2021	90	$	2.64		3.02	$	788

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

9 Months Ended

Sep. 30, 2021

INCOME TAXES

INCOME TAXES

(6) INCOME TAXES

Income taxes of $1.0 million and $0.7 million were paid during the nine months ended September 30, 2021 and 2020, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

LEASES

9 Months Ended

Sep. 30, 2021

LEASES

LEASES

(7) LEASES

As of September 30, 2021, the maturities of the Company’s future minimum lease payments were as follows:


	Operating lease liability		Finance lease liability
	(in thousands)		(in thousands)
October 1, 2021 through December 31, 2021	$	599	$	38
2022		3,569		154
2023		2,982		143
2024		3,496		80
2025		3,567		76
2026 and thereafter		7,576		15
Total undiscounted future minimum lease payments	$	21,789	$	506
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(2,672)		(44)
Total lease liabilities	$	19,117	$	462

The components of lease expenses were as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Lease cost:
Operating lease cost:
Total operating lease expense	$	1,072	$	419	$	2,415	$	1,181
Finance lease cost:
Total amortization of leased assets		29		16		78		44
Interest on lease liabilities		11		5		31		14
Total net lease cost	$	1,112	$	440	$	2,524	$	1,239

XML 25 R14.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS

9 Months Ended

Sep. 30, 2021

CONCENTRATIONS

CONCENTRATIONS

(8) CONCENTRATIONS

XML 26 R15.htm IDEA: XBRL DOCUMENT

LITIGATION

9 Months Ended

Sep. 30, 2021

LITIGATION

LITIGATION

(9) LITIGATION

The Company is currently not a party to any material pending legal proceedings.

XML 27 R16.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Policies)

9 Months Ended

Sep. 30, 2021

BASIS OF PRESENTATION

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

Leases

Leases

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term;

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise;

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset; and

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Accounts Receivable, Net

Accounts Receivable, Net

Revenue Recognition

Revenue Recognition

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Device revenue
Purchased	$	2,076	$	1,618	$	6,734	$	4,121
Leased		6,995		3,683		16,530		8,905
Total Device revenue	$	9,071	$	5,301	$	23,264	$	13,026

Stock-based Compensation

Stock-based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Inventory, Net

Inventory, Net


	September 30, 2021		December 31, 2020
Raw Materials	$	4,102	$	3,213
Work-in-process		466		1,455
Finished Goods		4,738		4,119
	$	9,306	$	8,787
Less: reserve		(152)		(152)
	$	9,154	$	8,635

Segment Information

Segment Information

We currently operate our business as one operating segment that includes two revenue types: Devices and Supplies.

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 28 R17.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Tables)

9 Months Ended

Sep. 30, 2021

BASIS OF PRESENTATION

Disaggregation of Revenue


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Device revenue
Purchased	$	2,076	$	1,618	$	6,734	$	4,121
Leased		6,995		3,683		16,530		8,905
Total Device revenue	$	9,071	$	5,301	$	23,264	$	13,026

Schedule of components of inventory


	September 30, 2021		December 31, 2020
Raw Materials	$	4,102	$	3,213
Work-in-process		466		1,455
Finished Goods		4,738		4,119
	$	9,306	$	8,787
Less: reserve		(152)		(152)
	$	9,154	$	8,635

XML 29 R18.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2021

PROPERTY AND EQUIPMENT

Schedule of components of property and equipment

The components of property and equipment are as follows (in thousands):


	September 30, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,232	$	2,362
Assembly equipment		100		143
Vehicles		203		198
Leasehold improvements		1,033		559
Sales rep demo units		122		361
Leased devices		1,223		809
		4,913		4,432
Less accumulated depreciation		(2,660)		(2,507)
	$	2,253	$	1,925

XML 30 R19.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2021

EARNINGS PER SHARE

Schedule of Calculation of Basic and Diluted earnings per share

The calculation of basic and diluted earnings per share for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Basic earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Basic weighted-average shares outstanding		34,768		34,486		34,805		33,564

Basic earnings per share	$	0.18	$	0.04	$	0.24	$	0.22

Diluted earnings per share
Net income available to common stockholders	$	6,107	$	1,333	$	8,209	$	7,287
Weighted-average shares outstanding		34,768		34,486		34,805		33,564
Effect of dilutive securities - options and restricted stock		725		990		778		1,151
Diluted weighted-average shares outstanding		35,493		35,476		35,583		34,715

Diluted earnings per share	$	0.17	$	0.04	$	0.23	$	0.21

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Tables)

9 Months Ended

Sep. 30, 2021

STOCK-BASED COMPENSATION PLANS

Schedule of outstanding and exercisable number of options


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	295		295
Equity Compensation Plans not approved by Shareholders	25		25
2017 Stock Option Plan	388		268
Total	708		588

Schedule of share based compensation expenses recorded in the consolidated statement of income

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Cost of revenue	$	12	$	13	$	42	$	22
Sales and marketing expense		48		13		78		45
General, and administrative		473		704		922		1,739
Total stock based compensation expense	$	533	$	730	$	1,042	$	1,806

Summary of fair value of stock options grants


Expected term (years)	6.79
Risk-free interest rate	1.59	%
Expected volatility	116.76	%
Expected dividend yield	—	%

Summary of stock option activity under the option plan

A summary of stock option activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Forfeited	(198)	$	7.22
Exercised	(100)	$	5.31
Outstanding at September 30, 2021	708	$	1.55	4.97	$	6,963

Exercisable at September 30, 2021	588	$	1.04	4.52	$	6,088

Schedule of restricted stock award activity under all equity compensation plans

A summary of restricted stock award activity under all equity compensation plans for the nine months ended September 30, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		317
Forfeited		(83)
Vested		(87)
Granted but not vested at September 30, 2021		415

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2021

STOCKHOLDERS' EQUITY

Schedule of stock warrant activity

A summary of stock warrant activity for the nine months ended September 30, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.02	$	192
Forfeited	—	$	—
Outstanding and Exercisable at September 30, 2021	90	$	2.64		3.02	$	788

XML 33 R22.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

9 Months Ended

Sep. 30, 2021

LEASES

Schedule of future minimum lease payments under the Company's financing leases and operating lease

As of September 30, 2021, the maturities of the Company’s future minimum lease payments were as follows:


	Operating lease liability		Finance lease liability
	(in thousands)		(in thousands)
October 1, 2021 through December 31, 2021	$	599	$	38
2022		3,569		154
2023		2,982		143
2024		3,496		80
2025		3,567		76
2026 and thereafter		7,576		15
Total undiscounted future minimum lease payments	$	21,789	$	506
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(2,672)		(44)
Total lease liabilities	$	19,117	$	462

Schedule of lease cost

The components of lease expenses were as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Lease cost:
Operating lease cost:
Total operating lease expense	$	1,072	$	419	$	2,415	$	1,181
Finance lease cost:
Total amortization of leased assets		29		16		78		44
Interest on lease liabilities		11		5		31		14
Total net lease cost	$	1,112	$	440	$	2,524	$	1,239

XML 34 R23.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Breakdown of net revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Device revenue
Total Device revenue	$ 34,786	$ 20,026	$ 89,935	$ 54,517
Devices [Member]
Device revenue
Purchased	2,076	1,618	6,734	4,121
Leased	6,995	3,683	16,530	8,905
Total Device revenue	$ 9,071	$ 5,301	$ 23,264	$ 13,026

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Components of inventory
Raw Materials	$ 4,102	$ 3,213
Work-in-process	466	1,455
Finished Goods	4,738	4,119
Total	9,306	8,787
Less: reserve	(152)	(152)
Inventory, net	$ 9,154	$ 8,635

XML 36 R25.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021 segment
BASIS OF PRESENTATION
Number of operating segments	1

XML 37 R26.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment, Gross	$ 4,913	$ 4,432
Less accumulated depreciation	(2,660)	(2,507)
Property and Equipment, Net	2,253	1,925
Office furniture and equipment
Property, Plant and Equipment, Gross	2,232	2,362
Assembly equipment
Property, Plant and Equipment, Gross	100	143
Vehicles
Property, Plant and Equipment, Gross	203	198
Leasehold improvements
Property, Plant and Equipment, Gross	1,033	559
Sales rep demo units
Property, Plant and Equipment, Gross	122	361
Leased devices
Property, Plant and Equipment, Gross	$ 1,223	$ 809

XML 38 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment
Depreciation			$ 1,689	$ 1,042
Property and Equipment [Member]
Property, Plant and Equipment
Depreciation	$ 200	$ 300	700	500
Leased Devices [Member]
Property, Plant and Equipment
Depreciation	$ 400	$ 200	$ 1,000	$ 600

XML 39 R28.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Basic earnings per share
Net income available to common stockholders	$ 6,107	$ 1,333	$ 8,209	$ 7,287
Basic weighted-average shares outstanding	34,768	34,486	34,805	33,564
Basic earnings per share	$ 0.18	$ 0.04	$ 0.24	$ 0.22
Diluted earnings per share
Net income available to common stockholders	$ 6,107	$ 1,333	$ 8,209	$ 7,287
Weighted-average shares outstanding	34,768	34,486	34,805	33,564
Effect of dilutive securities - options and restricted stock	725	990	778	1,151
Diluted weighted-average shares outstanding	35,493	35,476	35,583	34,715
Diluted earnings per share	$ 0.17	$ 0.04	$ 0.23	$ 0.21

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Additional information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0.2	0.1	0.2	0.1

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) shares in Thousands	Sep. 30, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	708
Exercisable Number of Options	588
2005 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	295
Exercisable Number of Options	295
Equity Compensation Plans not approved by Shareholders
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	25
Exercisable Number of Options	25
2017 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	388
Exercisable Number of Options	268

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total stock based compensation expense	$ 533	$ 730	$ 1,042	$ 1,806
Cost of revenue
Total stock based compensation expense	12	13	42	22
Sales and marketing expense
Total stock based compensation expense	48	13	78	45
General and administrative
Total stock based compensation expense	$ 473	$ 704	$ 922	$ 1,739

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Stock options granted (Details)	9 Months Ended
	Sep. 30, 2020
Fair value of stock option grants
Expected term (years)	6 years 9 months 14 days
Risk-free interest rate	1.59%
Expected volatility	116.76%
Expected dividend yield	0.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Summary of stock option activity under the option Plan
Outstanding at ending balance	708
Exercisable Number of Options	588
Employee Stock Option [Member]
Summary of stock option activity under the option Plan
Outstanding at beginning balance	1,006
Number of Shares, Forfeited	(198)
Number of Shares, Exercised	(100)
Outstanding at ending balance	708	1,006
Exercisable Number of Options	588
Weighted Average Exercise Price, Outstanding at beginning balance	$ 3.04
Weighted Average Exercise Price, Forfeited	7.22
Weighted Average Exercise Price, Exercised	5.31
Weighted Average Exercise Price, Outstanding at ending balance	1.55	$ 3.04
Weighted Average Exercise Price, Exercisable at ending balance	$ 1.04
Weighted Average Remaining Contractual Life, Outstanding	4 years 11 months 19 days	6 years 5 months 19 days
Weighted Average Remaining Contractual Life, Exercisable (Years)	4 years 6 months 7 days
Aggregate Intrinsic Value, Outstanding	$ 6,963	$ 10,483
Aggregate Intrinsic Value, Exercisable	$ 6,088

XML 45 R34.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) - Restricted Stock [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award
Granted but not vested at beginning balance	268
Granted	317
Forfeited	(83)
Vested	(87)
Granted but not vested at ending balance	415

XML 46 R35.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Stock options outstanding	708,000		708,000
Exercisable Number of Options	588,000		588,000
Proceeds from Stock Options Exercised		$ 0.1	$ 0.1	$ 0.6
Unrecognized compensation expense related to stock options	$ 5.9		$ 5.9
Weighted-average period of unrecognized compensation expense related to stock options			2 years 10 months 24 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Restricted stock were granted			317,000
2017 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					5,000,000
Number of Shares, Granted	0	0	0	14,000
Stock options outstanding	388,000		388,000
Exercisable Number of Options	268,000		268,000
2017 Stock Option Plan \| Management [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Restricted stock were granted	200,000	100,000	300,000	300,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Warrants (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Outstanding at ending balance	708
Warrant
Outstanding at beginning balance	100
Number of Warrants, Granted	0
Number of Shares, Exercised	(10)
Number of Warrants, Forfeited	0
Outstanding at ending balance	90	100
Weighted Average Exercise Price, Outstanding at beginning balance \| $ / shares	$ 2.63
Weighted Average Exercise Price, Granted \| $ / shares	0
Weighted Average Exercise Price, Exercised \| $ / shares	2.50
Weighted Average Exercise Price, Forfeited \| $ / shares	0
Weighted Average Exercise Price, Outstanding at ending balance \| $ / shares	$ 2.64	$ 2.63
Weighted Average Remaining Contractual Life (Years)	3 years 7 days	3 years 9 months 3 days
Weighted Average Remaining Contractual Life, Exercised (Years)	3 years 7 days
Aggregate Intrinsic Value \| $	$ 788	$ 1,084
Aggregate Intrinsic Value, Exercised \| $	$ 192
Employee Stock Option [Member]
Outstanding at beginning balance	1,006
Number of Shares, Exercised	(100)
Number of Warrants, Forfeited	(198)
Outstanding at ending balance	708	1,006
Weighted Average Exercise Price, Outstanding at beginning balance \| $ / shares	$ 3.04
Weighted Average Exercise Price, Exercised \| $ / shares	5.31
Weighted Average Exercise Price, Forfeited \| $ / shares	7.22
Weighted Average Exercise Price, Outstanding at ending balance \| $ / shares	$ 1.55	$ 3.04
Weighted Average Remaining Contractual Life (Years)	4 years 11 months 19 days	6 years 5 months 19 days
Weighted Average Remaining Contractual Life, Exercised (Years)	4 years 6 months 7 days
Aggregate Intrinsic Value \| $	$ 6,963	$ 10,483

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Mar. 08, 2021
Subsidiary, Sale of Stock
Stock Repurchased During Period, Value	$ 547	$ 2,045	$ 75
Common Stock [Member]
Subsidiary, Sale of Stock
Stock Repurchase Program, Authorized Amount					$ 10,000
Stock Repurchased During Period, Shares	35,000	135,179	5,000	175,179
Treasury Stock Acquired, Average Cost Per Share				$ 15.22
Stock Repurchased During Period, Value				$ 2,700

XML 49 R38.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Taxes
Income Tax Credits and Adjustments	$ 300		$ 800
Effective Income Tax Rate Reconciliation, Percent			23.00%
Income tax benefit	$ (1,921)	$ (71)	$ (2,499)	$ (651)
Income taxes paid			$ 1,000	$ 700
Estimated Rate One [Member]
Income Taxes
Effective Income Tax Rate Reconciliation, Percent			25.00%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 50 R39.htm IDEA: XBRL DOCUMENT

LEASES (Details) $ in Thousands	Sep. 30, 2021 USD ($)
Operating lease liabilities
October 1, 2021 through December 31, 2021	$ 599
2022	3,569
2023	2,982
2024	3,496
2025	3,567
2026 and thereafter	7,576
Total undiscounted future minimum lease payments	21,789
Less: Difference between undiscounted lease payments and discounted lease liabilities:	(2,672)
Total lease liabilities	19,117
Finance lease liabilities
October 1, 2021 through December 31, 2021	38
2022	154
2023	143
2024	80
2025	76
2026 and thereafter	15
Total undiscounted future minimum lease payments	506
Less: Difference between undiscounted lease payments and discounted lease liabilities:	(44)
Total lease liabilities	$ 462

XML 51 R40.htm IDEA: XBRL DOCUMENT

LEASES - Components of lease expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating lease cost
Total operating lease expense	$ 1,072	$ 419	$ 2,415	$ 1,181
Finance lease cost:
Total amortization of leased assets	29	16	78	44
Interest on lease liabilities	11	5	31	14
Total net lease cost	$ 1,112	$ 440	$ 2,524	$ 1,239

XML 52 R41.htm IDEA: XBRL DOCUMENT

LEASES - Additional information (Details) $ in Thousands		34 Months Ended
LEASES - Additional information (Details) $ in Thousands	Apr. 09, 2021 USD ($) ft² $ / ft²	Jan. 31, 2024 $ / ft²	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lessee, Lease, Description
Additional rent per square foot \| $ / ft²	0.50
Operating lease liabilities \| $			$ 19,117
Operating lease asset \| $			$ 17,234	$ 5,993
Weighted average borrowing rate for operating lease liabilities			4.12%
Weighted average rate for finance lease liability			9.37%
Operating Leases, Five
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²	110,754
Rent per square foot \| $ / ft²		26.50
Additional rent per square foot \| $ / ft²	0.50
Operating lease asset \| $	$ 13,400
Operating Lease, Weighted Average Remaining Lease Term			6 years 6 months

XML 53 R42.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS (Details) - item	3 Months Ended		9 Months Ended		12 Months Ended
CONCENTRATIONS (Details) - item	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Supplier Concentration Risk [Member] \| Cost of Goods, Total [Member]
Concentration Risk
Concentration Risk, Percentage	51.00%	64.00%	36.00%	31.00%
Number of significant vendors	3	5	2	1
Accounts Receivable [Member]
Concentration Risk
Concentration Risk, Percentage			37.00%		26.00%
Number of third-party payers			2		1

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 152 297 1 false 30 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 10101 - Disclosure - BASIS OF PRESENTATION Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 10201 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.zynexmed.com/role/DisclosurePropertyAndEquipment PROPERTY AND EQUIPMENT Notes 8 false false R9.htm 10301 - Disclosure - EARNINGS PER SHARE Sheet http://www.zynexmed.com/role/DisclosureEarningsPerShare EARNINGS PER SHARE Notes 9 false false R10.htm 10401 - Disclosure - STOCK-BASED COMPENSATION PLANS Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlans STOCK-BASED COMPENSATION PLANS Notes 10 false false R11.htm 10501 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.zynexmed.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 11 false false R12.htm 10601 - Disclosure - INCOME TAXES Sheet http://www.zynexmed.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 12 false false R13.htm 10701 - Disclosure - LEASES Sheet http://www.zynexmed.com/role/DisclosureLeases LEASES Notes 13 false false R14.htm 10801 - Disclosure - CONCENTRATIONS Sheet http://www.zynexmed.com/role/DisclosureConcentrations CONCENTRATIONS Notes 14 false false R15.htm 10901 - Disclosure - LITIGATION Sheet http://www.zynexmed.com/role/DisclosureLitigation LITIGATION Notes 15 false false R16.htm 20102 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 16 false false R17.htm 30103 - Disclosure - BASIS OF PRESENTATION (Tables) Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentationTables BASIS OF PRESENTATION (Tables) Tables http://www.zynexmed.com/role/DisclosureBasisOfPresentation 17 false false R18.htm 30203 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.zynexmed.com/role/DisclosurePropertyAndEquipment 18 false false R19.htm 30303 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.zynexmed.com/role/DisclosureEarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.zynexmed.com/role/DisclosureEarningsPerShare 19 false false R20.htm 30403 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables STOCK-BASED COMPENSATION PLANS (Tables) Tables http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlans 20 false false R21.htm 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.zynexmed.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.zynexmed.com/role/DisclosureStockholdersEquity 21 false false R22.htm 30703 - Disclosure - LEASES (Tables) Sheet http://www.zynexmed.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.zynexmed.com/role/DisclosureLeases 22 false false R23.htm 40101 - Disclosure - BASIS OF PRESENTATION - Breakdown of net revenue (Details) Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails BASIS OF PRESENTATION - Breakdown of net revenue (Details) Details 23 false false R24.htm 40102 - Disclosure - BASIS OF PRESENTATION - Inventory (Details) Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails BASIS OF PRESENTATION - Inventory (Details) Details 24 false false R25.htm 40103 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details) Sheet http://www.zynexmed.com/role/DisclosureBasisOfPresentationAdditionalInformationDetails BASIS OF PRESENTATION - Additional Information (Details) Details 25 false false R26.htm 40201 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentTables 26 false false R27.htm 40202 - Disclosure - PROPERTY AND EQUIPMENT - Additional information (Details) Sheet http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails PROPERTY AND EQUIPMENT - Additional information (Details) Details 27 false false R28.htm 40301 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://www.zynexmed.com/role/DisclosureEarningsPerShareTables 28 false false R29.htm 40302 - Disclosure - EARNINGS PER SHARE - Additional information (Details) Sheet http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails EARNINGS PER SHARE - Additional information (Details) Details 29 false false R30.htm 40401 - Disclosure - STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) Details 30 false false R31.htm 40402 - Disclosure - STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) Details 31 false false R32.htm 40403 - Disclosure - STOCK-BASED COMPENSATION PLANS - Stock options granted (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails STOCK-BASED COMPENSATION PLANS - Stock options granted (Details) Details 32 false false R33.htm 40404 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) Details 33 false false R34.htm 40405 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) Details 34 false false R35.htm 40406 - Disclosure - STOCK-BASED COMPENSATION PLANS - Additional information (Details) Sheet http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails STOCK-BASED COMPENSATION PLANS - Additional information (Details) Details 35 false false R36.htm 40501 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) Sheet http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails STOCKHOLDERS' EQUITY - Warrants (Details) Details 36 false false R37.htm 40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) Sheet http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails STOCKHOLDERS' EQUITY - Additional Information (Details) Details 37 false false R38.htm 40601 - Disclosure - INCOME TAXES - Additional information (Details) Sheet http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails INCOME TAXES - Additional information (Details) Details 38 false false R39.htm 40701 - Disclosure - LEASES (Details) Sheet http://www.zynexmed.com/role/DisclosureLeasesDetails LEASES (Details) Details http://www.zynexmed.com/role/DisclosureLeasesTables 39 false false R40.htm 40702 - Disclosure - LEASES - Components of lease expenses (Details) Sheet http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails LEASES - Components of lease expenses (Details) Details 40 false false R41.htm 40703 - Disclosure - LEASES - Additional information (Details) Sheet http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails LEASES - Additional information (Details) Details 41 false false R42.htm 40801 - Disclosure - CONCENTRATIONS (Details) Sheet http://www.zynexmed.com/role/DisclosureConcentrationsDetails CONCENTRATIONS (Details) Details http://www.zynexmed.com/role/DisclosureConcentrations 42 false false All Reports Book All Reports zyxi-20210930x10q.htm zyxi-20210930.xsd zyxi-20210930_cal.xml zyxi-20210930_def.xml zyxi-20210930_lab.xml zyxi-20210930_pre.xml zyxi-20210930xex31d1.htm zyxi-20210930xex31d2.htm zyxi-20210930xex32d1.htm zyxi-20210930xex32d2.htm http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zyxi-20210930x10q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 152, "dts": { "calculationLink": { "local": [ "zyxi-20210930_cal.xml" ] }, "definitionLink": { "local": [ "zyxi-20210930_def.xml" ] }, "inline": { "local": [ "zyxi-20210930x10q.htm" ] }, "labelLink": { "local": [ "zyxi-20210930_lab.xml" ] }, "presentationLink": { "local": [ "zyxi-20210930_pre.xml" ] }, "schema": { "local": [ "zyxi-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 345, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 4, "http://xbrl.sec.gov/dei/2021": 7, "total": 11 }, "keyCustom": 23, "keyStandard": 274, "memberCustom": 9, "memberStandard": 21, "nsprefix": "zyxi", "nsuri": "http://www.zynexmed.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - STOCK-BASED COMPENSATION PLANS", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlans", "shortName": "STOCK-BASED COMPENSATION PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.zynexmed.com/role/DisclosureStockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - INCOME TAXES", "role": "http://www.zynexmed.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - LEASES", "role": "http://www.zynexmed.com/role/DisclosureLeases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - CONCENTRATIONS", "role": "http://www.zynexmed.com/role/DisclosureConcentrations", "shortName": "CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - LITIGATION", "role": "http://www.zynexmed.com/role/DisclosureLitigation", "shortName": "LITIGATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - BASIS OF PRESENTATION (Policies)", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30103 - Disclosure - BASIS OF PRESENTATION (Tables)", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentationTables", "shortName": "BASIS OF PRESENTATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - EARNINGS PER SHARE (Tables)", "role": "http://www.zynexmed.com/role/DisclosureEarningsPerShareTables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables", "shortName": "STOCK-BASED COMPENSATION PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.zynexmed.com/role/DisclosureStockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - LEASES (Tables)", "role": "http://www.zynexmed.com/role/DisclosureLeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - BASIS OF PRESENTATION - Breakdown of net revenue (Details)", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails", "shortName": "BASIS OF PRESENTATION - Breakdown of net revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_zyxi_DevicesMember_frOqa447TkyR-3bdf1xlCQ", "decimals": "-3", "lang": null, "name": "zyxi:RevenueFromDevicesRelatingToPurchased", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InventoryDisclosureTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - BASIS OF PRESENTATION - Inventory (Details)", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails", "shortName": "BASIS OF PRESENTATION - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InventoryDisclosureTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_R_5l_8X1ZE2ChiaOG8PWUQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40103 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details)", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentationAdditionalInformationDetails", "shortName": "BASIS OF PRESENTATION - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_R_5l_8X1ZE2ChiaOG8PWUQ", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - PROPERTY AND EQUIPMENT - Additional information (Details)", "role": "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "PROPERTY AND EQUIPMENT - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember_2uNyYSdsI0yNNpG9FILLMQ", "decimals": "-5", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - EARNINGS PER SHARE (Details)", "role": "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "shortName": "EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XVneKPffvE6Lo9jQWU7AtA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - EARNINGS PER SHARE - Additional information (Details)", "role": "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "shortName": "EARNINGS PER SHARE - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XVneKPffvE6Lo9jQWU7AtA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_wOL5wB_takm7zvZOLSAG7g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_wOL5wB_takm7zvZOLSAG7g", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_us-gaap_PlanNameAxis_zyxi_TwoThousandAndFiveStockOptionPlanMember_QmbYa_b-TEuelmBKDtClgg", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_gFkhWxZOCk2VbMsrGkBs0Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - STOCK-BASED COMPENSATION PLANS - Stock options granted (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - Stock options granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_gFkhWxZOCk2VbMsrGkBs0Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_jWD6bJd6c0qiITddSMfgCQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_5SPSsqcj1EKkx9PJr4aQvg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_5SPSsqcj1EKkx9PJr4aQvg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40406 - Disclosure - STOCK-BASED COMPENSATION PLANS - Additional information (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "shortName": "STOCK-BASED COMPENSATION PLANS - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_rZ3OFxe-202rij8wpLkONA", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "zyxi:ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails", "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_epQF39ouYkikRtkfnTCloQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZiHz2xXNOEuX36mW8ShSLA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)", "role": "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_3_8_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K7tE5SPoNkCU4MQzH87V6Q", "decimals": "-5", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxCreditsAndAdjustments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - INCOME TAXES - Additional information (Details)", "role": "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "INCOME TAXES - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxCreditsAndAdjustments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - LEASES (Details)", "role": "http://www.zynexmed.com/role/DisclosureLeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_S3h-B0WcW0eMZNrth6Z75A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - LEASES - Components of lease expenses (Details)", "role": "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "shortName": "LEASES - Components of lease expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_3DjwZHhNREyYr4VrhZJJ7g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "zyxi:AdditionalRentPerSquareFoot", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_4_9_2021_To_4_9_2021_T8pc4dfkG0KMQcRnD5fR-A", "decimals": "2", "first": true, "lang": null, "name": "zyxi:AdditionalRentPerSquareFoot", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_sqft_3AFFgnPMF02bzcXbzGyHcg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - LEASES - Additional information (Details)", "role": "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "LEASES - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "zyxi:AdditionalRentPerSquareFoot", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_4_9_2021_To_4_9_2021_T8pc4dfkG0KMQcRnD5fR-A", "decimals": "2", "first": true, "lang": null, "name": "zyxi:AdditionalRentPerSquareFoot", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_sqft_3AFFgnPMF02bzcXbzGyHcg", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_EKqt-Ln3dkGJBDaDnC999A", "decimals": "2", "first": true, "lang": null, "name": "zyxi:ConcentrationRiskThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_RgaYwXiLl0CNSfhXHe-Dlw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - CONCENTRATIONS (Details)", "role": "http://www.zynexmed.com/role/DisclosureConcentrationsDetails", "shortName": "CONCENTRATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_EKqt-Ln3dkGJBDaDnC999A", "decimals": "2", "first": true, "lang": null, "name": "zyxi:ConcentrationRiskThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_RgaYwXiLl0CNSfhXHe-Dlw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": "-3", "lang": null, "name": "zyxi:NonCashReserveCharges", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eacQy4LU0E6sm8mhvLGaoA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eacQy4LU0E6sm8mhvLGaoA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mq-Alag2PkW0luYtJM0xrQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - BASIS OF PRESENTATION", "role": "http://www.zynexmed.com/role/DisclosureBasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.zynexmed.com/role/DisclosurePropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - EARNINGS PER SHARE", "role": "http://www.zynexmed.com/role/DisclosureEarningsPerShare", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "zyxi-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_BTfj_8615ECHDH25uY8Jgw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.zynexmed.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ManagementMember": { "auth_ref": [ "r143", "r328" ], "lang": { "en-us": { "role": { "label": "Management [Member]" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r140", "r210", "r211", "r334", "r356", "r357" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r140", "r210", "r211", "r334", "r356", "r357" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r85", "r90", "r213" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r85", "r90", "r169", "r213", "r332" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r143", "r328" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r14", "r144", "r145" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r11", "r337", "r347" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r160" ], "calculation": { "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r77", "r78", "r79", "r244", "r245", "r246", "r293" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash (used in)/provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r215", "r240", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "totalLabel": "Total stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r73", "r123", "r132", "r138", "r153", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r279", "r284", "r304", "r329", "r331", "r336", "r346" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r40", "r73", "r153", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r279", "r284", "r304", "r329", "r331" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r216", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r23", "r331", "r364", "r365" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r61", "r305" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net (decrease)/ increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r168", "r339", "r351" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LITIGATION" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r170", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "LITIGATION" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r77", "r78", "r293" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r196" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r331" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 36,436,593 issued and 34,774,723 outstanding as of September 30, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r112", "r113", "r142", "r301", "r302", "r366" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r112", "r113", "r142", "r301", "r302", "r363", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r112", "r113", "r142", "r301", "r302", "r363", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CONCENTRATIONS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r110", "r112", "r113", "r114", "r301", "r303", "r366" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r112", "r113", "r142", "r301", "r302", "r366" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r69", "r281" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r53", "r334" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "verboseLabel": "Costs of revenue - devices and supplies" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r52" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs of revenue and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r253", "r254" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r66", "r74", "r262", "r268", "r269", "r270" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Provision for deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r66", "r158" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r50", "r82", "r83", "r84", "r85", "r86", "r91", "r93", "r95", "r96", "r97", "r101", "r102", "r294", "r295", "r342", "r353" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r50", "r82", "r83", "r84", "r85", "r86", "r93", "r95", "r96", "r97", "r101", "r102", "r294", "r295", "r342", "r353" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "presentationGuidance": "Diluted earnings per share", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r98", "r99", "r100", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Accrued payroll and related taxes" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted-average period of unrecognized compensation expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Unrecognized compensation expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Assembly equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r77", "r78", "r79", "r81", "r87", "r89", "r105", "r154", "r196", "r197", "r244", "r245", "r246", "r264", "r265", "r293", "r306", "r307", "r308", "r309", "r310", "r311", "r358", "r359", "r360", "r377" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r314", "r319", "r326" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "verboseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r313", "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liability" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments under the Company's financing leases and operating lease" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liability" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "October 1, 2021 through December 31, 2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Difference between undiscounted lease payments and discounted lease liabilities:" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r315", "r321" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r312" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset", "verboseLabel": "Finance lease asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r314", "r319", "r326" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Total amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average rate for finance lease liability" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Office furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r48", "r123", "r131", "r134", "r137", "r139", "r335", "r340", "r344", "r354" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income from operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r162", "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxCreditsAndAdjustments": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.", "label": "Income Tax Credits and Adjustments", "terseLabel": "Income Tax Credits and Adjustments" } } }, "localname": "IncomeTaxCreditsAndAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r75", "r257", "r258", "r261", "r266", "r271", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r88", "r89", "r122", "r255", "r267", "r272", "r355" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r43", "r251", "r252", "r258", "r259", "r260", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r63", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "verboseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r343" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "verboseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r62", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Net", "negatedLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Schedule of components of inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r34" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r37" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r39" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Less: reserve" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r37", "r331" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, net", "verboseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails", "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Components of inventory" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r38", "r70", "r104", "r155", "r156", "r157", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r36" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw Materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r35" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land Subject to Ground Leases", "terseLabel": "Land Subject to Ground Leases" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r324", "r326" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "verboseLabel": "Lessee, Lease, Description" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "October 1, 2021 through December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r325" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Difference between undiscounted lease payments and discounted lease liabilities:" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term.", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r73", "r133", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r280", "r284", "r285", "r304", "r329", "r330" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r73", "r153", "r304", "r331", "r338", "r349" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30", "r73", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r280", "r284", "r285", "r304", "r329", "r330", "r331" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Other than Long-term Debt, Noncurrent [Abstract]", "verboseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r61" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in)/provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r61" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r61", "r64", "r67" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in)/ provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r41", "r42", "r46", "r49", "r67", "r73", "r80", "r82", "r83", "r84", "r85", "r88", "r89", "r94", "r123", "r131", "r134", "r137", "r139", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r295", "r304", "r341", "r352" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Net income available to common stockholders", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income available to common stockholders", "totalLabel": "Net Income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r77", "r78", "r79", "r197", "r276" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Non-Controlling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "verboseLabel": "Schedule of restricted stock award activity under all equity compensation plans" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "COSTS OF REVENUE AND OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r131", "r134", "r137", "r139" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r320", "r326" ], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Total operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r312" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease asset", "verboseLabel": "Operating lease asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average borrowing rate for operating lease liabilities" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r182", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r58" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes withheld and paid on employees' equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r56" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r216", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r183" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r183" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r331" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r21", "r22" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r57" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock under equity offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r57", "r243" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "verboseLabel": "Proceeds from the issuance of common stock on stock-based awards" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r57", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "verboseLabel": "Device revenue" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r41", "r42", "r46", "r60", "r73", "r80", "r88", "r89", "r123", "r131", "r134", "r137", "r139", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r278", "r282", "r283", "r287", "r288", "r295", "r304", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r163", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r24", "r159" ], "calculation": { "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r161", "r331", "r345", "r350" ], "calculation": { "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of components of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r159" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventorySuppliesMember": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Materials used as supplies by the entity.", "label": "Supplies [Member]" } } }, "localname": "PublicUtilitiesInventorySuppliesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r197", "r247", "r331", "r348", "r361", "r362" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r77", "r78", "r79", "r81", "r87", "r89", "r154", "r244", "r245", "r246", "r264", "r265", "r293", "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r71", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r47", "r73", "r120", "r121", "r130", "r135", "r136", "r140", "r141", "r142", "r153", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r304", "r344" ], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total Device revenue", "verboseLabel": "Total net revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "NET REVENUE" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r322", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r322", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATIONS" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "verboseLabel": "Schedule of share based compensation expenses recorded in the consolidated statement of income" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Calculation of Basic and Diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r215", "r239", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r25", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r216", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r221", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity under the option plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary of fair value of stock options grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r200", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of stock warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "verboseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Sales and marketing expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "presentationGuidance": "Restricted stock were granted", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Granted but not vested at ending balance", "periodStartLabel": "Granted but not vested at beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "verboseLabel": "Fair value of stock option grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Exercisable at ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited", "negatedTerseLabel": "Number of Warrants, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "presentationGuidance": "Number of Shares, Granted", "verboseLabel": "Number of Warrants, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "presentationGuidance": "Aggregate Intrinsic Value, Outstanding", "verboseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r223", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at ending balance", "periodStartLabel": "Outstanding at beginning balance", "terseLabel": "Outstanding Number of Options (in shares)", "verboseLabel": "Stock options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]", "terseLabel": "Summary of stock option activity under the option Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r214", "r218" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfRestrictedStockAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited", "verboseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r216", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "verboseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r234", "r248" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "presentationGuidance": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "netLabel": "Weighted Average Remaining Contractual Life, Exercised (Years)", "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable (Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "presentationGuidance": "Weighted Average Remaining Contractual Life, Outstanding", "verboseLabel": "Weighted Average Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Shares of common stock withheld to pay taxes on employees' equity awards (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r44", "r45", "r46", "r77", "r78", "r79", "r81", "r87", "r89", "r105", "r154", "r196", "r197", "r244", "r245", "r246", "r264", "r265", "r293", "r306", "r307", "r308", "r309", "r310", "r311", "r358", "r359", "r360", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r77", "r78", "r79", "r105", "r334" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansStockBasedCompensationExpensesDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r196", "r197", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Number of Shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansSummaryOfStockOptionActivityDetails", "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r12", "r13", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Treasury stock (in shares)", "terseLabel": "Stock Repurchased During Period, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r12", "r13", "r196", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Treasury stock", "terseLabel": "Stock Repurchased During Period, Value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r73", "r151", "r153", "r304", "r331" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r45", "r73", "r77", "r78", "r79", "r81", "r87", "r153", "r154", "r197", "r244", "r245", "r246", "r264", "r265", "r276", "r277", "r286", "r293", "r304", "r306", "r307", "r311", "r359", "r360", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r32", "r198" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r32", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r198", "r199" ], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock 1,246,399 shares, at September 30, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r106", "r107", "r108", "r109", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r97" ], "calculation": { "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "verboseLabel": "Effect of dilutive securities - options and restricted stock" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r92", "r97" ], "calculation": { "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average diluted shares outstanding", "totalLabel": "Diluted weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r91", "r97" ], "calculation": { "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "definitionGuidance": "Weighted-average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Basic weighted-average shares outstanding", "terseLabel": "Weighted average basic shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.zynexmed.com/role/DisclosureEarningsPerShareDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "zyxi_AdditionalRentPerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Additional rent per square foot.", "label": "Additional Rent per Square Foot", "terseLabel": "Additional rent per square foot" } } }, "localname": "AdditionalRentPerSquareFoot", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "zyxi_CapitalExpendituresNotYetPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capital expenditures not yet paid.", "label": "Capital Expenditures Not Yet Paid", "terseLabel": "Capital expenditures not yet paid" } } }, "localname": "CapitalExpendituresNotYetPaid", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_ConcentrationRiskThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Threshold Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskThresholdPercentage", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "percentItemType" }, "zyxi_DevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the devices.", "label": "Devices [Member]" } } }, "localname": "DevicesMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails", "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "zyxi_EquityCompensationPlansNotApprovedByShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for equity compensation plans not approved by shareholders.", "label": "Equity Compensation Plans not approved by Shareholders" } } }, "localname": "EquityCompensationPlansNotApprovedByShareholdersMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "zyxi_EstimatedRateOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information about effective income tax rate estimated", "label": "Estimated Rate One [Member]" } } }, "localname": "EstimatedRateOneMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "zyxi_FinanceLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due After Year Four", "terseLabel": "2026 and thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "zyxi_FinanceLeasesCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Presents finance lease cost abstract.", "label": "Finance Leases Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "FinanceLeasesCostAbstract", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "zyxi_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Definition Available", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "zyxi_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "zyxi_IncreaseDecreaseInNonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Non-cash lease expense.", "label": "Increase Decrease In Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "IncreaseDecreaseInNonCashLeaseExpense", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_InventoryTransferredToPropertyAndEquipmentUnderLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory transferred to property and equipment under lease in in noncash investing or financing activities.", "label": "Inventory Transferred To Property and Equipment Under Lease", "terseLabel": "Inventory transferred to property and equipment under lease" } } }, "localname": "InventoryTransferredToPropertyAndEquipmentUnderLease", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_InventoryTransferredToSalesRepDemos": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory transferred to sales rep demos.", "label": "Inventory Transferred to Sales Rep Demos", "terseLabel": "Inventory transferred to property and equipment as demo devices" } } }, "localname": "InventoryTransferredToSalesRepDemos", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_LeasedDevices1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Leased Devices [Member]" } } }, "localname": "LeasedDevices1Member", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "zyxi_LeasedDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to leased devices.", "label": "Leased devices" } } }, "localname": "LeasedDevicesMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "zyxi_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "zyxi_NonCashReserveCharges": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of non-cash reserve charges.", "label": "Non-Cash Reserve Charges", "terseLabel": "Non-cash recoveries" } } }, "localname": "NonCashReserveCharges", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_NumberOfSignificantVendors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of significant vendors.", "label": "Number of Significant Vendors", "terseLabel": "Number of significant vendors" } } }, "localname": "NumberOfSignificantVendors", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "integerItemType" }, "zyxi_NumberOfThirdPartyPayers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of third party payers.", "label": "Number of Third Party Payers", "terseLabel": "Number of third-party payers" } } }, "localname": "NumberOfThirdPartyPayers", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "integerItemType" }, "zyxi_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Lease, Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "zyxi_OperatingLeaseLiabilityTotal": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/DisclosureLeasesCalc2Details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability Total", "terseLabel": "Operating lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiabilityTotal", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "zyxi_OperatingLeasesFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to operating leases five.", "label": "Operating Leases, Five" } } }, "localname": "OperatingLeasesFiveMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "zyxi_RentPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid for rent.", "label": "Rent Paid", "negatedLabel": "Cash paid for rent" } } }, "localname": "RentPaid", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "zyxi_RentPerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to rent per square foot on sublease.", "label": "Rent per Square Foot", "terseLabel": "Rent per square foot" } } }, "localname": "RentPerSquareFoot", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "zyxi_RevenueFromDevicesRelatingToLeased": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from sale of devices relating to lease during the year.", "label": "Revenue From Devices Relating To Leased", "terseLabel": "Leased" } } }, "localname": "RevenueFromDevicesRelatingToLeased", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails" ], "xbrltype": "monetaryItemType" }, "zyxi_RevenueFromDevicesRelatingToPurchased": { "auth_ref": [], "calculation": { "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from sale of devices relating to purchased during the year.", "label": "Revenue From Devices Relating To Purchased", "terseLabel": "Purchased" } } }, "localname": "RevenueFromDevicesRelatingToPurchased", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureBasisOfPresentationBreakdownOfNetRevenueDetails" ], "xbrltype": "monetaryItemType" }, "zyxi_SalesRepDemoUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Sales Rep demo units.", "label": "Sales rep demo units" } } }, "localname": "SalesRepDemoUnitsMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "zyxi_ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for outstanding and exercisable number of stock options.", "label": "Schedule Of Outstanding And Exercisable Number Of Stock Options [Table Text Block]", "terseLabel": "Schedule of outstanding and exercisable number of options" } } }, "localname": "ScheduleOfOutstandingAndExercisableNumberOfStockOptionsTableTextBlock", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "zyxi_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardsExercisesAndVestedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock-based awards exercised or vested during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Based Awards, Exercises and Vested in Period", "terseLabel": "Exercised and vested stock-based awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardsExercisesAndVestedInPeriod", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "zyxi_SharesWithHeldToPayTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of shares withheld to pay tax withholding for share based compensation.", "label": "Shares With held To Pay Tax Withholding For Share Based Compensation", "negatedLabel": "Shares of common stock withheld to pay taxes on employees' equity awards" } } }, "localname": "SharesWithHeldToPayTaxWithholdingForShareBasedCompensation", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "zyxi_StockIncentivePlan2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2017 Stock Option Plan" } } }, "localname": "StockIncentivePlan2017Member", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansAdditionalInformationDetails", "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "zyxi_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Stock Warrants Exercised.", "label": "Stock Issued During Period, Shares, Stock Warrants Exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "zyxi_StockIssuedDuringPeriodValueStockBasedAwardsExercisedAndVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise and vest of stock-based awards.", "label": "Stock Issued During Period, Value, Stock Based Awards Exercised and Vested", "terseLabel": "Exercised and vested stock-based awards" } } }, "localname": "StockIssuedDuringPeriodValueStockBasedAwardsExercisedAndVested", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "zyxi_StockIssuedForPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "stock issued during public offering .", "label": "Stock issued for public offering", "negatedLabel": "Stock issued for public offering" } } }, "localname": "StockIssuedForPublicOffering", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "zyxi_StockIssuedForPublicOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued for public offering shares .", "label": "Stock issued for public offering [shares ]", "negatedLabel": "Stock issued for public offering ( shares)" } } }, "localname": "StockIssuedForPublicOfferingShares", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "zyxi_TwoThousandAndFiveStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2005 Stock Option Plan" } } }, "localname": "TwoThousandAndFiveStockOptionPlanMember", "nsuri": "http://www.zynexmed.com/20210930", "presentation": [ "http://www.zynexmed.com/role/DisclosureStockBasedCompensationPlansOutstandingAndExercisableNumberOfStockOptionsDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r371": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r373": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r374": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r375": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r376": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" } }, "version": "2.1" } ZIP 61 0001104659-21-133085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-133085-xbrl.zip M4$L#!!0 ( ,2%8E,EL@D_VPP %-^ 1 >GEX:2TR,#(Q,#DS,"YX M-#S1M(1-2./77_[YCP__:C:_W$X>D,-L;XVI1#;'EL0.>B9RA69L ML[$H>L2<$]=%MYPX2XS0U=G[LY^NSG\^ZURTKZY0LQE(NK4$<#**M,C.63MJ MZ052&;U&[7:KT^J<=]KHXOK=^^OS2S1^C @?0R:P?;9D3RUHT"(: 2&8+U\V6$34"TO,SQA?ML(63=X\ M;SLK2L3::# MJ(:,T:86L46V0KHIKDX6U*!'N_7E\6&J7;J!I,676 ZM-18;R\8)EC]?*-ZN ML7-FL[66>WYUH2:XB]7\O6=\?8<7EN<"0M\]R]6S*>9 >=X?-668]^?+EI31 M(0"=>NM.EGMTS@%VB:D@C@G(H+FEFK4\I6;, MA8139G CE#ES<]8!W9(Q$!POMJ"E# M+T_R7+VN6M :Z56L5%(ABI=JX39(5SJU K*0RY*2D[DG<<(=/9IRR*T@Q9 U M]Q MK&?,)8YRNEO+57X[76$< EB"SH0:3 R-6B0&?N^-AM/1P^"N.^O?H=ON0W?8 MZZ/IIWY_-JUQ*H53]%",%J--N"L9 ,MA,"/7,2,WG<&/Q_YP-D6C>S0:]R?= MV0 (:@PK8]BSQ.K>9<]E(=S1FQ&\J()@KSO]A.X?1K_7"!IV/L@9"2 PCAE] M"\GB-X<]T]%BB.4$/T&HB.^PM(B;V@6KLIOP?0=K:WM_1[SM3@<:SO&D/P5H M]9Q4S\->$%L@B!@0]SM"/P1=_5BC7@GU 87QDXR_E$ND)^=XHK;)V5?4'=ZA_G\_#\9J]:TQ M*X-9W^*4T*488SY=63QO@G_6F-0WD<>J!YQPA&@J(0D50&'D "D27(09T:FPK8 ML/6&43^BUT_ZVPVF19.GD*L(PU10L8,P$JV"1%<)1SB07@-[3"UE##L1E2LL M"5A5MK"29"JJLER6K[*@'Q*B:T2K9^Q3R>QO*^8ZF L5%\J7DJE[!J,9V7=5 MK+K2=I$8R)265 +XO. M#-IE#FA[$ZV&ZK!*2M=QM"Z6.Z +QM?Z8?FJBI&]J,*2 C:OPK+K!<6ZJ:.B M0\LM54"OS%]4F$F%P#F%F03LI(;]N(I-%<@K\1;5=E)P9]1V:JC?*(X:>5*= MAE"'^=3\W6)N$Z'VR:&WGF,>1,2CC7XCF>,-KRW>[##OTH6G@ABMB6)J(/@! M:7.D"*):$Y52"Z4+8KXRM6<=Z5G9305%E*/E%?E.:K$I]!WM%T$64'/M9.\EI-,L)")"E5*@=Z+4N/OUM<[=G& M*-3(8 ;X,B=%V:](-E$HMP;R," K3^;RW$409V<2:8CKTN3A@ \H/,0S:XLK M+=MEV,255 MP5%TN"*5Z46'*VHH#X>R MQZ@-U@:?+>2@ETUD!NSG] SLC8:]_G 6?,Q0XV/ )_@&._RIZJ]4PJX7FSP99XSVH$J%WZ6X0:F&HO2LN\ M#"V IO1)]!J;\F\SB]Y8%F!2ZL1YC<=!!9@*198"E"J_"JP1JY)<%R?0!?B4 MK(/4J)3*@ U9;@$.!9EL/?Y%:6IV*EHPZKE?R-3C73:7-">1!>-?F#W6.!C\ M'KI=9N8>L1;S^%]E^/]@-OA8YQG5$\ Q<3FO"Z*'\8NC[F?E@FGPV7@=*,5R>-5][WY35@E=/[;+!RJ,Q 7:2! MROJXO :I9*R<#4VBS0Q(_FN:_R,0U#_JS.D$+Y"^M?-:W:=WTQ!DO7'5U77Z MV4I?(:@N5&R&]R;^ >:>;==N2*+D&ZZKU!#NCU#0<2C"XG9*2NI641"B5TH( M%%JA\@W4>C6S8$BKFI5$X12-GX-2SLA#DSG]?C04F* M$M=5L6!(JX)-M17]L=>G\$ HD9[B^LB9M[EI^&()=)NI>B1)1ZQ.(*\="O0M MRVG;4ZK(X +EJHQ'+@:S9S9;,4]85%WM>T^><.QS"/6.[2]%I[0VU7'SS=7B M!KI(#,*5Q,YY^Z>_U$:S"H<:%GO9HY.@T!B?67TQ0)>O;$BZRQSE'7F] J'< M]N9X4#BO8F(AX-,,HI&V,MZ6.:^R+7_;.;4'LA >K *>TF"L1>BJ@_\I6GBR M._CF545*<1>MRFH: LU9>@@.-7D"?ZG"RG6,3:B/&%+$Y&$(<@XS1@CN3A8Q$FL"?[? M)SSXT;V\,UAOQ0)SX($YDE'R_TP=S#4@NZWJ(-Z_:30S\#0M9N+N5EW+"[J*WZ-1!M:[:K)>:]/9E1S*V7O19:F5IGN$B M,GQ _7&*AO$OZ>KO#RK":T!F*\+!#I@Y8 SF44!H:#YFP]D3=@*8@D-SR?7]8.[3W (@=N=JD;O#_L\!'3*J_BN$^#6HL4"_ M%/$)+Y?V"CN>BT>+2G??&2!TK2J]$_AG M1/&>Y^>UGJ9G3RU7A96;.[QF*MS?F\?YS2=JSFZ+OF=\[,U=8H\6$,& SV5L MXUDT)SPM#8K[*789$R/*OW^'S(XSXSXGS"'I/NGI8A=L 1,L,'_"O97Z;PMW MD4!.X^F:XSO1[T2N/F%7Y0;6R\S:JK_5A@Y>!FZ7'>&M^QO3>)SL*IOUA,,"VF]D+RQ6X"HY9UO:8D-U M9*ZM2:(C7E,4V[F#:W\)RS4H/K]$CCT&FE,S)TJ(R)*2!;$!]=\P=1@7C71] M(8OHF(K!818%GIAK4L_:$)@D.OT%Y_1@(1@R^14'I=3=^F*F>^,I9K L/Q;P MSUSY1PY^^1]02P,$% @ Q(5B4W_*W/7A#0 EL4 !4 !Z>7AI+3(P M,C$P.3,P7V-A;"YX;6SE75MSXCH2?M^J_0_>G)?=!X(A 4)JYIPBA,RD*@DL MD)USGJ8<6P3M&(N53!+FUZ]D#+%C2Y8,C(6IFDL"4KN__EI2MV[^],?;S#5> M "80>9]/:J?FB0$\&SG0>_Y\LB 5B]@0GOSQ^]__]ND?E-2B64 M=&416A-Y1B"R?EK;?-,-I2+OTJC5JO5JW:S7C+/+\^:EV3 &]YN"]U3+"_5Z+B4FK1VW0K@;?TJ($7I*@_AVR+3\@ M(%,O@UN"_599%ZNPCRJU>N6L=OI&G+5>";4RP--OH:#\!C:ULV%\PL@%0S Q M GR7_G(./I\0.)N[3&#PV12#R>>3G\LW6&%TSDZGWV\BGE#.?ZB*/(!N!M!IQ3&\VJK$!51E)U+^IN/B3]27\. M<,#H=GKS1.X?0-Y._XC$K=6_AL1V$5E@0+L12(4/,"#T,8%]KFC_ M\<-!KUY_\@#\(7@!W@)< ]^"KC2:+1ZP7W"W'GV:C_!REX"20G<(8H 1]5Q_ MV?&/.!YP!G\RGTV3-H-&.:1L78B*,_=_L/H_[=[75GW+LVKCIWG8=N MSQA][?7&H]5X3_5VD1T3[[) !N&X_1D 0A$$L6XV:F:CW8RH'G&(#HZCL+"]ED]_3/A(/$(+2U3)8C8+I%4@)7A= M?X+1+-V&X0.1BO((.P#3'.+$6!"J$YJSYUGNB?$*X//4#[XIA!L6>G H85_I MPX2\K9/\<)%H2TO'MM&"]HU#8 /X8CVY@(93&2U(4*4<-"HC#.FM:T?O)JJD M #AT1HN4@[Y,1"%=9]K111."N06=,$*A 7;?GP(L,ZQ)U"P'N7F!AIR?:\CY M*IT:T'C1C^94_"8KJJ(/RW(AC3(6;?O:<'+(>PZRC"%3IC]YI#[*L'.8%-:) MPZ^;C59-:RK5P6C;$=] CV5O"DP*:AP:CZI0M.U:K\$<$>B3%=0'Y-G",917 M_-#X4\(1DM?0D+P)H&H[MYZ-9F!LO85PN"V07^'P"%1"$E+8U([".V@]01?Z M$! ZLH]\9/^8(I2-(=D5]2%8D*\ER3K#:-MTQIO'J B\#@_S' PW*R8(E8E027V78K MA4U(.PY<*3.P((V NM8<^I;+1ACD!:AXT]*9%4M$EG^ %<*1)5I"@ M-?LB'?G+]7E1:YO2Q!=4UFB68A\05RH1[3F :CME$5URD>195*5$+"O#U':H M#CNES:2^1&>>7CX.^]QL-B6B.A]6 M;1,ESNB3N@+\:<^\0$1WG M^%"NH#W,:P5NJ+NN%I<7M&]Y)^@*3! &D2"B]^9CBSH:=4^\O*5\!+M@:$U* M/57P^=;S 0:$OR5Z;T^,-XF&66^<:S!EENH.\2W5O]8B:A,V]:)C &Y;$I34 MQQ.*(ED0-V282=L9F_ @,L\-UE_KQ[VLY=/V$0@P:4M4%Y%@K]+Z,"AWP3%> MK$S$26'3=Z, 4[\_^8*0$RSS /P";4!&R'4$7*97T(]5*6[2*56 J&WK'(%@ M]* 8[BW\ S#W#BW!VX['K5 :;A4A:IM,?P$>[;%P1AV#(#JMG%YACY\J8QA&BN:&[&YI2.XV^:S7;[<&90Y-!(!=TI=/[R.=+(?6)2 M4Z1G*E.DW<[HJW%SU_]6S!0IP\;^LDUC+Y8+@OL@Z' ,;6H$]@4=H^,?1$H. M &6'+6NR[=C@&JS^I[^["R<(W.RIY3V#(35$;S(!-J\-_&HEB@D3@,\T'V#T M JG77"T?"5L29M*J =Y696D!^KG5EJ0FO61+8V1Z26'S2!Q+K98VM^A]4@3HYR;: M]CZRUM,VKXDNC0\PI%CF[+#.JA%)[!A(U-'/>;:D3KR=0 Z_5+=2?.*SQG"# M\!#,%Y@V# )H^)QYJ"V[XA&X14XCZ+MT04UC ^ $4T>WA"R8TTMY0U:]8W"& M7#;0=HIT[=OAKL@Q&EMOWZ _92>6J'FHRP=7%@JXN)& M:YF-BXO2.UL00XR:-'(=!@C=H$OK!#,^GP67C/BU=V)?X8 MO&^?II+9)%V\,W)LNMG D#?12A&@GT-IFVC)6D_;$31IEN3UO?P5ALRJ^KG2 MED2F+DWD,X.^DSK78(Z!#46A4K3($9"<"5=F)F6+023Y @CV"5LE93AIUP?P M"^C2@>\YT?_S"Y:8-T70:J8ARATPIYTFQXC0-Z.O M5$EKMU(52TSJED8XC- ^B2^\IGU]DVGJ=>W249F,L+CU+LRF6?3E7K\@3LMM MF,PK8PN+W)(@UZ]SX">&PCI'Z1A9^$/^6X? ?WB==9Z.(UGU*+U!T@RA4UQ( M3FKJXR$R%P I3P&(A!VE%^4V3.A7;>VFCA+WK$OM2\VH=02^D<<"Z[DB4SLO M$)V%3RUS! QGXUWSJ;KE?-=[E+=X2W"4&LZ6Y7.S9M:,BO'^%/K+56=T&^Q0 M'@Q[H][#.+C'@7V^?IJ!)H8'? .O'FC\,WSDOPK9R,PYDQS=O?Y>9">3!:$X MMM9U#8(CB,&B*W7$,0HRWH]'-"5KQ1VQS?YHL/7_HWTW67].0'L^RY&#LT&X MYT:9MDW%$C$GQI1S%OV7]HK)5XU+]H1UV9YP\X2"NS[%UU\6_9+.+Y@?@<0+ MZ=.>1*9.?2DG7_]#.<06 KEAQW.GP F.VV>Q%BNL,7M\=@249H,[,&J'UNN] MY0,,+3>X2&$QG[NB.01QM;+1K0)SSZO*NR;^&\(_V+0ZHD-^)MVQPF4C.1O< M82PY;P#=W=[TPX7T+&(C136F-6N@S4*ARRGC]XAR?:0L>II,+4:M)[/UP9#= MM3C^R^@\7!N]?S_>#M@)XX(#TSV\]-D\/VLW6ZV+^GF[66^U"VIN7"U%L:VX M4LQYFZ;9N"CZO>7*5"1;:0[(VAZTC;TY[GV7&?W9!0$OGM.9(>S#GZM]S(K' M<'P)X/[D&KH+=M]&<$:@O_");WELN[=@'E=94B'] M!4?+A'ILZLKF= I*,O1I^5N1E6S]VUM!VT$E%1K/-AWGOPOB"\:0G-*.RW%R MVD/^"/[^!HE@.86H#0VMY-!PU^N,>J."AX/42_77IQ>ON2]6S*ZVDW6BK,=T M)C[ ?P$+WZ %_J"JN@!]&J J.YNUI.WQ:MM'9T'CN(%J]<-V@IV@/8AK3GBH MQO2)>7NM3?WC<0(^7&W/8$K!>D7;^, K.B(/X(#5]OUG6: >:! V?@7N"[A' MGC^5N?](1LQQ>(04:FW?DR9$-P0S"[+;#_J3&QJ'6R[S_CS.D2HH;JB:V6@4 M?:ILY^XACSOSQ$]A;[ &A # >6-<=MHC7WTGZ8_LXS+3H%R"]/-H5?8V:='N M\&N;'LE"S$B35,64PTEVBE[;]$D%G2B-4I9SO$["AZ]M>J4$CYMF*4HY8@_A M@-;-VX9X176?PD55.S''A>]^TYYZU;B*/)[/+EY M!+N&P64/,4#XE(*CS Q>S$LMZ?:?%]XA+!^_:3XC:V"&CHVN0_FYP4%,D@. M(LP;,E7ZDT<"@FN_HB2+'A@]$D"D)^_3QOF M/E57MJ/_/-&G_/Y_4$L#!!0 ( ,2%8E/H5CBA^" &<1 @ 5 >GEX M:2TR,#(Q,#DS,%]D968N>&UL[5U;=]LXDG[?<_8_<#,/,_O@^)*DNY/3/7-D M6T[KK&UI)*5[^JD/34(2.Q2A!DG'[E^_ $E)O.#&>\G62R)+!:"^JL*E"@7@ MQW\]K5WC$1'?P=Y/;\[?GKTQD&=AV_&6/[T)_1/3MQSGS;_^^=__]>/_G)S\ MYW)Z:]C8"M?("PR+(#- MO'-"5;&'&\VIF?<(4(/QLE)4M.EZ=.2V#.B*B_>GN]^N4IJQ=XGX_S\].+TXNSBW'CW MZ?UWG\X^&).['>$=Y7+A*"E=Q_OZB?WS0)LT*%S/_^G-*@@VGTY/OWW[]O;I M@;AO,5G2TF?O3K>$;V+*3T^^DZ'^]FY+>W[ZG[O;F;5":_/$\?S ]*Q]*58- MKQR5P#G:T:6X^G,8_4E+?^>1'3=UBRPPB72DA&$(*]M?)ENR$ M?75R?G'R[OSMDV]O^2H@4,B)_NI(Z'<2HBHQC!\)=M$4+8Q(%)^"YPWZZ8WO MK#>EHC^ZV%UZ>,X+14E:>M Y@%V/JZPJY->^7P MS] )GAL#PJNZ-J!KQ[=<[(<$T4[MT%8F!/FTO4ABE[0W?[7Q-V^\N$?!%#TB M+T37*# =5UL_-1IH$-R$8&H&P?/ LYGH-DRDE8%(*VN9Z8%M.TQRICOR%IBL M(S$VBD3>0H/PAB;QZ$SE3Q"9K4R"FH56KO8&847=-)HAK_!Z@SP_:FGBFIX_ M#@,VD++YF4G\"1'+\F^0YHX*!%3B/=)QO!;Q.>QU#GR(_((X5S7N4>O#-)'8G,M!JN!MA M-#L*5FZH:;"9=, Z=.AN$0-?^%EV#)0Y+9:X%U22,1KR8Q-HRG'S,-X#\M?D6A72) MR/Z+_,Y3NG1?G";TI]\<:K$G'NUY^!LB;Y3 >?ZE2\BN/M;@2?('%=#Y#R?G MYR<7D6/[MWQ;:2A;'.7['5T*L9'>LZ]"/\#KP9/C7^.UZ5#=+LS0#?PR@X1V M95D)\9#H2-+?!AP6IO\0R3+T3Y:FN8DB*:>(-LB^857Z$=,G9^=)F.!O"-GK MHE45*HJU0FE/AT\!G3PN$Z<:AO'3\H954[K3M><&H[ZYWF3=>M9CZI M0 L+A7R(T$6U-< 5_3 MS&;K;8#3%66*6.$#.MD)HD%^N;6GN:9&XGA.W.F\KTDCC+&ZG3<- 3$Z&]F[ M;YV -; O;J3*&_'89MQ%,O;+LMO@V"QE_N/'CV=GQHFQKYG^L:W_[8*!K^MO8'V-QVYIK/B W M"O++Z7\_SPE$J\1I;\#3W%QGQK 6V6#+HU)FA8@GL47W2X-J88T/.+29T%?;3FR8MQ"=!RCKH M7WG+H%_]/B'8#JU@3&:(/#H6XO0$$5G!*F2$O:#RZ2B4\.%S35Y**\/'IZYL M^!HBQAKM=V;R8GZ9I2OY;,'8J\\#<5R !7&PQ[:#=.8"7AGU?" JU9\0(J7(@4K2:*A&:BDIG!9YCJ=GO3 ;*4:$3HN0E@]21EW+-=$1-M9@ MHE,71,+TUN^0,MM[+YA9R#.I(Z3J 6DZN?7G*3L&EK3^Q?,WR(I.28@M7T3+ M!RBC;L;R!4+&&@ST8_59AG<6+V.T+XL??_.HX[!R-@)+S_S.-8 "14\ A/:< MHY"#:,AV16+#PN8ZM=0<>UL+Y;#5EUVR[-FD-PDL,T?!52N'IC<80OLLT*B@ M-&2C8@%B29.=VFF!Q:VE9S*V<;'BD0A&(B&N[J%4UA-6\=>ZS MEL22]F1%&"!TQ.TQ-'8N(4B?1;M4;11HE!1:G&99@&)1AHDT2I872\.AHW*J MPZ49[+QS:@%*=TE-(!!ZZ(WID%],-T27SP/?1W'RF*1?"NF%9BXC0L2+<#9;.1Q,)]O08TB;FWOQ)TUN*4CQWO_$=K_2O/3#-70[G M?A4SWL"B5R0BS&VF6_]PS];.,\RR V&BB\\M[J*#VQM;)%.=I(1PU%64 0=? M.F=)RY0508.SAYYB< F6.I\$I!#2TX"2=0A]BVVF.K9CDN>9Z2*-0RTB>NEF MM[!$C\#WS-R;:_IQ3DS/-RUEUU(7%(M"JV@C"0 J'>&R7/62"R! D M0E=C+B5C418Z29&(@P$YHOX1R>,>&2(EJB:C&7QI8EFCW4A& MJ1T(S]::SMIH2KQ@;*FQ^AMX @O![?/>_09?%FMF\=D2QKZB?',FA/&"CF7. MHV.'P@Q6+ATWB":D[!G8KTZPFB(WOHQIY6SF6'*"H4(->L)0UU$KZJA2$Z[, M5J=12@&,;<2R OL0)N+/[&X\%,6'0MFV78%..%MP*8$ E,ZI'$H]D W.:#(Q M8V7SG4]*'';3$Y. S=X.@+.$&$0V)@F>!2$0$1G_6+. L.ODQ$U(K!6=V@=+ M@I)[PK.,29(6-BVV%))-Z=V6P>IIB*<"NYH MK9;:4).LK?K[':V:JM*EK2V [K=6VA"8VB^N+2@((_#N$N4$AS3>S2=6[+_S MR"'AU4@\*)*7P-QXNH%$_H5, SXC/249%!DOYA?P&8;04Z)KNJ\PN_+:"JA; M/D=D+>DK(G*AY<@*P$(M[3'B J60-]AK-#2!=9GIO.>(F4_W'3G3$'I/YKKX MJ>-_59Z[D)006I*B#"#XRKU320E]^ V?I]!3"=9FJ//>) 60N9M6SCC0'G6) M/&NU-HDLXTU5K$S?*A2$)(TM;^5Z6:Y8"6D4"[;1WT2ZDG4Z#FL0>EX.BK3[ M<2" Z(,$V4YP8[)3#E+/J4@HMBPN*12,\M[$(=7$V62ODZ^$R MG?%XA,Q"Z!7)TP;)BW%C,G66*][%)4IZ\>@I*P$,N'S.$)L0^E:44L:R.$GPG#ID).E;DA)"PU*4 M 0=?VK>D9U^)+M=^/Y-K1=#MX/4U+@Q1UQ/WMQ]/<^*]I7_&OU1]LW'_H!SE$KN. M;4;/J"=?TC7L>),\&:GW8N/9V47T8N.N"OKY:GP_&]^.K@?SX;4QF]/_[H;W M\YDQOC'&D^%T,!]1@OUKC7T\T#5G5ZN($J=R1*<-<-KVNWDI+K4ZHW:?X+YU MNK=37M?F"SGWV%R.^US'[5KD]1[U:TWXQ5=\^9)7&8_RH;^:"BB^M,V^^?T: M14UPK]GA$;0EQ0CB[GEAI0C%QL#DR&.\!>LM/;1-P@?7L;X$++#M('_DL1<0 M,'F>A9N-ZPBT4+9PIQJZJ*BALJ @:&]_%XSC(>;@*I^+3!&VI)7H87;-H;[ M=B8Y-C\N]I']TYN A U-RA76U]2$ M0N0/'OPH/4BXNLZ3]=EORNFJR/N&.%$*860$$/K*ED6%]/N=3U0FPY,Y0%DG MWH"W'#ZQ9&VEZ4OH.]7&NSI]0 ("G(*NL!^,%Y\QMM.3X@R[MD!#L@(0.HS2 MXK+Y.6(PX%0U0RZM=$D9O3/)5Y3"*)KK)04@S"BE5"4# TY5GY%'H;F4V8&] MIN+UH_RI1R37E[(4A"&PE-*4B,!ICHT(;"S8HI.,@EFR3G7SOJ&Q+PL!G#)V M>.(#*;?8%U__Q:&$H)*2*X8T^^#4<8\]G&4TL1W%HDZC7*>J^E!'51I@P"EN MQ,Z=(S_(\'N/1/H2DT-8X&E;8?8(G@@2.&4)\97M73 6>974)<$$3E_[(?N& M F9X)GF.1AH*F,6OJ'C="')LK<+^ MV6*+G=K,=W5&XE;% -3,*(JD)US2I?7"D9L(A[I3]7Y?7[T<".!40^<1Y0(U M1].I&GZHM=[),@Y.^$.3>+3G^A-$MG=#.!9U:ZX=-PR0K5B::I?N5&$?ZRA, M&])AJ+*,XF L4$M:I%)W!Z"I!)JFKG;4$-:G#6IKAPNC1#VN9!T08I4U=%L2[:%H/$%>@%%.Y^):((3< MFM>Z&*]:[S^>=II^&5UZM<*NO;LH7C,-\WV9-,S9?'SU?S^/;Z^'T]G?C>&_ MOXSFO[VNA,SJG,9:8;>784_QW+2BS"&D;&I"@3!DYCB3)L +:'O.XRQE:YF5 M#!\.!*U0IM;8BX8U:0HBAPZ$,R SJNQV7(%_".(?V+83,S Q'7OD79D;)S!= MJ2H494"L^G75HL "045S$CT#^ZSN(UQ*$ MU775P$4!0PA0%E&5D;Q>?4CV( MB$&LGG55(0(!01O\J+Y4)_(B$/:GM34CAP)!/\=T]4-(5R_ZDB//0>!,1Y" ,&=(Y+;6(V53F$U82N732#&%RL23>:U'>\J%92=Z7@3\T#<)'% M1*_^V3>8Q.>1QHL%(D49:]!#6%W(9:T!HE>9QS905O+;4A#6$#7EOX72I1:N M0];RA+:/[5],-T31;]$3 -%3=[M[_>V!9_]"1\C"/E0C-<+/BVD$9ON:53UL M*'K74,2]O^-^Y,5@N>KOHEGXR37=R0+<*F5@_Q'Z0;1-,L>"L([@=9']0R+^ M%-&5F^\$*#DL%,.=(@LO8X4+8V(=M7XXF46=B:2;,#,)U(^4B$0U7%VN"G*=6&"&Y@B<$PLZ5<5]-[O:JZW>($H##CCE30A>.($D/SY-T*TR:AW<3+/==2[8M>.S M38(PSG#SQXL)U3UE.)HT+PDRO]KXFS=>W*,@N2'DFFW9N7H7\[T_.S\[-TZ, M?2OTC\O!;!0E@$VFP]GP?AY=Q<>^W[9FX(7AH< @<8/&/Y(F_[>?[#!KA>R0 M/>&>7/PT\A:8K",!21/&U.6.E_J5S!#35<7QGK_C/7_Y=?7QGK]&9^)<]RM, M<,6I65RBO\UX#2"999-Z .I^HU[0(9+IFAUK32PHNN^7+O/F>+)=]_$ZBF9! M"'OFFNHK ZOU,(&,C^C=S])*V9:"L _>E$:VF, Y(3 O_A/X'R6'MS)W +;E MAE"6Z;HP>&:7"OT9.ALV3)9S.2Z*+L=DRN[\GO]F#.ZOHY,F$W8*I6_'XF". MG6QU,G%-+T@K1OGHKU9)0 Z&\@B*%B (XY204<:F]%B*5DD@AU1*6*:6%M,0 M(6CQ)B14N'00HTS>.$_LDSPK7%8 PE&6$F:95I@,%@0][6!(E5.@ K*&KJ*1 M A8(:O@%K1S+5721/!&097,5)>2A0-!!M')GV[&C]8;@Q_A,L50ATA) EM%5 MM"/%U$+H$$X(">WO,Y%N]4H+05A9:>_^2I& ZU4#RPK78?1TW#7:$&0Y M462)?G91)&?/'JS96:2_HN^%^ 2:;:YZ" L[S2S6QC"#LQ8AK^*K@^5%("P( M:_9LS3N#NPRQ[E.G4\'BLG'7"\VXZXFQ;\YP]NWU'9!-[^X)ED2Z"1_2XK Z MXHL+XI94XS&\>PSOMN$*GFOZ@N<'')^5H('02VY,AT2IR)?/ ]]'P95K^K*[ MTB3T/8QO(K>BQO@F 0A*7Q%S_EUT3P^RQ]X462$AR569_A%>,'PP'T_O1_>>9,1E.C=G/@^D0;.S@8)*YCG<('^\0/MXA?+Q#^,#N M$#[NY1["2FS@!8[-'CIP'M&,>1]4UNS%-'9%(;+C)];6U/6(INSQHK"*6.-0 MO#'83-T0UGZ:NX+- .YOD;B_ZBE]%0=;\*;O0(R>#XXN>V#&OWLD)74]3[EU MY/MB_G_TU,3)Y6 VO#:NQG>3X?TL/G4\N1W@/4.&%W'$#B7[ MC"UFU:Z_GQ@ M;)[4&CL9 ^)]*.VB M$%:P?#O9[4)I8VE#!_O5=6:6N\?!8!/E_MI)1TVN;A:KI&I-$)8U"@U5A=;1 MS5V>10=/:C:,J8NS\^\ER=-2>@AI9PI-R % F!0J7R^J= \;J+A'=[(QL?"W M"&HO. [6!QA@0S#\'\:/K&/J'3Z?ZXH#PC0M MXU5Y3E2W,!!/M)R-ZVH4VGV P_7&Q<\HO;4MOW%.3 _!6RUGH)E$83$P"'HZ M;E\>MR\/P^"2#8OXYP+GHYNM:6#'B#[LTRN+.'9IO*US&RZ M0>'ID#H508BA]V%9%40%SW"..46UKO<[O &M4L+1@5EE:CGQ*W*6*R;C1T3, M)=KVQ0EQ+&$0MZO6(=R@?8 6K"W?P[-K8=1!O!IIP\ ;9P/"[>40+;UQ0;\\ MD]\"[-7@2S+1J;E__W+,O:28#\_8]==F/:Q;M%OOU+Q_.!SS;DJ^,.WZ08W\ MH?2*;8J8SNGW5]B+!!^:[AR1]87,QKOFI%-[_PC+WKN6]8NS?7&O%TGAO"7; MK\1)MQL:9R_&^"L)&Z;Q-^.JCRA8Q_,=*[J MOW02[Z];@WY16[-Y44*TUR; MZ;19K!T,R84&NS588#MV+@ L\9Q11Z"JIFY_J).Z37:,)%G< M)F/EF,1]&$G<,0/REWIR-*\D)3N'&LR450GE'HQG:]V,UDY30+*ZN4;?3'!2 MAAZ"">6F#6F:MX#V(-+6:O2$M"$(1 !!D\=D\&,R^&$87'SR8N31KA1&$AH' M*T3F*]-+5N'WV'N,UO[MI 65;_^@\Q_EAMR=$&%Z_*U@_TRK"%K+U"W=_$$G M6?9DOGD9OB+K31)'D-V; 7,X..B,S9YLF"/&5V3& MAB!#L T\2O;^[+O2(5>8#Y3M_*+=T6E$V(N] AN)+TMQV,,B[)W(I>?\14TD MTC:[,LS7"[4VVM;Q'8FJ0=<65'Y\4^(EOREQP#?B5WL]HO,;\7T2I,R9_I4W M9?K5[W,V#8T7(\]V'AT[-%W.*"2A@_AF>4M#D40*8)3WJQ.LILB-M+AW>F9\8K9>[8QR?I<[BK87A;Y10!09C1 M#V/[6Q1BZVHE=MP*/VZ%'[?"CUOA4+?"FQG^5/OBC;?2WR9Y2P+C[Y@W.CF] MOMWSW=.U[%=_$ 8K3)ALF@YPB]N!L!O>A<4V+[F7L_O"W27]3+#?>!:1K"4( M&]N0+5$FNQ=GBZ_EYC[!YO0!V.%KN*GOM5QJ)=AA/@ K?-&76!U3T\I?[@/9 M9@\_3VU"L(60[=]0F9>Y35*C'(2K8LK[-J[%T]^-4FT9"B7H?CA[)R;H?CS^/9Z.)W]W1C^^\MH_AO] M>EM_WYF(!_.F\HZ)6#_,Q+#'EGJ2/6A%&4#9@HQW?Z0(R,Y0STD-[I.SYD_9(S,E[9_J-JLCQN(1Z3*FK?%M"),1U( M7L2K>9]+=.Q>".IZ^7.(ST!4 M.I; G:S[>,BG# <04A,:,LDFQ?+RS/+XQ%2US(6.C//%OPIU?/6OO4R$CFST MA3S4]Z!>UCR47M8GU+*]=K7]902 ME+V*PWC]J 96P5L]*1$,EDN"EE3NG5A@#7ZZM=!>-T!J2 E22FL#-W!^.+O0 MS&]-W;LY@G/O9OC@.[;#7H(BL4SN4+#"]BA.848S,WJK(+K$]+E(O"63YLHV MVL0QT[;Q3-L63."8IWO,TZVM%;GH; SA%FY!8*Y.%$O&2F.O][32#-0Z]0!BG MT"T-(A6MO(WHPH/GN&4YY^2^Z&F46Q!$*EA=97*1@=/CG""3.A[/\>NM%AUZ MR"Y4Q4X:4O8CW@7:U"\.(J.KM$[U\8'3K,PHPLCCWY) M)_LGU,3#'M\5C\V.[J_&=T-C/OC/L/EG/ 07[:= \5Q\ 4UG]U_OO)V9A3R3 MJEYP ;V KG\?7"KD[8W7 N[[NG1\R\47S]\@RUDXM".*KHB7T *X#%YJ/COI MBR&T\;3%T \Y*^]B]:B%"T-Q,K![61 ZMA*Y[ M'U;)]$ZDQ;'D8/W.'90KNF)S G_@V0/[C] /HM08P=I'5:A/+U-+B[I P*U6 MAXL%LMCK-#O.6:]F>^2.%])EVIA.BO$3#Z+ :HD*^O0O2ZFQ#"AP*MWQS';Y M/!]=(H^*.U!UO3QUGXYCM3Z71P!7,\B?F([HJ$Z!JD^WKYHFMISWY]?=(NIJ M-N'2?7_V+N_2W0X'LQ:V&KDS$ M'J:$&,(&J]IV=FZ1! FXN9W?OT5^JG:I_G9>-0%ENX5DC#M8C_;6].Q9^/ ' M]0CF^#/!H6?']BC2J9@>PFYI%;V*$;4>])E2:V"[/7^&)D$W&.?]&!$1A+W, M$J(6P6A=OOLUK):DI>00]AK+REP*J'7I9V>X6\=\<%QV_16[?%8]M^?I(>P/ MEI6_'!&X:3[+[I0=,1DOOOAH0%&+0BR*,A"N,Z@P*2A0@=-<##'']?904/07 M6XE*UVGJPA#N :B\<%/# Z?4+,NY(U\L:,/RN%CLE@[L5KRN5/=0G6H@G*FO MW6EU@()3^8WCF9Z%ZBF\;"40CJ=74'=9F/W%:Z^PQUA(=E7*A6A_*&;=7(WO MKX;W\^E@/AK?SWJ.R&:P31W_JRP8*R+N*9<_Q\QE=#.K)!0K+0$G&BM723;- M7P((PGA8A**ZW%E: D@T5L/RI%J"=G?S+-QL7 >1 J/2,S+*4A "NAH&F#V? MH< $05T#*YH<_2FRD//(Q@:IGL3D$")^)14D!@-!,YR!X1)YUFIMDJ_EYJ5< M,3CO$-2:G'*H8*ILRV.Y::I0#.Y;RX&!HS@_&B\\8)^]A*0YT\HE! MSE$"$\RJB(\'AF)R> INH*HSW4+88U3#D"_R^MI9%$3SBPQ2&DM,C R,3 Y,S!?;&%B M+GAM;.U]_7/<-K+@[U=U_P,N[ZKB5(UB.][-/N?MOE=C2?:J5M;H2>-D M<99':?*7;UY__^H;A)-5&D;)_5^^V>4G0;Z*HF_^ZS__Y__X\_\Z.?G[NYM+ M%*:KW08G!5IE."APB+Y$Q0-:IMMMD*"/.,NB.$;OLBB\QPB]_?['[__T]M6_ M?__#F]=OWZ*3DY+2NR GF&F"&,D?OG]=_^6TI)HF/Z'7KU_^\/*'5S^\1F]^ M^L.//[WZ([K^6 -^)%RN(R-D'"6__43_<4>&1$3<)/_+-P]%L?WIY/E[>H!;X*3*,F+(%GM ML2@9&1Z9@[O/[^ M*0\KOCIL&80G?PV+&D$$_N-+_L=OR!0C].Z62.5]_?IX\O0QPQ'T!_.*$_,&G)?_SC M-"4^;GZ7%UFP*BI*C/^_?"/Y^\N:%PHRSYH,!=FJ(D%^-,A70KQ'T#D2C4O?&3B&@@$71YP M?6<9>]97%OSG]R-V!U=^8PCC\C-U(M3@B,.[].=9D.0174^,JM %!?3S"K8[/K\%!^/_I4QHUH(:WIT^\/CB M!M]'-*9(BJM@(UL7Y&#N]4#';J4#,ABGWU_-0.?;E^'='A918&??_727943S MN+9%R?UM$12[7"F2"AQ*#_3L-_5!#@N@%SI&5/I1XJ :"7$L!XIRBU>[C/!P M_K1Z()QAA8.0@[E7#!V[E4+(8)PJ@IJ!C@)4H*B"=>4@JH%?_W"WC(I8]\WW M('#?N\UF^UM7?P?YSLW!.]^8_0VE:_3ZAQ=WWZ$*R]DJ<)&0(#18%=$C)ON1 MH'0V2@>F H=:!?3L-US=."!O465XL$EBVP$*65,]!@0&0.C.PH M\P<,$S'4&>+(2,!VH$YEK/H^RE=!_"L.,O4AE!H4X!S9P'9]I*R GGE8S<^:PU#*) #C[F,@MHI'G[O+E+94RW_N[^8TH9K#YFXX]./Z9D MY.X! H=!',AIYN=JM[G#F=+'B""0.9\FF]V$#_\[4+9''%R7ZD$AL&)*.&A=,D@0%.+%, ^J/E1*4Y! DU ML5R[H7D8DKG(RW]=1@E^K111"@NE)AK&FRHB 010#R47*M4H(6?5#XCBH$7B MSI.4 Y^2'Q?9,OV2F(03(8'5HLNT5"GV8' JT>;!J! 4@2XO%,6Y,O ES2A3 M!0:M!DUVY3K 80 50&3 _/4YM.L/?YWF11#_GVBK#4_EP,!*(&5=J@H-2#B% MD+!A5 N.@PB2JW"3NJ%YA@.%0C3_#'"V)&&O/D\2_N;V#*DS6#=[XM T,,;JPX?QWD=XS)77YR M'P1;_I%Q7.35;]C7/GGUNKQ=_V_EK__!MJDT2;E8OX^2(%E%1(247Y%17#[N MA^I61X:(176G#YXSG>K/5->/+*YN%Y<79_/E^1EZ-[^<7YV>H]N_GI\O;WU0 MNF5PURE[5P$!*U*#5:G*, @XY1"&[UYQJ(#09P9V^+7V$3X^WD!_;)] Z M0& EZ+ L580:"DX96BSH%()E%!AL1RM&X;<06IF,Q#2@]L[S'!>Y865L \%H MK9Q546.;$,ZU539\]Q25 6DZWL+N[1R+LNR,RLU[(6C1[KQN,*%_.ZK'0K0TF0A1F.%TL"[ M7ZB,S'37JQ(%[7%FB&#-5+=AW>P3#I$D$R1),.0&XB)Y)/RFV3-A7B%H$P1& MYV5LBCHN_MVY3G<'[WSY&H1I[C0*FQ9!K%/8?FQ*U-+5"G(PHP[MYSK#VR * MSY^V.,GQ/ D7Q0/.&@&M0DHK3!AKZR&4:(06:,YMTYJGCHJ5F*A$9;TY&3)J M;:"@S.1PT3!'S9EL*<7V)55@LU'T(C5@3 G I@+L4@ PZY$-HTM*!*T:>WY0 M;Y^2S57Q?$V8+(C%G?]K%VUI"E@=/>E1H/R[68RF8U?# WAT$S,2?\=19H@A M\3;+%=J$$9EI"W& *$P&O)=AJG#-:,6'RJ#_#@YM>T%X"FBGO4L94*[F'76@P8J[800K1I#;ASBS;RTM&@$L.Q-5N8 MPW!1_#"%,[REE5HYC[VOB-II]UMJLTPQX# M9@T;R#^HEJ\Q83&D=R W>!D\E:PK_;T. 4K332(T=5T%#:#M>E8D^L(1V+W# M6N?I\0Z\X@\5)6(8J B>,*0=<'ZUZ1?8))HZ>P:4-M/FRR#39-K\&'A>[#(* M[J(X*B*W089>TKGJC.MKC.%;X?8]UK(WOT M.H]3/'M03':H7!?S=Q>7%\N+\ULTOSI#M\O%Z=_^NK@\.[^Y_1:=__>GB^6O M?EB:756E#@'(\(67A9E=%&OD)<"-G8*I "U/WS MS39.GS&^P7%0]-BT6.#!V(*U0*)-&)&2<81W6U +&QEJ%"5 MX1-S(4/%;-]1R0=]K&%M,?Z8B)U->& $U@KB;I=M.B"Q9KE93"PDL_S095:^ MOWP(DLLTN5_B;'.&[XK]&:A]GM>:$+@M]!1982N65"!MJ1>+>EOC=U *0@M1 M8B=DP[!!E)QX8.Y7EOE Z6LI/Q"H;J533%6ST^F8(P!T M21V??4FSTOT@WY;%FC-4#X3*D9 X%"I2U!P,5:-YD%\ F#;,AH%,/5QGY14# MQMC/0;Q3]:N60H*UDU$QW6H?TP:#:!OT3;(T"/%^P_T^M7LU2OV?Y3SY^.#7?&09M'O./P/ ME*35;R,F,&\ALW]?'@4Y;45X2U0#TS<%T)M7,T25F@&>X57YV]?LMZ^ @UOZ MN)[!GKI@<&&LC-UV["K"@ 2L70:DT1U9O7WS6D+))^.;AR%[ M-R*(KX,HO$A.@VU$]KW"5U#5@%@@ E4&68O4*!$R8KFO%;)DJ5L[4",BBHFB M!)6X]*6POZWG-T$W],2G*5)R?NSSI8R]'KVPQ]^G+UY^[9_4G O_#?H4KNFO+#)&_;/&JB!YQ_,S(K=(9#1 MAMGY?+7:;7:LLND,KZ-5I$K'V"#"6)2]2**%F;&<6YPM2QTUKA!1A8E>"+BH M1/X.*JH\7"Y<8GJ5\[3.S/B3>[3+'WJ0 ^R1Q^LD[:X#N&H\:TGX 5A89 M>QDM9&'G-@F8?IQL]@S+K##!SS_[!&06:)"GI#U#L>;!J:]QF""?91"FQ0#7-YOP2P,. MJ5^6@5=3KWR*NCJR:$,N);0G.J0.MA2@\+JC#;-D>J.JY(!4&G.$I4?Q1'T, ML94.'EZ1S%&57)O\B*D:!ZN<-9LCV K2@Q/W)M/*(W<.!GOF+O)@/'3GP*!/ MJ=(V,RP*VYCOZRNAH1Y8U3+??&M5"@KP[*J&CZY365S=+BXOSN;+<]K4E_SK MX_G5\A8MWJ/%]?G-?'E! ,;3GCPK!,TA_]76&O(K^G96N%L5)/+'V6.TPO.G MJ.U-U&!N]<3$+E40%8PSS= S('N'C(*R0Y42&GVF\)T[#6[T@)T-<3[RLW03 M1(E:/ADLF$:H&6^I11<00C=47-@I",<8I"*_/S]%[/N_>OOF%?OZ]#?_.,., ME8^LODWS1,%WMJ),/: &F<8J4Q31;,C;MCE(\8!1R MC&DN0\HTT)K/$@9]YE C>J/^:>K=71RM/A7E^7/][/;M;KN-(X7.]D4&2EKW M$JV1N[;"=)_"[L%6MZZH!/)!Z6XPX7R'J*Q!%F@5U:DFF$H:5!&F8LO '*_,X@LU MRC@LM*%H64UPH>(3HG/:>?ET@<'%:^"!.Z6I!)!V2&L#PW5&DW.BZ1Y6(7BP M(/05XG1QR_,[Y?+ GG,J=::@2HLPF3",V3"14TP+F$GA7)J41>T.NS#$5,">2(8L%=6!X@![L'7"X' MZ*3:"O/JXG(C 'G1!+,6'42BLP M8L&8@J4PHCT84)P;A14_'9TJL?C;9 T\:/,X7)Z@@0<<0M&%KXH)-:MD$PPN M7)*QVPZ21!B0T*C+@"*08%>K% _1N=FJ6[);=O]O1S^L;U&]W?'I23U^OGV9 MYBJEED("[XN[3$MWQ'LPN+UPFP?-+KA\0>@%!9[F$KE1R^W9+IFE'ZC2[#2! MU.BK-$F;W)>F:LC^6.#!:+NU0*+N&Y&<6X(E1]V4NX!7FT:)^MW4B2)C?Y^A M4O%W-; \,G-:1L8[4S9XO\+J.C(5.%0AF9[]9B69'!:@E$S'B,3#EEU0V\H_ M0P0)*JH?*@2\RBM-MJ^)>[<@]%H(_%D ACA^F+"HKP@-+S^CQV+@%<,TE'M/ MU(GW0]\1019UU/8.K],,"R]=GC^1-2S-PB@)LN>+ F]R>5]CI8^8<$3(RN5) M)[%;_3S)<$ 5U!/*HMJ;\(T4WZ+LAT7[<=$=&[CU[JRB&3F,YP&;O-;&KIJJ M2'CE%MRG$7%+/_P.)WBM[*FGA(;T)4KFNWZ@ PIDPPH^5"I$P*ND'7I18HR\ M@#<;5IH-J:<$1,V)XC- N'A[(-\>!-RX,&876S! @;6,T48P+0),4WI./FK" M&O]^V$4A?2K,9L)4$30N*D<=/ 917'7L6PG]Q,O67L[JTOORWUS#7?8>-*9^ MCN +F',>>PHG M.DY+5.?Q3"^^.BI7M_^M^Y_,$*/ GQWA-#RH93Q,2L&'D6T ;[\-^2J15)H^ MDGME/];6XH=M]+4$F*6Y#^O3L3G4,G6,UJVY][;HD2F6#L52V!K:#W-L,:\S MR!(4W"0;?%@998DQB;Z7]UT#B]U+/T&JE=2L^S#NQ8I[0#/]!4?W#W2A)QXI MN,=7.WKGELE57<_ MFMS'C2D7*HD@3H6];-;IF3E)I%(G) N=(QE#5AX6? 'ZDD9?.>KGK(2[8S*; M183WL:7SMVT(UYN*5W[6)*R%IU61+O4$V6)\&^9/X"A=4E.LL?8Q"'+Y[_I3C\"*IB\;G] $^_OZ, MH>9Z "&PH\&!(K?.#WM2<5^E-Y!%:=J84D(5*73WC%Y0:BA*OD/[ZPY[BAZD MRD<3?V^HZ/W-XJ/0"F!^NKSX^6)Y<7X+F46?A__T%GU*DVH!=[@'&>/^)1L!.\[5\1U@ "= M5K4LUQU7I5 PG5V00KK/!@+7QZ,4^K-DOF5QKF#UA*2%1''YS 9YC_^R(IC?"2_I?\ MOF(?1("EII=(]=)CA06S%/5@3;,TU0XSIEA5M;[CA>D042I<5"&3[1:5BF^R M&(%).Q#IUZY#))-_&M ]#'__L=^M)R,6U$['2ICFYD>+ K ?LN!'LOLH7_%T M=SW*?B$<)A)+.N3$3Z)UFJ&P$M"?2X(M'U G14Z#;50$L?GU)&L"8%<)>XK8 MNEUHB0UQX; 7:^KEZ45%XCNBET*:KR3C08[O8%G)UBRYIW=SQ>Q;GN.R<5H< M!7?EX>B1WI&RGB$9JB\FJ!9+;WQ=/ _,3L64K<%5 M^&A/ / *\%#A:BDRI12@EG2=X6T0A=4J7O6B2D+6B63.?('UK-@1\\7:^HBN MMS\;2AY8I#V;MC9:4JRC4;IH\!8VG)H_!GN [)60K!4G$RZ0"N?%BG@=/%,? M0WOGKE;9CDS3?@WO[=WTQ'RQXSZBVZVC.DH>V+$]F[W7VI(D;PK-B2*!JC^! M[@%S4 N[%80M#;L4V8,^NUV1JQ?3^EAR \<7@Y4(HK=+ <$#\^MP8VME J(_ M"Z.--.5+?5Y9PQG>IGE4# E39:B^V(9:++V)=/$\L!054[8&4^)[%TQ:RU4" M@G:WMJY/58C?AX#OI=8R6[+']KBT>KR2:K"N0H=+VBHN1*;J0O^LDBZU^1@7 M(K2$O+)2"Y$MK%5#Q1>K-;+8UWIK@GX5'H\F?OM"Q,75S^>W'EV((%O/LKQZ MOOK7+LHP$9EXF>+YFHA1T!=?R&^W%$0Q4WT( #U"WEO$QD/DUMCN'R/OR5HW M*5@2H(7M)0E4T9@A1F7&'Q^J"$&%KX>+2IAZH,%YNJ9+*L-EHF&5:%XNI >[ M*_\7SL,63(\7RO$62*_"VWZ2-L-;\O]*.I\CVO=1$B2K$2):+2&O#--"9 L# MU5#QQ5"-+/8UV)K@442T_<5O1[3O+Z[F5Z?^1+1<(LPJ7:^SB BW#>(J?E!, MC@$'QC*M!!&-4(O@W-XLN.GH5HG#ZZ=)!%JAH0H/*OX<(DP=7=,"T5(P7E.= MWL71/?B3@15_[]/L!F_+^'BQ/F5-NMEM#T,PKD.$W>J919)M\=188%L[$TMJ MI:,ER7M4NNWAR(AA0^_C^LLE"%+0$XQ=]LP;R4-:4):N, [9XS07>;ZC)FYE M0&8$/NQ%:AA/B8D]]9CQY&LH)_A\>=_*LQI;<<^@AM'JDB02GR/ >V2D+[: M]J]=5#R3/ZYQ!MO%2RXN[U3VB?)Z07Z1T*?1YTDHO\E(DT.JD&\\\CZ9ZO#I M,5MT?]J>&/Y0QI66-&OX!DY^AL3;O>4ZA^991B\GT)]GZ/QI%>]"_@@;'8K\ M F>K*)^H]>%@ES+Z?''/4SQ@M?>I?BCG+_@29*$/P?$-CFE,LTR7P=,O4?% MGZTA7Y#$+[UNV0\G!QM(#Q5?%E[WI046= ]C5!6*S]A51X&.T5- !^ M8T1?* $<\\IS5H).3!UOMG'ZC''^;15P@!N\?7[LX 2;_ZG>PU*\'J=VQTOI M>G4&TT]23?^R=2VI%^$%]W3K8[RK,8J18=C%L.G#LI"/&ZAS?4].E* MS'X0!I@A/@225#'#N#HOYHNZRQ=A-1$O:6\'/CM1PMPH9)>OW78;LW@QB*L6 MVQ?).LTV+"@S-3RWQ0;J ]9/N$9C,#M4]YW"^O#5[;XE8'/CI?A((##U&;.Q M!>6( H91OHK3?)?Q1 $5=TW%C?;D8'LY\#?DK\EVAG@(Q7QTH*"NYTB9;=[$ M:8 7+J1C"^Y7\.A$ 6;T1;'<)=I;/AE5LIVO/0L+BIQ1FR7=T.,A;+0XK+U M-X"F=VW&ZKYVU1]@6M0R[>VC$59@.+LY'@+$%:5YP M&ZN[_WCF)<1"XS%\A(*>OQY".P%]_8.4F)?>0.!@NL/#B07\B M4 \@#.6T6R'S0-2V?A,AJ@BC8D^97LV6WUX4TJ M??K+"LT;UR45Q^"I&C@^.28)8YIW690^**=D4(:W**2$O' @-J+)_041B"'3 M&U*(H7OC'/H)9><+@IQ]-?*/QV@U:K!3=NAGG8C#J-B16;I*BU^Q\ES*@ #@ M ZQ$J*U?"PUC]Q8L2;+<_/D'+""1\*% SYB?@#DV\$-D$)$0P4($;8)3,BN; MGN1; *8LSEEUMN%TH0T$DUR0LRIF#)H0SM, LN&[RK"XNEU<7IS-E^=GZ'9) M_O7Q_&IYBQ;OR7\M3O_VU\7EV?G-[;?H_+\_72Q_A:P_(QZ))>VY7/1"0)K0 MVKOY4Z2JD3?@ -6:V0C2J##3(;BO*S-ST]$R#HKVL.@SA>Z<'SGW-#5'9^DF MB%2WJ12PD'Y'P7C7_;0 @;R0E NCFJ#/'!Q23X3[SA_QY@YG"CDE<$"%]2J& M&[7O;2#WY>ER#KH+E' 3'GWFH)#Z, ])R$0B8]J.)0HODC*:TNJ& 0=&3ZP$ M$75&B^!8=:AP6KY]$R?Y=.GC-6I9M1LR^1@H)HT4:ID7=D8 YUQ@E M#]T\>=7PQ1NOP<> M^!WF .E]?)SE/#JO[[1=IQF[9E,4672W*^BC4,M4+KYR)SD.<:AM_)A3T]SO MCT$9(#$P'MO=FDV!^+>(DY^A>@!4CH#$(>@)17.0VK8F2=5NV270\T1[EV?2 M67H7Q+3>9$+I;HL@*WR3SZ5#9+V*%KLB+X*$"J6:ABXY Z2X%:6@E9HM$4 N.SJ08R);Y=ZDKTP5EF=VVQ3&RGHYBG\V+/+56W=* M?^^3-1\FS^=2H)&OK(U@W8?)]6+:E?F,.7G>W>;G(-YA]C?6D6_..NC5+47G M2?@S"=RQM KK4(JP7N* 29!YD 'DP+W+8)X[&LVP:>EG(Y@(:$6SFGBCC9LCW6##'*L_(D@A%'G/J^FR^; M(3X 0 G:)#/2E.V1@8[4L%?E]*2M1H4NJ>^>]R!EYU(FE$K&O);Q(N%3(IT] M%\-"N$]WT[GWL=./">2(70G6/9O8T1,(N>>M/71(K_V4-EKN"JD#7^TRVI4% M\:R$:S\--F5BLV5Q;+'C,FU]*FW*3(>4.?M9[>USP=O3.UB<%PB_#S;#EHO# MH7FKT0J&_KG+B^HU47G5BGPNV43QUOWY#;U=D4<%OL49O53!)^@&K]+[)-(T M@GQNR*@W.7F:@[;W_RN.Z:74X'G8$Q<' M4X.*A@\2OAGD#B(%&+L>P*\F@< S>O6##_0^8O!,>Z?QWW'R+&O&0%%7SR&" MTC'G@A-DCWT@-@?T8CJ9@]8+((C0Y>ZR#"I%TC )T8EFHOW,CT0Y<.[IBR!< M!.KYB?"'/?\SC!1D@<(PL;LU#/WH )4Y#&%2N\^4/O\E. =F M01MAW#HGX9 M%JJW\=@S,H(/F+[@04R4'54 M8F:TQUE 9= #[!8VT:@3AVV#@FFQ-K,D<+"!$3I*2-8"#!0JJ7V7>YI/0',%_'$ M!4A+OOH@^N<$NH5?]EA>N0&+0T ]E1YB\768^/E7R&>"V\,+7W^K7S%X@4%^\ZW*TYV;WR;A>3O M7 "J\2*[#Y+H=[:A.TV3/(VCD!]@)^$UF9EJL[=8ET\+!''=^,;T^L5(M&&, M9]2)$>UN%,+.379$KKOW:^:W%ZS3UO7-^>WYU7*^O%A<':M-G-7O:"SQ4_&. M\/G;%%,J'>8(+44S7:,9C62,X[(?I0 =4Q*'F:'&0*Q(2!R*)HCKP=!^-+0? M#GVF R(VXC2/W%@LI(ZFSCR7L'XD/%,[RZ6G#[X_RFCO]RH2 M,\2(M/KXNUP+C.F$,:3US0JK?DG7F!_RFGK^*L&!NG :V&\TXE3 NN_%J66D M6V<]O[FZN/IPBXCFH-N_SF_./=(7DXO6P/NA,5KGJP0&UQF3HZG@:<:RK#GS M(9CN+89/NK]W\XNU6 =S@V.:4C]-\R)G4MT)=RU,6:I#B<)8T3A3(9K:812= MV^,8[':/'6BK]Q.R$SP_0Z>+C]?G5[=L&XBN+^=7M\>@^>(MH]RT-AQ,U7/= MUT_&(.67D_17^W7\=M3_K/$&<./27DD8,$6GS?Y46V#[UTP/?%\TR"*A7- 6R!WJGYHY6$R_K(T7,RR#I[T$!E>MQ8"Q* LA1!O2@#NW&B,OW;?^KLA2 M?XZ6\[^?0R[Q$L9-GEF/XHWJ:/VO#MX'Y3&YG[)XB5XS\LJM#A'%#T-@;_2: M8[Q8HNS@+ZIS9DV.3\3$I1& MV(C2U! =!H#&F-GI:A!#FJ$:C;\'[D.B8)@\T!9Q$^6_T>Y GXC"9?2]%?JF MO,$E&G" WL*Q$:3Q)(X.P?W+.&9N9 ^,GIY?+6]8Y@A2B4[IYTF*C"?&B"3V MD:4=*M1S?_9B-5\ -.,!/ IHRY3DG4 !%5%@+Y9 M1-80G*R(%[#>W_>D ?>&9F]!V^]K6A, >7NS)W?=H.!B>?$!NE;42A"S=^]' MQ&.5-'C\/A3\5$KS*E 3805]#3*^+0@CR.N)%0K%Z=?DI]6S142E00&+I(QB MM"(H)3Q$Y&1@1A8Q[5%FB".AS^6_/:C9&B#3=181"]K&O U0@P"@@7S*\6)] MGA?1)BB4]^;;0#!&(&=55/LFA'-%EPW?40,"1+]_#>:C=@\2!#PMR3-&=DY> MBP&9D-0*T%.APBG[]D_XF2'WQ-=9$]?!ZN"-GX\W>5%NL&9W?K2EPA0SG^0J(U# M@%X4W)\*#&"OHZ,E$43G#E5D6.M.5!'R*7@;569-&WK7[8<[K59Y@WGB>"Y8 M^CIZQ/028JY=\ 91 FP^/$SH3N_A?F1@6@\/X='ZA9M9^>0"R[S5]-CUVMS# M#=B($R(\HZ!KK>[0FM\'4<9:" K=(2Z2O,A8'UN]_5KBPEAL+\%$&[5"=&Z5 M/;CJJ!W%1?5S"/N6)@*^CXF/B44&+5HE"SHA_FP7OZK!H8I5]>PW"U7EL !% MJCI&) 6J);ASR["H41TJ">Q>[A;?4\.[P5O:H#"YY^S;F8 E+E!PV$>P1CAH M@^@^ +3GJAOA<%Q4(_NXL(PAX$6R3K,-=/16EZO;+B0J<.!;#U8+B1P6[K:# MK?NM;CKX: J#A0'-LE_A+V6NDEIOEB;DQQ46HD([<^A/!L9,AHHKFD]?&L[- M:AB#DJ;!7]">#FH2\B^6&TEJFK"GSSJI!(?MS!'\%:O33,B! =,VRYDO7%$'#ICKM*67]F^/!V-HET/F00^EQ[U:$ M9Q*LK[VJX>$R"GVNO98H?I68#I#D=O6 PUV,RU?TMFG":FG)?T45,1];MPYN MV IN*O8B635G]; EZV&-6'U9:0:+I[:H;4F228PK>I"9O)+5Q;K=+O%=D$8.I 67[#A.^D?\;1LI]1O 0/K6*WNT".D.,)M/UDJHKV[9) M'4XV$Z=!O-K%=8C9G01<317Q!?S5*C\\0/DX[BW.'J,5EA^6SV/&3!EZLRJ6 MWW'(WZIB3>?8=)GG?,RQP+W'^!.G\"WC#03I><:60N^7RM%0.1Q2U[+LQ^1; MPVK4ZC5>-F[IPCI^RV5C[%$F\#)*\$6!-ZK;*:./ M2$>YK):K3N'G<(]PV_ MI^#?NH9,?,(>W3W+&JZB.7VE?=9$HX.BSW14Q(8%VB4<[^2-^=!][=P7NR(O M2+!#XANZ9>*O7%.'>;7;W.%LL6:5<[SD+M=N*L8D[-;UC#\EU-N,1W42!Q.F M*U:-Q?1KLD^I>@TVN",1=X;"?2YNG68HW0_$=]S[H5#"QJ(+/7]!-N7#?3^) M%Y%YW\DGI8Z"%FLD4$=SFFT19H(/0*'X6[3E&.!Y&'<31)3 3E5*)?%BNR;Z M<^K.WZ=9I^&WL#KDXAHD7Z782O2.Y;MZIGN<\@*]W0.8>/EVT"$C@-M%YU+J MDSN=$)0N--*P2^"IO;=4AG-\BTD".,(&J.D20W^75ZYG\N OXA>K])'=GE,;PX@)'*^+YUB+/=QN+ M<'JJ0:"]\9A3)7>S8XP Z#_'8U]KB9J=9R.LG*%Z."2,YZ6OFW+J=IM-D#W3 MF5O3&RZ/U0V7QFX$W1-'"EKT)9L,T7F+DS%?%=%C5#P/]D-]"?OC>X9-BW\A>@@45#.P2T*R1Z413OF7+<&'K.Q. MDT>LIKABJR*,T0)^R1 M@YAR3KAK^,(IU,X!L@$%NYO/N[Q=1L%=%!-^/@;%+K-=Z'M1 &I&T5_(1DL* M>W3WC2GZ\M;MU< I\/:#,U03F:&*C#>!^N'"BK:XWA7TS'$3)=%FMT$QI8JV MU6NQ^]"<;@6"Y/G;'*UY(XODG@/SWM5I_7P,^R7T&U0T,6MEMTIHP%>IU,QW MGJ?J@L*\4Z7B0]X<R)WP +&WKZ@PO+,$32%L?("',4_%R#R-;+]\TC?7]O7BFXT?([M MF=5K19)S#-'\X@H7AE<$Y:# S2XD;$N;7 AP<,TM.DP8&DRBSQ4X=#,+,^>G MWC6NJ)F_";Y\#(BL41#39]]N=]MM'"G?A#*C :N\01RI^BMPX$Q!RY#.+ @B MJC%9SK;"G:$/69IW#EX=6TH_P1K2^& KOZ39;Q<)V<^2-*#;EY>O%_TZ2<.K538S#E]S_(G6JU5?E<##U0N;1*@41.M G9?^*SGI%O=7-\@KS%0A0+4KGJP!/LBI5PA@0_M M0=\]+\G@\Z=(,4(!7P_2Y+(EI[2H1['SW1 MG_*/F+IJQ8SH$( JJHTB- JHE=#NZZ4-K'1T:K%>TZJ;=87G31?@6K&UJM.! M FKH)V>VT9"O">*^H9YL_.Y9>IZ3/\?/7JC S_@A6L4&Y]$&@E$ .:OB]V]" M./_\LN$[7[\"@B[RIW>2+C;;+'WD_5JT"J#% "SVUPO1*?B7@\,4_>MXD1=L M4 P4"2AC-G(,8EH]LCW#F_036:7DZJ 'A6BVJ&=[WSY1#@?4$%''C*3\:$OS M3;3"@59.14(-,@U421Q:%EDQLO391A02PFA'*;ON:MA+,LYPUF!X1)7F14YE M891:G:5@ *JL8;=68PD,C HK&1FNOJQ&,*S*!QTKKKT\EPTV?4Q!Z,[?3$B> M)1Z4YW-Z#'_2#;I#,4.F ? VIDX#LUEOB(NC;[.0SIJ%!G:%./%7TW!4%PGR%PB"^W!Y69)QM+Q%KT3VX2VPAGO)*L087 M]F:QD;%!;]@-.AFPV<:\MMS'O/9E(_/:9B?SVINMS&MM['^5$K^S)CL6[IH? M@RBF7QMPJZ+GM]RK5'>6/G-@T&.K(,IHZU3\[IEFP8O3.,ASS6&]!A[HT,HD M0./,2@7L_LA*SXGTB*) # K^L+UFGG%%MN@C7"0W>+7+Z)U"^M1>_BE) M[VA=%C7)BV2[*^B#.\DJBGF4($JN/:&?;CA@E9UH^J0:/_)8< 8SB2!Z>X.O M+E &1MI#(B.69]DE]6&1 <6?_))V^:^PVB$J?!B@E.?2W G'B.B9EG5$LE*T M2\CV.%8L]=T874(_V#>-8%XD'Z0O&;][/DTWFS1AJXKEZ[RV=*#3$3T%[O%B M=Y>(;V]UJS@<]DKWC#XZQ GR^&.&+I)5O&,/HBV_I&50\A$7#VGH0?)UH$/U31 MT#M$J8E3-T"Q:.TW1![..ZZD(C$+?R;-(_,XB^)=@<.>!M+!\L-$%,+HC*2% M FXF4GZL#*7$]-!4[&2J^/?*7'[!]#4 PCL1.[@O'[@M.>5OBXB/X8;_W.6% MIB9A,#48\SI0>-'L!I)R;HX'\=EM>%)20R6YZH'G2M7+]W0:3T+7-*&L=]PI M.%^O\8JU*0PIB>@1HYPF;*,B(I*?U,_KT2U\^[4=R.*DI(@JAF]K?L^?:/2+ M0]K?C_8YVQ7E;,ZHJ,\:A#526-.;$-&J2QB#LOB!I/*Z[1Q ";;0G MCBKJO,NG0%^55N"CP.3XCGB"/'K;4WS&^=VS_#%4NX3BP?2A$XTC35"?!S^M MB7OW[F=/SJV?%6Z\E"X.0C-&RO>'/4A6TO."JV"C;4?1 $ZNY*PV3BE$O[N M_CRJ,WCW@(;\%Z(P\+4J%;?Z'A M(-BOKNGLT( ^_+Z?@W[;W] W82B]G+Y M)5T^I+N<;!?877\25.S?\:4CJ\LQK5$!*C1[BE47;5KB.5.4_DQUU(<,\,?& MX]+LC'=$%>)O/HHK&!T@OTJ+^9;=Y W+E;)\(U*M44,I 2C884+7^C:,#$P9 M\2&\=OLE/D0YVC (Q'(?.5JGF?K57Y2D!0K*<6A0Q#.9Y5".[U*..A/EDZ^- M"/!:*K)( ^S6K9LY MD?CRUW\:QY>/M<\V[9)4FZ1.$4![(S8"8:"=]6A3TMA2'TS5_5YZ)):[FVB+ MC;-AWWP)7:KG[^03Z278'S; MFY7+>CX3SS!GY3'G))YJB[,H#<\3[=UG5Q,H'MP&!<+\I[L@I@^:3RC^;1%D MA8<3<(?OHR29>@ZF6ZP.D%[L*\U/M%]$"=_TY=]!'>4[B$Z ^C]1B0#V#8A2B^1J*$AS@410#+Y*W42@& MJE%0A0-_MJD01GO4:<#Q2J'4!Z%:!%^42GM,JE$K^.OFIVE>+-:L':CV@KD$ M#D:!E R+2M,!D&$TC@G1^P\XP5D0TZ9AX88^<%?0EV<> M\?D37<,-6M*3!E#X.T301FC;AX#[L+4_=XKVP+12>Q-DOV'V\A#FB( ::A!) MJYF6N# :V4LP41.M$)UK8 ^N.II7XC+="QK8D'<$8D:]O!71V=.4O'S(.'82Z#\O@WB@C6J M6>#]^^",@=@Q:K?A.W_B??AU]31.[Y\-MUZ=C'QDR;[^DSI*^L]^V.-)"/:5 M:8H4(>4!,2:0P 5;9P4^/+A3##?+;(H>V121'5DN''6@>S(ZZ*.;3.0[\ZS< MV&D4]AQ@).,!N/W)A3%G;N;H6IX1,<'=7$N M)[26NB! Z,4S#K+N6?6Q1GHW4?[;^PSCBX1(A_/BA@3(+M86^;A?092GF]#) M8CS9H,<=X:DE(LH$J/A!EY*N([GK,, 4]6=-IB*IIR"33<*P^L'+P M/Z$+%PEO-+N/R?FM)!6V089]1/--&CV&$Z=PM] MV.I>)N IY1*;OK_+\;_-47GE&KS<4"??DHRNK3NT1?9/%[NBV>KB'M,K76RS MU5\79XC2\*%2\7RSC=-G++88T5;\:."!>AB;!&AT+U8!N^];K.>DN[*6\,UV M !Z\?'/HA82?<4Z;I29AG7%/Z:^F*BVP'?7(]A?])G/,&T6&(8]G;]%'GDEO M&W$.^*,\]0E3RGX]=2'!Y%=#!\[N;K,)LN=._0#!(/L,$MKMR$J;H>(!5W\Y MUCXIY32]3[,UCHH=^887R36[LSS1!Y&.=)S.3S-I8SH\R3!'Y^24,DSJV(11 M490@/B[4^^[NIG!_?9(1W$\$GE3XY=2^?,@,_!)DK.9+,P5-R[R($LNKA([LK_F5W 6)/4 M]7$UQA&'84+_CM:K'I5TUUFT&OT4K._HQQFN]9SH MB::[UV(U,@_^K5J3"#AH^=*_KV)*5<"L9(?G9-W,O]$M3Y3U&+$JQO>).J:% MJM[J0BY3/9DXTD5JT%2/ND3UXN#X%J@!XDV[/$GR2#"+DPNO.\;L&WWNUY"N M$GHV J2KK$?WU,N..[D3-6T]+K\ZIESN&KP>JQ^==+9M'2AK&&M,5AU#BP=C MKNH&T^)-\OO3-&'5*[L@IM?%?]!]0-><'%E3B,,G?91N$P?DS*$7OWK1].. M>5.'!:IY&[VWT2&<'.?Z=L"DC[F^#6#CZ-:WP3(";CA++]!K M3:LS.BHG[?!TYFAGCVWG/%GDQBDXN""21DD>K=@UY^D+'-KC'6?VRSB!$Y5G M-0<[N@R701)W6ZAZ=-Z[P(MMDL-YG=_?9ZPDMCT1_FQ]?)@-: \_SC+9G ,' MNY7.@$>_*5%,X41[C]9HQ[S%D(KB;B?AHYMW.;$:/R_0@GSS@DI'>S]HNLZT M8(!>L) QVGBH0@1P_QY%=_2N,E"8LM$&=.N7X440>TF3D-YJO@HV^D8QTPSE MZ;;E@&D;IP!*/8Y_FY7!0G2[D?".2MS"/.AB>RZ__B>.NRQ)WB4O%/?P?US[>-*-L6&I5PR!%80XP45A)G]=J;F9]*' MMJ>]'3C2I'^@G1+(1-[M"I2D!7HL^P)]%3SA3,<[:'_]KH>+C!,;.#_"':+M/SI""J+CU]'D3! P6R$U*I6GIT M6*6SX4VR_=\CT*[S'&6",UXKG?P8) 'WOM(C73F(>ZU2L5FI3?OO3O5"/GCG MP^_!COJ@EI\6+-;LK_E\5SRD6?2[NG'S^.,<61!NFK!1HFW5(,<35NLEF")^ M;K=41OM!/>TS=Y1S=PQ.39JK_I"EN:J$=)*1CLRQF2=MS#M+DF&.Q[F99)BT M@+U]_D9_0T8^VF.XWI/9[9VO.&_R_K3M -'W#X/ '[9=9^D*XS!_3QQ1GU= M+/!@?*BU0*)'-"(Y]V^6''6TK,)#=%8:#RCFZKY_;F(JIR)!/"N*L\=HA>4> MI2[Q8LXC7Z9%$(M_/TWSXBHM?L7%#5ZE]PD-W\1)4LRIH[&!GSMU,;'2IU.G M'!CN&=;II=(\Z!,Z6M5JZ"0H6PWQZP1TH[<[ M1K=<[DZU]PI;,#!.31*>DW"! M7E-9IO170@^LN@F,DU9_!_#CJ>.=^@.,>>PVF!G_G/*TDDYZA%?6\!(V4,4= MC=[IKUM]"*U;SWE>TC#11S'WKX+UW;N[/ JC('M>9+SL^2,N'M+P@N\F\6U M*Q!9;HY,7 >X EO2)ERJ+S+J$$ >=H)I:CC-$>F[]X.C,]]U;3462K/J'@(? M!57X,T0'8H?N+,= /9T,K8)'G]F(H#61-7_"'%U&";XH\$99"61 @K80G2AR MG9=A &JQFAV-7K:U[S-%10RWHV&.5L)1!8*T$CK^#=Z2&7H(Z&XIO<^"S;[^ M;[Y)=TFA[ IKBPUD-_V$:QB0':I[2^K#5U<#F?GLT5&)/Q,J/A$G :B3RPP' M^8Z8%N5VOB(K2U9OZVFJG>SW69BIF")[=!BM["N>J):VN,[ULA]CW6M=)7KI MX"L"LSHSPXZ3"!&^P8)Q^K RVAC@[\]/$;.J5V_?O&(V17_SCXMDE6Y(#/B$ M<]EF0@'CUCJTC%(3D (XTW/-Z)T/S<$0@QL_$+:Z"79;D%TQW7[?KG 29%&J MN*JJ@'-_)TS+<'4Q3 KD]':8AH/N8EN"P-Q/K4;_E.1;O(K6$0Z5-U$UL ": M8&*\U@85H%N-T'.AU(H9$C .NC"J1%M:&7 #?G'(L'2TW@M), "H&>Z M7@;D8)-\]S!=L3X%+-5I/WNJI:% &2ZO5= SNG6:;7@>.;A+=P7"ZS5>%=$C M)G]CBT@1/*&,9CAQ-LE70V,*#0BX ==CC5',ZITC@8.-JJ1)FV4 M0# *K>:D>R$E16=X'?'J)A+'!E$L>S'"651FXK<9F8%ED0YA&W!?7G-\2K8M M49'/DW >_G.7%^RP7K%I,B'![,'M1!%WWGH,Y_MM&W8T>H1*-'8(*2#";*P= M">.R,+U:QVO1Z(I(WXV,DEV4W"^V9,NOO973@P!007AO$1O%W-;8[@NQ>[+6 M#8/J($[04181T5K@9!7%45E#?8T)W]USC&##&<&1*P/*B&D(NCVC];8_FD5M*]M26* M)^IEV@CJ5&SJW:R%EQU;*$![*8.?Y)YQ=1D%=R2:*2*Z?+"RQOQLA^=W.7L& M7C$;_4C 6-(0,46SZH/OW,;Z,Z?4S9I4I:45M>=95>9+-'='G\XL"0(5)HT@ M\U[6F-) \9X(^ (F%^^Y$NX&TU.4D'9/>Q_EJR#^%0>J"XB'$(1<]@Z9@NZ* M.(0:T&(YG-5#S#J?H9HR+=CCM!$E#F/AHT_&8E6DM*W4ZQFBMH>*ARS=W3^0 MA7C%SF[0F_(OOEL_<6U7^*E8?L'Q(_Z8)L6#/JX=0LYCR]>(W]ON);3\M'HE MHP?:/%W+*6'$*2-.VF.+MY\(8F(_'($I4X^U_)(>."JE)B;RYEA,D8RLSSSVHG,$YB@*/-@@*1&_37+/X6A& M24D>@5EJ)"<&\XQ=$]K^2EG>UXYG1;-H"@OTE;6=606&9 !R9_W67% UKS MQ-(SM=9U&L?I%PJ\VF49(['_Z_?H_&D5[T),"X@)@6C#"I^")*&/8?'6<3GZ M\H"3^N_5+X.,]HO;IAEEF?5"KNCGU<4&*N(Z2H)D%5%J:^VU'/,+\IIM?WHWHW67I0Y4481RI6.+COQAS\RI:%O[V&F MAD<0[1RXP/@>W1P2U7@;S8P5Q4QC<+21YQBQB^K&)Z7?7"?6NV)'G/ F2J+- M;M-<)[P]7OLD2$#6'@+*E\,ALZ:FY:%UF@2W-E45(;_L5L_E(",622).4]%@ MX##1[5^N'7L&?D)GT7I-EE&B:N@.%U\P";P:-M\T"&!I S'V0%,;JF6ECF*$"\*#%I]*?]VP[BH=7XO4A !.%]!=1##WL ML9W'&WU9ZZAC2<#WNKO1Y/3=\ ;5V@TAY(\A]J^MZT_%"\,<5#YF-%#7%706 MA>JC"7\,M7-:8>UKYOJ3\=""+6OD^M+PRWKM2\%L;->G2KB1Q :N@#-)H:]\ ML\;VT_PTE6Z6J-X9F[[&R];&8.O9#I,1N([-BGE-_5H/?(^-2E6O9HWLIV%I MJK3ZF19<5=JA<@)7H]FPKZE"LT?WU[A456>VN%Z:EJ9 H)=EP=66'2CER#5E M)FZ,M60]"0 ;2@ M'4VU#V.;/H5C*.J1P$%5$"L8;E8'MX *G^E'$@<)M-A]A@1=%5-+Y[1B@!. M5SRK44DC-'CAK$H]#: ^%,U:?/ZK%(7[9PB"ZAD"T))7"[8[!:^@-G>H#'%M M@]ZT;:3\*SR+#-"'%HPBR^I&BQ0*N)WBG@4[O88J];+FFD="[6NZ^(F^.C<4E*B F6P;$1I;DMR# MI66H /%AL=T$N^Z;Z/ZA6*P_Y7B>Y[B8;]*LB'Z7*5]O;/B=N85PJKVZ!A5T M]V[DR[2?9P1.TO4)(8$8C1D2J< ??O<7D2]W@0#(#RP)L1 %E(@O&>L+>B:) M\^*<+\46L]'!@#3R51(Z%P>0+D*__H+4G-.+,++O)@I M5P*>!]/FO^#R7N9\%U23"9N-28(+/[;8);L)B]UV0;S$V4;RNK09'%1+E>Q+ ME+8#"Z7#"D84Z5 !'E&$T=^A'D5UI(]2VR#XHS[=YZG-T%ZHD/:A:I42C?]2 M=3-%D[^/'C6/56N P;/L$M85278!TH<<>X>=CC;<[%^M+AYPX^5J0JD@&D%S M9D7:3J#1%,HC;";>+%PK89G/$$6!=)1!$M[N[OZ)5\4R_9"ENR3DG*F,6PT/ MY"9- C2\I K8O9/4<]+UD;10I$2@RL]12BT".C*=4H0#G/P-\1W7.+O]UR[( M\/LTE::[)4 3EW):NW,.Q P3ES!QG#GS2J[R:]0SDBB-:%)]\'Y[HYY<\=^ MW%Z^DFT.B2@H0(:[-[O"+(]H:?,P9 ?A06QE#Y)!]@T\Z]_)&YE4_T5W;\J]H1VR/QTZU:*96G)V M,;WHP:EBRUQ<\0NF9S\X1/-'\I=[C&I2Y8TE2FP:[S"H]__$DGI3?%1Q6S)[ M5I:3WP0%)JYFA94W+?J3\:%PR5Y<=5F3F09PT9,M@P-TN:*%*+$9*LGY\(CL M8*%K&8-2QKLTR_@MU8S>#I4]B^#'69MX:CC8COL2@3^D'F;#_2B 'F4/5N76 MZ;;7UCN*P!W;K2VV61(7JZZZ.+364ZKE])B"AN8W4?[;DE9_*V9'!0QC?7K6 M12N30SJW)AT;'25J ",*C3XS>,A#R(X$[YZ79%#-$;86PQ.]Z0JA59X].+P& MM7FQ42.* 7^>W34&,J3V0%N+X8DJ=870^Z$:'%Z5VKS8J](!I]HC*=/M;KN- M(YQUA)*>A5MCP2B5I3"B8AE0G"N7%3\=!:NPD&SMXYB02C9?L?@OO\$K'#W2 MI5BK76IP&+4RL2_JDPK6N2+I&>GFF$MPM(?W07,DR_8[G*P>-D'V6[_8J87F MR:JG$,<0135PX-<_*4,VBV"-YF%05?/6+[+JH/FB:')Q](K6Q/% T60,]50T M^)"+%ETOUA_2-,Q9D;5V+50!0ZF5CO6F,LD@ 51(S89$<7+65Y"!S_CS3UXN M@I=1@B\*O+%>_@0$3_Q11P2M)ZJAX7U0BQ6K[!/%00P)J*/)"%*,6"K4W4 3 M\/PAC<,R.QS M*15>LO3-7;6F?X->D%%#G*2;**%*^!TE2F$PH48)S\A_13DJ/R-M+2L6/S69 MVM8B$I(9X:+L0$LAP^@QR@F0XZJG [Z'+/-4(:,]-D 9U*A"S32R'."HKG9T MZ5^LEP]1%EX'&6O02:22R:.&!7!()L9K)Z0"A'$\>FZZ5Q2)228,A49M!45" M6XI%6RH2-,=FVI/[JYISAH 8!N(H /8XF'LV[R?BO$]@@;?1?1*MHQ59''[& M29CJ;5 B%:N8[=M@%A;5$%3^F@N*]6>9["NB1DP"R2VM9]KHMH* 2!] T M!P@@F7U1 /)S/1C9$OQ&?EG]BOSC+LCQ?_X_4$L#!!0 ( ,2%8E,EZG5\ ML38 *KR P 5 >GEX:2TR,#(Q,#DS,%]P&UL[7U;<^,XDN[[B3C_ M05O[L+,/[I)DRY>.Z=V0;;E&,2Y+(ZFZI\]+!4U"-J)%(D M0( $")!23$Q7E0V R/R^Q"612/SU?]\W5N\-N)[IV+]\&OS4_]0#MNX8IOWR MRZ? .],\W30__>___-__\]?_.#O[Y^WBL6K !MM_37:#YP.C],/W7WLK9 M;C6[]Q6XKFE9O5O7-%Y KW?ST^5/5S?]ZY^&YX.;F][96=S2K>;!FH[="YL< M_C38_>8N;M6Q?^X-!I^'GX?]X:!W_O/%Y<_]46_^=5?P*^SEVBPM:9GV'S^C M_SS#3_:@N+;WRZ=7W]_^_/GSCQ\_?GI_=JV?'/<%UNZ??TX*?HI*_OSNF9G2 M/\Z3LH//__SZN-1?P48[,VW/UVQ]7PLU4U0/ZN#F<_A;6-0S?_;"^H^.KODA M *7]ZF%+H'^=)<7.T(_.!L.S\\%/[YZ1]"O7K1+AX6]-0OF=V%#/O=Y?7<<" M"[#NA?+][']LP2^?/'.SM5"#X<]>7;#^Y=.?'^_F&<*J?W/>1]W[S_N84LF? M8]N8V+[I?TSMM>-N0N5\ZJ'VORVFF0[]^6&#]PTP?M*=S6=4X#-=6Y_K=GGI M0Y:B]N\;8$;@EP/ %R3X@6XT[S7!\OYP:__J1;%=W_I._H?KXYEP$EE\N\ M&AXW.8J:KBW0O>GIEN,%+H!SD@F_,G>!![_'-NB0&^'8R;GK0#;Z'VA8@RK8 M(M6P][*X%8[=G&BN#=<0WARXRU6C)]\Z7BH)>N*W9 GL-Y03>KH$EL3&RG5]JSQ:G+25."9Y2J/2:U M)7!VJ=I=7#O-S#15>TW1I-!9IU:_"UOB/MA7[6*VMMA1X=8%VA^&\\.>K9^ MOP!OP [ /? UT^(S5I _(%:XJ0V_YCON!T^!\HV*%6)L&";Z4[-2O@.> I$_ M('B,KRP(L3'!G>8+"?L7!$YBE:7 -B2PLWQQ8&N]F=EY%OC(NXD\X8@>[\#5 M30]-#$_!YAFXL3=BM@U7XI4EY]Z!9I13_*O)._HK$*(-RB\V*'ZL^2^N9OO M$"8SYC,-"1IL-IK[D>':6/?--[AX$R(QS?<:%GT!/-\U]= 7"4N/?VBNT8@. MJ#[5/R1T6_.;YB(;JSEZD9L4*H D!C:%^-%Y"L3=S["?L6]0VUP M.55/*P"\^\ V@+'[J>FCK_3[_9M^[ZR7-)3^*USL]J)6>^EFP[[#WEN.GOF" MA<(F'#>K8R2%!\4((Q4\H/_TXKQ]-H 9!H>@OX0 A,J'__A^Y[P!=_P,)UI- M]Y.6+.T96+]\*OC]9Y%]2?2P@BT6="7]Z^^7YU=7@XO+BZO+B_[-97\TO$QU M+@WSV,UV5'/UI&WXUQSRV0"/N,3G;7B(?Z:_FM8.S[7K; IU%'_-H>RUX$9 MYI=/@T^]P(-]<;:1N7WJ02G6P'6!\1CI -O+L(NAHAH""&Y330?RW[C7?!)2 MF7+M@ZR\^S%VPQ9A]X] %R!H.BX6S_2=L4C7A%Q=H#"G7O M8T!&+1CO(IGN A=I)>*8:;^@:*K PP)87+QM0#)($0-Z*='"ED /T)B$2.-O@F8AD>S MX-[!S?J+ MX^)AS)1J&WSEG4]@*W)*-#PHO@++*C.J=*&L/%?]T?50:3!*^YY@07(OG#>S M$7(V&\<.S[3"")-T= 5^.T2HU#:LF&5)L"OR/E08_O: #P0#'B^8'DQ/UZS? M@>;B';6XHNT!ETF"!-(V^"\21]E>L@?XDZ*U):9D>S!D$2"!L,ACH3:$T6D" M'8BILFV%L4R$!,@B3X=J0,8S2'BN;$UM [S_'>!7- ?EV@,@??<3\(H$*J! M-X:<-$)>6EK14B?S^_: 5=[M!*0B[XAJ(*U<#2W$EA^;9\$7?U#OYUYJZ<'W89//N26'1=J# %7/ M$Q2HPBG^^OGP,D7=*Q8T>0#3.L1>L!CTT06+77/P[W>SI^7L<7H_7DWN>[?C MQ_'3W:2W_-MDLEK6N%VQUKSG$*7 .WO1M&U$+&#Y7O*3D&%G_4&!['"B%%<2!E#JJ3E MO:DQ2,?IV@>T^6?' X^UW3]U\8X/XJA@/RBK#/H,\.$PIQ%-"/2\SI>K\P!E MV<3 CGZE*,HT@.7!Q@K4(;/6=;2?\19 !^9;F'<#^,41J#15.@4_LZ"<+HKY MP"TP^'HKX^H,V:6C@L)C&)$NTBD&E I&N%C6LH%@[H*M9AKQ_?6Q;PCVWEG&%AA7=Q9\:Z;H!:+[C:Y;<,2%* M'(=RUOCI[''XJ8!415$6,)L_HX1"5P6RM@'Q8P'V2YA 9&&^O,(-]#-A.K,N =;Y%[S(AT^ M.;9.7$?@BG>#$TS2\5I6*#61W,==WR4MBU6!'2?P%;I""2;Y"'?[VTN*2&3B MSJ(;8!-D(>0(J+J)D _LHZD]FY;IF\"#2^>"Y(OD@P7:ZLJ0@]-)4RVY.>T_ M%/ [I-1 =Q"%KZ ,0[A 3&0,C>3=.]"8:Q_(8P]U"7_B!E" G$9*SC6"O)V9S)*;^R(1\Q4&N[2":>X?%I+@WZ_/[JZ:3DGV$3MSHG99+.UG \ %L!"\8[4 M:Y'2>MVC2#61.?G&5'.64A/E&)C!1H7:'C'9IZ\I<<,(@]6K9C\Z]LL*N)M[ M\.SOO<7TNV#*AE3F#N?=<1V-=&#)6HHBO[Y<+% M?BE]2FH=#WFJ*$) 7(GL>:Y\ CL>2I0)S6NW+'N9@U+VF3XZ%T%3^YUCHS$4 MV#J>#H0:*M.#Q\*%5?3NQ"?G53>U=2M B7?F* $^1-3W7?,Y\)'?>N4@NX/J M@=V'?7D)LTT#KVRES/]"265 M84Z#T.?Y1JL8 6MH^==N4IEL2>0Y+'9B#K56NK-[WS_?.-=,8VK?:5L3KNI2 M6L"=/)16//&IAIZZC?,$3?QCT4O>\ZR;BBPU>T,G)JG ^ MNY#$H05ZI-4&QD1S;:A(;ZSKP28(CWCNP=K43=R:O+SBB6,U]"3DX$R1'2+U M+N_$( :]=/!\K= U4S$&61DN-11[+&0FPW)$1D*J>:CB5^";NK9+6UV:G6I$ MGYVJ]Y?,)_Z[L]FJ!J-+)=PQ4-TS-^RQ$:[&YL -GXNA\M#@*F<-8=B_NKAN MB>&'L)3Y7YC$5N:Y")3#BMUG"%4XBKSF#I?9DP] M+V!B153A*!A!$)63AT0U-N"?7:.L=12\*).7TR)2)CE2'D+&-0=%SE$JGG$O1@^W(P ]\W4 MP?C=/!QO<<64 98!I3VT3%)AP6T:I_",*NJL=^]L-//PE3!B66408U)^(6:4 MPG$"[L^/]^BAG?[->3_$!/WD^ST(O_\5%#RUDR^0[>!Y?W0I*74XNQKW$%"* M)=1@V'V8P;-EZM_\^)QWE_9\&6RWEHD!D*UR)\#E(#+V_$/N<@6N4\$4_A6W ME\@75 ;02K,;HUR=?-EA 2!M U#VB--A,76!)V.8!Y]*LNZD1DO$+<%9.7RI M8,*CVW%4=_?.XP7(P(9ID:N82=3NC ]+$,8$0Z&_:NX?(*5"W%(/6Z%SI& 4M3LCQ1=@0\U9 M*+VGL3%M$VG--]\ F1DEM3I'CRKR=N<&,QHQT5B9*(\PAZ2+=8X%5 (*"WB7 MM9J,#@ >'0^'>T%)Y:"OOX(L$4Y $A;Y2?J?'-O)RI^\=4?>6936ZPX_JHG* M:Y"0?1\XN5^6D9ST/&AQ<>7H4 W5/#N8!!;\3K2L]^&QNF0=/#K+$C:)>7F@ M92\P]A/J ]1JE,$J@!K81[;<@K7C@E2*Z,D[5"N4W[0U]R,F$UK22NO)$ZDX?L>W>PBWC&IO+ %.Z:S2B$Y!3D+8".V4XM9=N MES)EN@-XN5A"WS&3EJNI,3^#:#WH:&J MX*BEO8"G (63S=:Y.RZD$82IC8YSJ+XN!*3RD[^*P:@EUC'MC3/&5HZ3:DS: M$.8GEG!CZ4[S7A\LYP?MA:5SE@M+=^/EWWH/C[/?Y%Q82EU!C:F/:$A-O)#Z^X![#_NAER 4/0=!'EB-48 M_GGJE>J%,#96OFV#N=OXY-A(R 74O_L&[N#"_B47(X$*563M"[V#)FO62 M'2N-W=DJV<_0- MG!C(36M"HG?DWXG/:V6LZTX \8'H /.-D-6)IFI6E9?]R]&Y7 +69 $-K2BU M4->ME7W\2'),X($*YB[8:J:1#/I)O+!MA$\&CST/^#@W:+7&CI%GE?52=V.I M,O,2XYMK'\CRT%5&77<#V,W25[>K-7:,S*NL%]7VH,)HF&1(8F%;JLXQDJI, M?+Z/!:HU:MV#+$_+!?>G77'L*.AVHU==*5Z]T8-<3O M.M2?)@D-*<YQ*[ M&CHZ_R4R/SCN FP#5W^%&H$VNG],J&2)A:^85>-5?W315395U(407[M\CR?4 MKPZ $2;/0$^2(4.C8E19O2,B5"55=-2#7JR,Z/;8-QN*/(4_L%$N2I3,MC#H M#6UQ<#,BK^:/G9V<-,8IA Q'8MGS[ )8:+!>.2OM_3?3?WUU+'3U$XM7425?.") .T/^15_%-LR)3A(HT=6@! MZ!=P;LC^(%5R#J!M&/GC&]T*C#!Y,5QAVR]@ :UILEX#K..DV4XHQW$.3A<% M--B5=-)(.02>=I4]0B;4&--M2##84==O%[*#KD([X#:#1=A.;*GA..$C=J&F M-"O1U-1>.^Y&2[_(C+NC1E>[BY9?1W1>61)E9ZY*DK[.-=,HSP@>E\IJY+H_ M&EU()D,-)(O"L\JE%>QJ9TXD@[F-N( J06(473A,?M=1-,ME%.S;OI1FTKN4 MSV56?5BPHU1@%+B3N>-0KF^HP'U\@VWLMOMA:MCRQT+HZJO'(0['^K6$YY01 M5_I:88$RY W:X3*V3U< /U<-,A(K"+SNNY M(O*X("$](#8,_0(+E?R93D:;Y@R=.\7,WN_OZWV>/]9+'\K][D']^F MJ]^E9&R.1,1L3>&'OQ<7_'X^'-Y&T M^[!DGK,D4D9Z00$YCHVLQ=Q.I7@)+_ MXTY)#\NI"Q\U$@5'IE12JH7@V("+@K #:#TPM>/E A%-8IU.(LLN,7:3+@7E M%0K,"=R/ADVK<+R>_QM9LK5*)Q&I/JPHXYU CYCJY; M N/!<>?!LV7JLS7L5Q[1TO+M1[::B'6/-$NB$IF=XA6@CJC,"GA4ZPA@)P@J M)$FH4/#O R12=(OJ5\T*0/B[\,KJ^(?F&M[D';BZB?YI&[_"V2SW7#:'%KM' M&EY*:.8@M"Z="F\YCUT7Q14A+=Y^[(O$EZ9#+>"4XNV4,K4C'19R3OQGNT), M29KB==&8#WNY'5>DWA#!>.6+%1YJ99M*!!F2O^!BP4R*=]5$L=4K.U]I-.A +J7C\H M65-*?8DQO,<#U5$O4TV5IMK/->[2QT2[424##=OF)5)#^,O?-+2R\?=K;(8= M"ZF9K-8&_='E=T M;::50'TDE*Q[%4F-/$-\SFA;314JT1+4^60..T2=_Z6C>]/3+<<+PGV>Z+!GWXO]Y9;]\2_,?M>#D-;Q/-%Y/EY&DU7DUG3U)N$N2O)B<&I;BD77ZOL>ZQ5DQ:V%3YK.^S/*C2=< M^94>;QK1'*=(HM)LUB('KJ*KXY0CUS _K(U+<;_HAQ.6)K*$'T+"2[X@3XWGP<:GGL1"<[^<-V'@R:T( MN.,/%V&4QGV>-^[)>/$T??JR[$$3[RW_-EY,Y-QL/A"(YHXSILKW$7*ARKD8 M<-"E,MO%EE?&4.D5GK=3-NF$S+OB+7$?TH%]O:3$*"_R1ADF'#B#.X;)?>]N M]G4^>5J&VX7>_''\M)1BH/O^A:_:["2-'VNX*R?'!_0+^JIZRMC\?38D9W-+'(*7<<+3&NTER^5@I?2;B_S=CM] M@FN$26\U_N=$SMI@)\6^6Q03/Z'6]VM)=EO0IS)3)551QCH9])XW4F8)6SF3 MAED5::WP*F^%CQ.X7)=C?U'7*4PN6_#[!53U2):I/0+/ R";LK=T?4RNE"7C M>7\TNI)O;AB=Y\VL@FSMGP#OG/#A23=LA-;ZKO/6=S=[NIL\K1;A-EF.%2Y, M[P]TD>,;E,A%R4L(S\2G"4*L]WTHRY>500;UD7Y*I*FJI*V60Y$WV\K"MG.6 M-'WSA>4D_*9@IIRNIE_D'7^CG&YF=(,%0@WA0Z,ML'4(-=/ZE:F=[T-9%P.H MNEENT2R-*&G;[' 5V7IM-;32Z@L"8>:.9>HFY8)YV!_TAU0!,;V_) W_]RDV M1J'8F$Q_0X@^*%8!V"K*C!#"8U:8M2 X_N1*$H&^>6"VGGB^N8%:PX5I9PL= M#TDHY.:4Z48U6D2;WFBO2S>L$&H<#V%8E2#T81!9'J25JQD :G+FOP)WK.M. M$#YUK0/S#86F1WK!L(BJ;E:5%_W+BWY'^51='6J]+L(M*>\;L /P )6/%OE( M:^@:\%W@^ O)3#*1V/:DNR!\UTPVO'*<5.;:C.(-0LD7=4=8^':=75 M(3C5C:QL +LWS.BF4%SQXV$0DP8$O*PK?Y6_!"](2PNP1;=/T254I @Z_E#5 M/1XR55='W5PV)<.1]' ?VN&HN/CQ,(A) [P2VN!8[0[;P_Z)]3'KI%S9Z.W%0Z MQC[34*H*.Z1E-<]G@&ENCJ$1MC)^681(,LI M=$)H)#E([EHVBS6?YZTYGT% KB7S3"5P+2V=L_X*C,!"82$'?4.; AWR]=ZT M A\85,O!BJTI8^C46!7XO#B*WKT4!4RV?Y&W?7*B KGC ->,!7P:1:SJ7YS? M7%Y=70_/!Y=7[+>O<%F\=S1/I>-#LUJ43]G_[J.-[;"?H4[N.+#_!# VW!MQSA! M-MB7X[(*]50M)*16LBD1WIV*1Q@4CQ"1RO."#<4T(.8CQTY^83KD%.JK**MQ M#TJ-==]\@WOHRDQF:_C$7HYZ$Q!"+.=2;S\TPDENFA(24RPC 1C3GGZ$V=,?I &3NY/O0#ZP_2%JYB[,E]?R/(&5VU-ND&#,%\95[I;Z\^+,,"QF?I4W\RA?D5S#KI.XZ%+6 MZ7ET9ARA\&AJSZ8%R?=5\P.7=G9G:$$9>Z5 (V^N=05MYK!-!NG1XH>**YC2 M[>8%BU!"0RB&DL+X;EV@_6$X/^S9^@GX<3C2/? UTZ(;TB^HGYA!/T^^UG/6 M/1OX/3?Z8.\O\2=/@7\J!?[M%SESUS$"W9_::\?=[.,_2Q>%F'K*#!KB;SI4 M4@6GZ<82%*CNN7Z*1/!?AP2"/_H>RSMSXY?5Q^_F8;8-7#'EZ%$-Q3T;F 3% M@M\T="BU5-Q9[][9:.;A.]W$LLJ R*3\0LPHA>,$'.9@_1Z$W_\*T%EMT0%Y MIH"*VJ=4X\'Y=;E80@VF2KSCP0CQF+QFB ]TQ-50!D9>(V%5F05G'>+UAGTJ MI43,V]#';-HO*V>>O)%<9+Q4%;.:N>I?78[DLH$5Q0/3KBYT,_F&!9(AW'@R M,R&J=4PT($@L=#\NZP'Q6!>XJ2+Y=8SP>0)E-WJ*BBIG^.*ON)5)+W0M("L#UT[ZA?;C*U27"_46 M[I^"[=8RL?-#637EZ$.-,H$@++)V\B!GIXG?'/>/J0WG8KB&*J5(IG GB5$N MH= UI'0ZP!'7].!^_8OC&*5TR!3N)!W*)12:G58Z';ZX3OFH$!;J)/QXR7C% M?:9V%PK!_CA]F"T@8NX;[KRNJ&@G*5 F7]W0RYN("#;*[Q&752%/5%IU%'N- M3D*/DXM3[M02VV_8S3 V##.2(^60874Y4*9L.NOMO]9+?>[D?U#2_Y#<]=P] M[Q?G8L0M#+#EL]9TW1^-NNJ)8%-!*]]5*DJNPS9>#/-18+CL.E+'A:ZEU]E1 MF!B0E2FDG.562IM#(9.H,"I9AT-8/=U^K.#'"R*L&&HJQPH*@ OC"BH)JEP, M"28E%/QT82@60TWE@*Z*&0/Z)=*KA?Y#X-JFCQZ!M(T'\QW]K3CLJ[Q">[ N M02B/-:/0:D&\$YN(ZT&I#H-)(RG65R\%P5_!JZE;)8:9+=1A_"@$Q?K6Y=U] M0KKFY8!1%[)5&JQ<4ZRHVM*)B7=%R'0N/)>'K^8+* 5EI*TDI5S/70E79 M@)+.D,F5U"4%&5^&729>SJZD2ASK>K )PJPY]P#V73?CHZ6M!6)7^WB#WG2* MW/!836$8Q*OY[G!-J$;J#EV%Q]UJC5?X$V]2E>[PAUG*5D;:%QU?<3@#'^;# M[C%G6IE#<%.90_#.'7:E;Q]BEN:T>0D(U;.&<=,?74E^1Z;: 5D=:0D+EB,Z M!5, ^EHHHP&ERVA0Y$A1&:P2%9-\ M1B19*09J:?GIDD?';S_&G@?\.TOS/,+PC"V?$7QX!1>J*F5!J#\HLPFNUCG8 MKN]AS[VOD+=PI6S,[ 70 ]Q3I;/R%5^(<=JZ16?-U!V"07FI6_ZVA/PIS:T M:/"(/[_.E%$&\>KHY1E0+F%7#JI_ ^C9!6",(?>TE_T+A^%C+*F'$$,M8OC MU$8G^5)? ]R.F'UE+M87*I9E4NDD5>@E[>'2".QR4P&E$ M*>*6?+]3H7YB5>>4-#;^%7@^(?*R8FO*3%8-<*^B-KJSW,%8)$XO;(,;KI5C M8ABC%@2D+5-I&=T6#=RE= M\:5;M,O4\\6C\\O!Y;7L&V454]6H:-5$+>?-F4(ZODEKY (=O8>+GMQV;'1Q MF!#\1:RC' TH<"2 3RVB6@$3!]TFQFD5EE471FI$"F9H:DG50A/V>./8X>O5 MQ+BH7#GE4*1'((\>G71J(VS[IH$V >8; M6*)(/[AP!=[D7;<"N )&;R@A0PB25)>Y]LNZ="Q?5G84R>VS[N8M\!-5R M-;O[^]GM>#FY[]W-OLXG3\LH+_'\G!/WI@WZ&>'?8(/4;MH3[U M(B \R1N_O7RS=5J[X:MH2.&>[X4,>T;ZGVL?-#F+ZS8J^;YG+KI")TI? U)C2H/6D;XL725!'E MJ" 6N#Q12I71 JS)=T@SA93#NU3_>,@($HF] KKZX:Q>G<"#$W28SO,-I!8) MJ'?X6Z&4596%B:#S/5"U)14+WWX'GED)/CG^>!NF#33B@05E$H2+5CR:U5KJ M +@=T0127@Q%Q;FKK4 .0@:B3P_[@BI"(D5"^ [@QBZ=6'M32)0%N15#J M>ZK=L'+D:'HA)4B%G7SSL+*N8C]$RDL0N2EXTQKW'?58+H9U'.G-I$JAKK;S MEK(]YY03Q/;<=TYL%ZM*(3'T#;]G1W M%_]J\H[^"IA]R;G8H%)?B+MP\ARKXCFN&VNDP-@DP(=;+K#"SKGH*LG^. ]]"J&!]\L2:BB' M-@4V>4!9!6P?ND1/++&.<@BS@D4-MWBW+;>8(\^'NV>M[-V<7+F,;.=]^5E3 MV)$HBCVBD5(M!)? @HV^? $V<#4+91\W-J9MHBD'^;^2I1@17:8V.HE\?0VH ME02P1! B&ZCJ=I(%U257S(?,*1Y1!5PKK<(HY>JDXW5LA:W'=]9P>W-M-%PPH&89^ M=> *PK2@8$V94/&73T;4C!$Q:%](EJ2.FM&]^68:''<-3#^ G)O:\U F0590\*63'0BQ UI-M< M9;I--"?5SI@Z<;(R,596'X38QJX%V5@'_ *M6A.>? BRU1\;U,W)LY#9B4JP M(LJOG^8FT5Z(JI/2H-\1YT25NZRE8]$"H' Q^/,[QPZ!#30+77(=DLRIV9Z< M3 MO6@H@D9A9[6-\PFO9+3,W_*B%4RWWS '5>W(R-R'FQ@N)Q-QX)K]JY;(P M-7Y-H=Y,VS/U\-*?^.U4]GLG@Q&]?Z+0=V(6=>\]=W,6RBJP@&(CM>,5"#8B^U;S J( =X0H,R J'6JKZO7F49WKS>ZN(_%-9PUU MY731N>S&Z\WU\$K6@-O.N\X2AU,!R!>,DD+5IM:EMJBS\#.$6\V9,LI0H1FT M\NPHUX9:"%?7REY2VZ!Z7E?$IY3C6SG^/$],&16C%O4.UD;$"]&%994#OS$@ M\QRB5Y!:)*B\\WEL^-JT"O1J>"X3I$*AZ?);%YL1I4J8VM!\@Q"YF?\*W-6K M9L>[ZB?'?@NW]V+BV%F_KYY5B&$I1W/@HN+3[50Z78;/# B[LLKX^9.Q2-&P MD-R]';.3.)89&-),)=>#D[7(4C+?V[3=-)CHC$6:M60_?S(5*1JN>\/V&.Q$ M_?U*6^/)U3$5*AUSNHQ;'#0NZ6!W;!AF),;47CON)OP-ZT'N)?-![OZS/7/_ MW=.A;?'1W?E(^HGM+I,E<-],'6 L,7HU$/X-!0KHSHMM_@GE"?D>"DEW>LOQ M6UE#/N^/1L/VG^0B.I".<47K3RV'>W*Z0#C131=1AA'-XY;G3*EBU(2:>"I+ M.FU2 .Y2E>-1(DC$":<_/][-4/G]F_-^J'KTDSC%E:U#T3L2 MZ1B=%<7!J]XX\%^A)'_B,Z[S_HYR]&^"@AQ/!9GT*N IF3WUS]M&_<+0M2^N MXW&/7L=_Z43_1C7+*0:Q^'+SWA0N6FH*BKQ1<#(#H7JM&U=8DHBSK>17Y'&" MB_[HKF%4%8LH:2E>!C[CHZ (;W '%F>8NL MM-Z)NS7TQ.D%#+5VKE0 [*)Z0P/V5HZO6>G?(Q">'/]WX._A2>NUCA>S[K=/ ME)>L:R'O6G3+5B)<'QPW_A$JATM^UVPG3M:CBM*%/%W1T)6)5\>"G?>BE=]O MFALN\-@N1XSZ@\++$7^;/=Y/%LO_ZDW^\6VZ^AW^.&E?\B6(O."8"PXT%20] MD:OYX4J>>-L@4TBYX:(P3M*7"<#J^L%1YGBF:N:?0YMY14HPD*\R &2M%55HXF-1!GHT^)#A0-<-FO^XF1 M3MCRK<*[!"+"BI%*[ Z,$+M!-5(86O@Z=GC?#C]_$.LHQX]*TP:[B$*O/+"; M>[;;Q'&^L*RZ,%(C4F#=U)*J-7C'>R/B@)TIHQQZ])K/HU8NF5IH[9CZ6);2 M,E9+DX!1-T))I2K3@:E:A'9E'CH3!9]AY[_D;U(B&/ MF;JTRNE00L7P,CK:\QGW@0M--A(]BFEF.81G;ZA#M.,C.]^L@RNE#MSK6F:< MMS%P@;" */R7.L34AI3#-S%@,95;%_"GX!)5=NH_E=>HHE/VM9>V$MYYI_SZ M::3FH3!.(7]MV9MAKW,7[@I$D)]?#X[( 0KK3L!?+4UF2A+J@TP=>)D!ASU M)B0&3WX,4&W-%FR&9!@&8S=.IL%5<[%QW)Q.8=J]5[CL#V4?\K9KKQ K+#G' MZ7=FC_Q=\"E-MRY: ?I90[?GEQPZ.^ M1HA?N3\GPQ"CPL1P!">&;/;")X>GL4;](>7MS]2#6%-E'L3JP%W0X-DS#5-S M/V9NU*&OP']UC&ETY1DLM?#U^?!]M(]\X:08\28IQT\H.#XQW4,5K0I"S*ET M9[38>T0J<$$TNH1 >FH%J743@O,M)!5(P(Q('E5Z2=5"$_9XX]CE2?)SY91# MD1Z!/'ITTJF%W'XT2@U2CV6WDXB5E,-4QO#,KB%.@?>*G;8AN1=@&[CZJX;. M6IP75]OL$XJ/-TY@^UA_*%UMA0E'C3XF\KZB\)VX?9X1O^#V 1UI"BIF57;5 M'UUTD"^T845D4N MS,(RREDKJ^;VIDHOGWI+2:J'7G?>F*4.; V. YAGG0O+*0,T/4Q[:-FDHO ; M#"A;91564I829'CS>X\*8G;R_<+)>@UTWWS;;TK0B(4"&$T[ M@+NQV1;NY\-X%]RA&W4#G>%.39&%CC4CV6,-BH:R/7 +;+ V2[=RV=*=80B+ M?'Q3WN0((>LEHY3VYIJ)RU1S4*I[!"#()?@QN%$3KJQ'H'F \4&'J[S#ZG$R M7DZ6DCU2D2P8)Q3\\/?B@M\O(!27L@*3X[G&?@D[]6AJSZ9E^B:B71BQZMT' M97XUEB:R1+[NCT;G<@R4 H^\5=:65, 24 IK'H'G 5"LCH]$&=%U%@.][_T MC56S?@<:+F"G>H/*,(H;2?*\XZP=H1L160M(*AU!U3_!>67U UAOX"M<<+_B MMB55FSO1D5$WG=S-T&H(F>CJAU.3@W$K)^K1J41HZ("LX'#XS)NPZ+1L'V59B& M:^OH:<>DF+IY&DL.4WA-F!A1PX>CB^9%4ODN$Z2:\+SR$2HU$#V8MF;KH+J; MG[X!91A5RD#+\X40).H[)<^2KEBR)J!UZ%SYK,T=. MNZ-VV)=IANRHIZQ](I@TM[RLAXZH%$)PQU/7SZKTIC^Z'AXCM["J$.I\5YE= M!*<[;?43MXB:$.IBYW4/L4S"4MB+^B\A4&C"==WLDJ[ ;*$T33W70YYT@\G6P9PD(N(2$=4%TU0@65(4$5,/-F M3BF@X(,?7I:>7CYX98:.+:P,Q+7LG$T\H80'.*G0GIXJT0J9P]PKQ].,E.@5O#FIDU';1A[L@ MF=?%>7*%1E!.8XQJ;Q*7K2&*9];6HT\6B]?A*CFD3?SVG$.^RZO^.79KKF2F MRQIY!2[ZPQ[= T]WS9!QI%=\"#64L50*;1=9)IM@:CW<$(\KF06_Y((P\9T@_E&2)") M+=P*B @Z)KK/RN14;6@M&H(>2Q[%*:FE(+[U!UIVB05O;J2-U9IM+(/G?P'= M7SE?7">PC8CX.++@RK>$)F20"ZC")*]0#PDS13##_@(J#CV%\>\ ZO#!<0J= MI[E"'<.704BU4O%B0-UO-*G@)13O(M"LXJKU&$S3=S8[ CJSO)W,IY+5PH'+ MG^I4]*!.QZA276:A8=JR8MB*;KY']P>3?Z'M%'$G45:YHP2J(;S0X&U9.XNL M)GX#R*)VS['=Q\&B*$\YG(YU@ V^96TFJ^!!?W35[P*[N*B!5X2W4A-<^IRK M,LO8&NDHQS@HH6YD-QW#1!X+WCDVDBY^+X'M)/ ZGTC\;O9T-WE:+<:KZ>Q) M=D+QA>G]@1X6^09%=&$_;!3,37$.2*SW_2*3$[_9U]M36*%.DHX#BPLK8\J, M^LY;+X-\:GFM0N@ _,-#5]$ MB''%.X@MDZC8K-5&L!R/7FWW)I5<2 MH!Y\!?6QK35"D^5LQ<%N7B&PN/?J6$;L>M->#IT+P,>5S4H_A-)+SA%8#W F,=6Z]%@"\M)\ MLGEX:2TR,#(Q,#DS,'@Q,'$N:'1M M['UIDZK(MNCW&W'_ V^?>^[ICBAK,PE8W;UO.."LJ(C3%P(A401!&53\]2]! MK;)*:U8+:],1NUHE@5SSD"M7_OU_JZF!+(#M:);YSW^P6_0_"#!E2]',T3__ M$=KY!/.?__OU7PC\+_R#('__OT0"T7J95A51+-F; M-%9!M(+E"0I>:.[Y"V M-9M))E(#MJT9!I*Q-64$MK>D;JE;.H4RMSB!I5)((O%K_[$9R8%/L)0FD47LZ?O.@JC:T)=O? 0IOO45W\\!1 M^OA-/+ 7F@R0LC5$2KD[)$50-(T/\82, C5!HDDE(0$UF4A*=(I*TDGLQF(_>[4J+X_!5$IH MIN-*IGQ_U]I?/;YM[9M@-07*K6Q-PTFA*0*]?P><@>+>C]^?4/+GYN)NJ+9R M$PZ0'ST;?K\=68N?F@DG#P(L_W1MR714RYY*+J0,?!"63*#,'A8WRW7T)7= MA*AQ[DS-@"#:'H0AA&BU>4;:$3E53(D$*@8,)/+$.)%!NW(7!;5!W7;'U(!. MIG\@IC2%\]TJG[NL-9UJ;J#,G;2I9.'SH & AD #S@]$4_[Y40RG+JY9:M:> M&(TL2R6DKL&H*6IL+0-,/(;I$C!BN$A@ 9"H.)NZ"F>L.CT]D2 Z,XW(]3%L M]%$@*W.;!U3) MM-6)R%!8DLT6>;]6P;3C:O.;)D M](%DLZ:2@Z;Z?LKE(2W[8]2<"=F64ACBZ') )=(B$4PYD_N+<3Y=>@')S4F$F@M<&Q8626)A9ORF2P72#5WS=7!OP!9;R>+;>>I!2 MA7J/UKEY;;T<95L8*HS$9##;)G')N:;A1)5PLE"F[^?7K->U9O4 MR*$(Q*9(!?-3)<,!EYSB1K1:8*0Y@?5QZ_#*_4S!L$U4\$%NI6L+6W&+9*/> MS35%.ICIH%]G>TBIGKW\;$O0*;=GUN994'VZ(&MY4#?X64L!C[0775_-JZ4Y M,]M62=#]_.>6[@6@1AR2-@1<+M2(M6 MHZ=34]$N4\9:)O)-J ,_:I#>#>P;K-#)H/5Z]00Z5K&1X&-HP2WT:F]:G-^\>YX!1,./- M5P6^;#4S-%ES-U-#% U>#:/M>Q9X$9V/Y.?Q\"> MA6;D?M:N9+N!O0Z,&YI 21A9W3_G_MH]_I2]H52"0!]>L;FR^[Y[R<]'+/ B M1V!['$'VY0CRGM95(#D@<.8#W>=)1AO8TY 9 L4E3:.P-ZN(\A-EN:$'$$?]:4> MI!\:H0!3P=B6YN@9/P/MTA@&\/H3->&XG%JP+,5I6ZYD;#GCA>>TH9E\] C> MFT&\ OM@[/99;&7N)JHFH>B%TS,]CA M_.'EKR#]G#Q/OY'GX=#46>SB%?"\S;4FPFC*F2Q%X=S"!.N$[476UL8\_QK/ MO]7R1X#G#W@U+F4)E-%LB,;C<;Z\+5(Z*T^ M 'HN?1CR_%[BZ20*D^5L:=*W$;EM0[WAV?X^F8?I_'IJ&U)/*(S\A"_@[6FB%ED% M^48R'P'T>R82]Y=3J!-R15*K<5U#F/FL-/-*95%O)DOBM0O_A;GBK4LJV+F6 M7;']9==3<$6QURAW2V,^@VH3F:8FK?ID9,5<<:XDVVF67I_6\7R>#>@E4Q\K MTTI7UVKK)AA([9S:C6QV(1IL\-@WV+<"'_<-/D?9%G ES00**]DF#"F<+7&G MDW[2Q7(9G9UFVC-Z2+?YA1?91%,A\&6F?,5-RU6"-8H,A6>"J33^Y7A>7S+7KKXN:J:@0^&4[E7580-0J MZZ10X: +ER[RWE) M37V6Y/6)%+532W@);#F062E%$-VBFAROR6LG[H45=23H6[?,X&&V91@0Y!)\ MK T<=U>>2DAEIC@C?8%R&\N^1:W:-?_:J?P2Q-^;UB_;Y'ZC54J455)&IUQS M4BUV$PNS<>W$_AJ;?):%J%/8Y$P^D^S+X_02];/5P6($5"N!7[M_?5&;?([4 M]8EL,KO4I%PNCR]1G%>RM1&5GW7;U^Y47]HF1X&^+]KDH8KV>F,+3[,\,W>2 MM62"J''73N6OL+:.?QB'@F6.L_ZX[M)^XQ+,FFMICE>8XHZE>M:@"OUJ-S@VHW5)5V2R!#X M19]DZ1)%LTTR?13068.OD=.!:EY[6'%YGR0RQ'[9*>E.6UF/;SLM?9HB;+JZ M;([I];6K["]P2DY'[I-NBS[LB-!)#JHM2L6+0D)<&"O36"TSW+4O55VN[_#5 M;XD^Y(A>ODXIZUF'%X!6;=G9<9*IUJY=!5R4(ZYL._0A"]16\X0_*Y03J":4 MEIV\*2:6=JP4KFKSY"%5Q5%NSJZ&250 ^EH1L+*_'&>NW9.[(%6CL-OHB &G MFF.U12S7 J\10@]P&N9T8UF]KO+\0[(V1YF%X=.5*4MQAM9HEM9\=Q(+ZU65 M\AY25=,+D?52!2#'5(UF>1,EL.XK. UF3E@ ME*JOYF(5?%4KZH=4G548Q9"MI*MK,]PMZ<30KTQC6;VN98E#L@));OID54!9 MRIDRT_&B6I"LV+!^55;KE8[A;Z-R5[*#1Z0]^A!6X63 J/&D6*&VKY#@>L)T-UC9_'_$$.YT9E@] *!2; M>[?\D1K21(4IXB6V:_7%U;)O%.:5R/+'V\!^8)1GX?Y63/.YC-=C?6%-*$.: MV5*)!8U!I^E7B72%OG9#?S9]<;Y,UXG4/T=UNX5!:HRC79]O=%OZ6IP0UV[@ M+T'.\^]W/ID*[]LC8X!Y]9H^KYH23!006GA J MO)5DT0+.4F/:Q.OS7&39(Y(!P9?SS',YG4-ST5Y:[;'E.9*II$TE.#)L#S/! M\-TB^G38E\1AHLUZP)AF*CDW:XPBF^D[8CG>".AUY'<^'0AD:^IP-I(;ME I MV/+4I>W49RJY8L]MF(VQ&DIO["E]C4)Z\?@OE:ZG\QT3[HY:EA6*!F=:Z6VHO U M=92-K%1'TG2?O?H4HS^JLSL+>S:NS(<3O3+V#7V6&?!,-K+9^$CH;(P^;4G, MH>RFEY*M')R*W *.:VNR"Y3]>@FSOR8\J4Z,4(]QV%DK*]G->F3%\Q%D^]OZ MCH!V'1)X9!GE/>1+\@W>F)(1$C2X4I-,:11F$+9T_ CM/ZBRV25E5=RD7-$K=AN=&(RB6EKD M6 9BZ>XH_G[\"BX]1>"SW')9WKP&2Q3U9:3H2H[*)!W;!J;/5A;$=W7;J,KN0TYXNJ MWO7]$9K(+2;&@NG52EKDXK-846@X$WW?)?]7FYA))TFW=;R6(H:)B M*R-Z2>! 51V#:"ORCT#ZGA'9.RE];].\(<2!X&J&YFK *9D+"*YE^[PW@\BY MYX(1-VM64K.DSW9%C%Q-K&E=3%\1%]R;@S>!^STYY/F8_:VZH(45VXLU4:-0 M+\?/JQ,V+=2-*^*"R^J"J)7VG$H7\&))Y'TL3Z )*<_KHJ,7-"J2N92HZX(O M]PN.Q%)OU06L-2L/UG2N)OC+41$?UX8C%%P1%UQ0%WQIU/Q.2K]3%Y0Z^9DY MKZECG2M*EC8L*XP^NB*+$!%=$-&\REMUP4S"%3*WJL[0BKUF>_5QM6]'KR5. M5'3!E^\XE2VR]X49.[M]/ MXR.P?F?Z[L9VP%B3C7OJIIU4LY\Q%PF]6W#F;5QF$N-#'D/X. MM U9.BAR+DW#NN=@V([0Y5&JVQECB9%02*M5>NFOD^SH>Q#Z!;!_!ZKG/1N: M*,\&X4Z55?#I7G?75SV5*%MCO=L9FG2S0;#F\KKM\V[P\U#_#C2_O[;;P[&0 MT1M5+YCM1=H5FK!ZKB M-)<=1K@=0T2=[?,WV_F4MZTR0ME/Y94QZK'HO,,-T7+.^09$OIRW'0T"/^-N M,WG4;/1-!PA3N;"B"A5F.>Y>-WDOZFY'B[@O^=OIFE+Z\OQTMLK_@-7CG-=3CVYC?/G;E(Y#+D"!MA>J6E"PJ7= =) M/++4?F,7G/.?N1B=ZJA3'.+V#&_DYQFGH.?YJ5XAQ^,DR\Z:J7ED8^_(\L9U M'^?V#&_,\&J.XXWU1*KB5#[->D"!OJO:+[-^ M[&^\ES?>:E/0<]D4=-^FG(@W?'.P1+,DXBT]6[5+*J9,Q;[R7-]Y1A7/> MPT+#=$HV.!5;DEU/,MK GCXDB3GX LA2YB@6HZ6]FZAR5+ MC@AZ4W49N;*\1TFC(U!N\\//@GD=ZSTDI.M)B%IS>-_VLL6L[@\+[J M$8-\ M/B;JFXD*-7[JA"F%Y[=:W.LU7@:F!!^\UX?/<;4IO*JTX!_.W)$V/1PTI+1K M$D*EWQVYZD1?,6[D2!L44!Z%;==L[RAP$7'^+[+I[G/K?-B6&R2A8^2F=+&/ M=MM>JY[6AOV,&#EN^.1"'_:=4THOTNR.9'@@XZ<=![A90W(>NW?/XG3+ M(;A7]_N\XI10OUZ?%5+Y4C7"Y\$_"^]>Y?7+ ']/+GGE1(Y/Z9!^K5<4> MHW,W7<.R+:V@13>[%%T=$K6MG*?3(4QF8"Q2.:+%3K%V*NWK+=;F(LLAT=8A M7^Z'/'>JQZ=T2,(?]$ ?YV7!GU,8E;?&I6QT#^V,J Z)X!;0T^D0H5')EMI^ M;:QW1^NQR[ =-^G%.N3*N.25DX$^I4,P?Y[U>Y3&H=1 ;#.,WF^HM5B'O)L[ MHK9U]'0ZI+%4<8Q,$'ET3E>Z[1%6;%"%.):Y#BYYG+A&1968D"(M@S*KD99J MDP(&RK.SIR[>EPI$SU//CZ5$>Y@C4:N5+ IX)6M5&Z-!Q3I_8^]W07^&X^)/ M45L%?YY:YGZ_N5['!)6&JBY8JFJE)LVN0*>CEQ)]YU+6 9B_8V+CHQPQL;%I MSYOK/9:2]7)!;=4*R7%D#444.2*J8>I'.8(@V\V,D:Z2J#>I##R]U[.=Z/6C MBBQ'1#CH^"A'6%2[29I&1=/Q:CZE8U(ED:,C&Y!&D2.^+M!XV8\HF;(U!?<8 MJUIR>-Q^0\: JU: 4%(& M:"4A:FRO3V7QZ)T,L&."%^!_X)1W(>![^AZ?YZ)7L+?E'DI9B(4:VW&%2F=, MU*<#(=MS(YO8>!/WO GPF&N..Z.>0 R._)#2_'+Z>W1,/DA*]/_'Q+P+/2TN;,A8H*D8ULKLL2174!]W26 MB%T,4GJKE)+9.2I33+Y,^PWGNKGGRRW1-7/-H252.V4JU2&;;7W*2Q6[-$+; M@\IU<\A%+5%4\R:GMT3ZH-=M=H=-GNV6[6%U/9XT4X/K]EFB88DB7 9P.DO$ MV;*_%.=)@?6;Z)B"J+&SS'7KF:^U1%?.-8>6:&YVC)6W3-,Z/C3RS0*+RW[K MNO7+Y2Q1A/.UI[=$=;>=)VO '^IS(>-VDX;DI8S(9G*ORQ)%M9CD=);(5OW$ M0.PE1GJE-M5=0<'J-?2Z]?.7UEW58@[18.X5QS%=8WAQ_6AA\[AQ6RS2N"X'\=B5]6*C MH(PNT7P@H3M>)(<7. M&YS2GRTIJCV+&/18 D,3./UYZ%^ITLNTU8G(4%B2S19S13SI]9GR^0]2/&]H M^7&_US.U#=:"D[L">VLJDJV(SEBR@2,.M.(:7_7J'.OU"&K:A;XJ7WW0&5,@ M.9X-?FWG&-ZS>\_NVNY[\*)77BKP.7$Z3Z0-:80W]"YJ>'VW7$-7=O/@C9IC MD3A&W\%;WO_"G+: I E?MX5SR563RXSH2OJ47B\&7)5/%_:2YDIXP_[#ZMXT M:(UIV1^_=L),8./%5LCJ;_L:54#S=9Y M==PK@D1NK[;C\6>NNF([6;6IF2O.=8DAF5YN.6\9Z4/2>ZY]%XS_ MS.LV#I#8$I.&R/2P 8MGQYK$%9A&5SA\8]A+9'O/Y[@M )-(Y_,CLU'+H_AP M+?>&ZX)?E*/$:V]!\&GX3(.NKEBIMJC%L#PF!;Z\Q$I>5RWG^$,=$Q(AN.%E M"OS45G=01BS/EH&S^3H&DA*J8#C!7W_#/XCC^@;4Y%-IE5AJBCN^PU#TWW_- M).A4FZ.$ 53W+GG+, \_V=IH?/^;Y82N-WR-$=9V_/7CR5/MD68F7&MVAV.W MD*'_@HA*C$'X"(R\)>$O>V^%-\]VMZI0-R=4::H9_MU_VC X<) Z6"(M:RJ9 M_[G9_ +_[T"-KO[GKW"THZT!?%#PEO"]=_ C$OS#R=&=:]E0R-K\L-[!N?PJL34(RM)%Y%V 6SJD=MO=3 M0-S@^QYL,@0$V'\-+1LRV_T]MP$I',O0%.1?:/C?;D3P".+(Y07 6QX!/GTCO.W?#ZT# 6. M%>JE-IM#^':ZS?)__QQ>$O_OF";/9H56J5UB>21=SR%L+UM,UPLLDN5JM1+/ ME[CZZ>:>>F7JH:+"\ =%]1B.QQ/OIOEBJ5YH<_4;)'>;O45P-$FF3HAH^MV( M?CS!/->J_>^_, K]*YP4M#RF98;&5Y.1K=O="M3PQP(4Q)2"\$,!VEW.DKW M&0G:G?T():NU! MW-NT>VV*7U#OI8Z8U+TIMOI M;(V+;!F&-'/ W>[#/DD"EV3KC@3&5-X8X1VN0^\G@=ZB%(HQ#)XBGCA&^Y9Q MXQ:A^P[-+8:'/HUK[Z:T\WPVB'.5W>\+8+N:+!E;SH#VY[8FE+L[NA#20]L838>=5_N[\N#:%E]ESP5V"J M'P$90KAQ4K9_7>5-H!&W5.J;@I:B;C'L&F'[Z=H!NYZ$-4_%!Z>."()G/K9' M:N"MR5D,5=.3;*CW#;\%9I;M_M@IM\*$6HUK_I03 M?'51R@Y,'F>99?"ZE$4'HPL@ @EA/>G4.<^U=J!/4C1)/5@#XY8MI.Q]8D- MS6O&I2FD6VVV5>TC+;;!M=I(0VCQ0KK>1MH< GV[-G3@-DX(1B!<"\&2?RA_ M;G[@\DB[R")[#N"]\Y?.MA%X&4L1Y+W->A".GZ&).0]7'K?] 4Z>D,3QAM&* M>8[XW*GC+G?>LA%W#)#Y3@J034X6 :8"E#ODB+NX+YY*L"((GSI6)-^'<3 P MSR2EC7!6["9_O.=7YMC1M(+.^0KK2V2[/A%5S,BFWX4"'LSDGP452>,P)#CNC8,8Z@AQ4[QK%C?,V.L2H9SKD\X[8MF1OZ M/'&-T6&RMF[,"F.=HP54*N2K[L _D6M,?DO7N-U*U_E2X !_0]_X"[WASWHE M._?7O6?UG?^KVM9T@_^O^HNX5B1<)O)K'<\3!SQ!+US-"0H;$56#/ICIA:[_ MN=/B;%A9X MY\'0S38T$SR]$KB8EGVW6\X+ZH*P!,$P*!G9B"?J7(83IZ7(P#?!ZF:C $JF M?'NY!:]7EP[8E22[(4L'Z^,V&(4=)$P7D1S$F0$YJ"93$,U$--=!Y'&83_@S M$AKL_4$?!J4BB=&42*DH(9(IF0GB/4E4*)D$$@9(&56?!GVL,_ 9-M>&<@PZ M@^:WH]4F)RH5=9&G4W8 MLRR5TKEVV4J+^.$SV^G)*)UOJ[;0U:WYD@;3:CJ_A",/GME-4"1!K'MK/4'@ M"VUA-V:EU$A,'CZS2[N\ED\*)#LEYLDA,9"P"1Q)'8Y,-GAS5-?HBLYE*OE2 M/;OH@%4:CCQGP"MYKK7[81/5AK^$_+=AKTO^)0;D[>]@X0!P),JBMGJ^2*) MLP0([Q&!A /DA+9*;#C^KAC^3Z3KJWFU-&?FNH0[(TYQI1+6&QW*_P>5S,N5 M-P_Z\1$,/W[5V4XZE][HBP=Y?-GA?T0<_'G:A.[=+$A/NA>-"9YS[=X+VC7P MW=F=I[:T*FVKEC?-:_8]*:B#)DZ.[@Q7B:S.K8=%K]4!'IYL4O3L%L4>_37G6!8GW:;L?;OM!8*!DP4C)1B:>K3F*)H?!DJ4^ MCCO?+*F73:,\OY+S\<#FK:F(JZ9]J<4C['1F6'ZP=>L@P_ .]H\PE)H)W?'9 MUB,/&=T>2::V#K__&3/X=5/WL=1<$#T3^+D X+Z^KZ#KT;?I40Y"S]R=MM: MFGOY7P^D)_9XK@Q9H#OU07'86ZX3[\G__OC%FB,#+"U+.2J_;W_.S87RX#MT M6)[IVOX>+D8N[:M+/LFPA=JBY)AB46Z&/4?>D>#G3J3$GF?;"Z43HJGJ8FG> ML6_#\O"7O#32>F:O<>PIU/PXR M@1*?\HL^_N8_S^Y/!8W$Y44P3J-$ M@DRAU/G*"CZMB%KWZ]>!L&/T7P[B @/, E1NBT)N$&B(#"]0H AT]B1(N7W% M=24KVE^/ZKQE0]*'3'L3UC#"+]+6WDNFLOM)U1S(RYL%LF O 42_&M01F", M[1XD!4 ,R7$1.RQ&C 8=DJ>-L$^_ LE##\K67 T^8%.Q 6R(S9EG.UY0NN%: M"!P1)D8Q_(_AGX'_%=3#I67W[H3(/7\J1*56EX.L\8$YQ6:(GJDQL*T$WA7:>30>0*; M^)ULFYX(P0HC]G2D:A360J( ^NS<;K09T5M[SVN];Z^QC^##4*/=)I$I^4*NN M+#>)%C2V8N/E=J[*CS:UA$$%,R0S[UJR?H/\#]3>*(;,)!M92(8'@OIU)&S& M]MD4Z'$%%9/_=.1OVU( SV8_S#WMJ[-6LU^F>C5T2E&S=;[MV1FRN=E=,^CW M2J>@ZZ'B_,WINK>U*BB:O L4:D"HDV]HWHD\N]78@1J_)[UI9;-F(5LI"HE. M%P6WHEM['8COI!H!5<#G9P(0J\:H["H3,;R"!, M/& X$FZP=Y _X/,@FR*.!\V[,[:"^OK=;B5W++E/Y[Z4'L\RW.X2WKR%X<^; M,/S^ ]_ .(3,#J\/)Q""8'PX%-X4S&+[G&!7H!-.(IQD$(VG4$21?.<6>5S? MNB'PV5=BLIX=K,)M]B<&JM257,_92X)ENT4O/^W;KUK2N_>H'GQ_,"WT"F!K$$Q MFVJN"P43&%#<;,L,K+7A(P!:;A\I!?9*DL.EKYSD2DBP<>RIRGEXQGXZI^7! MD22:#+1*"XP\8U/VQB?:R!\!']!_(3AT[+#] )%D&FV%X M&?MK-^Q@P/;ZS6[ L_/;/2CP0;9CGYGJ;J1F;M0;#)<3^,ZKVG>E;J/+==L$ M=2HET1A)2B)!#V615%,45%ZT*M(D00PQE $82AYLKK/L.I7.,H0P%5N =&H# MOD"FCR6H!]WR2BU/,A6!FY:I\0A/,I/YT00UG<& @R8Z(]UO*-4VGI!Z_?)H M+T']L 6QXV)KABEK.F]R],A-,F.V'KR=>#IR25>YA5^P&RA74MTYQ^1:&=LU4?9*;+ZNBFSZV65'".]1R!?AE].0L(3X^>B#8LV6;70%0\9._"71I;M MGSS!]M!IP\YNWW&?7^/UY$@HEM-=EDLF?:KEZP-9;VZWT[_D/=>/>5^G:%04 M?>U)787VY#=>YD9SWKN:FZ];+S)"JO1I@OJ8+OV*GK@;V0EQF?$"R_A'PVQ+F6>LIH+Z&$*51G# QCQW_('Y"K MPD3FI@=9D"?<4O2Y9.&?C]I9EQ7>N\;Q6PG1\RL- 3-O6U=" MUMX-"E1DLFLEAEC7H]A_]%#LJI]243#,B"7!5)%5&%AF5!*)"T90B#Q4"8PYZ M]Z56N0KG5%15K^0-Z;*>%Y(.R\WG,TS5"TQB=;1W'UI- ME'K9L5]<541'.+OLZ;H[W>?=%.7>\F]IY6\&/-!0E($#EH_18T W]E5^(M ME=J>7X4^G%\5U9[C;XE$7@3S$;01@O1RPOR.PR'?B?[OQ'G708\W9@M>(LQ' M6AH>)=PE]KAEW[C)X\/:(%+M)[\7[?B-?\3M^4<;1X>372OPH7!Z=_+/Q=H[ M?ATC/]H_\+!Q8+.3(-(<'L%F"Q^E^WG$_VU%[_G0IX<\$)Q+'H:L3\Z@#\5% M'&C%-;[JU3G6ZQ'4M,OP8[Z:_O$H5PAC$,5R%2!K4\GX@00[>"$(Z.. ..V( MG"IB,/ZE-R'P0D!QNDX,*7;>X)3^;$E1[=GH![)]CO//CU(]?Z3:-^3U^Y^1H\Z%CG_.U/>R8^P"R<3SO,(T%O-KM)"#V4I$O[_+.' MTSWV>$JT8]38)M9PAJ0(4E%$12$QD4SB0 R.!1W=(*5Z]A9)UW,(+V3X4JZ4;I58?B]#N*':Z:;YJ>[$]1S; M"\X RW.M&O)PX/T%M.4;E<^ILI3G3T$^VN5*WY)?>;+AUN:&+SY(^WPTT?AX M&^\M_:WA8[!;\L4JB:N'\(I9])V=)%Z#]'1L?TH&>SCCZ(SRE\-ODBX>QGL/HW;MKC72K7=QY)ZZ,ELW+I@=4@J7:/&_[F>)[$US0Q_I MU[$DU8?(\8AMO[Q-PY$J->+#S6M>4SD1\:Y.I_FN#Z!7%?#U@709KGO'+IQ/ MMO;_A%;Y(AU?:K,U[%Y[\NTT_,[6V[S(T Q*XQ$(UTLNV)XLC-T>1.HG4.I7 MJ2<^!.F7*) KXK3\?35L>(;;]&ANZ&1NQ'?U%&(3?H[[->JI1S4\[E,N@K5/LL7618J?!*GZ106 86?M@OWJ&8D0PJ: M9O-C %QG6_#"@QDT!$')"X%N2EZ0/SQ3\A0-WO)GV(LC!^3M""P<@<8FXWMH MEV^G1*)BN>*H+K(L$EO4"%O4AYB)RW,-MA4F.?D(V%%A9Q&11Q;U(8H*:T=G M8+//ZZ$CI@L! Z$1-343[/KF;;8T'K&\P<#O;&#)V,!>MTZ)BH&-#5ELR*)L MR/9#PWVCEDWSQ7R5Z_(BA291FKX6TY:5G#&2-ZSE@VF+#1I\23(V:->M6V*# M%AE2Q 8M"@;M454F?8OO5* &5;SIWB4V/[W3[/%M+ELI(5&P0KULWQ08Q,J2(#6(4#.(SID[",FF^ M!&U;H\7RT,IMRD89#$=3J4B9M[KEPA>ZUF,[]SM5@M"Q3;IN]1#;I'.4JN&U M=#U=V+CHN1*?%7@>JK!T/0=_KO9#W9:/@"9[J([$X^K(*S:85\1R-+HR^%UM+'8^ M(QM;M]BZO5_5$$TA76^7 K^\PT(- []6M]\"S5/E>*$5 5436#>$B W;E1NV M*^&V9M#B6G/#S;^AC8(_&+OO@8DS+,<+&J.EAY;G[@X4;FF._EWMUOLZO,5V M*[9;9]8D9):KMUMC$#E_(-;;WW*?U..>!%6VD*Z&#AZ;*]4+T,/#DBF* MB8"'%[>^^#[11(39K I&DK&)($" D^\;0IS/0XA-&Y]H-3S1Y+%@V0?*2[%IV;&]B>Q/;FXM4& GU%ELH M\6VVQ>;X=)7EN7RPXZ3=Y]FLT"JU2VP4^@G$16W?Q_Q<";9>@@[MO0X1:9(BDLD(J)('ZQ57KEV[];H2ELL!50JKJ859<%0E,#7+WK-: ML86*+51LH2Y1,E0KU5D^G6?;_?O"5J@G"#J%45%(NL3E:=_'-$6=UVI!PP=> M4@$,H/:*IV-;%-NBV!9=0#\DPZJO_5.;4B3!)*/05.W!#"5C,W3E9BC";,:Y M8V C)7-S +MFF;'MB6U/;'LNH!0HMEK$NV\>#DDH%>KI=I@*H^A>GNF/1X*^ @D-D?72RK$QIUD+"7?V?EGS"U.[HZIOKL_DCH@ M#I*\99A_(P\?P]#C*7VGTBJQ1\5'/8\W=^U^"C7![C?+";L[W=G "%MF!,]^ M]-2058)CLW'LE@JP"[]NH<+(6_),O/-$)G<<\\AHM+EL!,Q$.U"9X7D"W*D V=JT%[N#\@5L0S/!TRM/ MI&ZS?W83+99ND1<.E[^HIDE]RL)M2/GZ*;QGI.0+YO$<1 Q@W6V?VR/B ] G MIN%[.7?0K[.]FRV;U;.W>V1ZP^&97R=Q^Y-#MK-#-M/[0FS^D:YQ B0J%%*D M7>2$H&T'?X.PO2S;:"-UH99A6PB7AQ--0T?\SQ/.].,*"L[ZX331$W/C:[,Z MKF.8Y^7VXTI'5#&@T I&B HJ4]#BJ$EQR"0)D5*&A$SB0)%2R4<6IRV+90)K M+NJFQK#9:D](5S)3C5&;(B;B3T+ M-875R(Q>FZ1M,5M)BX2(/AU9Q1S5L<3*1)B.\81III/51G\IDHKP[22=S%6U!#[0 MI]65+V-IHU;.ID7Z".RJWZ.F6HIDI\E\T3:S>JW +$7F<*30M :EK-@UV<1B M1*1 2>]ALZ68.O)V/9$:$BEIAGK%Q2*M*+ALE)8BAAT.[>9IH/#**JTG,*]M M-,#"=6DX%#\H:A!]QN:(LD#E!*M5*7.NHO^"O+H$9+6Y/I(FUDSP%:67*&CYLUYQY(MI$4H4>C@4".A@JN6'0UWCA"ZOCSA+S<&A1PB[ M+)?80FXU7**5(:ZE,+)7KEEI$3]&6*K63UKX&5WT6&[/L0K?DRRY%2KVBQY M:P'O:HG$4"ED:[T1],P/AYJ=F9;/RI6*X(V4F>ND[ 29A4\]0BVK/:&R24^3 M=8VN5[M^G2^T&DV1.$(";]E1G,ZBR[$%AA<9(>U"5..DLRLX!TQ1KW8(]AHQ, M'&&.!=E9FS/*;Z.>[19'==/5I35$S1'F8$A%P_K*I(A2:YDN> 2QFB>7(G&$ M.3K>PE?2;;RJ9^N#@C$DJ_TF/Q*)(\S!S"V=X[TF(X TE['<_LH)D#!I$7CRAC1SP-WNP[YS$Z0.MFF#(.B5-\'RSDD)LQ22YUJ['S8YBO"7 M1YF,O4SI=LQA]LJU=Q/;Y2DVOM,;5P:(,#'R?&9V+Y+?>[X%GZD:UG+G6.V^ M)Y:V-+O;I'V6$$^O9ERV_EKXXMU0:>A8AN>",Z=:3ITN>^."S!@ZT@GX #E( MO 3HVH*)WQ)D3(@($ *[)6.)B (A4F&..";$EQ,B5DT1(42LFB)""*B:\)@0 MIR/$>RM"7_-:+PSYD#B%\BZX:*AW\/I/ID M*FZ;7]JM9,U62'CH)[);-(ZP# 0'9%^+NHLT&UP[%Z"OJKV/E9&>71\R>QG7 M, 5+W^)'T1'^HIE0";IWBG$+>&3#TN,X(^:YWX#G+FL,WLQSUQ._?4C%W^_. MHC;J7G+&W]E=_.W\P?_Y5K'24ZE%B$=["Y&_M165FQHZ M)9N)IK\4DT&I(Y&\(2CF[Y^/X?S6$5XLLE<==7V)R&)X4 H=)&/%V=15.&/5 MZ>F)!-&9:42NCV&C4\OLJ#,K$&+;P84L5\/)FM4:#HQ 9BDHLZD;C"9>D-GO M$2P^\232L@RYU740&\A 6P15Q#>("=SK].8O[Q%_@>(Y6<@2^P6?\@MVHM.Z MEYPZ<+>)F".ZQUDM6LV\C$U9BE^JS1JII!T\+5*!OX"3-SA!OLE?B(7PVPEA M;.D_8>G?*87X,.WG?='(LE-YR#7JPW4#&P:[,J$'@!$W#$&_SP/XQDF&DKF MPRS;?]8AB&.7*XU=GM=><Q!979$BS$42V!>M;EF.45?X@6IUJ@3 M(Y$.? D8QB3?YDK$XAN+;^R5G,4K>45^QZTTNT@M!@PK28I#+8E$GULLH?Q" M+X2YH8CD[Y:&:-A@)FD* E8S8#KPS9">B!5T'H]CH/>HH2^LR3Q[HN*K8?MJ M;74V9V,K?.Q&]M*F$K;\3X>E),]'4GD^4\%[I>D ]1TM9?#MY'S>&8E,X(-@ M-QB*Q^F,6)2?<2R^&K:O%N7S.1X?D^4.5L+]I5M>Z;@B=*P&RA0&U:"O5) 5 MN2'HEY8R?Y>D2-BP[<>OMN5*!B(_JK>+@ZLXN(IS(Q=;=WE%F;'<*F'VVFH% MY6J]A%^J#$OSYBB8SX]?5.J&2<:%&;$ Q]F1KURS>46""SXY=$H#"886IE:S M!;+M)L4TE&#HCE#$#8I?7YG&%X<4UZF$HJ]KOFO9?\RN,;M>T8Z!TP#YS2/9 M,,UNS>#$_3"]#N:>-IO"H?'Z?NP"QS'LA5/N&T%L&)+IIDV%WKU=+9W(Q[ :L&\M4*8.-4P0%A NZ(6IJH>)UIKKHXZCN3)L229^.M M\("78%&?CC2 ^%Y&D=K#G\+Q15]_10W:(B&3[$3E4VY4=TRY6HZO!OJK=>$979&-")=""6Y+JZU./!KFL"NU4T,=%V=QDR\V49]>9!KA M*?=!:TF:BK,;L2XX?U+CJX'^:EUP3K_H'QS=@/K_Q\K?0;R=08P24:,7RA@;X&CUVM'_N";R6+X#K MJU75F;=:'M%*:&I82J_\X4+PDF/,K6)\WUY#%R7L9IE";^@7MVC%POJ;"NN! M6_$;"NNYMU4>D=;>9"BBPT$IR\Z[>E?2%Y-6)QU**_0A:/P&H]]9;AKE!$M4 M0XGKU%WQ,O'U%(=$%?J8\W]?Z*]\_V<$[-GYS_JMEM*94K74+K$\DJ[G$+[- M92M%KIIC6_S__HM(_86P3:'4[E_+N=G1<>(CDAB,I+7Z[B<+QCP7/3L1GRSX MTN&QAB:%/*J!XR?(QO[@E?J#OT$[@#>8C)A]8_;]#M;G"HW,!7]LZWE;@&AMY2YM*>B-MU0>7[X5VC'99YHU. MR6,ICE!'CJ%G%KT1G.BF^PQ%I>*UOEAX(VQ=KWU=[U/2JYO=@3+MHAPJX=J/9A<0^W$X$8<3L;?R-5UK=DK.?U[% MU;51PRMS*5>?3U(E;-*UD]2J*>+;]G@D%I=,QQ)]W0F"*W=AWBW2*2,Q2:*I MI/>]F\Z)K\%OKJFM52[$]\56^9 M-ZB>VBC)YY+U&B=0"]PJ@[HQT-(C$=\TP<->*I6,1? ;BV#L )RHTT(WZVFQ*%-'-K$SL4%EU:" M5.S]7LZ74K%DJY;SN96=%_BI(>0&G.XE?:C5B,V9N:(A[VOB-NDG'&(Y;DN$O,Q5V1CXCRM#E&:B0!&]!I,.1#E< M-4FE\#AS\KB/C'RX]R$.N>*0*\Z?7,IC>9->6\RJ2D.8MO,HR/0K>-=2:W1S M*>)A1SP,O<%?5&RQ&,=B'&=.SNRNO$F.JVPU2ZT]>BI0>L[UK"[=0]UT(,=4 M*,?8>XM1K] /@6^N6G"\"^SIJULN?PN]=,WJY]J*-;A[LD4_MLM\\?[ M$+[;DN!7M7/X:B1\M::[[(:'%]5$ =M<2KF:\L#CJ@QQIT/&&WFS]%"OSBG>;]4%S 8G:7"Q@_T#4&^ M%)[%\AO+;YQTN5Q=P+&3:21:2!06CHOZJH^UZ$:/PM.A <% Q,(W9ZWI5'.G(&BS'.S$"VP^? 0PY3B& MC7W@*!JBLU>MQ1P>^W*U_UO6/<,W-VR@ ML& 7Q0[=\@__-R9C.G+30%A'E-9RS9 MP!&77#6YS(BNI$_I]6+ 5?ET@1Y]=GFB5,^_([UY#T5HNQJ2S=F\&^S7[DB& M!QK YH.YWF<^T4WFLR[9MLBNZ]5DS1Z+NE1>#',Y2EE8M30DR=G0\*XL[^7P M4$?;NFLHPHWYP6 M]/9"E\N4D$KJ%&%/!G6\TZG8$'33>CNS:.'CPUR:Y;E.@!9H\1[Y6_M^QLP& MB=#3^/$+D1S$4A&$!S,73(? WAA[ KW9? BX(WQN#LC[U[&'ZVB8 MN(M\\.7%4SHQ!S;SR[)S5&KW1\)W(13Y_1R "FQ%(FPH6? NQC^ M5UR $LOP5:)ODWT-5@PM M\ZJC\0T([P]!9ZVE7JO**BMXTG)"2I9MS-!77>.(AN(?14+::LT&5*%:037, M(7A\2B;6Z.\2A^\A[4UA:$)O=:M%8R&QB9'16TD),-*6KR9O(AF$OQ=TD&X5 M77I=) 6*[ZKEJ;7JR$PZB,"_80C^3M2]%'[WDKUF=IZMLI6\7/11U&CH@7@1 MU T)_R53AYLN]F/.;X <[B%L/HHAJI$CBC6[WA*D&=9>Y1J3?%$,,$3>T#3\ MAQ_!T%XHO@VS[Z-L! ;8R'UL_1T$\P7N*A?*>I>8+DKH=)IWQ82]3*A,,^0N M#*=NJ!3S)=QU2>R\QE[#G,M/FSV!1?F)W!Z6PFQ1Q:.2.L-(7!69Q'N>0FGCU1?2X(&\YYWV=[:\#.^U59;V=4)^LT16+3 MA#S>?_R;2EV<^?C$UILWB!V[$%F_C_(RFG#X%$\T\HE9(Q0[*O =XFW N[-- MX-T! B0#AKF: F]#9&FFN9(19W/C;&[L25SLM+5[.6Q ,2R9V8T0[FFZ8[N$ M^X6!,,JN%6'>35@XVL:=P6HD$F'W<(*YP5_<9!B+=2S6L:MR[G/7/B+7"=XI M-F8=(\%FC4I^WNZ6"4X+Y3IP7N@;G'CIY*)OLV[3MH'D>+:_6;FYPD3A#H"] M7,[QQ#-31)69!7R46Y"BE)5G0%TL@Y,S<9*Z(5*IY[+,-XCD?J.\X%OQU9B; M0J'>[JL"WZD,W=5JM%Z $%\HC1VU>O=9>?]?FM 86[8_K\E0?">ESX7>SU9OHN4%-U+4!V>-'R7("[<#PFPH\4^HF MB1VN>/P9"]QO(7!?OB_E3 )W/A_R31)7JV/:.+&?OFO1J 5?23* @0+)-^)RX;<"9@^*O[I#Y);FPKP;ZJX/JLWD@ M._%EM]*;EF5OZH6'B>: JLG:L<:@[6+.6GM99IA5QG/8-=5SLX43)P]GO%\.&0G=$3L(,<2'FU $3?$B]W.8]G]C64W=D/.Z(:\27BMOLC/"K,2CGKJ M8#@JZ'*W0*0#X85N1Y*Z89+O7.+[ENF:YXXJ"!>XWN.?Q%';N:(V FH.Q?*& M!O@:M?@_ET[D? ' 7ZTK+W$(0MI4WJ0X*\O*M-":K7NH9$B-G%9/M2QR)!+A MR0@I].AFFE@CQ!KAC#FJA&EAJ(A$,/(#HO$;3?8+>:.@0,"QH"S=D#8A3N,'X)D&Z*&QW9I M80X)_A#VZCXA)&]!+_9V]/Y4M,6OO^&?W5-D TAVH G&VU?="WKPRJWB0]%_ MGT6<'],&)_>\X0W 1-0Q&?[][__:Q^BA]MWJR3U4CT&@R.[P4&6.0&)H TE/ M2"K$QIUD+"7?V:*>8?:\LKM[71L0!TD&\0SR\#$ ZX"^4VF5V*/BH^AD<]?N MIU"W[GZSG+"2\\X&AA34B@7/?O34D%5<:W:'8[?!0O,4?MU"A9&WY)EXYTG8 MM..8X 42,K8#G?VO-I<]1M^/OG+S-7@0U*E0KQN;7Y8;6+<_[?%T@-E Q00Z M-E >V<">A#IARSO26R3Q,=&.44,*+8)(X7@2QU1:')+X4"23*4J4*(P4":!( M#"%+&*,0/S9O/0T)]J$?0F/UFJX=].ML;]L#K53/WH; ;R;/M]-MML;6VSR7 MYQIL*]TN<77^2V>;A1/@JJ49@?PN61AQDB?P]MY.>O/](U3@@NENI( MN\@)?+J>XV\0MI=E&VT$CD;X8KK%(O!AZ3\O9-SN,PD[L1@^>N4^)G[\^L,S M)4^!SI\"IS?\M4<9D9%1,I6B,!$E*+Q3&MH.VEGXE64F+T'5Z.I(L961R*1D- 7=;5'?MC[D$UH0CF:LC 6,H5U,!+#G@YM M,MWAT-AE!;)PY&) MK#0A*[URCL4M;]5=][M+-=6$(P^ IXL2:[8KQ1([7Y1UQD?9QLP(1AX [U,S M2U6<5$WP!\9D9/?:9L5;PI$'P.-KNMNJ"$:&]3-@7562K8+F!<\\!'Y=E!;2 M($O1*%\Q)3<-ADPY/Q*3AR!5'5&M8-U* 9TV2]5\OMQ/!&BB#D<.W:Q1$(<+ M7>A6YV5KPJD5-K\4F<.1T\32,%999\%6TBFBU$*].O/_V?NV)D65;=WW$W'^ M@]%[[Q-K192]N%_F6GM&(.)=40%O+P0B(J*@7%3\]8?$JN[JQKIVJ:CY,&N6 M5C;D97Q?CC%RY!B%;6S(IUI6\B;:1SK5%M)OU/CQ8-35BOM8[I!TTTYWO1E. MO25B6Y1HMD.!:&*V&8\]W13MM9 ANBJ+MM'9[L+A9M"I*APP&U)-38*6,5LN MD@H_*PM=TLCK93]N>F3Q!ZWB,E@-.R.A'Q6];M?G^<8@;GIDJAH6UBDQK75? MJ/=*4]?54%9:Q'VETTV1<%GRNQ:V$:QB98ZH4F>[;&Q5],BT[M5U-S_QJKI@ M*$&^Y>YMG)AN8SLHW93 @[I,M*J\LLYK*LGQ!-NKQ=@[,EF%/=4HH[-M0Q## M;H,92$:CN8N?>F2R\J-N@]VML(*R+AOXO#F;3EC$!$U3\N],I]5@UQO7A?IP MN6E[IKKTBTG3% 6\^VTP(7A7%DSMEU2E6%[125-4P@@BWV5;EN\9ANXLG?X M%1OS<81+B+K7M6Q>6-? M',<0Q([ 911B-;!S1-38%$=^U!N=UM"A;O#0AZ58Z\ MI@F:IJ:@69S,J,V>806>$.7YS,:&3"]Y:FH*.F&GSXM^R5.D1I%$=&5>-?9) MT_04J'Q+Q/?5> +95Z[NT+@6O71Q-ZINAC7F"3OJ;'Q57R.HFV[*FP7&)LA$_V!KK?@C++J7'9 MT_).VJWQC:T5=H&DNM'4?LT[^$S7??9\-W[F=.%NGXRMI\])WMV_#H81R!_\IDWR:+ICWQ&'\.G^O16*47 ]$&>;DF6<8N6;< M8.;G!&=B3%ZL-_@C8@,*UA<*%OV=8&]1L%J6FM+/5,HU"DD+9O;V9=- MQ8UN<%\,K.<%WW\M_CY^@92PSY(2BG^_[!W6+YXZ<+GJRW:OUT^$LC;T\TH- M>MEKW5\O-LBU*#T?'_K+DO&U4H%]9VY*<_Y2,GG=FWG34D'?E-K[A5QQ7XKL MIS(KG$G#_5QFA7?+3$N0(YTT^]&R86OCK\5 M4G;ZF]*O[BVG%803Z^C9$/97(Z#N3MC/NV5F2=@OS>Q9$H37PVGN:R[>BF&Y M:5"LC%W0G[G.UCVXQ]W] MZNRXHSFNKL\ PW\?UU=GJRJ&G@:>H](J>LA@)[O/TMGY7J"V/7<2ZH'H288' M0,'M+%_=1SM+?01),SD25J>>N-8(@I;MJ)O'QY,INEOPG3](5KXQG/!9@;.? M^:PH'(GWF3]"(XOK")^E4XOK!M M>78<(\]QC'P(QX*[JHWV=+&I1%NS@LV:8Q,Q_J08R8LX+LO-)E)K$@.['-00 M7)_5 D,$. 8I?A]PY$0XOLO]^"9@?&EK^'PP1O]X.^ZB%7FSQYL4$A:E=6,N M<$IK<9+M>%Q86QNF,=PB2V&'I2O"8.;SJQ+M X'K1$Z ?-QM37'7J M[(J,A+Z*$KNYNVRIW$F4QNE(;'4W3L%2\HZV*VZ48K3B.94$/AR,?*#1UU*2 MWV+ 0;9(![\\WBY/.N3E)R%3I/->+?:#I%/ME5;.NCF=V6)%X4A(Z1S^3G(%.><2,]AMY45X_"ZI42M M>1"MD>V,GYQ$S\%ZQ&93;VQ8A5K($5>AV]/"!AA7P)-'H \$>U[2N2T7WY5[ M\@X=.90,=8P@YQWD"!ZM_D&HTZ7I\W-;"/3#?;4?#B_.MZ/*K-45HJ%']+S9 MJ%:C/U_K[[5#5R3J#F:M0!2T4EWO+]K2;DF:*@7\9WALRC(G.:NY"3?9'7G# MH-/KJYU>W@@72SLC'W_PK#FS735LL742P[%7-DO3/#-T%8IG^Q,:W5*[\39& M. 7N*I_J-/9.]_#+"_VY X]3*][F KR=*XR%$H*?*58PSU%U'JK'2,UB4$$MG#VV]\,^\#B[_-&WZ,#Z([\/-"=\\7N'+-DS_J[ MD M2UK7,ANW8&O#;"=7F^WD2B;CM@S6#-BE)\YZR8N2+.7$TE/JRQS7*N;$MM#E MY&JKG!,&;:$E"=*U)%[.I,/RTD;J5T<-9"JQTU>HTO=H6EZ=!?G5)^-0BN^2 MBV]'B"^=0>.%P7W=$&_!XKHZP^J+3R]O64!OR];)\N'R1MH6=.[;W]0#@[\O8 .>1][D>>39L@[<%?I/ M&V#](?3'\SD.Q0EE"N5JH56NSM%^'^G$G:.^_4T\8.S[(J[AWG^+AZQGN_Y_ M'^ _2_#UA\ ?"OO-OC E#05CNCYFJJBTK)MQY]AO?Z/L \LB\*+^_9X=G^LB M_EVA_[21V1]"/U]>&+S6GZV1_H0T)YL%5]X20/%/DE^B#S3)P"OS]WHF_IC\ M,A:9@^*0"C[>AO^9K_362L5C$\Q=3=O,)9L)N93B^<>P:?"0X M]K;<'0C6Q.I/A#XGY*..BB+ 80-R%C,XO !H0\,O']^[R$N9<,Q/&V1>#6TR=)R+#\ KTYF@\0GFS=98F/ M+$T6S$%X9G?,(T/$6P[W"S^\O.^HWE"P-^2B91NR$BXU95S'N_&^@SX&T6#G M/DB[ 5_-_93VR-)DP72(9W8C?9QLO'%KXQLEBK&I+F:+;-O=]HR$;)*8'0;& M[,"2'EUW'W<;+9NWA%"+'*6EGSVPE67BS8 3C91@\12=C9 Q)O MRZUWY=Z[0T<.13STWZ^I 6>>NS* A#EFSCB(V-%K:O>HW=Z<>PX6^+A:YUIR MPS3>%!ZW@6-)A&?*5B@.VN.UH+F.-W-K\Z4>FO$FD%3*I1YHXGW;P#UZS6[. M.08K?5RM:^L=4#=EC"H+ H[;&#;@VC92ZY?G'0!U*K$OJ=.[!;O#].NF4BY)3:Y85IK* >GLM[]I]@$E8>T/6/L# MUO[(N%?G'4C/+]L:TII).T72=F:WM\4Z_3P'D)[48J4>2.HD4+\M;TV6@["N MQ>5["UK>[602RM)DP"(@-^?YN)VD.UF:#%@$!.XH6;UIE:6Y@$5 ;LWHOIU$ M+EF:#%@$Y%8-U@S8I7\>7E!U='=IY*:>NWR*)W =&$< XPA@'$'&X@C$IVB? M V0;KG\TE, 91@5[O*<5K,4CC$.6*9?B5)0 H03, T*\+U;^'NUI&$D (PFR M$DGP/K#W G0M47F])X@3O#[:A0MAP)L [""8X(% 6!A+ &,)8"Q!MF,)WH?U MH1Z09"AI7<%8&SNA$0Z%1L+]%I%X;\R)#VBRG6P!V$%% /[#D25(QW99_!@84P.,?&%!PNP$%69J- M6_!_P'B"VXPGR-)LP/T$AA/ <(*[,+IA. $,)X#A!'<63B &,\-[2D< SQK^ M((K@5MR+EZZ<\L+@OK :_0V8?E=GX=U2F9#32^A=$9?O":$0+=F7=9X^ L]7VS'A6=FI7< M/ZXZ+/H)[X=XBLRZ MEY (]>WO=+Z7$W,(5$1N(5;[CBH-G)%"SA+%_1D*,>EE6Q21QD+A V*-#PQM M,\YO 86 %''I$,\3<\@->&'NI]+ >4CD\G.0+0XY;7#X9SBDSUH=>C4/RH*& M+OV@-*4=U# !AR0U!(CSDLAM>)/^%$RZZ-F'[BF2TT=*(E0;T+K9!F8\XLN[17W5';BGH M?4":#_?O<3W/1OV9D$?499]QE]"OBT M237FO)+O(M@"4^/]7D2$>K+G?\!I=(^^H3MR 4%/3\8]/9]"?D>J[>0P$N9V M>536>NMY:J VTP=D"V@W( _!>8. MN,W< =D""MQ1LG/!)4MS 9,'W)JM#I,'P.0!,'G G44J'*]%D!L;4]*AG0Q@ M*.P"3W.]>-HU+ZH&QM)ON0X8@>,K3\N3.@9E:8*:6=^\C=Y2IY2;]2_'.\ACI5C < M8VH=VSTTP]TV<*%65K =(O:\S2!< I4136ZU/+ 8^J[- P9HP 0M]YJ@Y2;= M5._A#@[C!C*_F9A*Y+7\]CH45M4Q![B#BA7/=5.F[+!W;EKJY#1UI&\!B]!$\S M_R!NZ5?RPV/RF[CA>&%D8@?X[U-E7;G .+/!\N?)NF($KQ9B5AMUP9:X?46@ M!CB9KZ_Q*;KJJ!@&7%'4 XK0,$SI="E6;A3C*=_1O6/\Q.E5WL X4EIH&$&7 MBT+8; QG1*T=U@<-K-<[<0/T\BE3<@WN*T\B30 M!=&V=!OWVH-ZN"TEVS@+HHTQY'W>G7MTXGR!K^9&,9Z!868*XB?.F/(&Q'>B M(VCTN+!3^M.^OBBT^YZE)[OX(>0(8TZBJM^6N^560XZ> ) EG_8-J'\P/0I, MCP+3H\#T*# ]2A:F ^XH&;K_E*6Y@.E1;LTHA^E18'H4&$9PMV$$N97AY?R9 MYAE_P9.(/X@HR&;(6#;MQ8]E9[[$BMZ G7AUYN MI?;(AA3?)1??CA!?.E?% M"X/[NB'>@OET=5;2#>55.+6 WI;A]'JEG" M8\<+7OJ_-^:XM:#MKV&.#T=NGX(YEBJ][!/MCH-0VUJ(^3MO:?,=P!P48(YW M9I6$.L=Y;OW?&7'<7"CX'Q+'9^/!3T$<",Y//7_1]I#\I!!8S4#IY]$M( X6 M$ =V;N*X =?**>_\WQMS9&#\V2..#T>9GX(XRKV"49!]) MQ@&"S6/F2)?AA8?U=W)8?W!M%:U%&!@3>"3T!\?S%V<_>.'_+CQ2CU@]PO.> MOJB9<\1H">N1O)KU.]1Z4X@51.K1)P5O_\/;_]"1='6.I)F?R::NVPJ2EH=$682YZ\W8%T ML=2C!^A$J3]NP-%S)_X/CF49N#")3#CD _)P; M!C[(WAB_ QY'_$' P:U<\;MT/H!/IQY]=#".K,H>VPU:HA .<&K99Z29U. N M62?@"7_< 7ZM<#DV/'&:>!M]\2?\?@T8^YF==$[V&H*.A",APDNVU6K,V.[. M5#$&!!+@Q --G:@*^@W8SU=G)M]24H1+0/FTY0#^%,H5NH9:]>:H*XCFFNIQ M'%[4Y Z ,I5 F6 H&"0 ,T-D+C/$69%\EJS_?XIDBQHM!D*HH8@XJ7<*>F0L M!)$#2&83)#,("8__80J-S*70N 223YO<_T^13*^*;"M8;53$*$Y':-F@- %/ MD R.]7'\@:1.$KEW6YZ2+!_LG\"%,CE$B;S3B0*/:F[RZ/\LE7NA/^9,_IC' MP*_4OG%DRY!+>:IJ8/NIPOO",.RI3HB#JQULXI$A'PCV?;&?,-3A)D,=SL,+ MT+ES'N?.!WB!*-;&@2K75S8V&]7ER=*>M'LFX 7JP OT^]P[4%^XQ=".L] " M]!2=R5/T 5J8+<- ;:-6H-07KCHR/&]3ICN %MB$%DCFW.K"#3B1;B>4Y3R\ M<'^TT@XM-/N(,?=;PM[#L$X_L2(2QQ/Q0*/O\R'#V)V#1^I? M@39>&"<09]V(I+GQR*:B\=@Q?_ ]+1%;J5Y0I:0XE]8PAVF MD1][AF;GM6D\&W]IBZT6^8]3SS#/LK3\]>-2(UB<'/F=8?XG]_-7,*S4^BZU M7?[9*O[BXCW\JZ>ODKWHZ3O7MP"-_N49BWBOV!C@V;\\-1&5P%W]A<5[)IC= M^./CJ%#B.W$BV?F-$Y\D!KQ R\T\L+O]ERSRQ];WLZ\\? 0/BC>!>,];'+[9 M'L;Z^-4SF08S"Z@$4"P@"1[LO D+/,J.]AXD_KIHQU9#2[9'E<%U'$'9>",? M&[%AS>B:JDUP0F4GB$[0$V/*8MBWPUN_9@F>CW[L+B9O<>IHV!(&#P?=K=KB MOR>#/W2>%UN2V*@6.5DH2G+\LRFT9$DL\9Q4*37$OJ12"(G0]$7[_[R3N9^] MS(FE'.AG+NGH^;:H_XQ_>^4CPC"2T!B6-%0#&1,J@:*TJF$,KF(X3>",ADTT M''^44.U'H?3E0K(56NXI_:8GE.\L&[G0UQI G-H6;JJRLJ&Z] M;*JXBOS>TMSN@_*^PB]LJB)3];X[;ML*IQ+IEH)$^WMOT:P+&!()@M^Q*RH" M6J;Z25;6>!TMY.L(Y?61L6#Z='7KC>#;I&J=2Z99.!:TN)CI;L"._@YJ5OMIVM:U*IUMN MJRUK63;FH6)0E7)K4M-H(MRJ3+JE-UI0JN'N!P@EY8V&%!1'9,6,3:94R\6Z M.QXVC\)!& MQ-%2U8XTV0GUTICJ3>.G'EE\>=.IL@&_-(2ZJ05(;X$UZMOXJ4=62D7%GNNC MFPV"J32#T$[4T18=%3VR5--5L=KEUCU*6>O+160/!MV2%L_ D;5RJ_+2XY'B M4*DWY]5!TYUM:J/XJ4>6 !^6\8V!H[P@:0V5,&DS($K!Y=NO'D,<%<9BG7;W+A!VG$W^1;JI,BH;1=W5=6$:[ M@FI8!55$X@XFX,]WB-A$W/3*O,Z2U6B'301$)E[5-,9\W M1IWE%L1TI)K6O&)UY\ZKB&*M%-2N])2-&"7.N?1J2>NAY-HMS*[75LO%>M[A M98(##H94T\VBY?H[?6/:98EK>^U:8;7AXJ9'EB!4ZE&WM%V30KV.$HAN65@X MWZKX$11,_)'2*"+5H<#7ZE1/RH_%'%K:<=PE+T-LR8LPP0E;G;1O=QQTX MLK 1/F\CF-GA[/ZJUQB*HK$N=9.FJ;[.Z;%K)\HE<0A=G,+C,8AI!^BY_6X@X<$<)=O;E! MR=[&LHV@6UO7R;U9!AV@TQVH!WZO[S%3!PG'BY"M,M;4]9.FJ0ZL>VUHR9 MM;V.C-$"&DQ M<':2W^CNMRIQ!# +PR^ALH';MNCY7$M;%D6U;X*FJ0ZLFR,;G?3$HA I;%"H M2':;+21-4QUPZ()?0W&AH/0=C+5:T\&^&^]PQ!$8>F.K6C9(IX-H>::@[]2Q MY8@=T#35@:+3S.VW7; M<=,CX%YNJJN9K*];2MZAQEV25RW:,4'35 =DK%!B#;U55J(EBI+$@!OO^>2I MJ0Z,-ZW28NJ@KFTXHZ+ R&)?,V/]Y@C!(X+K=";E[D P8J;L^\C*96<=T#35 M 7;=65A+:U,6E@-\4R^@AK[>)T]]ZD#BBOOA.CCD--+=&%[\;/G"[<[9-J_O0Y#QRP?QT<)=MXGM[T43SZL9(7 M/S75QKX+_,XG=DY\M8/I#R,HL3>B!^%"G&DAT.\X7(A,+ 3ZG7GUI ^N!.2F M^UH(R$U968BWPD[@2GQL)3Z8K^)-O?5\HV8^,.J3LG"FAQQ;2>#+__U&?OOL M\)GO%/U[2EETM]Q(1 C%\7(G\K \R+?OQ;\'K\ &.RS@$'Q(\5CK@HP M( (V-3%0,+Y",%+%-ZY-,) WN?%3MSC/1)H?O<7YUH3\C'+(E;IB,R>VA2XG M5UOE',?+U5Y5K@K27R]!Z:M"+B^@H)PAW/@-DRLK,8,G"[9^W0=S\FCKWZ@1 MRB^4WZ^TTR\GO]G4YC^77F#U5.VQ900YR]'=I7$-.MM)1#?[^/RB^BX7WA@. MUW ^? <'E&]9KO/<0C.QMMU'%N$PJ#61G=>YY+V\&#?5!#8-U_>/7*_A@N[0 M%_"5IX1X!UWQ=L\N54"\'O[M;^8!0]A3)'6!^,LV_BZ[L9T9?Z>] /<6_O0B M+5=:DE= (G.\&P85S,:7(+*6^O8W_8 QK]4_O7'3]#<-@)O,0S]([E3E C?G M&?&BZM;"R#D_5 /P/?BD:_XL]X_0-R;Q'_[YKY7G@@);D]PXRKDK RR_8^; M=&ZLP#+\OVY,]\^2FGQ^$CS+16%HNT+YO6KYA;;K.7:NY([SM[^+QBK>KJQ$ M[8#J\Q4B[^HVB)NR89_#YX@*[6D%HSOL]]<(UF\J#CH-&3TT50J8L.@#Q4 3 M]EXQ".W8+[-CW\"@'P1FRZ7&/H)MQLI*L6V#9L 530I@$"$P:,8^*0,MU\DG M!BJP8./QQ 8HU-]O2'_/TN@OKH< WOO'52H?^VAG_15CE8^AVC7B@6\,?A:/ MRP!>O'BH\6..\& =*?7;S:+)*#Q+M-19V,1PPE3IQ)V>SE_W3XA\B/R;-?%/ MCOS3J#R?0WYA7!YVHL&@J_2]4)2:VKCA85R,_%@#PMAT1MM_WKK30PI"%!TG5#,>'#I!L$QAT@&1+!WDROI(\F06 )/X9D(Y5:1EU96)4TG:VB%;Q M8M-CO'!KJLS!%?*Z&0;1>,MHA*Z0+W.%O!N-A1:VV)2$H864O7U>F/8&6[;$ MJGR,*()S9G[,"\'@WU@];1E5I']W N?Q-:1V+_5!W= U L M&H?_5YU'BZ@!/@D'?!XK[E%@@^Z(#RVD3^$:3E@TL2^!;'FQ!L*^L]HCA#B$ M.%1E3N[B^"S$O7TU+_-RU!,PF_.8'CI:,"& ./!T?#!>\094ES:(+O3!TL?3 M'B_$U/"\)/#P$)&H[8Z?[]P%EUTS94'EX[(Q'P<<'8*G96WWR$<%PS&F5G#, M]^%RQFHF%,8(-4>['I"!V3?!@^.*A"#EN M395=6$<5J6/6 Q>;1M@FR8@=ZPH$_>J!Z)UY0/B9YIA&K#8\OZ+@^T;@YV+I MR"TL+0$ZO*X ;::KTTRRM-7BOXU9RI0&%3^ITVNWV!*;N#RP=4:7+ [811+VE($@+4]P)%4=4 M*B8H P/,6^0!9].NMZ/AA1"3MX?)B^]]5V[B?A*3/A/JL=8RD&R,WZ#3IM+< M5)@$DZ"2_0.)I^-M[M# ?509VIZQTJQ)8LVZP\1IT]>OT=G'^=,1 !:+L'L:SX_O#TNS8OJ-A(PWJ9Z\UK;V)4Y4(0.!^># MKP4]00* ! #UG8OH.^]$_>]@G^^$%L$ZKB*LUP(2#:ND4/-, ':0OXA(Q_O< M[K6'WSTC*RU*JGL]TW=TW0N-R5-T(PP+N$8:NSIUY98])NT#QF*:X@[8:OP\ M)GM-1QDRZ$:P)H,*8A4EHU)?5=B-;8+JMT!'80CH2;E7K,+@PC,X5=Z [>]H M'0AHM;4N!*A=YF5DL2[6NTR0U*I.+E)0V&MAQ7?F9:DZF[B=ZT70JH)6%=13 M+JRG/*'Q.*^MG#DND1'O(>M@N^QN2\-Y/.$J2AZN:S(L Q-&0%A#9TGF])C7 M83VJE$<68UK"ZE4V-@:I>,] M6H^HEFD"L(,4%@\DFO;09-U!KO:I< M%:2__O.O,0P)A[IU!OOH,)!IVI[F5!QRY M090$ZAOKT%J!&L-0QX3G6O"@^O3>V[86)26]99?38^QY1OL1CNV%Y@2<,Q&> M$'G$CU/JFAV/[90%)91JG7JPTCIAR8S["9RV!)9.^0>/JR&LK^"X^OICYOX( MUM&D&$W=IE<6ZKX451%+\V=.!\ :7"HD7SV+N7$+^^TCZOB_C>'#8VEHCURY M/7WEBLT+!U35)W2^[UA:Y99#:;,<]Q6+Z&I%:V7VBQJGQMW]B(8#H0ZAGF77 MPY4K.U\#=6FM],3QFMXA_,2J$N3.WA1]$T#]4UI/!I0;>,8'S_C@F324U[N4 MUZL9Y8U;S!\]DRY56UR+AV?24+&^ 1L:GDE#^;UFP_ NSJ2IPY'TH\<\!PK) M68[FZ,9C,5QW'(\I,6?A]>EK1.0U;AQ7[GPM'0"4%+)L>Y:C6RMM\82P([X7 M665;LB!CO""VE7I/*WJZ''14+,D']WJ9*@C$6P;BQ7? *W>-?A2(S3J&5HI> MWD26OK6DR,DF(A03 !'<38;I]'^J"\\BV )P#3STHKA?KFY#/1_J^5#=N$@0 M6\GUNL;J$9GBE'>72]>1 "B/4%V-"PU9#38MA+=IC!UU6,S"8JI+LK]A#Q3U MSGH^$-L0VYG58*[MSO'>\-R)YL^^!.&;!1ZIQ4E01S.5!AXGE8F)X231^$,5_ MG,9=<4QH=%TAEUV=.G)MY7U>I*Q'I)5BH%4?0#1J2C0>_6._*+EA',C)89O@(LB&K\A1-8&U!J)/FZ $ >\RPHP)5T%-Q'.N:(+G;W,[HBV66; MZKBS_JBDJ;,:IV))/C@4>RU+)J0,2!G0AW-5FM>74$8_0BJM5C.R!8-#JVZ[ MC"^$I.N'EG;Q:_;6L%L9BP.=9^3 M"QR!C+U<*-#,/_?_^% ML_]^\O.\K'O=!5]>_Q7MB]T,N/0LW,7I5M=8:($QD=T8V'V :GL=Y M\@A%[N2Y;:,:6K;YKM29EJ>./)&V*L8D6A4# VT@&]QV9H=KTZ7>.@_[ DX8 M$I,]V4"I@1+QG.WG9^' ZB:<\-E3LIMT;+VO)L$AX@0HMFT20DCA"#8H7SG/%[L2NT8&<@+WPP$?@5]?68)/W-8%&LX_)H^UK?[Y M+^NQVE6LZB2*#S0(KY"NH IR=A4$\!#X#R3:V\1,DQAK?N!9>FRO@3]PSN37 M+YZU;,?SY4[2A>;T10B60=CI,\TQC6YL^PG3J:$'KZDQQ2$[%_95HB3TI76M M:B]&>ITVP;AC-09_8! 2NGWN%>50]_@RW>/L@/\=YR%2JBZ6VZEM\\,F3>5K MYHHN)C@'^@O]@!ZIHG8W?ISXS6#*SE?%J8IB*OY(O*ME,!$7N][ SN?QWLK"BT,4-?^(:X\P($T[ M,AKE:S12+B&#^DJU>^S,!)T F@[[@!ZY2@ZA#Z'_]0Z=2X\Z*]!'6=4;%PG$ M[9(5!:OS;J-MCNKNYNNAW_'7JCJ. CL_T*,E/<\'M<46=")6?E#B ?EH=/9U MZSB&,WE=N[D+)OL"PL)CZ$[<<+PP+L-8_WVJ()T+#.S2I/33UR/ALWP!Z>M] MQ&B.6EXPHT8TR7TU)ZV:4T)KS:L%Q0@;1(WW,(8OQ9R$)>H(^8!3#+S,!;'Z MMOYPQUA%U"D^)U1:-VJ"1;A3CU!0H[;Z7K"]S%!^%S20?;3?5FC$ M6VG%H=#=GM!=/!/JNW.!9]GR^:Q+-;DX&;-]S/F!X1G^T?K44!>\4EWPJ./F MR@R;FPZFJSZBKAW#L&4<"WY9:Q.FT=K)"P$;KGR2ZD7[L;U5\22;)_UJXF(( M8 C@S.^^5YZ'_&T AZO=S@[[O1K2K^2C5JL[\6+& !.#G"OK_KB'ZL:7MP, M:O?7Q3E0-SB;;K"/=M9?W1@C@%..1824AP6IW'9I06IX@\UN*0RPO:GB22Y- M](%$WUF\&<+MIN &=_+/[>1OP=;;:L(1NH8.LV\O!J$?,?SDD].ORUG8_A!DN7(F1S->03/P[--:[=U M'G[^)8-R>05R>?&M]2N#K&[,'.Z"V7L<:):39-7+&8\W MWA-KV8E[XJX,H%;$N\RA*O?"TI+9A GVH,)]1;O53=5_2$ L3A7?X ""Q4?\ M5IVG?!4EUQ.?<)O4(&X\HC8ZHIMKY?E(':^4,5*/0D^*9!71^Z:*)^GV4/R- M CL0^A#ZV58(;BK;S=="7Q%7?JL]:0X1S&\S/,%.S-J, ]!/#@\(_+6\#3=C MEW]8)SI8WL;[-**[8+\K)3FHQF1=C3FD$#7>9#(2U>1NSW>;MM1:]1OMAEA; M2J9*),GV4#J=:@]"]>:A"M6.LZH=[X5JM;2M=?L";RM6==VYOA3P_-B'21P M DTR:))!->;<@9 _ "O_Q*OLMA_1RCD3X0FK296]A!R/<&) ](:DO0LW2'VI M\2%GMTML;ZL2Z"'> 2-?2X$.\0[Q#G6A\T1B?A'>F]6*4JCJJPJRG V"2O$; M'3?(14:0W F!-A2TH: Z8%X-Y(,#-\ XA#4@,#U"M_NC,2-_*#^(NDEOGY^O_+Q![^\J-4 M!U#>/CK7$\M?+;0(B(GQ[X]U?&$Y1GYVN('SN@#\'"+R_B[^:V)M_OY/_./I M*?K"T#S 1[-__SKPI+[Y(QLAR/^%9>_3!@\@MEX#TSB7YT)I.? M__?_/)_1]![PF*+]V50_+C"6$+MIY,>>H=EY;1K/QE_:8JM%_N/4,\QWC'A* M__[7CS3O8'%RY'>&^9_K^(NQ0GPGR9]?)3O TW>N;R5I M3#UC$?/TQ@#/_N6IB:@$[NHO#/U.@=F-/SZ."B6^$R>2G6?[$_CO26+ "[3< MS ,[RW_)(G]L?3_[RL-'\* 8SO%^L_CW\TMRCU\]DVDPLX 2P2X R(X'NU[" M9H^RH[T'B;\NVK'5T))-2QWK%$'CK*:R$Y14"9TFX]_(^".&Z=ITC* H,?YV M>.O7+$'JBN ;W#H:MH3!P^$>3[7%?T\&?^@\+[8DL5$M<;M];7[I?\('2V,E3-C M\L\?=T3/O^G__*?LL3G_O$[P!-/)5)_@-*'B])A0"8K458W"<=68XBQ.C@V* M8(A',=>>M-$A,M<+VRU?LLM=K\!N%*FC,&:L+]._MU2:PY47]OHF8NUH>^7P M)0V;;(%NS?[>M%DJ-D8CIR CUEJN%HP^TVW&*BZF8K^WC/IN.:CEY9I2KAD. MTL,C1B3-N&7J]1W"Q_=+K,O;QI(JN N\U"0VG;@EBOS>5*@V&RC2:\T4J:S0 M'4KKS99-$V-?S5UW2KJU8H"UFWF>\A4KXS'IHJGQT^U^5#C2]%(R>]*AL9A M!&8CV[AE:J$Z?72[F6ZQ"#'JG59S-G2)0@VT3,U4OH].\DB].[:7B%$K-/!B M=^!UXI;IF4)GPS8>%-@I4M;M+FKR.P,M@8ZF9\KWU[4%*0TCA:J5D$V5F].. MG3PU-5-[TBUMUC+!**$MEA>[K=PD<=#5]$S1W;5ASSI[#[%0FI-DIAR9WE8E MU%17MXMEW\$FDQ%BB1Q=4Y95=DS%9E-ZIG:*.]-\0V;M:T'2-#53 MHVFW@X;SAB 8RK!,YXN^7W+ F([(U'JM-8ID$Q'*RXV&MWUO6C9 5],S90P+ M];[-3+>*N#:KPXF\WM"QI)+IF?+6M>H(D>L]86V55F9[MQ67;"=N2:;FU%G. M:FUQM;?+&TL;*V'/V;#@F2CZ>]."Z586MC93!&U<;G267;\ZKW*@:6K^E\WI M:CF8K"2!GW4EQ-=JP-M[=(^"9J>$KPJ3 V.3. M1_H+MX0MUK+*Q])/'1G^H%GVRYN>5E T;SQHJIRT'57 Z]/#;Y5"F:/$Q4S( M[UN31:W4ZHSF'= T-7RBL*T11'F/*+S,X!6O5:O/:AV53@\?=;LA[P9#%+%( MOQ 1:VI(3;=QRS2C;NPMY=4\2ZBC=K6!#WQ-;X%GIH;/+II\9-4,7*&&/*T& M5!CZ"G@F\WM+O-M%>&)=KR%8:;]BQ#9C\%TN;IF>*'8X#2E!7'!VWB1&8;$Y MJH\VX/5'%K]C(05$5B=(U&7,ICJ9H%-RJS+IT5JMXLK4'+-$MJ-;D7^HT5$FI2C?"W#DZWN+AE M&OL%31>-N3.<(/E*7=GT42*<3\%#C^PGZ\VPUN:8KD"-2_E-J5.;(E,3-$UA MO]&79421.4Z(^4P3)JA0JPI)TQ3V0X:<4'V+C)1^L]LAG>U4IN6.RJ9GRE8Z MLZ:8'^$(UC/7#:F^JM %,VZ96GW)T5=Z4/(P.^:Q/JW)-,9L0,OTFN[IB,,* MRY(G]*LCH62V3&HN;T'3-/?V#=53S=92B>R:$ 7Z=EKH@9ZFE]\B"'3MK):! MW2]X-"44!R2[YN+I3X^**V_:4E?(.*73NL M=P39Z8J=CMM)VJ;FH#$JX4M:)J:!(L2,-)2VXK-MV:5);>I8H&2="#% CZU6Z+U^DI%PG)YB;A& MMSY:F*!I>KXP!:JYI\?:-[:H[MQ:"-NH5^VQQAJ#%N MXNFFQ2NV&/,J1 J]4S7%?9D6N MGS1-]];CE^V5%3;V0B@4BVACC##C6%\%;=,,T^N[JT)C'0I+3N!J(Y^G(N_P MW-3(AKL)Q:H];67SV-!:ZXC@-5;QDAU1;P;J;L7B[&!DQ\I^DUZ,A[M&O!7' M35-+Y@H;CJ1Z:U61<*K,;T+,GU8XT#0]LEI!))B!2W242'?][H+0U;J>/#8] MLL6N4S+V+-"PW(V$=L+\IE(UD[;IG:N*KMF^N0EM8ZSPT9P>^1,T'MD1=81: MK>K1PB8II3[869O\CI=Z8,W(M-Q6V2G3D+4>96L=?!Q@Z]9.FJ4F8-W?C MI3<7%0&3EXL^L9GQ:R9IFIZ$ZC!O[6H,.;#S+;+;]O5%G]% MMI*7/6;@-_HD&>OYZ!']I;C/KS<.T9.1?CTDQ%*H6RW0VR,*#-;V>CS5[5+" MTH'T?#7SHV@AKENHD)?U MVM+MUQJ6FSPV/0=UIUHIK!1:0_I3#JL-:UI^ P3AB YC2;*]\];]'E(N]6)^ M'@PZXJ%I:A7XMA&TYU1I*80%<32,;$;S]AQHFNJ 43'7AK4397LY'2F]X@P= MS D3-$UOY":[F:N!49D+U((BHP$IS/G8A -M4SNY6BZ*LY#U.,'0\#JQ82LU M@3D\-[656ZMIGQZV:X1M35H.(]/B5)X%"9& A(#5E9"$@-65D(2 U960A M(#5E9"$@-65D(2 U960A(#5E9"$@-65D(2 U960A(#5E9"$@-65D(2 U960A M(#5E9"$@-65D(6)J8N!"?-U"?# AUYOQ N<;-?.!49^4A&]PR&\<@U_RZ@U< M]M,-^:U=[@:'_):J"T4]Z^NNNPOPY?]^P[Y]N_[(Q=T! MJH:V^*(*F5>]X)#;(+=!48>B#D4=BCH4=2CJ5[?N7Z*QGC9IZ9]JK+(;_*ZL M0D_3G4@U\5FI1JGO%/.4Q^I''I75+I>D@,L]II(O.6 U?[+E9;]@S-#[T(+O==+'?7.-0+A,M]%\O=@@>M,P?F^%JP_DH3NS4!2TA>;HQD.N M:.C&OJE67)992:I,L6 MLFA^8I"K(ZNRQW:#EBB$ YQ:]AEI)C6X7RNC<;XJ3D&&71P41D-9-?3SIJ:M MP,,.A;$.2.7=Y"& 8^&%V\,#\*J2$_"JGA:KU>"+4A8?.%*5%A MI]$694V5 "E5<>R!9M$'BCI6J/F>8'=9E)T\O.ICK/S?IU[[D\=678!6WEMM M\0*<\JZJJS\HY9F'_M"3JJ,O0K \;=<#,\ %@6>-PR15K^RV7$?_>8SSI,,> M*>C8*'=*'9RIN0H5^%&_M*^S" ^*>) Q#Q&0?R#_0/[)/O_\O",#@G&JSJ,[ M\Y&+^LLN'TJRW[67+.[1C6UG1N]?K15[&2[B_-5DZY-\WS;>+[C5Q^AH&@TU*1\-QH+^0+)[&U4BD9T4M,,C?6A!X9(UZS_)R0A2$*W M2D)7K!,]12X^'>4\4M*\NUL6)8NIV%2Q[QIB=4 51]O+4]+O3%3%9ODIURD5 M%'[17&LXSQ0G"E"&0-D?E'C R30502:"3'2K3'1MZM!QH#^2T#; *XY,,$/$ MH/F%U"26HZF3 >_0BWH1)01R82-,"C9?#9J[,.1XVDK8B/[V-\-"I0A2T5FI MZ-4T:'>E%'GC(H&X7;*B8'7>;;3-4=W=F)>GDM\9)$]R8R:BV3F"$?G]8%.V M220"A:4Q)-9GV >*Q-_09]X.0K_HD;JP,SS=\HU)+E[2W":>!0/T,Y[._%A+ MOM[&"^U?0PQ)]J+KLW7B?8)#[6+H:>!1*JH"8&.(*KLJ?D!Y_.%/CZ-V6'&Z M4[;T5(E8C"U11J&PZY@?/^+>1SOK<+Y= #(-WF\X?M)SSO,TQTPZ5XA^-FEK M$?B* \*?]"CY-OGH/T'&YYQ)+P%,U6G'2^-.CIR8:X7!9&^KLH7T+77/^<+> MS7.@,CLX,6?(!Q:ECQ (!-O'AWQ^?>(IZ"S[^4$^2!3);2KL*T8&Y1#*X*G32XDM378-9$G[&EOFOS8FXXHM>/8>)?1-M520B/2)BB-8_4]%^])S+>_,0R%^Q'D M@6SQ -R/H!Q".81R".40RN&=RV&67,AGUL_;AAJY_JH9VOV"L9XP%4UTO(^? M@9]&IR8)(XI$8A$H&-/$ZOF.AX3S#O#S(&\IU==Z&TMZYB76G[G4>@'H$^^[+[P MYN-'AXG^(Z[ KW[7B ?DQVLO&=[&THV#.MDU=-=TDB<><\/NY('!3BW/S@^- MA;YBHWX1YU0*N&$)]GW'@I!^(/U<(_W '16*-!1I*-)0I*%(0Y&^;9&&+NL_ M=5E?WE;9%.B!;5A%2@G1AC(>K<>%"0]L%>#>?MU8R7@ =,L(DDOPGVP.+P-A^DA!NC!+BU03E^V;5[/7)\U:[?5W>E+4ULAT.YU;4- MDD;UR19CZ\PVWI62X.,W=J5K#3]^3S&(G!;DFIJGSU*U(# $YOJYUQ#ERY1^ M^+JT&*LZ,UGH+AG8U@H+JC8^CNK+[6DK/[0:EB+DE5X@+-?2UFH+]5T4=%0F MR6.!/Z T_4 R&,SM=U?'QQ=/J)6E:(D+)-0Z)Z5D(Q]7L$:X;F%?* I1N\UO MB@PC=OQM3$.P\ .D'T@_UT$_K\?W1]'66@[;(6-C1 DW.VK$.V$&LJ__3D4U M3EW.FUR[(^1+HX$R$D6EQ $J2NH^L"A,= S9Z'[8Z$T&.DVBX\]2T+&R#]61 MCM 46UDIE$W+NH6M))?.6?/A M(><80;/F:3-*4J*BB#&M M38-CNIVKJO^@\QS#"X-N5:D/RN0XRL]4K&NJ+#@W1TGZ@4"/G5I!L'TVTNY: M(^FRY#B!$9]0#C,AAZ>*V/R*W>KU0\SUOAGOEZUQB*SC/_*=!HYA45;J/^!U M+"*%2D.UH]FL05!*/%TZ%^])S+>_C]8S@S0 :0!N1U .H1Q".81R".40RB$L M_W!V];RP,+7=W!05.[]H<&)G/C/GXY V=^EJO7\'J#]DX4L7CZCJKSM MU+"*.Z!MK3U9SIN*&=583D61Q M+I^.4(/] _KD5_H%;*A1I*-)0I*%(0Y&& M(GW;(@U=UG_JLKZ\L3(O#P3$'0Z;]KI=INU6F=%K:&*L)/[M5ZV5C =#P_H/ ML/X#7&N8S!(F985R#.48RC&48RC'4(ZA'-^I'&?Y9/"%+"F%_5QK8%2)$T)C M,E71Z; F1">J_U ET0G"-6M+P=AW?<[HLVUY'QO":)+J!'] 4%@ G+"C7$" MW-N@',,"$!=V_KZZ+2&%3=??D>VF4E]T=E11VM?(;0=L2\ _^]:V=*TAR.^M M %$+'>.Q 0""T# *.4+%8#XNKP8)"DZ@HB*O!)VF+7!3!K1M&B>M@ $.:BW M]V[7RR.27?(:7M>H:,U8\\4>*T#@./' LC#I\4V?(']H+E+8NC0%92JZX@*I MN,Y)0-E(Y:6V'&9C#^HVLJX895Q@_&ZOV@&D!>M%0+*"9'6#9/5&<0FN9<]Z MG*DAUEQTJM&*V$ZSD./]=^+J]]UBK5T=%)1UIX$W26Z%;\R$N)AO?Z/( TF\ ME8,0DARP!/O9AU M>;9D2]Y@.:_:ZW8]/^WEV)K1%?/L;0QYP%(&*%J0M M2%LWH&B]6N=B/$4&@YF+<8+$K'VR2>;QII@!QGI1XPKZ86%/U<:^P(M.<=)2 M=C[*F@EUP4(7D+I<.B.3.@F*8M!/;#DL1B#YXSS]DVPMP3G4GG.6GG.G4P-DCH-149^^-989 CAE90SZ67 0^V4'<#@A=PH+KD$@X;P^ M"NW!P/,I[K.5,7YF0RRY7CN1;_%1O ^A 6D]Y&=@@(V7Y@M]IBA(.%[-V7G4 M1V; 58TG)2X>,!)Y0)!C1A3$S6>C"4\]Y&?(T0VP)61K$BYM]ORN/IPHK/!2 MS/&I-*HIXGC-=#$MPQK)5-55ZFQ>GFW4@H0;"660,65 JH!4<:-4<;(0Y*_@ MBM=/SH=MHE[I6A/*KC,=E)^(HZ(M?_R6S1_Q!AIB?,UJH4.AW]G,)T@PP0H+ M$_ &$YL@Y .&OR]M'B0/2!Y72![P'@Z4:"C14**A1$.)AA)]PQ*=I<.1,YLL MW@@72SLC'W_PK#FS735LL75F]T3>0;M5I.^$=C@=;8T@0+5&\^#11 YV!O&: M/_,/KE-F\/SCBXJ%PS/F6[]4>>^'*!Z(%:&C&[.RWFO8ZHH M<:@OCCU@%*PD<-LQ(.=69VXE> UFNX;@R.SL7!HO/[#BL_5BGS1SAB- MEV*$V%O%7N]=JRJ-9WE7[(#-F_GV-YZ^X/=/R$V0FRX_.Y?F)KAQ0W!D=G8@ M." X(#@@." X(#BNZ]SG B;?B0Y[OMA,\%?KU647@]QV31#:,@[<2,RU) MKOFJG7:]5UX>3W?T9\[LG+$#O\-"2;=PY04&*L! !1AZ R4:2G1V)?KN'?"7 MKWR)#$?#EJ6P,A(K@(W6/JPL?72KHB3PT=,XO-<(Z>=FZ0=NJ%"BH41#B882 M#24:2O0-2S2\;_"G+NC+&RH^HY:@E%":\/BHAV5)1,8*L!+_;JE=53#@[T3742XGCIP\-CW L>^%Q2/:S\6OI5BH1!<$%S9FCT( M+@@N""X(+@@N""X(KMOQZGQ)#9."LK.WZ_S %/B-B*Q)0QL$[.>+7+Y:P-OO M2XOMJCXN"GQSWY,1KC)>C#HJ2B5U2- '',?A-6Y(5)"HH!8 P07!]>O9S?6 MZZK/=E[=P*L8U9V0+5]0Q+ZEBHV%*SN'#1PK__1=*(?_&D8?#+V"-7BI)=(>,>M77";ZDA,X',D,=JNA\72JH M:9&T)T&M[BKK&2:C^V['WF';CZ>"^E&&)QF*& 8^&-PAW]SON9M4C0U-N];C ME;(7$&AS*&Q-=:NB-,C=A!,/-$X_8!3Y[O*#$#,7C_?X&$?^]Q>M9,9BDBY0 M3NN<1)"-6,; N89[J86RJ7RG@/D0<;D 4D#D@8DC1.1QELW7[K5 M?&U*Z,A2[,P;E7Y^X[0_[S4\&8'42V9?T-?;CMUO,02!(I5>9"8$ I)/40\$ M?2QQ)"012"(9(I$WB>,T!8@_RQRR9VA^Z$7/%0ZNVT-F UMK(]',78\$HC.B MRQG@BQ?3(?2:[IQ?[)E $>T5N6T:5%19=P!QH&C,' \,0;V_]#!D#L@<4/WX MBM-*OYD/\^AVI L:B^/]RI2<[8D,\,CO],&V:F9]7HFJ L_1X;X@2X-B,=$[ MP$DGACY0Q#%/*:0/2!\9HH\K4SR.H_.1.4)#EUJ)S>C###' MBQI(W]9Y8H65*@BV<^L8'Y:Q-F,F%$)_^YM)VRU0_8#\D>E+;Q=5/Z;XG%!I MW:@)%N%./4)!C=KJ\\>D)],I5!!8Q1IT6/NR(8E5+# ]PQ$H2#QB& MO:$Y).>L_TI>?$ZTLN]'JY:,5L4UG9JBS%0=:[BA$MJ85!E"1U6<-@P"ITD6 M92;QZ_ZE/?T+4(A]L=]WA>W(4NHUS XW?+=4W<6:E4K_WE)7T HS7]A+A1?: M:[2X)>AA+R90%65_;[I6E6JHETIU0<**.PVM<&.9Z:@8.*/ZM:6U6!DF:NBH M75\/Q5*SFE=)=1NW3+V>=QOJ3BV65:0<<78%]XV92H*6*/)[TV;172_K*X84 M(GXVCI 5AW#=I"G^>]/2ENVT]?%J9Y?SME%K1WY)-I*FU.]-JTRIKV"BBN>BUL2O[=$9LJ0[K@[7RBC@V4D];I\BS#CEJF9:@ZJ[2YGZWVEWV!U MB]D4%*(-6J9G:EMIC?N%E8 @FKKRA 8J] P)O#X]4Z9/;<8D$\P1;%LR]'RK MVYJ-.J!I:J9&+J6.5Y(NVVLDMC#00&2\>M(T-5.308VB'+W6%\2HVAU;7-\L MY;NR(DXB8K TW%HM M[BF1GBFOX7 (P4L%A:=%A6Z0DC5O@&>F9ZI=0Q=Y<GK'[:"OJ&^6EY>_!J-*3VB*;B!1CGA&H$MW>,UYW5!*Y&%BI41" _O!$M[, NVH&EJ5 (IE8<]JJ_8_5)K$A#M*H4.3)5*=[4Z=J/\ M;&-RBK0/PZ!9-$O=%6B9PE2^X1=:O%@+E74!&Z^6U+K2PK9Q2_+WEE*UM>PR MHTBTUQLYYJB0,=L5+FZ9'C[+5:(:M69QFZ*TN2J/2G6ME#1-#5^/Y+Q:+A1Z M=G^ZOB3G5'CV7E0M*.UHK7#1>@BK*G2Z>&/!AW3KY<*.Z0\ MG(V&=5?:%N+WT^E!A56EVMWOF$CH*_^?O2_M39S9UOU^I?L?K.QSMO8K08Z- MP4#W/2TQF'F>X0LR=@'&Q@8/3+_^5I5MAI@DG6["D-26=K\)*>P:UGK66&OQ M,4Z,;K-*;SV,GEF4K:02R^HV8M/<1 HV)YED/)M'#_4O*I';S=/3JFXHQ4T^ MNL[6E:(=1C/U+VK,T+25+S?#O,W,TXR\W.W:PF08\R]*4ZL+)5;:A'F(5+18 M5U>JS-7A2-^BU!7?#MJ\S;530[,3HRHE"@FUJT>7P2[LCY;]0UUD4!#?&0V#D[DR MGT MRS>RWQGL4G4-U/CJJJ](?+4IA$0TTK=3\4%HLY+RC1D=C$*=14^O)]G1 M&H[T[=0H5BPV5^-2B.Z&I($C0\ MU+?\Q%1:)G;=JMT.BAF]6@H6$XDF5+AH_Z+,K"JS";M1IXLLMZJ$BWVIN,9# M?3QMSK1TDA6ZC)+:YJ/TF+ZMN CBW+O#C@)_BI?F+I]7;Q%A^W=KR<+V=2H"%;V31^K'\/ MFJU&EZYO8RN^&6G.%ZO*9IL2UO"A_CU@8FFY5V6R+ UH.=$#BUY31_HIXY=K MBK0KB4)M,N&#'29FR&Q>3#,3--0W@0%;KG.11B[6WFK#>;;6J[6V$-C@4+]D MR_:&[>VND.FUM]E<=:0D&@4KAV?@%VU*KM>6>L3[H9 MP45PJD&+@@[FZ_1HUV3:R18<&_)OKI0:S**%2@?0U5$K7)-R\)0A@\.A/JKA MLBTQ'F/T=;NIKP:EC58H3* B H?Z2:$T8^5A49_2[6R:E2.UUH(O9_ ,_)R3 MA79'/QV9!96Y-H\/Q844*]?P%,X@QR!=%H5@4Z2;(NC-V\/*JM-*H!:BOI6- MLWJH4.]'M39'![,M*928AZIXJ(]UMH."(L^9G*P$<_'9N-D1Z'YA@H;Z-B%7 M4BPZ'\LN%3!(U+*#:'&8#^&G^C=AWL_L>+!2DG2(&:]J&4B^DQ%^K'\3@NG1 MN-%?1(.*'4E.X]%NN-4WUGBL;Q/DJ-KJKMAE@0]IR;=2R9>H_)M$&*B0AJM)ZL2G6W@.0+PFW.\[%P M2T7L1CI7QD_US]8833B+2U!5(A&*[K5 MW$!)IO>[W;S0Z282^"*4[W2[0XDWBI'Y3IFS\7E/S=?[T@0_]@PLZ48FT]ZN MH'4"AKWTM!M*+88X[.#;@TUB)<_R\6:+3\42I8G5'X;M//8S^'$\M>P*\EH+ M*=WDP)([4]:T9.R)]$W "J7*F5J=7O%VHDMGPI'U=EC#V9Y^'!=-9JG#\>9"=.)=@>[#6_':D Z*V:GLJ) DL/'&^+'\=+.IASHTRDHLC= MUB([G_9V$1&./:,G!MNI.NAU>A8_GR=III8VZEV$=F<4Q2TO2FV!*4S;6WW: M;/5V?:55P$_UD\*T4D\O)HU\C-]&A6Q>!$P\@TCAG (8JJ]E9KE()]O+W8HK M[+AM>%!9X[&^79@GJ[GDQF!-/C4 .W6IROH2$?D9O6[2"RT6E=08\,UB1&WT MI]RBBI25^!FSIA[.#N.QG4+;8K(5Y=:-,6_AH;Y-4.A=V_6,UJ!* M3VAGK&\3-OE>J5&M%7;M8$AL:1!4HFMH,$$N*$1B23E M$I1[H3/*G:AWC$BV52XJ\V*]'JEU4I%^!0_UKVS52^OFZUM9*SF*JI+&J@K824*.K8!P$SAC?2NSR]W\0E*R\?;<7-3GG#1)-J#1 M'CJCW2W#L8(4FX622D@)1W@Q(B2WT3H:ZEN9L0#%[GH#H275+8ZTK&R*5:CA MPZ$^N%-[ZJ*7J6QCM*#SD[*^C6;[A34:ZE]84J^HLVYN;;:7E6!8-B:<$,WC MR?H7%A>GJ>ZTT+<4KEBUB]MJD.U-X6S/:%9=8=4;,+K-MT-YK65QC5G9'N&A M/KHM#&:IO+32.64;71G&-I5*1I W[HP29A53XF[(S,(T8'?16EA,E7,0;^%0 MWQY44I.^6@<;D[<[*V:UFE8RJ3B>@)\0^'6CFC$*^6U[RPG9Y42;0LDSP6/] MA[L9SIF&6DGR*7T93S4WD8X-Q6GHC XFS6LA5HMF1TJUQ9KMIMTMC0L)--1W M"FJE%^TF8I%XVXYU:X51:"N#)'ZJ;P)11<]-M&J9:R][RCJZ3&EEJXV'^B%? M&(W&'<9N+>EN/CJ=1JM#,[+#,_!#?C)+BP6;3O<4(->6\E1AY)3MC/5!_M"L MU@<=9B;20BK6G79%C5Y*:SS6;VK0T%2Q(^5L.QN.)OMR>:+R<6>^'N1CU_G^ M%IMS[TS45558F."']\.QBYQ;6#^G3CAC+FR". ZA>5[SH K&U@_!MG3O QPG M<3YQ(S+.F*,0C3L&?>)&Y6CZOY'OW3*\B;DO9!R?_*M!(DO_[=M3DKPZ\W = M/G"LZFO/H^_]'D21IA\C PA*< TWZ>="-W'*Z \#J((EK\"+9^[_+HQ,7;4M M\!/.[R8#X08(0+V?_[J?'53SX%]P(E?K'O0+[50;QSN8R< V&([W40 M[Z5!D(.X&C*]G?A%#H) T__45R M$!\[B-\OP'JE:JOW=Q/X&UY^_NP:JX_0'O0;'OMUVL+>U9(_O9X&(?6/GKNO M$L ']T#45?3A_SZ%GOYP/V+/].?7?GB/)MZJC'"HQ/@E"WS\+040]"/H1VB? MT#ZA?4+[A/8)[7\'VK^(UAN^:ZVWI5LO%5[BOOJN9![^4S)GN&?NKGJ'?9@/ MG.8=3B\I7'2.&('?TPV VC $98T<__<\?J^J/CG_[WG^7D%TV@!RFHP^"MY] MTM%?2L ],!TDYKJM680.OCL=N(T("2%\=T)X*&\8(8//(@.O0QBAA.]."5Y7 M%4()%[&"'Y@2G(X\[QK&(T%4)@94*R54WD\W?OQ+% $8CW_^>0F]*Q-%4E % M300!*@U$W.?,H0F6"3@_H-9'K['#[Z[^YGQRB[222VW.9R?7WZ #EXD-\N% MSNU"FUZERML]EIMW8\UILY0XUX2+"0U9YD\:^CFQS^,^PO5)K@P>P[X8#5!%Z52/+G8 M91+J%+7'"3W]8L.!:)P)Q%GFM[MY?DVVNRV7/4K_OLNARG?O*WQ53+F/SH"M MT+ 0KZK;1IN++M+166%2F&Q0[ZT(Q"%_-W*"/P1_"/[<'?X<;O.@A)Z\YKHS M72Q*F3Q@R\5=I%VL%MK;<7B57$W7]X=%.I^K\X7P1N>+W+(P$>.QX3:*VB#& M(!9% R$V0O"(X-&WP:-W,>AS&J7_,0AYR60G:E"E$TS+\>2.!XUZ;M:M]+=U ML7Y[Z'FU0?IV'A.-:4(HM.>I9((WH^UD-H7;EC(0A *QL%\G>K5%.@$A D*/ M#D(/K!1YR8U>+,>%)+&D\FJN%@OSP!K7MY'=+K>.W:%E5MLLJ\$%VVW353-9 M6=I-M#,8B<)/OT)L(,S21!TB2$20Z!P2X2S&T*O9;H0?"#]<@!_>K"-V5_SP MV9)Y,;>DJKKI])1@D.TL9#;=9YC)_0G5[8"K<.RDO%"JTBR;6O'YB=#"81?Z MZ5>$"\0B[_D8WD^%OFE@E]\ 0Y1-(%'P2*D5W 6 Y@FW,S@2\,=K>-#F(V0R MW%^.]WW%73\AM)JV#0$]:L@,,6,SPY8^9%TN9_XZ*-++5#AIM^@TVT N-8S4 M-!(KE>L?#[3NMAO9B;(F$4VC]P/-Q#-/&(:@3?#DDMO#D)JP11\E$/'C&>%/ M\:^FQS)F0I,ZF&'R6@T>C2Z=B=L.2U)FV"J#93NXS1>C)E,/;[;U803%;2/1 M0)2+G\$/PFL?7S*IJ?$H^/*[2L/-P>6W5! '6]!S\Z9I PG.&FD=& \Z@FJ# MU^!#VL/'N3!KQIQQ2G$MT3;#2+OF0"T4C02$C#A4^_G&OX.>@QZ!8KP[6O:BN5!>)PBA!E^+5&D*/ MV-.O$%$X"'Q\$?C8>^T(_1+Z)?3[O0Z3T"^AWT<^S.])O_<4 KFR^3$U;+5@ MZOFRLIWJNWRR$.OEM7MQ..3ST=(T6Q+T-@A%ZKMI?3M*3=;(3TD__3J;.?#H M5]J:1T$.\<@C3($-^AF0./!WO)SVEDPCI_\5L@"\"\O?)O.%D#0AZ:]&TM_> M<>QEOB2DF6U::$YF2W_ES>5 Y MDZT?C+>&)3')+MK;GA3O*\76A,VMAU%<92T0C?B!XA_"-"3X_=6T8T*_A'[O MCGX_(NB^KM__<)7-1#(N!W6\EEX3MA^5>0?=.,Y8 IBF^7%[/F'C9C Y'2TJ M2.;%GGY%_,GB1. 1P'@,P" "C] OH5]"OX1^"?T^_&%^3_J]J>_]!@;'15/$ M+VDDF-;05$1U0K>#B;!NA>20F*Q-D&.,?L]*>-3\\*Z 2H-8)@6\_'D22/R6 M&>'?UKG^UDT3!UWP'SU&V=\S.>-8MX?3:I)3DGV%J[/5!I>KLZ5\?1A#CO58 M(!8FZ8)?-FK_0'OQ0!HS807""H05""L05B"L0%B!L )A!<(*A!4(*Q!6(*QP M U:XJR1Y'RO<>0ZWUPC+R=TF\3&2A?U@CN*3-@P-L+ -<8J"2GZ'\1G7L":8 M,SFM"V6>JS7MM!G=14NY^C".*Z0':-I?>XBDH)$0\I=3T@C]$OHE]/N5#Y/0 M[UVK93>Y,W"N!VZN5RMT\]-FDI9G8I2;-2JSB?Z7/7!?4T:G)HT'RTO/YC5T3-T,>R5=)-E%<#]PE^_8SS83G*Y&(EL9%6ECU]TET7 MV\RJ4A\R]) )/_V*TMSOA7,(MA!L^0[80L0M88GKLT3LYFN^+W%[8:?][TG* MS:)N<$(NU>&%\&XDFDI?JLX22%)B/_W;DO+.D\S_W^CDD6N SAA2IBK!/R8% M5=!$0 D6518,<>J0/,L$G!_0B?R__QE=(O[T%:#NL5+37\BS-^G@$VJ=),QA M=7S!G/4.5Y^.&^QZUV[*;+L'JC)C=B=_6SF\:ELF6AP\ES,IZOTRUTI-6?;(1;#@ M=P7^]8'@XV%]5!D-&*8SD[PFJC8ZG9INH U(6)8ACVQ+&*F@I5=T#:W.T%45 M#LG#=4(8L#U=+;=M>IXKARNIU+9@-^H(/"(0/*($- AH$-#X'-!X MNR)[M2#S44D&+7K+[U(@-5X*IOSGG5@_#4!HNC,;ED2FHV27S=ALPL9B^<4: M 4@, 4B 95@"(@1$[AM$W@6.2_L7_@XYSMW+F P'IK*=L;%VE[;4K:Z,&TWF M#O#B57=4SO:[6RRG!LEWFS!A=2[8F"#C0-0XV$$=6O=^A09"#(,<=(R$8&)O9Z MH+AA*!2(AL)$\2#P\87@8Q_K(T1,B/B.;LW'*W6CJ9MULOH'X;]#BQ1?^Y,$:FI@=LMKSHW %9"8U6/8; M[,=K+924//"74DF<_W0B90 M1*#HNT,1DC'HS.?9%\E@H6FL$I*[9#<,./A<4?N&FOL^3S?1OIA;E.UA":FW>?K^]U]O+F4E(,]NT MT)S,EO[*F\_'MK&>4EV@'\T&@ LRX=DW@;&21>!H=PT@ZA,-/_&,!B?T5Q%I M/*#[O-U,=49@Q;?UP63(L,A#'J;]^>0$; C8/"38$&%)Z)?0+Z'?[[)D0K]? MZ#"_)_T2M^_?NGUO;V#8J50RTH\)*2685H# T6NNGTD@ P.YB-^V,!XU7=\I M0802\46<[^RDZE-KV9I.@2I1EDXMA"W*TD>C- K,%ZJ^!<#\][_8^$\*8+O4 MS>DG$;=OD+8 MTZ\H*55/P.<.]N+6X$/D,&&%.]D+P@K?^O@)*Q!6(,=/6.'.@C$WL,XNFGA_ M28LJDYL,$H-=J\:G4@,[V8BLV_6ZX]VDWS.I[CSKWJO2Z@1,2*CX 7/L22!C M7P2M 1:V(4X12Q]?MW' X$S8PI1*0K%HQ@PEFVFE^$5O+#7$]9")H+ %PT8" M3-1_H^:LOX1PR7<0[O>FSN(EOU,R_,9[0"C].RSY@0PW0K^$?N^.?N\^%G:N MFT-$+E>[:GNQY86%G2\,E7HD/_SS!I-O:7#XPO09RTQN)Z.;VC+8I[EL$C3" MR<@LE,4*'.K/$ K0X0C1WP@J/"@J$*E&Z)?0+Z'?;TR_Q ?^5[<0_D2G"JD3 MVI235IW>FJ5MKZ>H^7[#<8K1OZ%3_<45@O?HX0;^\0JP*%D3]?G9^C,D"/A) MUP)&NB$!(^B,_<$L-I2IJ[)$_8O&_WL,F?8PU.&C>J=G_>>'>F]XS _%$4B- M(RQ!6(*P!&$)PA*$)0A+$)8@+/'E6.*> T"O=.+-+)-F5LDTYTHQ/)U&>'Y1 MCR__O!-OS=#'LE723?.,8Z+ U&+5>2ACM:OAZ&RZM1EIL:H/&<[IIAN(T;&O MU5^$P N!%R)Q"4L\%$O$'HDE'MJY_Z:PU/+J.K5)33?M5(TM;G)%V="R"20L M'2_^V\+RSK/6W^S>G!1401,!)5A4P=: Q L'7!^0 ?Q)9N3^W;B.^2^?T97 M[P_DR#N-O2^7%#^Y3M2'.P,7!&C^<%H)MPP#"=F>0U4;71Z=1T [?PMBQ#'MF6,%)!2Z_H M&EJ=H:LJ')*'ZX2X8IU1.W@UGJUU*ODA7:R%4]HT#MI28HW0) +1)$I0A* ( M09$KH7V=N?@2ASSA[5"BTI3&_[@] Z M/LR$&GP=(4H,(4J BQ-4(:CR:*CR+I)<.N_P[Z#DW/6/5GD2G4]KF3D_'T2$ MAMTN;P7Z#@ $;C=\]1DD$841**>+W(8.CJ69M :KB9S#2((NBT0"<>[L37X" M)01*[AE*'E=!>26F.$WQL=RHG];I:G\43DOSR: R^O.8XJ=I)FRMHG:E64.G MN4&H %K)8# #'#Q!\[_+G. MKH-A4+&3DE4IMXQ9*'F' BZK;,ML-;+8M(NIW7I;#,XB'.^$!E"SZ6B I>EW M!-S7N@VT;]%-00J@5KA)-V4>-:YV.H@$* U8J!F))6P>.MOBH3(/[BD0^0FQ MQGUN0?0HMR!^L0!#KZ.!8FT\7O%<28_/ZMUV-&']0>CQ4'W/5UDO81B"-L&3 M2VX/0VK"%GV40*R#9X0_Q;^:'L.9"4WJ8';+:\[MQ3.13'6=3,>Y8+*H@.QJ M)0I!T.F7H3X>0Y',<"3 F\G^)3$'"'(0Y M'BIG\!)R_>V0WZZ0'K1V]66M764+M78E6MY6)A^W.QP1CR1UWC3M,T4%7I/B MTEZ*GS$V#-4TBP-3FO)"95"RRLWHMF4DD/1&<;XOEME/P(F $Y'3 M_*@Y:\^M1"&UM=-#.>CX5.EWS++W[Y#=882G>13,$8]\UQ38H)_/5H'[AKCX MV,$94H?TGO,3;B+*OJXZ1RB:4/0#4O2W][)[V3T):6:;%IJ3V=)?>?/Y>#O6 M9:H+]*/9 '!!)CS[)C!6L@@K2C$'HODU,DOPK80W[9*O=1W!*>^$+AJ(.)_;N8I MK5&7^FP(2Z5$"CETT6] M+B4&:[AD7#HMP(:9WVL^2?B,1-Q).@I)1R',<1>[A ,[;AMA#7BKPJN'HB21 'VFB-Q9UPMA MDN^I WQ=/9A0-*%H0M&$H@E%W[$Z=Y,0V[F&&Z-$9CC[:)4"RV[ZW"GP2>0+H=;:(3]K7B()D=0 MXE%1@LB]AZ/HNUHRH=\O=)@$D8D;_0+W)OY$ZY(;S6"O-UBLE:6PJ6Q:[>(Z M&W8\:/2[6M?7NO)0 18E:Z(^/UN)A\05/^G"PD@W)& $G;$_F,6&,G55EJA_ MT?A_CR'C"'5\5M3YAN3QZ%'I.&$NPER$N0AS$>8BS$68BS 782["7 _&7/<< M2'NEQ_2,32?#$V;"*,6&TI:J$6L0"?UY\_J:H8]EJZ2;YKG.-D)#S.ZLF,Y7 M:<;.5>E$8Z&NAZ$0[A/-!1C:[\ A0/6=@.HQ]NK18(G(_&_(2@\L\V./Q%P/ M'81Y4UP/1=9J32OU.KTM6NF8LM+Z^7X"B6L4;7E/7#_D!84WNZ$G!5701$ ) M%M4$"POK3Q1+!RAT,A?J#O\5 3NEDGS&%U?,&;#N7-,KA= M9 M!6F[GUYV,-@RNC69[01;#@=P7_]8'@X^D: MZ(XC,$QG)GE-5&UT.C7=P%WM+$0@>YS0, AH$- AH7 TWBE?U1ZGQ\FU MU*2[7+VYZUL@/\NM[P] M%%-F93CLQW/U9/-13\B]W>]! (0W"\[$ KYKU42 M$"$@P=X ;<;OOI< M2T<%&/7AM@?:R_Y@WK"VRY+.8LT#W>'A A'&;[+\0Y"#(,==(J!H M)LL$.#9.% \"'U\(/O:!1$+$A(COZ#;4/5 QK"DWB$;N M4'QQA<:<&Z:::7H+)J5D26]R)H/-9AS=8P-L[#V//0[Q_0]^\36YE?E];KW> MI")_,"E)-A>JL$4[#'Y^;(;P<$%PZA#V[TZ1_@#*2?+JU_^#_WA/$54@& @' MINZKO- \BY[JXCE-__<5\A="X0.SNPS/7?FP/T"!SD[B?__O_SG>47^^A)O: M<+35[@&',*).0' $S6XE*(SA;OP0U+6P-=VMCT/!LK^=]F.?'H$.APH_1R+_ M31U^1,ORG>]O;) M4S&I6/KB1XAYYM#NPE_=53'AY_ GT%P!,UKDHAD0(MI#WM")=$L/>2@=X2 MF(-^A>\%J'PE];R'_\^?E>_@WIIBI=KBFU2K2K4KB78ZW^+35*I::59+^70" M_9+)5Q*55#Y1HIHM^$&9K[2:!U'V)M:=LL4Y>A>P1!689**9;U8SM0;?A,]/ MM/+5RC#&A.AX_,DY3D>65NPYW SQ?-(/55*'2X6H*HR$SLU<55EWTV\U6J5@=.\P<$=V @4?WR+R\@_^D7)AZJFJ&.R>?"[.:;[A_MS.MK M?/IU3((7GOSKJ-044'##'UFZ(_FG!WY$'2]"V^!/F M)P4E"'J"I5/'+X>& WX+TI57P/E5A/U#%1 MW5)G%D()!G!V@"H[<_..P=VZ03D?\/9,@/.%1LDVJ*\U(.WW^_2@K"G4B"93 M=VE'J?&< +=N>B0T-.1]4DJ*:NVN[?7TRL^:&) M/5/P&YB,X.8#%;Y7@M\;J9!TJ!5\QQS >>W?ZAR0NP@#B !N'!R_@/N_@NDYVSY"F@0T#>#Q02*%#$!)(P']P9OIGL8+@F8C1HJ"C[3'D$AMU 06$0O\O@(05KQ 3&LJ6)0%C2B+$N$I M:% -0\,%T;8 1LL .JDU0.SDXC@\5SP&;( ARB;DK+P)(D"5D2$@06I";W@)X1;B6@B$ M /Y'E7$Z,J0T"8*'NW*\8@QYC@B D"-+X&2F\ N.;!)1%!>^:*X[ANR>-!$\ M0=Q475&.3AIJKE"M6@DF6JBS!\?+"GCR9[[5)U 3>'#@#C5(/M-(,^B-1E0 M9L(E0+63$FT#_;CGXGPFY0%<@-(0>J WP$<;K^SB_IN5,M_<8R-:%<1.#7[5 M$C2@V^;QUS5@K,#9A[3XROXA4#;"TX<+UFW#1S_H>!RJ [BI\ A1C26CI8PA M*FJ2Z@C>_1ATA%,=2@?;A.A:A8\\?I0);4(H,B'Z8!]:@!H)%MRG8T!QS@DC M+314CU:SL%5(C!.@H9'P+:XR@!!*T^ H9X+H($>ZM*56LN"=D(0TD'<6Z3"0 M@XA[6859Q0GPQHYHOI.(]WE"7W-6C]Z.\5L.D* M*^ NR6$Y[S,X9+\ZU!?:FXW#+X[Z!$6PB<0TVIZQC#I(FP+B>0,L]H;4RE/D MO >[*\0G8-IS;-B;]F*A0G$9@#_!XQ',HT/ [W-.'(]P3A!O\%1>+-SI.>2% MNU8+2)> G(-D#]0VK"FDMA%D2!.CE@8 !(U+"I+74=BIU86W&D(&$L. MIC_\96_I4P=3_ZJRVM[/2SR>UW@_+W,_+P_HT'D8 )[S%''5" - <0"'H[D MJW4"!:]J"(Q;1YX:M[L_< R5,$NB/3<0\4$5V1_ ;<2IH$_RPN6R:QP*A MR:=.A(H@BE#IP]HU1!PX\05ZCT.UF$Y%$9&Z=)XZX?L3V.@91@2 M5AJPAK*?Q=%6(SO+P5HH5/2Y;*&%'.\S!K*S&PUA"++17H'P#FD$%17(O)[V M-3U=R(%7S<7%"P,3O;%16%LQ5@4/#T5&O;P=*!<0[)W+TO< MDW^I;1T?)R1)T2,);#P?;>/Q*V7S9*_18W^?LB$\CV45_A5O.R9&/N4]YN7L M$AJT"U2J 9!>@' _ R=!,72PB-4)])4M0)H1QM@T-"\=B&4PQ-)P#^9H=?BM M< -\ P*N&F-@JQ1#)SPU\P/KP7+/=#15*(!_8P-,2!90BHZ0E!3P!L+OS&S- MB<#N=T5PENY-Y-RC J^>'F(2+/X-8.D!WVE=>INO J$G\8GC\#OD@" .P#_] MRCOKTQ>RYM+\P5YPQ"S:,;QXM&:A[PX9G"*MK1PXX>Y'WKHRH,Y!X$.]XFR!B&';-K!;R%>J_$H#<7$ P> M?"_HS0(UMN&VCF44F7=(#4T!JKSHX2-L,F 5T'WVR:Y"8PHA$T)R;Q7(M#(< MFGT^"4">A!T>+K0;O6(4-19[#H5?B:+B@"=U^)%$44D4E411+Q=%A2CEQA-= M?>NMV*,74_Q !#+T].D!V).@:PVI)EM_,+6X&??&Q;FIM%-C4=%99MT.ZO5/ M"H]^OMU9.YA##OL==N"J=N:)BO/;IN9>.\+Z,O+7XW">$^L]B>F=QN^0]PPK MOZ)GXSBE(CBBR;Y K>;ZG MN*XO57;" IX1=3#-T4 '7R?HS:]]Q[7HD7[J:K[G+>"]6N^?CN?:<\(LV--K M>G'.PW>PO8?U>\A_HH5L-T_'%K%Q*N>V%AH-Z"! MK*O(82PC_68/5$Y(V0D9N+8&CFV@1^DC."/@!JTD80X7B)8#=]C2C6V PIUW M@R,<]Q&/VA,[ ?25H-K[Y:HZTEV=V/7A]*'RC.)";L0(#I-0,@3R,%G"QAUX M$SPK06L,@!(*:9FO25^Z8_-C<9'DVJ%DB3$V[0RWE"=^1>+\N$]-9;HP\KV7 M<.3LTTWBMI!\=L.,WLL+NT]%HC:][#E/&,A;!WVTU? ./H<)02A; W#C0DYT\9_ M,T]C&;;I>*$H>;Y WBF+,EQ7I@304Y"+P<66TTF,;1Q5/YW'X9TOML=%>DG' MO@@OS O-L)/7GID:#ONB9Z-,%-TP]#5ZII."],>3/#Y>5[="/AM7).D0UE%, M&[F4G:?CJ+K[%!=K#_M,K:=079)Q- ]%J'4-0MV6$ET'.7Z<&XS'SFCW/:>S M."(R=[\P]J(-TF084 .]TA7T9AA./L_MU;_;(KWERFFZL4\6P!X$= *J" MX@31(.4P]W5YX_T\_,)T@E&C)RK LH M=**O?^!CM)QXLNOU#!"YQB$!Z_@++#?17?I2Y"=83J+&IBX-CO@9K@#!VAB^,_;@>W5\AP M*IQ\]5V93JB14.,Y:L1*EVPZOKE3E<#+G=H3[!P A^CFP@PG41K6(2XWAP2' MZ!/J IH^AY:H*H_!:S#ZDYKJ:ZA<& %*=D;XK8PQ-.:Q*0)?I:$XW@ND_:T7 M(4T=9>\YHA]RECE%4=?C6"#.!_523)%W1H7?E,=;3TG!^T38A[#/"?L8&'-Q MMK\I2\AMYAAS$UM L [<+-.SUA[ZT+3GKYC(>W9#V3HJHGZP$<%K27S8-2C( MQNG3_?P&)W-')$P3"KXY!?N5"DC0R#3WLIQQC$50(7!J3@Z&XX,Y*,#(Z+)> M5X"?7R>X\V%X#&S[!(#/MK!+?N^6+HJV >WC!4K^!\A':VR]=;DVM[M\U\1^ MZ1Q!6A?<(ME2P6&CL WJ?OW@WCC."W=%CNS<=5F@2S^&Y>2\HVC%PIF<8\6Z M,3$HR* T?J::,KZL38!Q\L0LV] .*9]>GCV*;L 56' O \=^ MA2/3WLN-]C)C)/O4A>]$$9 I?[AFYCU^OS/[C3SOR_Z?%_'JA\NKB7WWD@DD MV8C=C04!1"H6%XS(Z'0D1BAE*8B3#2*!J1.,FMG2!X M98MV:F*0TYN9&"_$%V6%7G5S*V&"PH8O1PZ[^KH7I5.U=C92C52E;;'9B:WA MR-C+D;G$>+M=A7LV'U0RN5VU-9ZR9GT8\C^SM1XKBEJE-3Y4VO0SA5R)7><3 M<&3DY),JJ^77!&-]+V]F4^92BHCMY548\;FK=Z4U>P) M'(FJD)X.+8 HDU.B=H2?6_HT3(/!J)1>#]DA_7(D/=U(M+WF,@I7#I=B^J"_ M*4B)8=@_L@0D/9B+C>DVUU6'8BNW#(TZ=3C2M_AFJSJJ%]D&H+=%L1P#\T0^ MRJ!G^A8_7\I:.M*I2?QV59WTVF*YQ8S7<*1O\2-F!R)KT)*4U+03DUKA5!D M--*_>)4-E^1IN97B[:F87I7&V4%ML!Y&_$MB.&G4*;9J:=I.%I-J=;-B4OQD MR/E'@K08+"3J_01?M<(-O;Q<;5J--1SI6WQNMEO;N\K.Y*O*N#B,C+1=II2 M(WV+WXW,NI[JZ:EV4)INXEPA.C?+=3C2MWAMW&MTC-PXQH?JF?RP)]AV?(/F MN5_\Q[/B0A_*BF-?S[Q[,P1^3@'ZY/!^RQ DD-"D*LKP3[BI$(U])H03\=\' M^O5MIUS*Q-LFG4J4YF(Z$^285>)KA.Z]Q5.-HSR0"K!N$:?F.#GEZ+XD MSF31]F%.K!!A"PUET*#K=D?W1PUP=!\0AX*%(_4<%U,P<:6,5V[WN/9*P'_O M#]H#*.5%E7'X^W!MU'RF\F=NI(QM=>PFYIRMBC&"8ECPO."N%8;FZCST-/0N M:RO=O8*^-S;V3[*FLB$%D9=RB[PK*.!OG!IOR3,)0H?-=>Y4C?']:A%E&UIK ME'"(C3K91-D!!XL.65;R? 2M1\>2= +_R*C&AM:+B9C>/1KTK69XDVH>6.XL7>%[!K=9_JA,*@[D8Z=AHZ M9FSMN;\=KW5!029GCE"QD;(R!? H\&61%7;S MH9M2T-R$-K1CGPLV8C?\Q)ND9[DA^@S<):2XHXJ27;BP%*1G>$C&:QE;J<4@ MTFS5=WE>KJA):U*A91.<*3YU?MQ7RMCRMPG2C/L=RZAC9'4>DZ53FP-()2Q/W'Y\6+P 6!).%^% MFIKO[H)S$Q_5=D"WZ^90\_/2MZ1]=817Y,LI7+H'>I1E?- MCDX$"7!4=PG5 MT87B#)\@>J:#TZ)3ED6"4&5LG1NF:%=U*'R0CZ)*3A7;DBCW=FD-]LOW%=M-)4C[)B4)I@!!A M]P%VP72H5/>"F X"(UF)MFLOMD3=(2U/&:!.E0&OBH7W?<=NC%'*<6W@<6(,O-IV+++;#QV[I'D0G^$*S0:WQEJ D[<.1? Z# MNS;!6$=9[5A?QCXZ-RL5%<7";EA)7SNUA(!U=-Z^C#U?MIS'&^9QZ1F4AL?1 MW+'P>?'76#A$_0>?EFZ;<)CYCY-*]\F*3EHVA[_AZ_@\G_ "U>^E=S_]1Q'D_5$"W.6P+?+++ M_])AF[]N#!%[LTL".8BK'<3;'3K(05SK(,+/\2@YB3LXB=!SF"4'<0<' ;'I MS;[QY""NB$T<.8E[.(GG&#F(^SB(\)O]L,A!7 ^;B 9[%R<1>F8)2]S#04!L M(L;U71P$P:;+G@1.W#^]_G!#V,AS>-]);W^1;;&A< T'R@O'7Z_7Z8>3CS-N\E +ES4MX]06BC^M M9NKB7()T*JO_R!Y1#$/@.$?@WB,+? MZ,X[W7,,$OI3!F&XY\A#\P>* E\(*]_S(W^M8T?ND,<^=_I19.0]G?NC'_KE MF/UMY\=7.O3(<_RK,?L9M<9_%544 1B/7][,O[V^\]92TR?EV5XC]H^N];:V MYAFB_]Q%O>W$N9/$K<]:_7MY"1?W'^#LK]>1[3,7^^DJVXWH]\TP^M>GWRNX M+.Z#?F_MGKGQ4;\3D_WBJW\OV/"5"/W3U>W; /7;<3M"OS>BWWMW>NX+_W#X M^37OHM$C^"X_A2;O7\/_KTM,^^:J.<6>5)RBW(LW&<.]#69KLG/M!K5+'38M M09,$0QJVF^GA?!E,J,(D5%.ZM&KWK4*9WACNK5_?99WHV>*-3U M#WZ%??**@62!/N1**BO1J7B+&1@T,UHL4'45]NE7*$!'.>_"MK=_#^&%OA,& MOK:)47')-;XT&UR]E1WQVBQ@X_O2+ M"T39\.=(X*O;JC=AX&O;"82!_X"!_T("+X20%$YO2@NZ:.SX7F5:ZANS*TO@ M;IM3M]/!RFXOLV:>7QBE2:LR0<4$0T^_P@$&Q7-?Y>"'#?*]L.]QM>BSQOT# MQ_'NR1.%,>&&\>V;.!\=9\*M5WT'2/DXS@8'",[I.6:E;K2&ADXOQ_VYUHEU MPSL:%5)ED9X3CT=^2\]YX*CJ?:');;/-;X4FM\T-NS,T>0#/QZMH4@U%\YM5 M?KIL%\N3EF)O"NMF) '1A'OZQ0:X&'M5-'E,?\AE8]RWYJOKH\D]:&1W@":/ MXX9Y%4WX54F-*(EH5ZD.]%Q[W8_&RX,)1)/XTR^&"T18^LK*R2-Z9RZ;$\P\=YAL]:=-/OT)L(,21C)._RSBY M.4,03O\&[HG?X/1I9EPHI@JM"+_LS#*I4%421 7UF41^"(8-T*&WTKM/.I*_ M;-MU)^QZI0Y43FL@8%KR'+<-03U7G/9\J.O)6%=E';6!,W34@.5<1SO4VXH.GD* $B;H#;A#S;[G6X"R#*!)J/W*R??/ M=-9[=0ZH/QMJ>(7:M^#.AJK3H64J+YS&.:BQE"'CCG[[WC?G&O1YS>Y0FS[X MPL/>H)Y5EB'(J*^/TPO]Y3P,,+8UU-EF"7<6-0.2 &*^>HW:#J"42:D6# M6@OA!CCFX1APURK<6E V%:?S$?QMZ[0_(T!3LL!!T_W"OL\#NT$D3]^@)NOZ#Y0@4;V=HZO8Y> M+GGD=5(\M LR][V!;,WME^1\^_0\O?:&:"N]MDI>@S*GEY3_=% ;'EM#'7M$ M>8$/!>VU;+COQ3W#\!' X BM[M$Y2@3WI>9VH4+=\MR>D["21KN M7%_I[>COUOMV"V^$PGOM @'P9]0#?;5(2RA\E-7HP'_\L_I67;0.Z?_]/R<% M5GT1*5B(IM'. MHB@,%F.09U'74P3:>]H1+JDY_4W%HT&_PO<"5+Z2>KYP1]&W9N4[N+>F6*FV M^";5JE+M2J*=SK?X-)6J5IK54CZ=0+]D\I5$)95/E*AF"WY0YBNMYB'6]2;6 MG;+%.7K?-VR/CS*=:7=!LTIVN\I,DNW&9-*;(#ODZ==I:W>Q&0]VF""7:%?[ M[,@,)39Z3DC D;YV\8DN8ZJE(:O0S2!3'*RD6B-:J0]#_F;UUE:V!J588=O> M9OMT7>TFN.T4C?2]G=L.U9F>>7L_-XZ&BS8OQ,H5 M(1$*ID:-^I#UO[TQU)H),*P:BE!I]SEV,V#T$;H=XQNIU5K#<:Z5V/'+7B57 MKG42*2V%,L)\\]3M6:?:G&7K2E!34^M<5M0+812>]7YD3@T4_/"]/=%3H+I-H:>M13B[TUL/HF;='(ML\S;1+M+QC,SUV MGHV&"A,XTGO["Z'IM>QC9O:JPJJ+?KO9*A6K0ZZZ;"6<5L.LOS'Q&Z/#3Z^^ MX\UVQI]O;25B#4Q_9F &H\CJV_%3AG/F$S#KT:=]#U[$]D*HT/76*%HZU$ MX_R/F:V-NDSU07J9>J#(=1 M:^ JTI1IC\=H1U'3<:R?;D\-W&,S\UA;QRU.@;4?B6TQK\'[:S8MU('U-5)3 M _N#<:R/$SMT=*:9/9[M]%B!'JLV4M0]K1W90!YKH8?N_WRL(Z.O(0IA27D-B4DH M=FJH,[S3$WW?*A2D"_RH.F!G?'/:YPTV5!3RZ V?TBK4)X-?!XL_ZG;^]*MI MZ:(2=#PQQYMQM:;FQWC@]IQU"-0\FIEX-+-]D]WC)L7[CLHF;C,-Y@M5WP+4 ME=EPVMGNS7@9,9L+!KBS+;3EUX(AX:\M;1FWCX:<8F.6.&KG/0>":>.NS$Z# M: JU*W<:[JX@MU.2;>Q= M:-B$=(#RU3U #]!,X'EB#JW*'8S<&\WN%\Y!_ MGBE4 AV_[J2=,)Z$.$78BL44W.7C[LYS8$&T0/VQW]FU%^W=<9]VV=J[O>!> MC+"YX/G03MX"PL<^&3(RT#B["#: MK(XSL@9G(PMJ_D#G+T N'VP!I=G*C-IRN-.OU>*\#<3)PX(<6CS5\3ASOW[J M: -N@7=[OACO9W0$/9XS&3O7 @=L/&@;1Q]"Z>]^@GUK(CP?B5)=?4I&;F[$ MQ:Z+SW5VBX)A;+$*X&H4V&6_<32/(S"3'%D/Z1I^9$ZAAA5$6BY_5V?SS.7F_W@"_^X:6':1FJ*2W+XE5"ZR282 ME*J*"17/T0N]Z!IF03@]V=LOZC]8)NNV"5]M_O,#;]NUB#,MFZ*J(^W)3Z @ MP4ZKX7#+5(*1NMP;Y&TS%OXL GW=Z7SJ;4>$^KN>9QP1WGN;G90 9*\)"Q/\ M\'XXG@CRS[J^6>3W$AV/I.?OQZY@P;9T[P/'$8P_.7$7'V45N&,.(8)H_#D> MQXY>R_"F=M2][.EWL^FYR'/LJIFG3K#AF3YR2/Y]:."ADNSO<0>N4,'PKC> M?8Y>-5GK#K?@RHFI][@#7/B;[P#[S%ZU!NNG;<$'[Y3=KQ3\@PY[=RH%8^]M MP%MQR=>[ZKRX9W>1SCIWWD;K@WOW6D_!"S9>NDJWK8<@GIN77+DP\:2!>$P[ MS(%V/JEYTQU <4-84V4W<\S\2A7>KB!U+K5 QKR@VBD3^_!;!W/4%NW3-K0I.:]F*A MRF=O![!L<<)DY%::KJ;D57LS+^:F.938P^*RE73H2Y=0>BCFO[4E]MG6LPMJ:IN.CTE&&0["YE-]QEFS *E+OS.*3(8O5#NY3^LU\0=WBX52(2_(J M41\H$D]7*3%F6PUDQ!@KBK)F S(J[RX0C'RQD]J@ND(RLR>84 M2%16UR7B [FA#^36!1+_#.(N["BY]2;< 39^OA[C\3QF^7.%T9*[CIU-Y=,T M6!>;TYW,&=QH[73."P>B[.\UWB+NDRNY3V[-,S<'#O81RLM^":7J/>0HUZR% M/&8J#+2 :(Z6YJMFM3!Q6O:% PP3_U*>EUM48?IR.M2C>68N4G2*.&4NILQD M#?VL?=>(!EB;NF"_JCKD0@Q)/S*64AMHCBN-98IMAXKS8(M5K,UHXS:ZB06BL>CW\,"4@&G^0-<,@;$"Q %#'##$ M ?,*)/IVA?K/@RHMI7RFVG X_EQQ2S'%9#E%#+>S46MB1[36?,JZA>F9B#]Y MY1_B?B'N%^)^N35L7$&5>ALWEB5VQ&?EK-P.T49N+J[Z"9-=.W7NW\$-XGSY MEOK3WZM)-ZT!_JG>F9NO\PZLP\_7A"K .F<:EHV,W7>*:Y=?VY1@/54-P[2_;T'!E*U3W1A]!'1V8 M(BY5Z!1!1&7.34K53=.MG@,V*'WJ:+@%#H\,X,+SJ-3)PI %"YQ6A'3KD)F> M:\M]X+YT^%N/1I5:CEH*"*9ISQ=NC?*1;EO4V$8%BR!MPBV3<'W(DT]0H185 M/7TLK'3#JP"F>?625#R[F5.W;01W2]"$B5N&_:20OK=W:P-!B:2OX010X<01 MV)=GZ<6R/U4#[@$WDH&:UR_=&*K@@$)'-<4!12J9S<^>CU" M:Q-^*S@7%&#@(_R"T#=$_4]5T&?_( M_/SG^5HG?, 49X).ZX81*@^%\D7I'6?6/>SAEMET^N_8JWU?:E>7"#XA^/5 M"BX87*]0;A>XMB52AX&! M"U4+&V36 ;=9V%%]VWV1ZH.IZ-IVZ#L U_!W.A@ J#T;@G&^1Q7N[@:_@,Q( M//R5M^$*L'.O'B^RIP[MJE!-7FS,XC8+4.U%,2T\HY&@8C79G * RGY"+6\- M5!4KK'M]!MG1CB(-YR'"51!@'_W MNJ/-=3@/558 ;@@&)1OJ[.75]C9146$-VEN66\\;_1%/U"E7?#6+8%^0W"% M;TZXD\)1*PSX-P]OX2F,?V>))U_:%RTW;1,]T=D\L(%+TMSN?UOO2[BLK U/ MV"EP?%KXW@+B5,,-%Q'(NLR%.T Z+[J)BP.>1<(IB8W\&X:NZ6CKCBJ*,FG8B/8(Z; QUNC/4U2 ] MKU$%6P-4B&:X )5)-).0>$U4JCS1;.-/@PP;.%^@G0I2*0<-2XZG\3\M?0%I MB UQ_T!;?FGKUL^CIS@?_!.@R@Y0>@T#3I\!:?GLR[SN"VZ9YM/F)EY3E:F^ M1JX7ASM6<5%!WRI1#+/WWO]CX3^O0 M@ )^?%03W6N'@2I0.WC]8O9X:E!*J0+N+B,)6_Q DW+V"'['QI"+INM\=&C> MBJN?0SQQ/M^#^=%0I\4D6N/QW(_G"@6E8>'2[ZARM=O.AT[L6JP%P8FDFE3W'X!-T+"TN2DQ+PCKP-NSPDHJ71G M,RC,24[Q>/2$('I"\"#14 ],V<#T@]?Z3.4MI[J]"?^D(B^6N1?\+H,=-F5A M&Y!><"<*3!1!YW% >KE>1VKK@H:)#V(Z(F;X'T=W05XQIUN)ALJ"NVTFX:9 M3M/PZI#Y2WGUV*"-$("<$ HYGC)<*E^>[[^&VR)!FL-M5J )I@+#56,W,ZIY$ 5#5][R1SO8U>BQ2W+>E> MP.TG"!G\" ..6M^Z'4P/'+AOXQ'XO;:FG^5+*>^C"+CIJ.=6E5P\,#!VJUL/ M)X]H;'$*XFB^D@Y,5X%Q.E Y$**Y77B1LO/B6X<=$BBO'>I1U]>S35R.5=K# MAN+Z^ YX_J8_[?L$W=[VF?WY/)TF>D,N*K$@'AD-8T!BAF$N&AH*L0@]%$9C M$!U'N)@P'K]LNU>UU%T]NIA)[6(XUBJOMYK5YM;GFBC&QDD^O3:Z2SHTJ=;3 M"R:N)9J3+A*%T#JI<(WJ6.8; MT[HX.MOP$#1GH4XEDTZU0YO,=-G?)6F%1B-]\PS1V4UV74S4^5!'RG;;XT5H M5D2%5'SSC-44;J*MY1%OKQ1A O5<,$RMSS51;,"MK8N2W.:%1FI>RW;38EZJ M#R/^D=-VLBTN)M,='UP5:U*[7+M:X?O\*CUC@_W$ M,.H?60J.1A$F5$NVJ[ER*6GFV?167@]C_I%5)1=1)$D=\]MBE5NW=J%H=0!/ MD_8/C26GE5)H#NJ\7>Z-JF%6J?%+./3,R;,AH3583@Q%X32KUHVE-@5QCH>> M;NDPIRI1FHZR<3KJ_N&3]7RHP$*DMK:H09N5T"#!V?("@<];G28&T7 ^L0!S MNYU=--I"IS5MFHTS$/KUG] _ MK]2V_0Q;H]:HUOA&JT\E*FF*K[?S->16/%@8MZ(+/S6LZ&6PS7-L5['3$44$ MTU7#%C[+170@KH=-Y"0N>1+W M?@/O+JZG7*%ST3N91*^WF/EFO8G>O+K?YM4_6+K_X]^_#3KRF^ ,"O5(?D.M4SWE&BOSS]7F/Y?T*_ M]ZZ-[R^(:\!Q&7F#?C++6"$=-BN;WI@MZ%.EVQEIT7J-Y;7U MGU]\?W56K]5!7$UFQJ0?FP;IXFY8:*>E5<54UD[;F% @Q/Y>M[K[%Z>W8.BK MB]<+,?2-Y>)5&/JH]L2%.3H;JHMZOZKEVL&.3D=R=+0Z3]6OQ]$-7>5X,QZU M^>Z23>>L0KC:U=9.;YE0@.7>XNB'-7]?J"0)TX2'@1(^B1G\!R"X_YN+?/I*2#?5X$RE[3Q3R+8FTKHUO:(N0QOY7)6ISC<\QVO#T;K9:E2T MNM,ZAJ'I+]TXYMXPX>JZSU4P@6A&'P:%L@YYL1]+<'QPRA6E<4Y73/F*ZM!V MF*37X59TUI;+]GI4F#O\W3 5!95\(@]>+^+P^62S3J) M>O(>$GD,X0)1PHS7^TEM%52Z67/9"HFQX#2]OAX0Q19F?9!G=C&Z&ZLEUMK8 MV$0;;D\82-G$S_(X?I9+\C%1*3[*R+$,K=7ZF@G:#LGHZVV^[[6"8$,F/>2"_S4W8GJ@P?\;W$VXS M;G:$[H9.Z3U0&L[3J9%P1=UE)W>*+"@UENVYVNMO>@*SGBXF3I,8EF.^BYL' M%9C#M>Z)>^=SW3NW[F)Y&_?/K5=]:^3\"X7)84^W$X673BS*AL698,U74ZUE M-9+G*S7KBM'V3%R4I+Y1Y-M@;4["X4B[DQW6AS'')Q0*$9_0M7U"MV:PV_B, M;KWJ6\/*WRADYW!E'&L7MO&,-*5MGEYVJB.ZD#:OJ(QEE=6,Z8%%LBW4E[*A M!F>%]&H"<05U[*,?V9%T(]OK$?4MXEMX9'R>IO2)F!$RIL&!WHRK;6$R =->(1FN M-28(,_ E\P@=?0LSB$OFRVA*%U"(6,CGDFZC*O\W@;<+5L&Y^<)N;?9=WTU3 M >?PJ=R3YH."S6]H8"86T;H][>U2"=1QQBEK$R%>FK_STMRJB8&I\_*0SV8WM6@K44\UK GB873/*A /1=YSW/P/[AWSR]=" M[D[X\+.[I+9T2U!//#VXB[)FH@Z8CAO(TG$[P_-]@P)PN*C:)NH9J8\I]20; M*$"M!9/ZKPN3X+YY4_1L\Z9]]25!-CJH:6ERBRK]6"E5,,V3I/A7:,Z@VKJZ0& MRPZ3XW,6&UT__:*?_>Y'"A*"BCM4P]/X[!VFCW>8ON .MVO%5+ZU+4^5[F0W MM6)\QXK8Z\_;82NKBN-%'4A\:CSCZ(AM3^WI!.VP7];O=]CK]FY-#0"H.=RG MJ4D!38)TOB\A3K$T[H'*X/- NX1;?2Z<;JKJ]IGZ_^Q]:9.J3K+W^QMQOP-Q M[ITG9B*./8"*>.9Y3@0J[HJ*N+TAD$41!&01]=,_5:#=VMB[:S<1,^??;9=0 ME5P MK(]GU54]T+;436YA7Z-N8CT:R$.<%;GU@L"(HCFMY(>3\U&WF5J(9-NENG1? M%A/JVL;R)DZ]82"<$"J#$B.^2Y+:L*4T MSJ@V/MT<\])2[-.JA5<=NB:4$DQ@]1%OJ\V'3+-7M6:G%E)X\Q,VG;=E10>C M80?VL/^Y:HCF''8RW?8WARU91=-QH6]ERTO9\.07.IX'?9KVVD^)X%TV#&A, MMUOB8[@"[H;GZ#_U8N\5/+67:Q#NQ1AVA=[G'V]\]=__==#1*W*2M0WW[-%Z MVTD,#R(_$SD1-@P3%$"./X+N"VMG2WN2?,!3NU#2G\>0$>0.DGX@R7\@3S_" M9448#/O6[K'QH"]M^*W#SK3;S][H6K:5%=>T_N#8 TP,F8-?=_W14@^I,PG/ M<[,M_=1P6D# S@6PZ7^Z3/X8?S_[RO!7^""@20!K]/"3;5.@[4=[0@TI"\W( MH-\&30-=AYE1SAER.8KG8Q&PR8]^(U4FOF'Q\Y%YY]5A'&O3;')=&D6 MZ3((UZ2X0J5+%Y \TV29>J5 P5^*E2;5S%>H.L)VP0>PL3?[U(7I5; [5(MC M\@ZP<]N'/43F5WNV;WNQ7\ _ ?B?-^= EM9PPU%=TW:.VU5P;[),*'PJ\&AT M$^9M@1W(T@4X%*B'[+A@IX3["MB/9!O&YL+]Q9!=9&R:&K*$+B8R#K:CP)8 M_Q/TM:,&/<*#H5ZPQX'?PNW*GZKB-&@3#AZNZXBONE/$ @0,&HO#*84CW+UE MB()AF"Y8!)"4.=Q(X1]%S[;AU@8W.<\YC^_W,CGG3[9JE(SRR0D9K#LTDF7; MAI, LP$C)C*8C3L57&0J@*="*JW!(VW9]6P#C@:0:X>4?]KP]X7V9B+40J ^ M?#8C)#-H"N,%193Y5$HB^+$@R+R2)#$BJ:"*J*1^A2 I/&8551*=A+=9H2AN MS_U*HKJQV90/+<_G(SN>RN8[N-RC%R8IK+OEIKLP*#"2?#Z297FEP_+&&$VL M>BX]3DQ[)7'"X]%G%A=X-HM7%S@]7_4Y8FR9U(*AP,CT\Y$UO):E?+H-W '3 M2(GU5+/;Z,"1D;>GV9G@:JU27E/M-4.6DF1I/O+!2 Q[/I2W>%7&O&(&S)]&$,["T M62._5*OPF9'%KY1*-MMJ9_+TNH,-VL+2ZC8X"HR,+GX]3CF3KI9T-<(A^^.< M4RR7NFT^?61)%8+:*%D%D$<==%LUM=6;,;"R0F3D@*!<;^YV\K3JL+7,C,S7 MQ[H^T.5D9XTW!$^DL?&9T\5)-3;N3:0K%%X,$EZ?'?JH* M[W='%N_.)9(S%-/CUBYC)9M]@;#S<&1T\4Z]YJS3'4>@YZ6%),CTL)U-PV3C MR)+$KJI7L+(BHVNMPA;I7-W'*D$*362HC#OU5JYH5FDAV?2MLKN8X)@/AT:6 M3_3$2MMC$UE-KN";J41V\$TA>&ID_1MFT.+)>G6$]I6&TYZT&AHO!D^-$,"W MQT4B/ZVMN!)1D$>M\K1K8T&*8)0"#> WSN3D.LGE6S4>F]"Y0MI8;*OO[(YQ9TAE?6P9#'PE[X Q^)%R2ZRHSGB2P-)TO%\IXVAN255@>[M##I@4; MN,$3IR7;[!18 %WP])QNBMJOG>FTJ;?;%5*HHEHBU]<'A7%OUAA2O\#^*0H6 M>))K>_+)3*@#5P=[;/NI N_<-K->-4O_F?S7L4ZIX]>^%;Q=_>>8U_OI+4YUFI5EBD1;=0=@RU:%/;*Z_3(6, M12Q@Z3F0M8&!)P*SR8,VRWB- "M;A=0.+)YM> )\#&V@D BRE 6C TLFCV3 M$0P#-E?XR,!X=6 D"CY&\FSX'_A]\%+5E!Z0@JH';SLR&]4YZV2@L7=HZTIP M+O P^\DPW/]Z'5Q>WO"0N>Q. M32FP/O?G$O[1M*"D;&V^,ZLU*TYER=-E1GFNX(%T4(:TY4S@\AY1^J)B)G Q M2Z!JM9"W-3"X/)F<2>DCMOV.U$%H38$6.* 19*CTLC@=QL+AX(^=O 8* AT' M73=]!_FG"IT!TW/ "?(A #?W7N=)+C"O_Y<)-+U3F,]2'9YC&>%:4P E73! M*ZY^R ,-06?'*#T/FR'8Z)12-?> M36P7;@J7^;X$X!3V@+V: +P7+MA[O@F>J0!F[JBV^ST!L[[^A-$[']#IS<#9 M-KH:O'@W5!@[)I3%,T?,3AWU//,5S9@1%V,$C##'C+@^(["'[*M)OS$G+J82 MV5?+/<2,B+'IAS$BQJ9;X41L-]T*(^(]XB;X@#T0,2=N@A,/9"9FQ$TP(E:( MF^ #@*:8$3? "/0!??5&?,R(CS'B@V47WHRZ7F[5Y =6?02I28\6;RD*+VU%=Z3*,7;T/61XQV*$,V5.5('[!$3 M\,]B I9\N&Z)Q*]B LPB.-F&\?H)1LSVFV([>B]VP@VQ'7\@[Y[OIU/WUR-O MWXSO]\[V4ZG[-[?E/E4?>VOD7;L Z$%>6^8!MYZE'XK["]Q+? M,SLFL?A>07Q_BO1>QK\Z#:=O,Q;^"3>H^71I3U@*JA[<17+-QPMV\ +<%#A% MLGVTC_3M[Z_7*+1]<7OQ)'6TKV[HG;E,]AO%'9.%F3\J3YL=>CVT4SU[.JI6 M,Y\OF@T4JQ+H5?UX=S._+PC,I*P6M$0CD6:F#E&IMF$)A^2OO\1O[$@CCGLX MJ(CU+]:_3Y;_M$=)IKB2$^ 76YV1OE77F.;G&T^\I7_9>3>!JLMQBB8\J],B MJK6A%^A?4*0^F3Q3HXF?L?_=I_I=V5&\E/I]K#S!F=1/2"N85"0*)%U3+9XW MB&3)Q6!=HNROO^1O_-7.X+=[KW[F2M[^;]CW;_"9%;=I?C9B\AO?&#<XRMQ H0*T"\ ]RS<7\5^;_Q^,"51.,>O=Y8_C^9<'%M M(MR:^-^Y!_V2Q'3)VE2C";X*0)"?@'PGY'.UL]AO?0Q_#> M6,JBJN]7\IJ*CU9)N5O#,1VVA$S"/O%8G'40XT*,"Y?%A0\G'9P#%PQ'I%II M9I!"O=5&R:[T.6>JL*DL 7$!O6S,_\?;"S>@)!>%A6C4X ?#PF<3"\X!"U*F M8)?@:_??XV7J:=P[57>I9L7B^N5Z@_$I]MQA?+35"@OJ+"=G?0S:I3? M5F3KTJ;FQ:[77C?9YQO7*(_E-Y;?&'_OM!KTQ:XJ_Q3QO4>/*1;?:[M.MR&] M=^Y!W<#Y35RC_!8B 7&-Y,M>P;_/&N5>-NVY)19;:$)=QS*Z+K=0=,)C:%RD M/%; GZ& URU2GLE4FZ0N"ETM83:;/I/O]7')APH85RF_NT.-N$KYW54IIQF> M;S52>1'U1A1-*5IC*@O!!AB7*?^Q^O>3U.^Z9GTQ^CX/UN,;W MHG"#'0^;C(=ZSSWR(;(2[2?:CR.#ZO.25;D>C% M8HF5I<*@7Y HJ/)QE>Z?D\-!*XHLNHBI(!+,7%>7,N+(HF>KK@I>G4!,"_+= M08 L(4"N7%L587I[D-L1'VG=;5WCE_'^VY4K_A$QG>VUDPCX4]+,<]PYT/XC M.X"-S]*M#3')T +O)#/)HE#G-\#HPV%T)X._S^+[$1&<6.%CA;^M>,ZG%'Y8 ML^?#8K65I/M]B9XWJTZ9DWVH\,2OO]DL&B>M?.70_-HJ<39]O_%Z[#\BEO,I M?>^6-A5B)@S6W%JHZWG+;]HE)=C@LV"#S[SO[.9'1&YB?;^;^O,_(H[S*74W M>HQ"I%K9*LH62VZ/6G2E8IJ"Z@XC.MAO+(W%:3G?/2UG5X# C]-SXI/Z^*3^ M_D(YC/(2^!^!_,I",/+4)JNBZTZB/^NOYLYFW.:Q9)"@D_Z=RK[O)D*<#2E_L MDUC;MU)]C>!J^9;G])BI1D&E#])T4K\SV&53\^X\W'.'49V=0B#$5BGVR1$. M"Y\%'QY7@_[&I_AQ._(;Z4=[GW&.6 %B!8AW@'L^YKU:OX!K4^'VY/\>?=]8 M_K]?/L15J'+G3N W/?,_UG0@#OK'G;?CSMOGZ[S]X0R!KS33W"KZD7::>7R> M1Y-:2>)*3D9=2%G'&7$4CZ5A(@#Z@+VO(%.3V!T$! :$ OW8#[AUL--Z G%T6&:/3@!R/#9S,-SH,, M9!KEQHR$,QPQ7.(KQ;%U16I#9,@&/;CC=((8&DIC<';Q1O M9J)GF$;1M!' QBGB3F7P?UN6@Y(A0-YD9 Z^-W40V9!D"6%ERY5A%@R21'\C M#(ET_WVVH)?#28H&RX],(#A,R;<\LTP*\.M5*=QU'Y MH,<-"\N@-(+E\#,;FP^\A3:@"5&KEI1.HY2>'F8.I3^@K)3AJKN2+.QC119Z M)>H>(&/1-N=P9IX;+(E1GNLV-0=J]W1)C A5NRG8-M_MV[P]<]4-O:[57+66 M;">XO \DZ=*W*;Y*\4'/D&LM15G21-W,SMI]+D.YU U2/)=3I#R>8ON<8'83 M15;UFEFG'0#I$1Q]]@$"M%.'_-A=X%(.&BPAOFS+B+R=):* :08Z^%3.)Q@% M)B5Z>C!U9"R+@N= -955&Y'#"D"^Z>D2,A7 -\:R; #M==7$[B$/YX*-8ZE, MNT,6_/W93#<%:.BU .V9\?!5]3*);CMEZ#55P^O%K(8)M40AX]^@>O&+!&NI M^4*53C!ME=%ZDU%N,+D$H)V8XLE4MYW3J7H*]6:UD:<-!K9#W"*@\6IG,)\* MZP3JV>EVI]%VVV1B$@2:[PG0;M0\.YC5*>((AV)14!U1-QW/EAD%"H!L.,%# M.S(@IRSE3<=U @'( =B26L(:2K+3!7/(Z8#R6R=AS.NY,BF#=ZS1]:"=5^<5 MKR#WMPJC&IXL4>XKXW@X#/N%R$"\+# [U_;D\YRA8N3S(]3@DV?YM7"[V7IZ MKS9X_V?J7_M-+7/7OA6\'"BI&7+O#W"(9%L'.\GSO^S82:"Q45C@&": -J1@B(#I4W)8.5.&?\,]0Z/'P2=M1\&_!I]A_ M_H7X*MAW!60NK-2Y-X< <7HHIQR>47@BU!TL\XC*<")-H"\!5&_6*Y4/)OBX M"OAW^(4M9/>6MC6M+<8SK39=ZYJ5&[%D_A"RB0] ]I/>[6LF9=N",0EVE-PZ MHIJ4#Y9^6/Z3\MRI:0/&2D?A6Y^RUDA!AU6:[7+N9E'J+69EX %$+Q(\QVKP M?]F&3 8K0E3'\01 EP$).C3NX),AE@*L MV?X)O %JQL&&!GX()@70%?X]>'BPUHELR+:@ZVMD"5:- .VQ 6$].Z3-6A;@ M+)\39$V/O/7"H8;H[VDO@A_TZ$#OF@MU>U1'' M$Z?!?.!?X+=W;$9,$=@0SO&M\]^2NOS[?\$_.R02=3!]&-F9_N?0KD]"2-G& M %'T'V<)Y4%=E>T=H.&IO3L4(:!A^$4\FKV![W=F0E(&__[W?^V3-!I.V^X3 M>[2>AML.'FR"$SDQMF5!2P@*(,%M;.E/4GNG5+_>0RT0NX@Z0>2_ ?R M]"-<5H3! )T3>VP\V'+#;^T^"@*KN\^ L@1[H VM#8"G\-D'3PUDQ36M/SCV M "^\S,&OVU5AJ8?4F83G^=Z7?K(&! 1X?V#'^!^P%Q_C[V=?&?X*'P0T">P/ M^G_V#8?M1WM"#2D+YM,-VBP#',G#W0Q89H^R(YS2&'A1F]YA(XV&37KP&ZDT M\P\G-E%>FU6$<:]-L3S<+32AJ$S/9LN>M49M/1I]) MSSK#:8\L%.B$V_-H%DLL%(4"(R//K#"<-"_XEL$EEL5^9Y'PZ@6*XE,\^GRD MW1[7]+E?':)]##-6LW6GT7W:2@I MD;4:79-<67"V) M=TVZ5.ZKFRPV7G<3DV,RO>1<8=Z?JY)6JO<,02QH]4'?/R;3" MJN>,Q6#:E&M'9;II="NXU%N0:$E)NKEQWUKC0*.(*)F*8FHL9.8Y41-:LWS# M*KFHFX'/C)!)DYQ4MDPL<4W-6]UB%_-)$RR>B)*)9LTZQA$UGO/443N97ZC+ M<@F^_1F9>#&=28I9,$',X#S0'31%C'&,$"**4JPMZT9))/IH MHI9K9?@9*7G]-A#_"!&DV63:$+)855L(LU:IU4:GDPT4P,C(=:4K4YJ4W&B+ M\88O*X,!*73AR.3SD4*O6LHD,\L%)R0X7Z*,?*M5GQR35&L$=*5BEG&.53)# M34Y,YHH"1T:>.5TDY5*WJ_,HDW/HQ+)93=0;_E'XPW,3>KH6EUK)I"4]X>;' MN@V%:O=,8(IO8RYA..S5^,PN[O*!* U^GB/6@F=#%^,S!X97.QS\8'1 2];E M,5\1\YHPSC=-?YKM-H2#$'JE63P(#R0<680A A_8Y8YLG"P^L'6Q2] G="I& M"[#'E$KV?G]7="]"L+"L;G[=2PPXV?7+J5FNAZTKUSPC_"CA3;Y:$AO# 9WG M%JBB]7&!9-MW0/C.VI.G?L-2N7Q>3ZY7(R9'RH#PAOF.P/HVW!"\<1?."*+I MNWC&B\&3!R2BC6\>.6#LM!9S*F^4<[JJ-RF;"G7%6U5O =9Z(M8DL/% MI,T))&VA3;0[:JO'9>%4K'_?\>;5CC(_R/EAT4A9"V[@:NJFD>3XL=>MF:]R M_DS1V8\R?K8AYN7\@$'99<83[E'=]@@L@D6 M*1AK9"I(9PO /R$]FYPF4)8^M'(^F> M[1&S6FE4TUBIJF>-O&ZN&D%F1_3"S5,L?8]=!P5Y POHQU&:#H/K,*SU"J7+ M\Z:O:^G)D!;R"8'*EDU9P -*1TL=/E):?GKTG@XHIJZ;?A"S!RK@_#GGH2L$ MJ3^L.)4E3Y<99;^4MR%%5LXH@6IN"1-$^J+GKM*J9_4MKJ!SM4JZ-K:9B52I M^V!S=ZX01)P% MSS5W'X3QYN"3@ZCT_LEP."9Z%.':NXGM8L[ARM]70(I(/J1?K0"[%S/<>SX\ M^%& 2.ZHMOL] 7-@_X0A?&B+O!D]WS(C>/%NJ#!V3)CG>XFP.4S4?8J_GO(D MY(OWU?$WJEG&?+D.7[#40^;52Q\Q8V*%B?FR?TV(>/4J1,R7&,B^(V,^6,GS M34/L:D0@/T"$LR+XEREP)(GRD "OG;]'K?S$9X/SV8 M_;8\)R'!-^$_\ >A1@0W'3\I"\1#ZKQUFTXL"WMA@4-RQ"!X4C1\(FV_(20R>L8*<"CRO6 [TQ$KS3Q5>3C ] M!]B>SK]B9+T@LOX,(3I5]=5;P^//W^D++BOE!5>>F/;Z I6%KJ^-%VA<=':C M]LUJ02^L^OQK_Q'\?2/L?6'EOW*IL+L1]ONSN7$432/[MU+#NZ7?PBAZ64WO M3P"3SQ=W@;RIE[,0N[[9W=H_E"$58;V-ISP>.'R;D-B>CX<"/TYT:4_6Y[E: MPCP(]'AY;S,)W2HU_F\GB:6:PZ?.\,:WQHD^!2\FIE^"QV^D5\85GE" M]JD<6 U.4'3AL2[*>+VM>0&)OJV:$OL%=V\*WQ;6/%4+GE>+2%KJW;9@T/%TFEO,DRBVZN.XMS*3I=MKA M;5?\LBUQ?X2F?0=+)H:=&':^:/'T$XMBMMQA-_1:27AUNY*7A,XDO#K_*NS< M8RSD\:[87BPD=O!NZT#PSI#BU0N;^88RMB9BR^9J)5NW^0PT0Y(D&<='WF%57%M[;C)^RZ0KN;PBB>A&9&!GV?F?%]-.>60@$_P8*)\>@GX=%[;!3: MT+H=ME>O:+*(RHMAV\3ILCNWR7=6% M-4PJ8*=:JI(GZ($)#O_2$ PA%*VMU;TSU@.QZJXM^:#SR5-)\_WN)Y\T\&F? M,&MN6JQI-;N+SG124DQUJWMRN/"ADVK%MV5C3M6727Q7T M<2??O$)UHU/(PZC,#MN*L&IR^?FJ-"P/^O-E.2AZ%&W->J2MCOW4.F"OMPW?(,%O@2XH*^/U!!\?\>LBQ<3O%T!]AKM:7:9 M9*>TH'E-:\FR9AG_?-^MJPJPK''6HI=OCC@/'UFFUS1K+.3]!$83G3E^2@45$_WUCRJO+0K!%8MCLK+-!:S4UF-XN!-N6IFP6T M+JP6)Z@V^+*MR2ZR%'1/?CZ1<':P(4[P8V(,"1<43WS,!I)7\&>(C:ISBNXQ MXBBZ>MM Q<$O-]V91M^L SH *$ZZ#83K.(5&NY]TP8? M&%[XV. IO@G7!-O7[#WKB>BWWD+RS$W7GDH [FL=[+56-.VHOCUIHT/INBEN M6_0=U]V@8UMN#07XA9*!DXGDM?!-;LJMZWB[H9=3 GZ9DH'=@WJ+CC<'?P4C MG5"X7]:5H->4".,$0;>BL!RI$80)A%#]MRT6 UPP+3GDD8,%PZ]!;Y@CUDB9@Q-\B8AVRL,#?)%SPN M'7J+?(F![$89$UMD-\J7&,=ND2U87)OZ-AGS0,8ED&^2+[&ZW"); ([%?+D] MOL")Q7PY&U\^> _NS3CR]Z_#^99_<*'6ZF>BR6,]Q?1GZRGBY$/R6]53+&Y/ M8;O!R6PCS)VA#W-GPLL#2?3W:>OFGUO4/DZI([P,R6DVTIKQ_3?&NAP,AO)A7H M=S?+1B M\NGNW%XB('(O=VK?R!L[/S'^]ZS+>RMKX8:O!'-L@9\O$I0N3/"6UD=U;^A6 M&^C*;G_H[N7NWDC%$,VYS.XRG^O;M/"#FR=0#1F%%71Y5V/-7AO=VKR6J&IX MRQR3\JR6J>N?K[&V34>7I>.YZ'28O7WDQO &90W-G/1:=%YHN-5A8K @:SZ? MY).__F+1ZXWG59DSNR1WAA]7KN80X\>)\>/9U;:OX='D\/6DF-'0H,4]LHSH)L _P@ 'Y$;X_%]L?E\.-[P\E4BVTNUN]J<%6IV98)V1[7/UU_[-'ST<95F6]K2YF0AZTZS M!8I5*6A^9'_]35W:_#ASE".&CUN"CQ^&'BM,@P)S#93J74/99-256]K_>&(I !Z8+#:_&7AXS+QL+/ Q_T=J0;"N*T? M $L P%O,VQO*]W *KSI=]>(?Z%M^P3AD95T'Q"G)AFP+.F5(E#17 M#=5Q[2 /IZJ MN%.GE:N.NQ,^!>-6J;/4]_X6X:F[BT+%J'"=B-/'4$$;#?KM_KC-TOVJ/:YO MIK-V=G2%:%1+H?)8T:F7M)*:9$I0B.-(YP*% M<7K&-F?K8H?#\X)O,\920;DKQ)CPJMM;DB8*H&"8[=>MI40-T#8 A>ROOYDS MF0K?()3THT'AAV'"Q0R%IMLMIAKR>JPMN)S;3^N"E]6O$#D2R?F::8ZI-2V4 M!_(X1VR(I@H-!1@Y2IVE?_+W"A#=:T+45DY_!\$CX4!4X[/)B^9&7;O=P+T0 M*_1;KTVMV]BNOA[M>F.?VFY3A+3D2PVZYW*UWC39G(^X_,"]@C]+E]B\YR9$ M&B7&8\KUI9KHKV C;QCEREPZO>(;Q+].FYYU;:6\%V+%$';*T-S[((RQQ;7/ M+]( MU];)>Z%5&">\-K5N \&^'D=\'X+1RU%6ZU2R(KU 18(L5C/KEG,%!&L[>&/@ M6X,<.B^RF[Q:&,A580(0+/OK;_;"62;?(K(8(]AU$.SZQ+HI #N["68KZ\2( M'R0F6JTQUUQ.PIH-] I>Y&B&3FR'-2W4ZXJ _$Y191MM & PV(G]SB2S<:;< M=\V4"QHV(V'/FI?;>L0'X5](FCL$U20 5SIJ%K-7",#AIGI"MJLVBB1DB=#%A]8C1[%$S!B MF$Z>*07F&P0&3Q#_BS7_9VC^,[O1'B69XDI.@%]L=4;Z5EUCKI$1FTQ:PP*' MN4E.%?#TM%-HI/'B!&@^#+0ET3CY[81Y+E=7B LH?C3@]6,5_V,M!B^M^(L* MJYI^;3ZC&1M5&Y56C[.J4/&ST+M#WWF-\B<&HF+5?V>DZ*=K_K,M?U+4IOW5 MB,EK>&_<<.R2EG/0*T2F%8TFB;*ZGJ!J8:&@!;=0P[I0\\/ #HD2<2);-'[S M[Z"]Y]\=:;;-96^Y'^E9* HGL L2364$2IQ@K&%_5UE=RA("XYI 6!%1<*:( M99NB+$NP_:LN;+LZF]8VA"3;H@I;PTK/&\V_WE\>"_LE1UY\^$)30?[WYO;U MCW3V;FU74K3->= !>MN7F][2[7A+;E=$QQPKVD--R*-LHM'WE%::>J-%^SN9 M8\!RU+?.FT\[6^?G378\Y+HRLY#I?&HV(]E)J>W7WN(-S#<]MR!_?)LZ/[%P MVFE,_5K"0!=R@Q_UI]WE*NE#8D4WIX\*?O9"X_#$4%A84)9BQ=K'+X#!4D%=#== M9&(+AHO 3\)CAI!CGV<4]AL\UO[H;H(>(I8'CSK@=W.Z .8$&&'"D@%;:;( MM^'#YZ8DZU#*)-F5[3F<&_R.(J@VL@3\D"'$[:\J7*SS&SQ_-[FG/NK"$^.@ M5KT7:]'+M$._X][GY"=;G[OFSF8E4P_8-=L'17L&@;GMK?!"\'>P/>; MGZ=KXH0_$#^TN=:-,0)#'](_M/W2P[*>X"(<8> Y49 M9BPW%6&MT$2BFU[B<]K.BFVXF%]_$>(ADXT$XV*Y?V?"V75!JZ,Z6D*!WID* MNS/(CHL 43U%/MD]<>E\9MBE0>B]!RF69\M\9R(,_8%:U]%\DU6F@[*<*,#+ M_"<-4:4^$*$Z?GX21;)('.88DD'1+@+)KFP%NP/D^C'"E<"?+CB166%B5T2= MF[?QYG!DC3)T>L+C$-NPA_3[H]Z\!*ZC3ID![[; MQ#?@#JM WR5DKA&P*FR%^B6H2G3L!K^<+R9: MWAGT,:?7[[9SL*83'LH*AO_GF]IBU\IH>:]6@FE!*52-$!S%Z_;"T.*NBS8 MD-33W3G1+O/L7&3X(^B^L'9VNQFY=]7ISV/V'^0.DGX@R7\@3S_"9448 M#(\&]]AX%%!"3ZEC"5>2&5PGE!D%)5Q,BEDT[]"O@J[+5&M38LY M56ADM'YJ"@P%QF]69!AWS3P?J365G(G5QPH'=+*S3+>QKLC *$;J^%]2NO7ZRDNZ5!@9/29 Y>NZZU:DBOU&_346&L5VH,CL\]'TLRHRU!T M3P +R;B,VL\1D^PD]#(.1Q9=;)+%C3;#]7TU1>H\VDEWX,C(/,E&44P5LUD; M]58S;M[=&/P:AZV%(O.D*^5JV=2K(Y3)"YL6JJETT:3")D2'(_7\H$N*:6K. M]7.]K+.J)UJ9=#LT,0Y'EC(])UG,#UU:'BP\KDC\YP*-#'JE;I5 MNM_LIZF,;\R-D@]&1N:9R)%;)_Q?<9Y64?B)4U= M3#+$9K@BI18LNA.99\ID#6*(]5R.:=ATPZ2UIKB (R/S=-RVDDSAN0'*INDQ MOJJWEJ3B@Y&1>592V9;718L=;4[-A4))S)')8CLLF'$X4FGG2;%3]7QTS4KU M6B]?R12".TOH\Y&MY:#2J1;T%,J4U$WP-Z@P>'LXDJ>-X8SA>X1& M> 3#RGPFE<;\8Q#5 >"=+I9R'KTHZ((\G^?+\SY4Z B]%NB*KHXY/Z^5L/5< M&O883:A#18F,3/=D@Z#YN86N[55MDZN->BC7/J8H:X/K637,GVC]S=#@)&Y1 M,2C_F%"3R5ZED4T."$X=8;XXR(D6-V[OB>HSLWV7?:CGRJ2<]H9K=#UHY]5Y MQ2O(?8J'0_$/'6.>+*5RW\G<3ZFD8*XG,*!?2*/,CU6AGYLT.C0[S/NI6F], M)]F+I%%2"/!NP2?K2'ZAL)TRK M(L2,B*'I+AGQP9JG;T8V+K=J\@.K/JO'=)$E[QZ;!W,>VRIX3%G6ES)6N]44/_^@;'-Y(,T=3A MA__O%_[K\S=MSEL].#8O;D$;MZFI,""A(D/8 M\OFY^]N-6CY?%>^F!Q-"_\__8 3Z'U,)_WLZK/M&_/\!]DV\U?TXZZ8CSP75 M #.*F?Y#[9N*X=JJX:AB;-_\Z/WMF]HWP7T@)[9H?J9%L^M"$.]N/\>D@34- M8"473]!CMO]0HR:H%O19@^:E95_(QHGSE3XL*N\7C## $?WW1$@1FD.';?(P M:X4XIJY*E^B2]U7%^:=JA 1QIZ8'1$>"U<;OPW8ZDR"%!\JY9WPW:#@RW;0=^M 2($G,^R0[9>O48:U5RN$9A<=P/KDMM;JM8,.' MQ6DJ0.Y6LM0U*X[CR;9#!U5>PG^IE>H\#J?GEFZN97FOL$TCD$-^:$_T$>8U M&]J$7*%1+/!"O[GVQ!_NFCKMMK.GKJ$1XU'.A:O-7&@+I6AC2YRZ8:0F]:Z M6!86_ H:%J/O;%A\QZIU2P7:+W][XFA_\A-BRF73;[^&*6$YXZ#7ZQ95?*:> M]G.\*VCSS&8Y8NHL5%VEN33,_VFKKG.J6'6>2-;*, M5^B^.>17_E O+6J3\S?O>E._'O,%]J+LT$=\*KC.4&3%8XIH51,2FKBP)J@W MZ$$-RP1=O5*92W;U^MD:=H7+.?%>_H7.[;>PC5_+.7A,0PF.;HXX";A*^@6W MT6F@:VTVZXSY46]0@KB"HX <2"?YX^6/!&:=R3HX.))[@::Z9IM(33Q#1CX,U%X7KHL!5O M#Y"K8K0 3TSI""[8LTUR-%>J33J?IC'>]+!<=@WK=4H3\7[%\IL?JC[S:G;0?=2KB0]Y M3G?0>L4\A-BA^I1#!5\0S$8"*P'\"$V?\(K#?HN31Q4ZXB\MNFYSTO3\*IU8 M5FOM@BI640OV(H+^$HJ^SU^*U?!T9ZW75L-+QV^OO=[8=;NFZ[:#IL\Z;ITU M10L#N33@A)+*N=-T:D'W* !?P'%+/R2Q^ #WP@>X-ZS.MT6NGRTLH?-X;6&Y M5>I\:U7Z'F=OT=3?QW9ZV]Q?]"GW%[O/0X83G\@=RG,2R+-D>K!YWPT(]*52 M?<]HVI1M2HUD5TP9RDF8) MF@'' .L8=T.C[5^REZ^/F&TQ<+P-Q!+F]>UMHOT(EF$: (S>(G?6>*#";RW? 9^JX&F^_2&OLT%X]LBQ\\6AFOW";NZ M*MQO0E1\.!,+0RP,W^?6X VM_JY5X=N-B&'7$ MQM-AK_H 023AWRY\U=\([MP(*GQZV\EU ME1E/$EB:SI<+93SM# 'X*)"2\;D1P?>DI[ ,DD1_(Y"TOQ'502SP5EA86D+&LF[Z?P)FW8C, M!!+]&#,,H5,T=5VP'/G/[H?]M\([R=.P!O9<6"4"*3-V$PE#6H+GFKL/ @0, M/SD(>^W'P<(Q$,0QTGT'W UKKV;U_9]6+C*]\7R2/PAB;VVE4OJ\LCS3?!, M!3)I2[3=[PFXS_P9V[*@)7Q IO]8IJ-"H?ACRSJ0CJ7\[)G;_2=X\6ZH,'9, MW7/EQ_+GX4)/+0KA#@,V^2>+=%\R]KYGO;_I"5C:X[]?VJ7QAU=C(C%;KL,6 M+/V DC%CSL:8#QY%O E?UR#"33=6>@-78GI]5.'/WESC" G?WYG[2]U9;U*[ M8G6)U>6$ZG*LT6NL)K>F)N1;Z[]BLZZMR-]P>Z8/TNN;\S=K.O\&\;[H\OZJ+]FP*0C,=M>6?!!+?A8KW,:1 MTVR+=1;B#*-KVBK;JMHIH;V<7#Y_) Q^5PPP1R\HUL.X4]GN3@5C&V%^C'F^ MF%#$FR'E5S?C&\$48A]3[F!/_0(8 MQ#K_A3*!'T& A-NO=694N8[6\A1EZ9EJ0Q-N$0$"L7^MWCKJ5_)9P\ZLHKB%); MSY0G'*,-2@,ZL:3-=RP2M5EY.PQ0L9M3A>!X@[,SG>"G!\]&I,;)]\#9MN M,<'N(B&0KX&1,=PD/:&9G* >Z=!6)R_8[>85;M"<( )2T7G6LGM6C5LL-E6W M5!-+2WQ;0#V%O59CZJI)==L$I=T6B[__1.$<26H.S$X[EC\&,\T@3P5CC4P% M '&699LK( .NK*^1_SUS!BF;G"9R:%_LHW)CU+3=*3'*I*D#,4U_0$P?,TME M>ZF*\G&I?92X0$"=KND*^O[?\Z;C-DUW*(,IB^;$ !25]HO]/XHH$8IH4[#! MYN^@?2./SO(<[D_G3/@;)P,C1[@)FT_@N.P/4:*>,'&&6-9XHA4>8AK!F[: MMO],M_>W,,N6@V0DH&4X9/96CY^AS3N^'6ZPD!C.P\$!(W@4)+QJ>$((<#>2 MVRD$5.,Q7,AFB+'(BV0RR:<4#.>S:0GG95$4LP0J$>-T$KS@W\+N&[")8*\B MSWUK6$1KBT%;T\C)D.+:?'#WXG!D<^/1Q8$I:!RS[O7L>FN6;*XF/,ZGGH\< MTGDL@:_'70ZW&4:N:BY=&E%@9.29=:67<++5XH@KD7R#R"<:'2_?!B-AIO;A MT+Z2Z-;Q37*-UN1)7F-R=#75H/@DW'P.1S*)6:/8+',5C4AF*V:S1=9*(,7"5J8%+.K*:6,IK4)&!F= M:+=4H;M^CZO1B>X\-\J.%15GJ/"IR@1UH3B9(+4T6+12A94'XR,3-2W-GF[GM M39 E%"WBG& ,X#.C$^U5 M\]G<4)LVM5I.=QJ=$>'2N6T\\W#DTA3S_G0PKZ-"C?4*>"OE^AX<&9GHW)?E MRFK#ZG2?S)=[EA)UW8 /AMLR;5V/CNF";FH#V@Y7Y,;T)2*/!,S[%35:;9\ M;6&F\65!EPN+K@]&1IY9*I?1X;PRU8","BI99N5&683/C"YI,T,;ZZ11X&DA MXW2[JEDN%X%?F8V^WEBF2O6.[ [14E+-L&1MD"N;/A@9>3W&].055\:3:*+. MH/V."I""G8"71Q_J>)S6Z8GE&3H7?)D?XYMAT@F&1IZ*JBVKZ4P[4Q0O&$,4 MDS:-J4C!H8^K.O-MB,#BF)JZ]'B3!NQD>\RCV)68P([DG4 3^%U9%.E_O9!R\O*W@I<#H] , M*?\GN&>AJX;\_"\[#W7K2O[ZRW:9?*W,U MTAX5[');Y#T*WN4IW^)BZ<1J* M1>;\,GFZMBP 'J^10 C.XA,\?R5C( W!%J<(N7,,3,]&W[Y+#)[C!OYGJ"+0 M^#,-Z&8>N,C@X[EI[+O'M8Q+I]F6V=3R7*K1WI3)3(]H?]KO"![=>:1!*R0, MY;E3TX9&)S4W/\J8/>X,]1)N#[;L.D$%B ML+*=[>_"JT!+ 5ANQ@0!O-9D^ DPGQU$5J'?C:A&X/"9P$3>#0AN&]FF-YG" MLFJH=\!?'PG?+WS./+)D]S*RP-2M,UY\'#5$.7 18&3A!_ :TTO M?_/0!=V14+K>,?-G96IF8_.!M] &-"%JU9+2:932TP.9JC2+GQ>J(RWHGI<) M".0)76CBV)[-%QRN*DHIT62+ED(!>3>5EFBB/C**76XU+;@4=!"CT?,GE0:>N?'DD4.]A4QY M@_YG;8IV/B9\I.C&;CL,WD")8"KVXSU_Z.(#;@3Z<%0=>*J=YPR+Z'+,?.A7 M<'IJ#E(07M/'ND[#0$BH$ \7V79?-83Z@ATDASP:(N3VPFO--OH/VR2YF+I)^WVZ>RP1]^19N"%Y^.-VGR[R'@GR/QT"F _' B_C19\M&+VS3H#Y+&0_H_= M%#][M?XZ%+R,=_'!B\5W5J[@&PGA3S7D;II>EW%^OJJCL=)=2(A$4X\>=&V3).;U+9N?VQ2:;VI]7I75YR_J]T%63R:V/!%<.39Z?LIN]DV- MGH_+_O.ZOM^;[;$1<^*-+6;U+=LPCWV^8BOF^ULQCTV88BLFMF)^F!7S=!G@ M>S,\ME\>N[''!LP/,&#V^I/&)LSW-V&".X.Q^7)/YLLMM] (#96[ZJ!QM$G& M_4O!RXP^@[5R5PP/.MK'+/Z@D7)7+*ZKBAS2XI]#6+_L1!I]7E/F=MA-W!F[ M7X7P+Y0 OC5;A_%AN]K\[&-@2TK;'! M$/U^:92=XFA_S;;Z'6W#SY+4Y2O\;JNB[NG*BY5\]?9J9*C3\92>Y_#4<-%; M\@Q.A8T',#1:[>A[:]5GRCZ3Y0!$I%!:1.A&2EXJDM71E.WET. M/ "'\=OX,?XP?CPF$.P%XKNR/<-HD85>1S6&L36=,;:JK6<37%Z.9U\]6>1QO9-B7!F9Y:]0^;NI9LTW&. M*/VBUW;R\GB8I1-B.5,N#=06;;3#-FM!*7+\/^_R3NY.94Y@0MR;KW'44(CC M&."(1[BBFQ[#3#&=7MCS'&N.B&*VU Y;W6+1\_&C M:5;?1XMN*])\@_YC?$!^OX[EUT+/;WF7.Y#YK(.YR.2_3:&FU-=NVT3Y= MH:H4 *+@U#P=I^K\7"2*3\T_U'KI'*!RH4/S+4C 3D/O/#3''@%D*!E:K5[H MUNE2L]T2&*N6(>JP?VQX:([B\:%Y?&C^0\#C/(?FIX$8[(#4<:0Z)4EB^#'K@D_VCM*?ZQD]>:9>M^4)AV[-D7I=:HX M=;L99_]WRB7C1M15;C,_5;NQ\9G[E?ZLQ]JP&>_>3T' $% MDY:H^BQ?7'/LAA3\:=%:I"W8@CX^\R9_+77F4<6KG(F?T1B/E@ M7*6?3I(5?"6(*%/CF.ZX(9L=QP>$B@_N?QS\G/A@_]I+C0_^;U$%;F!SBG4@ MS@=XUPU[0T+V0H[PQGVT+_OW/F>X5-[ H9XD@9Y(I@=I?@N* MB_CI4A>;KM,BSC&H,DDZ3KE#S]L\AD(W.!N?[EWW=._JVGGE1(2KK__Z[O1E M\>D^;O*75;W(LJM)AUML,F51GV#U2H."H!5>Y7_MBEP,6S\>L!=#&EUR'[]<5S2M67T+\7N?H1+BO"X+FP2NRQ<0O)"5U6 MW#_AMW8?!6BZ^\QT5*BW?VQ9!SBRE.&S#YX:R(IK6G]P[(& U 6_;E>%I1Y2 M9Q*>9YL?MFT*A?JVN[G_>*!T_&C;IP6^DTLP_/%:+OU#/X'W& MO3;%)M.E6:3+(%R3X@J5+EU \DR39>J5 @5_*5::5#-?H>H(VP4?-.AFEWVJ M?/\JV!VJQ3%Y/S?L?![&/^U5Y;K*C"<)+$WGRX4RGO:&9'7B/S:0L6JT\2PUI[3 WRU;@-S20;6@@4> MYMK =#@5$0]@"WLL**T:@$3NGP1VI-0VI.=[1.R?Q+]>Z)[P\K>"EP,[S R) M_0=@O6SKJB$__\NS'>#77Z!L3(-&NM2 9D^L="^OOSN5$37@*>(**\2R32AG MP!H&QB7X ]!/=8Y80;J)@Z@.L$#!1P#090GQG/#D#+#5!5:G&T":"YXG& 9P M7A'@1\@B5)C@R6#1\F]$D&8>S+(-'B\!$;+!\Q#@5,98-65%=!S&AG@"!0\S /@5CMC>.'I B>"Z<@PL07PZ.]8!/ M+2-S0(^I@\B &=*1D[UG4WF:IB_;,O*_)_84'A4QI0A4<'R@JRC1PN>"+6W"?P0?C,>S'OR MH&UKZ[(\S]2&ZJ3L37[]11^B)4L1()$Z) JD]=DH]3'(NARE!+Z]H#@U,:35 M4MDU6UBN/=4#2D7]G!VE?@/Q=JQ0-?3U T(=.VL.A!AZ:X*QAGHG>K8-9@%T M8ZMM6]U[4=>@,@H6T.=5H)O@B^_DC04@G>],A*$_4.LZFF^RRG10EA,%W?\0 M>OY4N-12Z!<(\G5AOV)J\RT M%>E^NO0OO2/+(VOAVZ#9I1H>H" #D"U8PQ-W$_@>>QUG931QN9+3/$]9Y_1< MG2][U*^_>#K"W7\\(+0@3I&%)]@ (G\'#'PW,D(6>Y8$Z?$[T"15.7B =.P[ MXA3Z[P X!2 >&G";T&C M8C?%(^^1/!DB\1(RT',0!:S8M)V'B^U/SS>EW6XE!SN2#7=4".N"&RX 4 ^L M18;,.-S D" J"W>//>4*,A\S_W' [N*X!PR#.\T3-?8VR8 H\O:2"*3,6(:J MIJMB8-@KVRU(\71 9!7*%0)CR0$;(J]]^0V^X%Q:9]\&U$MJGRARJPJ32ME: M7QDZIKRB9H[3!MH7W87^\4CU]VSW!YQX$J ]!D#N&DX@!M]D]Z?#%>5"&^KH M9I:9)FB>LHJ>)O37U**PZD[&"D [["'[([;]=Y#(:LW2PWJ%J&ML.I%+##A; M(*M4<"_]91(IG[))#\V$[:YP%0E%]\F/\O8HR117<@+\8JLSTK?J&M.D+D+^ M=":3PAHU=TDG7))=3%:%'%0.8&YAUY709R2:%+5I?S5B\AK>&S<@#]S7C.$M@&Y7S( M^N905_)-3Q_2N*(6-VDI7ZLS$S R\LSS5,$UJ'I;R*3X='9EK M8PHV3S2F7*FV2)9\256H9ILGHB.EB5I9I;SU@)M3*:=?%[R4LX$55R,C!WJK M/>JM-R@M.UAI;"F=QB0/:WA%1A*; 9U.]/Z.MGT\L3VUNKAR$))Z*\XUTMH^&J=WE0U7?#&VPMFAR/I#;[H MUZK).2T7+'-%:'I_G/'A(7&43$T\*R_G-&!2UZ263;.5-N@)D.GH4 K59K10 MF_90UET:N>*TW^R.@Z%1P2L25%42Z1R:SPI:L=XSV42;@D-WF $R5+E/O*.!X.P^XP M[IZY9-R]3E/LA2/N.]=3!/[PQ+3!MQ ]D(!M$$,-PAQR&-T6P&:E@@]MQ-R) M"P+L-44U!$.$OX1??4!"(8+?U#U)?HS7F(JBBJ%5YPNV#-MFRC"( _<5%8SW MIZHX1:;"4D;&LFSL34J"[WYZZ7:*8+PN(Z)LNX)J(/+"4ZU=M"D8(2$![:,3 MO#AY@_/%P+%W341 ')B,!&:""!-@Y@9S!N2E+%O5D>QV]_GCJ86I2#F[F<6!?Q^EB[X%&!]ABU%8,9L8ZP-AUW;7KZ*-=4H5/AR-A"_YTP%$:[Y>6L\YE2U4Q^F_AM "@*T'*^#8QJP5\(O ?Z>EP_91SZ<#"[\,:,Q MFV$%I6M2U9^ZOEU?5B>?8@/U2(;W,<2UJGBA6?8%>HX3RR6?ZG<'.>HQ=_QB M).R2EIB2%*V$UAIML6,4TDHG\>%3J4^1H+,>,VL,;:XX(C7+5C?-O)CVV]#[ M/5H)\SE\;KW?X#0$X(0#0 GB X D?2DG AS9G8X\0Y,'A+, :4.T!%XZV"_% M8-/\?7 V^73\8CPW%1!=%4+O-0!6 8(T]*G-\,YMD%26,)4$M$<$8 Z[P89Z MZH#&Q3?/#P5 #E_4@21A%,Z1*4B/H^$0@YMVBJT:6N=D659:-;Q&C2D?[*#) MAR/;YRX> @4@!"Q[=]%@RZ1@=]P[:SKF\KR4V_Q9(NH6L\C.K94-W.-TQ>'E MP5SQJ7??PCCF/#W>GPA^@Q/9HQDN&VDIGVXX-&NS>'N6ZG%E#0 [\12VW\5T M@J,ZY_@%\/-8L(=&Z^/!8,3NEDS$ %M+4>?PT%%U=\DU0,F@GR # M,LH'2NH%?H'KA/L25&*P$8V!-II^H(G0;@(2 +\",V& #>=NSR"GP"&8@_<_ MF2//5#L4JE>>:\L64'J807$L5R@XH84GK\'8_3G[IJ<')QZ>#;D1Q:'@Y#5X M5[##SH-9/QE=CU.UPH3V(&T(8I . MXXR_O;F#".'5G>M<+VX@J.R^5)C HL@_):#S]']OH !1ISPF%.80#.6!5Z.-'0>$2J:C[ MQ*COWMP07 !5[CK(L8[&TZKEQD9+3IPY77+^?WM?^I2X\B[\_5;=_R$UOW-N MS=P"3A)VSWVG"A$=7$!9=/0+%9(.1$*"643\Z]]^NCL+J^@(!,R',T-PI%S*3XFZ\,^[]DO4[ M6Y-'Z%XJ?#$&_L!YL0H$'Q)7Y@=SQ)9T&OITP3; M#CN\_BE]?]<@GFVZMF0H]H^]D'%K''E;Z*?BZT#1_UD=?7JMV,5[^HZ MM2A*Z_OI69D5/*>Q'OGVDH-J_+Y:>O7]1/?5,:WR>/GRTH7 M059W^MO/;'&^/FW/&?XM81^+@&V)@&WX:@Y6!"P,T;V7]0O5F^'U1"FI[;/+ M3+X_>.7+S]=0II'[]C/]9CNY:-MK&.ABY#7Q^6U_VNB,7?M_#RF0<;!29"U% MXL1%-;R?%DELO"+YT8M&\%V=W]T]9U2E,FP8&?WFUUB[S$,A%U8CTHEL;CU% M(N;.+='MKM@UOO0W=>FOQZ87MZ@RMO+52?OBME%X;I_=VRYIR:&_,C8VH#[&#(AJ":EV] NR2UMA<(*>$<>_I LF5Z[9; M%\2SQ@4:38Y[G2RH$V*B6%@UYSOF[ZCP]\85D-@=$0V&?TLS6<[H1?7WL)_M M9 ;MN_%3KY!-\^U:?HP9'122S'P_LGUS0F1B,V??M(A868BNL@!%V@NDR/C4 M=1_ZXO5SI7RI\"_/:?NTG?\$OZ\5)];%V92 MXRNN='O?Z%5/T?T86C+A6[ZP:C+IGGL=LK%5$CW!%&$C)%8DMJ1(G)KNPF2( MVJ0ZK I73Y5R3WC46\Z@=#R AG LBC%?QQDS>/08/'8[?!&.7T9"_OA=L@%/2O(@+,]-'=V8"$0Z;3# M;.1( (%J(;N&PL')+-*C:ET5I00\NT)ZM:2R=C.HY=N#\NM-Z^Q1J(Q?RZ5. M ?24?"*[4H#% B#B B"BCI,(@V6/)<);*LQ;DB!MM5^.;7%<&HC9EZYR)LFW MYS8TIB8)'0?J66F9T X+[Y.UYH&Q=ZO:I\1&VOY)P:V7H^SZP SZP ?+ZV^I M,PMX/-?./DIHV#OASU1M=-VH778G(HS!P!I,EM]S5PS(OB/N1%-59$%[3:Z+ MG#', IA27F::O8'K9NZOH5Z-1WMHS'UR\'K7#+Q[DRSB*@N(KN_[);M6ZBGM M$+]6R.3L$NF+NT"@39(E5;[/.8\5K9\W.[?=UTS[DO(.UFX^5=H7IT,[SY>?N_SD8=)L%#(]8&VLK&3FRV=^')*_ M94X/.213*TI1X07R,(T97S%A@,1A&F7SVLP.3GQP5AGQ,"]1: A/+Q!QC\7Z M=45'@QR/*K]SPZQEB,?G9( ?UEZ$8D(0#CL))A8$$?/.Q()@P_K/ B&@.O62 M=#$V%-X]OBJ:D]QUYE>5#/P$/2>WJOJ.Z#G_D)[P/Z,ZUG=V6_\HVO//_\/_ M>.O(6->Q@%S[[&4^,<)+IUO,;[@OD9@)"(X1G9#=2OO_T(.C]=L?$5"2?__[ MO\(@G9<1C)E#L&8]^D7"USV4[%I(&B1) M.1I(^EBFC3W7#91^%B!H@"Y8$F15AJAS,MJ*A648[TL]/).H_:>GX<%^K_$YP MU5HY]U<)NFBT6T3N;B5Z4A$).S>4[13ZK=#)B5NA(DISI MH&Q.YO-J&O'YXK>?T\.A\WGYZO$F*10&%]T;_2+7^.58IZ5%,]%?3Q6G96=S M5_S%^$QQKV_]V%,]$U\WQ\8JG= MLT%=J]Q9W>R34+B!F>AS:VKF6;%3J9S^YN^:O]VGXVLA>]*Y633IO,BCR\MJ M9MAJ:Z7"1&I=E0KFRWC1I/.'MC:\%#I&8:#5[.'8M5^%G@U]]N;>/KQMW3PV M1F>]RM/5N5)2\N>/A@EO%X391T];HM"P'X^?!N63GMQ6A1>W."UQXO&IY^F)^F' M855+\Q?'I[E,TBA>=EY[^,DY,!U?71SSI[^?'@;2M:-:S7'OY#D':\Z!Z>+> M$DZ$VJ3 GZ6?"YD7LS8:WL*:6S3GW6TYQLFX?Y=N)Y%4<3+=UG.>'R^:\]ZK MU'Y=:?=7Z4&Y>R%(M^W>=>?^9M&<][OFF.]?EY368(*2\J1[NK,I9JYL9]<5T01;(H_,<8F4ZS[_&N>OV!G8-I M_DP:]*U[NSRX:Y3'MOG0J&DMLNH<4$_/[F[L\8T@MNMBMEHL7#W5LWFRJ@]5 MK#NQ(>EDTM3J@>IL4/H6IKZ3>8FVLV0\E?5P?54WR^K#('?=/*Z_ONICMSC> MQG@J&*LFF\.1:=!1>2KSHZ&7$3+(U.]XM-,.1CME"ZF5$Q5"]V-H>1AGJ&(L M>4#S?D^"$7M$U=4Q!M.;FB(S)\B+O4>EKFWJKH,VK")^MIK_Q]&?0HR(:"!" M6%F;%2-B2XC(I](KG9XQ(F+1]-40$8NF2" B%DT1040LFB*#B%@T10(1L6B* M"")BT1091,2B*1*(R+_1]21&Q/L0\R39?"N9RG-Q30_.CDU M^P>C!PO1GIQ*>NEQM),_5S$4I'S2=,F8.-8A#B'2Q%'3C%6T$4O(F D^24+N M\7#6)AHY;%HIGXB%YW:%YV'232Q8=\X@?XK=Y;.MNTM8X(X%YWL$YY>F%CZFEIA:8MD216K9;UU^7K9\5D'U+G2T52D_T51'9-^3/I?%-4QZ7\9 MTM_RJ)E/177$_=U]K%43R MK6U)Q17EECAOTW M0V.CTS_]1KL6[OQRV'!/0K]!2WYA@Y;TR>/XX5>_UJA,[JW,K=5_.#_/]S[< MHG"Z72FT=%G0G_#F\N5^<'5??1V@VGWA2KJ3:N<=F"<./4H3_((.Z_O/SOLS MU3;F[[WF;S[,WWS'>DC73U]0$O]B:8^%\>AR4*]]O 7I6OQ]:UU>Y(?5P4D; M214>776?[7L=>GM!^U%ANT.?8NZ.N?L0N/M][=4VR=W.2>\B7N;U[IX/^WVN0FS?>[;3R$7LWW,]C';1S;*]G&VKUR9FG9Q)E^WZ[WZZ%9M/N2S M?;CMB]]^Y@LQV\=L'P??(AM\^SC;*X-(G*9 MS,&$XZI0@H=LA\.HI2$YG4TYUM!"!T4D958D/($[[!6S<7?UKL\6 8&U=:^$ MQYH5FEZ_0$A)6:O91O?]?GO8*A8GG<;C\;#6@]UADV15RD#$V3F:GOY=\T#, MWX?E?GB;ORW3'IRZXOT5G[PNVI.SKGQQY@)_Y[[]7"_E+V;OF+UC]MZ)F^%M M]KZ]Q>__4S'UW?,WVO["W9]MNCP]_;\"6_S M=S^7?'ELO@Z2_)G>[-Q,9,/(#TMX=R2K]YT^A#U.@C"0$TKWW7\/:;0=HM.R M((UE@6*Z,)1^)X)N"Y5(.S]P!*3?5IP3JRH8[HX?C%+G^*8S>+I]O;KHZ1>- MSFNO(_"TP%@0X@+C6#+$DN% W1JK),.K+%TY:EWI5IK5S&WO+'OQE"R,03) M:7*&C^5"+!=BN7"8_I!5NN@E^J&607\&<;H]B&A3$K2;K.F7@!:ZZ1'-WS MW"(]9.#G=+)?21EJAF8[%IG;[;6>LR%]!?:$"9IX/LFA;0?_;X@,L@/V+OSW M%*453!E _IKA2I2"(D(;4Q3[&7?W-..530/Z;M.5&IH].-%L63=MUT(M_*)C MW90'C!.[^([^E:V,'QYT7KOOWS]<6D*N_8"71)AG1WA1QW+1IXD^)D^3.E*= M(\$??Z09&%3.49)\,N-J!#JWICR3:B+,U!(%3TR(\X) QV$.3C#I& M,.J8FYK/R7@5'BV;0TQW$\[&PD&&NK31R#)?L+QVD#Y9]X(98=+I-'K2_?BW M=JGSY5I3[?_^A9(G^OA=WBI&H9TY"CV>'"-#[N.3#THOFAUZT';JZIEI*C9Q M-%^1(ZY:IS49H:DEFNYHI&O(FGN6K56Y>'*2ET9:&9R='Y]()T:Y6"Q.VZ^1%FV<\&%=N]S&I72,+_B+U@B!"4J0\6),LJU,UR\\7Y:9]RS^U^V;6 MNFZHHW3OV\_L?(SP;Q!U@%F;'LR&S7$:EJI(1[)C$;DKC28]GVLWSL5!U[]3SDV;I"V"Z6CN=PG721C+@>XQU1AL9 M4\C&XALO6E>;6)'35*R&&LXM9D73LGT4\R$,\R>:=9-^>KBMH.'D=,R_#MHG MOTO??A)6GD,R9P>KZ[@E0LG*"VE")_0JYX&GG!*\T2$C7?* MX0M1,\D%"PI>% 3"C,H913+)YI^2956R&OQ3Y?KVMOHXQ$>^V;) &.0-^<1Z MO!/XG)AL/8K' W' 8X&0FS>9%PB$;3#\06!R@PP_49-:I7$SZ/+)03NGB+_= MKO.(&5[%2NU:_)[:JDJ!M?QH:Q2+->(HDIU5;SRV>\.Z48/"I2/?#D;# MY^O&H,E7SG^W4;_*VZ!-C,WU9$MD]83%KJDH$L#=F?4P5%[K,N_FSAWW=-)L M&2_;UA..4=OUS?'./O60E.HZKJS-? '>B8>'G\AY$N87%# M9!#^="A-X&.)P]Q@.4D'64-.T6S+'1&"!:>G[_5+X,>8) .-&!\7)!IU=?K7 M%RQHF Y9]%G2=' B,[>CHL$RDAZX'-G;-4-V+0LIFX$W)-&%Y&U?4C 49*0] MP]8B=]_.,5A)EDW7<.R&OV?&66+FIE\O_SH^J]2/J^*9CO%J#/_X@FSU-4NY MEBQGKPG1@Q>0(EN1&9$VPJ>>U M7TKT0TE!G#N*K-;[F?C9POTU/AX^83"6SMN3BV+_5AO)$Q>+WY_I_'([%Y)- M)7:J$*MP74F'U-T4MW-V(O>>(';2PIL7W_KX*IRV%:M5UM-\4ZOU'D?\K\%3 M=KP5?M+-WDMVG*P8E6&_T#A_' EZX:6TY)Z:XR=@IQ-\&LI-0L)7,G?&3CO" MSQ;XR3PO5&XKQV=97KJ_=W)W^6S5O,:8$I>8?>OPDQ],BV"8=>.AM.%0!M6*/S8<2+NL MMJIG)(JVO2 :W !$.\3:(_Q_VMZE.I]L@EE,9!A^"GHE]&B'1U 5:6A;UB5M M:(.*"5_'(E8S)&N":="U; 2\U75M# (;&]LMDSR#80%:-!%\MHNU4K8$K!E^ MA:79>%/#0.\>FZZN (]BNJ$KV0Z1E0KHJH0(B=^&+(H5;6#D<1\9'"90T&-! M$5<0*,\D?D!5[2X^!NC%75\%IJOBW[:BZ&HV1]1JP]&I2BX% *>(P!O6L#J. ME7&%9A#TX#?+E!&"#S;D(9V51/0O?N45E+VLF[@539GI;P,;4MC:FL >T;_O MVQ,P=[)/1<#J306[Y]\!.45[_OE_^!]O%5E'D@497OU_I_&1AE590AO/_[V1 M-*WI*>9B)E0%10\,S>&V0(FA!]\+2O+O?_]7&*3S:75,*H=@S3 LDFNFAY)= M"TF#I*1B!'.-8<@H?22S*$ MQJE+C7[+^X@DS7F?F38QVH^H0^$9P=I3JQ):<W0J95&9# MQ#-S^Z0#4OD_B<.Z'-9/_M.JEQ?A]Z.OI+_"0IB?L9*I_QN^IME'(:(&R()$ M)M(?WU:@W,#%X=..M XK3B-M$38DHA1UY&PW(Q>R4@<5JK%6JE%?+_-KG@A!P^(N>=D:N?NUDVK+>Z91:;8O6^21^G5ET^E(R^51T2/ ,)!VERFY4JDM2R[Q\V%=K68Z MFHRX!E8L+*)BG)K6&/^8O#3- ?S>]/(+[1BHK3[6V)YIC*"@QKK/9A;<2@$4C5=4"I-:V>9&## M#M]38ZRM!LJWIUMCM?89Z>:(J,E@V#Z3MF8)>,D8Z3K\'Q1F#>N<,LD2M9 V M[(**3K[B8/U3P8\SE5X::5#.;'LJ)[Q0)17A\!L-A6%]O@G'F#D<-@2H<0\J MO&8\FSHXRO%[,93 98^5^@%5]5UL5%L --@I!99,%/R0AQ\#6%)5A+>,?]%D M;424?0O9KN[X-@<#$EXS00QX0L/ZA('9>Q@,&D7#BUG4^>7T33K1&3]@T_1; M4+=GCQ-"$7'2="<8&Y"$VT5]25<]YP'3YHG3#2]+3\E2>\D#M-4J1T<-* M!(?(P2"WE^8,8TK"6P&O!GQH)YA3@N4T=P%27#O5A)BEJ1 (GEANCRN%\H3Q MMKX#%XC\OZ38PJWBA [HO#&. D!J0GFMA M*@:*0V15@T5(PF3*$#?E6(.E@%7\5]A8/@".V 0"EA".*4<#+"9FMD[^%MI= M'TDZ9K$E+YG:3H+3L6 ?L'(1XY&3D5B/SVL'SI :)1G,"MAS%*NF4;K *$1 M!R4:]'L.DOL&OBE[4,[!R7W)Z*$EH FV%Z2Z@\\>Q %&F4A!MFQI70POB(1IU/6@T6^5 M#,/%@&I0&8R7PA?7D!/XY 7!%KQR@DF?9?+,.5^W8SA'^"8#4:6!4:<-0[0: M$GF$-@!Q(:'.KCHJ,AVX#6_\VW >$S<0L@2I3J*:$JN5,!ZQ]">K4;H'B4)Q M*6%2 AD_5=^P:&^44@S3083HUW@^7&D1DME,\;0)2:PB*7B?[79M].12;XVJ MZ>0V@D=MKYJD+V&)CB7YLV:ZM@Y.-&2P)_VS-I'L6N2&)HM67BBK<\3/:ML8 M+E^<-%=JKF>T2F9KJNCNP/ P,=!+@JL:GSH&F RL?4 M(LQKFJ))EL9\MP00\[*MF ;<^L1$,G67W9HS^VJ^:U\I#G^# M8)6I])!SQG5UT/FP,NT.27JJ]U:*'[^0#7^+1!"?\9>P+@.'^IC&J-"Z.2(1 MR7V+%QY+&M'ERA7NBJF&]&683H#@B"H9;%^2^Y D R(:B\AG9+A44(.$3G%U M3'[TEO>QC!5V"E6Z4H(KC9H!&"OM96 \00:HJE-03& 5A%P.K*3.08$?W=\, M.V102815AG7R?PE$"&B(/DHN4$-B23-4YX$G8%,(();B8F'^Z0ZDV.7S_HNS MZ0Y!WL=0JB''$P-$:/Z5SJ0*'%Y8]V*;?V'K@/<_4=]3<.B+AP18?2-JXX,[ M@JQ;**:*TV_*9E+9N3>]2PY-ORC%A8^'[VR+&L+YS-_D&[GLWS,'(HKT6H4/ M\^_!ZT.,F$ QEQ(^"#(P4_$-SU3DOX14VE\H)*47)&G/;Z*0$C\&S9D]Y-^Q MA[)D]SF7>9&"6N_ $4>WQJ=RBY9<9W=8=S/IG>LYYQ8GYY'W9(O!BX#L?"( M949(_TWOK;^R8I@4B9H6F\CO$*= >0W*9K%(#J*'$H8)TU2.F8<\'-. ,QH[ARH)$'7W2Q--#!1-%(1L>09'2E MN&MJDGA[\06DS>P@#(/I30>J'&1G2+KO0EM6$Q1*BL'KZ!KQG%G! U^ MYM<%/0,W4(A+$G("X@$W)_/HX6Q?4L6R<=Y&7%>QL[S,C; VTPG"+$U( R A M-Q+(()"%'R MRT<[N$X=:4#".::'B)D<67QS:"34"IGN) 7 =KM#S8&_=2F R)W+0#L55*7E M:!11_L5+O8X06&=!>@9Z%NM.80,%D4.'Z@ Y5C@ V+@V=4TF3&! #@KB! \2 MY7 TY]2/Y@1Y*&1W$K::F*:I(X<$\W7)F(I56CXORB;> _G3B+UV.Y?[[O0M M\/;+LF03QR2A4:AI0-01 <5]&&,T<@:]P4@>N/$O@-*W25.A>2$\(:HO*!/>B$-::JNU"!5091'"!R")'=X$$(K MWJM)4 6B??@M!*[/DNZ"O]F9V2! PLL]A_I/B#2PU37FML><3YSC=] ZSC:] M9=G+288,B2Z2D&*8>S$O$$$%K>P $B,,4)= .*CF7)A) >6K.D%FE$+)SB6@12\@^[V,&N]9 M'PFVMW80W%A D(0R\!>P8$AX_?M(F@-9!U/WB+;I6[AE"CW6A0^?W#6(^@%1 MBRG4S7P3$(C1KFVN,C8B$F6Q8_$O(>P]Q;0(GD8,LVFOZKL<@@GFHEKHA5WJ M!ERPM70VE0EO#9R?L+4I-^Q[W(3>SA9Z;1?N[/2#OE;X#DOXPVL9H?,QYIUZ MG^V]<-JJGI*$>9YZ@(4T1E"P-'.($-O(GG5:4S;6V1)&"+:^PM4%SR*1;Q!Y MQ$I7C\3U/!-^@?E^Z'RRTFUX0L&];<_A[J!Q,N=P"U&EI_?Z&7M+G&Q 7TN\ M:MSL"T+L/R.8!,K]Q8\&*GSN#P4'5C+_@:-V:AOACM,C"R5)S^EY](?N#3X$ M1D!/D:)'3"\ [QI"D_?0(Z37O3:X;0)HIZE^01 H$/D+';$AY@QP12\'=AL0 M\]YQ+*WK.IZ"%+JMIM)$2?9G."$F!"2-2#$F(8I M9E/Y/[MDL%H]O$7O&56@1^#69Q2\-D5G\LM -Y[%/R,L*:"?^# G[TZ[)51 MO"E[PRN/F#(4F"?)0R"[B:A\]TP8EM@B;#'\%HT0Z4J1'PP^8),XMU>-%U&( ME%F"KA=Q(6G$PK^>00!D1&3']E+>=@>H9;"83;V8>,'PZ4CXHL=L")VS:1GD MH@PE0>M2%SSPX$Y]1A9DGR3W'>[GP7QKO2PP)QD64F M0B[L6:+R>EV3K&33!GFL@5!H5PE_BH?U)A 5Y&T);T?D9U/JWC!4Z)Y%X>_] MN=?W+;V@$/>BB',>XIR'+>4\K.,(6G8'K)6=&\ICYIF!-14;H!:3L"#@L-CO M\SFW@(6&-'-1^\;KP"OB*_JE9#$S9&"QH..-(\M20Q?/ H$)] MG9E@M-6!13C4TX"6.*_P]J8"*K.1%,^[]4.]]4N+C__]LHKI?(LGR^@ MSS?G"\F"CLSAM%FJS&-J1,.1;DY0D'C&Z#DCI,/1*W+O%4-![I77WCK[>N=U7,C1;67XL,.-1N_7OH[GG$PK]KGH+J!M M)3%&[;D^%2P P1H93+'&'+$'IX*;A.2I'3RIKE*$5J%AR@!.%]YG N40C+Y ME0;P/)[Q2Y$>#.F NFF$A:NM&E#/1^WCAPUEBG"P7!=VEZ5NO745+.UAA8NU)7 M2<[H*G^LE03N2BKS%R@I(\M4D4W38CD5@6,S[*RDAQF:EJ.],N_EV\?\XUM] MD4-S/D-MK[2"Z$TKV@R95A!R#JXM>HFN.O&;*X? D1[E@72B:0 M91=3I3SQOTND%0=+OU,ASHA, M3R^$ \COS$OZ YX.;W=S+/W)["=\1",Z(.X+<=Z!,]Y*I:I*&SFTI)P4T(F$RC$.JL=!]3BHOJV@^F9&3=VTJR?5UCV9G% N75=;I4N8H%!O-\J5[;70 MVVE=-"EII=T!H)4+1>:@0 4Y;EZ+4!G:>ZFZ.69UT.%9JPKJ.K3P]\DE M_=TM"5M4M$@?VTB+FG0E6", ? -J(V@923J# VWJ&EY$@65H5[IP\2)$Q6$? M]++-A+*>H;!V?F[=H=L14/ IO]EW[5U&Y5R3MNF6<(;WQG!URL*W@B(C?JRK MWZS5ZJ']S7>^^Z1O)51H!DQ0,ZT)LZ>%%54\X=&B;%ZB/>_$"*TXEZ!!+E3/ M73C2246X9RL3C7RDL0QQ?Q($"_5A:6QK?G7I!#IG0 01!B7CJWRN1,3O//^L M6>Z"38:/,KW-8$.>+X!D ND@E?%[==/H3;9 MNY(\@J5=04#ZNOCV(/=!:!-O'NX/.,C;"!VWZ<-)G/;L$PZ@"J )(X;(E">: M6@#3<:E?[MS%ZPEY[YH_<&*_@SXU.K2 I^$\3WQ'M*%.Q_$F$9F6)G<$"$J9L;3S7(3[,VT4/;%)<%>8<#&@(0",>?F3;5(".$0UQ8TT& MT70CU82&8_CAHRAAFQ9M>^X1HGF!F:A+(QL=>3^\DZ1ZKV@I2PA\)SL- S.A;^3_'3R^EC!?JW?QPE_,>5NY[=Y3.,PL+V M'W,5$-,9[^_?< *[89+T]=!+F8.&;>Y__E/,Y8O_SNYC^J&=NS_JJUC04]F7 M])0&D1&+N-D]Q@XM8$+U+>#D9+?:)$RGA>^/WQ5-;;E1;U7+IDBN5R_5V MK56MG7'7]O$&A,)CH2%/6#FD$75WQ&84+IXJ%YKZ M1OHRCBQ$#3#FEK44(@JI;AOT/F7N7_ R!?T&Z6A*Y$^H:QMD%AYI>THV6!HB M<%A'.**Y@4U=T[Y@%H+9KHH!&0 %U MCP+\85/X[Z0WK;A^;UK=E/V4G\^95)EX_P1!\A+4M5SHE29F$]MNJ!$!PMF( M5*Z?GG+'I?4>#0':;PA3.'S',V5:Q24\;M/M@ MGDN6!90:&I%-9">8WL0>EVP3NJY..%T;0*8)Y![" Q*'*1X&<7#!7&R:7L3- MR6=?P">$;HA']7TW_V9):;E9XDG%M$B2 ^EUCD3"!K>)_[ W^#9K?^!#IO MVBZXL<"Q"K[/*/D']H45&]7F!=6$VI@;&ZU2%2M)N]2&=@??JA%<&B(O%!.8 M7PP32A_*IH49B@2[0$,B5ZD_[9O%PORYC^#[],<1D%H, XIOL8(C^#<17#]W MIJ4KW"\Z*[M.IM._LNG ?GT>5I]E M;*>;Z:J=C)!/=R0QW^WP BIFQ*R"S<;,-THH]!O55N4J?=,N866B56I5;RM8 MP\"_7K+?3JK-\F6]V6ZP+WVZG(;!-)HZV8("!2?ETJG_^8^0X_^E_X;/352K MT,DY_^C@@#JNMUO<5:EQ@4T@T,0VH7:M DAD%"_@#WQA8!XF\TK(N!_,%P%[ ML[D2V%0P6;T3XU%6*,Y9FCV8;M016"VDR@.J-R!? G-T.\S@@7&!-!)"-3"6 M VEBT@^>7 BJJAKKP0\=G&TR!<>A@]0A3\/$S)V ;/P$J[^U4,_%XL^$N=Q@ MUX &M&"G?:(#RM1V"T\8&8$:"/.N:$D#T^U@V(KOWO*CHZ$H*D N#)4H2A0I M)RM\+B-UBGE1Z&2D8J%3S(E8MN3E=#&3Y=.YK#0G43+E>JW5J%\V,5-=-^KE MR@FP42>7SN3SQ0,1)9DI4>(=F(B1X,A?4TY,;>/C8 ;O)KZL00, 3<H MO(;\% 6<$%^C81CX^X>^\S<1FB 'M9CA]%"2?-+7D JU7+)+BM%H[IO%?2]7 MZC^H.D2>"$E._XG3^H\$49V\R4XTL\.O;#/8S"*312 8=N0P=D8^=KCO>"4% MJ:1I'!:##1$L5-:9\"8>PH^V.X2DLU?XF0:FF".&Q1'\45:>[L_FK047JN5Z M'6C@"#[6UP@6?&]6RC\2K$V2Q$9ZA2$!J4ZR[ Y=FO7)QK$,74.3PVF@89X, ME(09VJ#4&DP\2Y#L<] %R/EH=UV-MBG#:HAD*=0&8D@(Z"12RL%FE$M*[5X* ML<=PS..U#L>0SAN8HPWJ]X:':)>C0-A10B,YBP'^@B)43\LT)LO>D@"W_Y , M5.#Z&(ND2B#@4]^4!2LYE.OH!DD>=5"67X*>?0=:G1JE;KK5^51K5V6F]JTCYO-BKK#@ MR4WYBJ:9_TU7T;>?L!VN6DUQ9.]<://;S8+YP.B>P"TG7%;.2I?$.U4YJ=;. MFAB!V:(/^'U)A2#N-R'%D=-PH>-$'A6;*3WR7,X2<0A1S0';+WX*#DG:P4J, MCLU+W:ONPA]$2SMF(D54BD51%44L$X1<)R.KN4X7%8L=51X8<[? M+)0@*'-:*K?JC68GS:\E49=2)+S$L:-\@085+:(N!RG%U+BFA!N*#!&/ MCV8/B EJ6E"UB.UET[7!@<*\5+0SPGH)J*%N7NOGH5;*.TPT?1\;J;RALR]"O-?60K,<6%3\:1HW'U4XX>C@M.1Q/LFA7X([M8O@(35J&# M'"=^EZA37OS>_1'<*GX_O$C1^>=L8X[2IO;U7?[!-4F'/"Q*O.KL X3"]#:T M:1VN5:_08O# \_Y__VB1XIAWU-O1MX)-R>Q)L(9D M:D5Y3@IBODJN8WH?4..5?#)EXO(C9\; G?=K.):W,<^ I<<,2MEFJN2HBX2M MDDZGBMF_PQ":*7P+F7BA]<%Y!$5G'M2\W\GTJB/J#QAC.+UIBH?J"_U'I:YM MZJZ#-FR#?[8?9;:"< G8EY8FIOABC(@((**0RF=B1$0 $4)*B/$0 3SPJ4+, M$%% 1#Z5*<2(B B8LD4$3P44H58>XT$)F*.B @>C:TF0F *\E38FIX.LH1I3O M&>Y949I"?Y6\CR7+B2VFKZTHW4JZRR3$=\V@/S@PGUHR%/O'M#(=)BEHVT1_ M&DJ36*V*U:K/5:M8+:HWWW/TPI%I6YQ7OQYACO*%;2Q2-Z=S[3%]C#P?!1&G M,9%\LDJVQY1Q[79U3=;9=5HR#!/F>#"E[=HR>Y8TC.EE@WK:'M/.!#%UK(L6 MZORD,8RGNJ$5)+5 ;YMOG2C+"*GJ[)CB+2MTQ5D2NR(SR@K0YBOH/UJ@K8@6 M\-(%)/0^+CW5H0W/;(0*2'"SW!" M/IL0\L455\KG83PBXO,=8S\W!(J-%R;,$?]?FSS.QFL,-D'WV90H'@#5[T#, M;=Z/%\NYPY!S&Z\MV*Z6-X"^&! M.<>F9)%Y/B>:A6@+4#)5Y1F&;D!36]#Q02>V_%9]G#N"#_X2^!3/X8WIX2E) MYG (DWU(=S_)(>U$)7Q[/F6 M2Z6AT2HPE&3;,A2/#?-F3*"+PJR2:6$2/#E_\B]RY,(.'KA:I MWH=>#_)"4XO&?5)'W>@&'1EZ>5$Y+[0SN70VR[ZT5YU.TRG..QD'1^/HV4(=3K]BC^R::422 M="6>%_AB3NCD\PK?R61YOM-5,V*GD"[F>:%;4#*2.D>ZF:MJK=(LG59:]Z$1 MI9UTOBCD]K+I=2;%P9$X>J;PW-4O2:O_E")(J:*L%%4!H8Z*U%PG@S+Y3C>TL5_G]JWI<;34[N6P6/_VI=]WNAEWGIH9=TW^]DVY72Z,/BNO+%X;- MHL +:J& .KET%YN)68'':G8.=3)%42H4<\5B,=^=PF8'ZS78?,P5.VE5Q=IY M%U-"4972'5F2)23EI(S4%=DWHMU@_D\"Z/QZ?=8KKWIEZP+RFQ>(J0!%7T$BR APO!-84S#8$KWD^?N]A MX5Z+'$W\25+!";)E2R.>M_+:?X%O:0%14CUG6$$5-DR@%:%&?+,QU_N:TCE*B](=LGLZKJ*_TJG MZ]BN9#@0O6BX6+,0TE)2R'R7?OPC9!7Z$XR5+RGF""(-X>>;B$0L:R:Q[(\EN61Y.DO M(LL%7DA5:\U8FOL0^7WX$U-VA\AP#B# M1$$["O--\N_8IJ? MIOF6]&(:YG""K3@'&39$P&>&R=,S%G+"$$RZE+M)C'CAT'KAN5&(>F.&!:PO9F-3C6^ -;"Q> M=P^9X*1RND=,L VH+#,-3I"J&=HN&2-*7I_8:Q<5>OTZCKM,3'[1([^R^0QA M$N@(4864>NAE\8PEH^1(W*FF(^Z["D$8!X(CDHV?@7HBC@A9R8!^A5C;P)\H MT#R#56)P^&+ZL:2C2:B$Z^-G2 6G\*H30I] G1WY-53VE1**:+B@-&RZBF:= MND1O14#7W'+DU:D<\@A8S*;\VIHCPS20#WL.ZGPXGN/_]>L0Z;\;*?V#4BIN M 3DKFCW2I**HD9U4YV\GS:J:3D95\1RHJ8D?A"RB?4;I%09KNA=*L MGM5*+=*E)Y\IBEGA4XO"P[ )2KV7ET(&N_E$3E]0F1Z^]M*YSU"=-R"4PCD] MD)1IH2=7LQ 8_K:?J(EDU\+4@-]2>9'[DH'U89;A(Q33F03[8D^SHMT3HET][VTLI-U_6\N"RRXQK.D"(3$46ADL+E4WQQZ$O=]);\@C M>F>-,83>O"[\OTM=V]1=AQD@<^<+VQ?KFJ;[>;#W^$16GS :U=5;W^/#?:WR M.\%5:^74QSQ-6]_Q)OTS^W.82*/H@X2_PQ$6\V?XQ_Z'.Y$,#>G<>8J[,DVK MCR1EKQ!P AUKC[@:%LNDQ:RX?)S$.G@!D;QCI.PY0J(MBY:DU,<0_K0]?K^V M- S;$09N &;PJI=DV<0F 32J9E!?YD^/I \G*A?CGGGE,I_J L;2M3[-&4I M37T$HCS-+_2:/9N:LL1I%BC@75.9X/_UG:'^\_\#4$L#!!0 ( ,2%8E, M@H:TG0@ GEX:2TR,#(Q,#DS,'AE>#,Q9#$N:'1M[5MM<]LV M$OXK.&>NL6M^_3T+D#(E M*XW3N(WCR.,D4JQ5T:F,\'8/P:CT6 X.#[J]T]/,-59,T:7,1N-HOUH M?[@_8L.#^/ H/CAB[]^PW8^3LSTO??[N;/+O]Q=AU?<9V^E'TKX.S M*#J?G(>.P\%PQ":&EU8ZJ4NNHNCB[0[;R9VKXBA:+!:#Q<% FUDT^1#EKE"' MD=+:BD'JTIW3$VK!3\'3TY-".,Z2G!LKW(N=CY/7_6-(..F4.#V)VM]!=JK3 MY>E)*N?,NJ42+W8*;F:R[#M=Q0?#RHTQ,D+WALQU?R%3E\>CX?#OXXJGJ2QG M?24R%Q\-CH]OFHRB@7[H M>/N^%%ORVPLCL^=A+6_E?@:FQ/2>N79\K.C$\B$CR]1S4Z>T\0",)L*#9=6V4AO"VG6J7H/+OX,+E\?7GVC'X?C M2Y;SN6!&S*58 %=+BW[K>8&_J.6:*^T<2# ^/^'X."OP9"17+.,)F@S3!7#)Z2!W2Z 4B;"6FR6)%/Q*8-W.G!9M M*93!DHJBFM8@@40:)$6((4U::)(*PQ:Y3')F:_IQ,WXAC&@FH0T4T@*]"?)# M&C7"5B+Q"M*\%533*;8YQ["439?=8WCL#G'P.8<0+),ECIRL=W/$/7@#Q-%M M.OVRS!!7G+(A_DY4G6).F+%SGCVX@*18K& %R11*PC +31LYY>S7I^$VYQE2B]LZS-&S*1U("Z.<6H,>D/+7L?TME7FEK:/ MW?J'C?4G:T=%:X]^&MO&ODTBH?#162;QZ _QDG$CO+EP_'*J!!TK$_"1J9(V M)W$2*P =!!_TG$J;*&UKC"-0,5H%NU5&@_FBV;)=F"D5L'NPQ<4UJ&()DOL2 M\?JA5I 8'?#^Z&A7[/FAHZ,T/(5'24RA#/Y"\S,*ZHX;!;.2+G=>*%M;*,-" MM,]-YX($I9[[3+1KS'7_<'#4LB()Z"M=W&_:;BS*VG]-SX:?->S9ST<+W-'O MR*""3;4!X+[8&>[ (91JE%L]VXHG[7.S7!C13[12O+(B;O\8WX/_]L'$G2[B M3@L5!9XXDKI]Q9>Z=G$FKT4Z[K#UH%0;A<[@7]HJW(@=-X6%2[N=OZOTII)S M"IF$JX; >JM!OS'2E1-].BL1 V0-K\:=19LS;93C>YLJK/>OF?:KCC0\TD10 M"OBMQEU.W31U^#@Y$!0X%Q9/"!^??C\?VSUB!@FO[=V'4(J>"L1ILU)(^KHV MF #830Y,&0%2HO3S$-F]R27=?!2J,P1^D_5O@K?7Y"KJE,@KT,5J)5-?0]MZ M:F4JN9&T 1FXB<^0)M)Q<^?Z#RA4*H9?V@BI,SU(I3VL.VO!(W MO ,C HOIDB_\-14DB,R$\?#A54223T3DN)'W] >3GIY@XIO Q/3[@HD[)^A; M:''WU'YGT #0S&5*6,"M+KW_<@LM^) \='RXF'-5^UQ+P2.R#-6?G,/M[98J;E6:W($[A,?M MA9V' PQ$WK>A?)S"SI_6X"[LAJ^D!=7&V> MU/CS: C'DBEY)51S$[HAW_OJ(_H^<.1/4./HJRZV_$N$M/7BW@U,4];H>M(- M8I,O? &WO56$KE3C*$2=-G9%)WT#IBP*Z9P0OY,3IQJ$E?I3"?W\)+OP-Z0@ M2RD.OZD<;H-$_%9+J.\#HBX3?XNZ]W1_]92F_E_NKUXJE&1XE@A]NL.EV^!$ M"L1J0QY7]T@+P:^(#882S?-!7USZ5UWM*X@O0H#FRB?"3 M:-&4I!B"D-?TWM=34@L^:NL"KH53\IMI4O#6ES5_29I8@P/O+VM@X%NV0,'! MCT] \'T#P8._H7H)6IH9Y-D>PE)X:H# ]F^.&P3H!58GR[E6\BV=L-AAWK0O=L)'0[="8].A=>NX1QCMB"G/O]QA]K.=/<2-H'H[F?\0E;GSUH=KC#^_J46WF2TW4!':3 MQ4;5-?/OSMBSH?_OK]UU9*-;'\(]V:EK)^(6W]A(3P;Z]KLZR[D$&2I[[+U! M)4,,O,?.GEX:2TR,#(Q,#DS,'AE>#,Q9#(N M:'1M[5MM<]NX$?XKJ#.]V#.2*/GEZE*.9QS;F;IS>6E&F4[[#2)!$V.0X &@ M9/77]UF E"C9N3@7)_6Y\HQ?""R !7;WV6=!^>1/_?YEF?,R$2G[V^3M+RS5 M25V(TK'$".[0.I MC-%ES$:C:#_:'^Z/V/ @/CR*#X[9A[=L]]/D?,]+7[P_G_SKPV58]<.GU[]< MG;.=?A3]\^ \BBXF%Z'C<# J.(KF\_E@?C#0 MYCJ:?(QR5ZC#2&EMQ2!UZ<[I";7@I^#IZ4DA'&=)SHT5[M7.I\F;_C$DG'1* MG)Y$[>\@.]7IXO0DE3-FW4*)5SL%-]>R[#M=Q0?#RHTQ,D+WALQM?RY3E\>C MX?#/XXJGJ2RO^TID+CX:'!^OFHR\SI=M.FPM-D)Q)V>"YN[,FBC!33S5+A]O M+G#?R*H=E^G2]3->2+6(7TYD(2Q[)^;LHRYX^;(76O#;"B.SEV,O;>5_!*;& M]IRX=7VNY#4F)UW'8?]QV/KE;2ZGTK&#T6#_)*H>:]&U-4ZHLYUV)BT65-(M MXERFJ2@A\-.+X_WAP?@D(L'31U2CL_<$@2#,AF+3M57FPMMRJE6*SO/+CY.K M-U?G9Y.K]^].HNECZO5$CF=-C:L>N^"E%(K]?<#>:FTH?'HL$<;);,%CGX?B*Y7PFF!$S*>; 0)=+RWZMN8$'J07:*VT0%(L5K$ .1(X%-K/T MD,8X=F-I.&'J$VV/)&H% ;B%ANW\ MT++7,;UME;FC[7.W_F%C_7#A^ M.56"CI4)^,A429N3.(D5@ Z"#WI.I4V4MC7&$:@8K8+=*J/!?=%LV2[,E K8 M/=CB\A9DL03-/4.\?JP5)$8'O#\ZVA5[?NCH* U/X5$25RB#O]#\C(*ZXT;! MK*3+@Q?*UA;*L!#M<].Y($&IYS$3[1IWW3\<'+6\2 +Z2A?WF[:515G[W?1L M^%G#G_U\M, #_8X,*MA4&P#NJYWA#AQ"J4:YY;.M>-(^-\N%$?U$*\4K*^+V MC_$C^&\?7-SI(NZT4%G@J2.IVU=\H6L79_)6I.,.7P]*M5'H#+[35N%&[+@I M+5S:[?Q-I3>5G%'()%PU%-9;#?J-D:Z$+X^/3[Y=CN$3-(>&T?/H12 M]%0@3IN50M+7M<$$P&YR8,H(D!*EGX?([BJ7=/-1J,\0^$W67P5OK\E5U"F1 M5Z"+U4JFOHJV]=3*5'(C:0,RS61*D,*M+KW_<@LXHD*%<(:;M(UYH)#D(0J( MHMZW+"&@APZREUDL#UO *^Y+D6)9BR @"A M1U2$;"2"%T@.83'B\O\STJ(*!8"$V%+-3V/GS&CR$:_&EM*!*/?OR50>;MG< 'BA% M. GH,Z;)M\"P!8;O" SI4P>&BQ!S=V.7KD6;NP/?JG77M J MYW996Q&3\- D4D^Q_'DT]&?!E+P1JKG>W9#O??,1_1 X>HJW=4??=%OGWXRD MK1?W5FA/R:?K22O@)U_X"J9]I[)>JL9173MM[)+<^@9,6132.2%^([5.->@S M]:<2^OE)=N%OR&26,B5^4XW?!HGXM990WP=$72;^:GAO>RFW35/_+Y=R9PH% M(IXE0I\NINF*.Y$"L=IPT.7EV%SP&R*5H6#TM-*7NO[]7?M>Y:L0H+G'"J\% M[LD%/,5 *Y:IX+-HT13(&(*0AV_T K.UH+6V+N!:."6_F28%W_L&ZL>S5N\O M:V#@6^Z!@H.?MT#PQP:")W]?=@9:FAGDV1["4GAJ@,#VK\,;!.@%5B?+F58S M0=2NY-?-6WW3L E15$HO!'KGN0X4@J_A"_#@47COX,D3.O])LQ!M#PJAL#0% M>AY,19\]PL!=T=1('FOH.MBZF,/=^C]%G$/TI;@3-T]'\][C$RE>?JCU^]ZZ> MU6:^UD1-8#=9;%3=,O]"D+T8^J\?N^O(1O=\OF]KJ:ZEB%W\C\VT-=%3V-5Y M+D7&WBSYQ?O.% MW%P;V"8ECJ5-W 9VY^/XZQT-T]J'(DJ6HM\\#]?X5OC(_QKA6FM:_G]!!3K< MGZ*4O>GS#+PKYC,MVWKE^'BP?[@$H- V])5)^+\%_X\0I_\%4$L#!!0 ( M ,2%8E-HZP9IL08 'L< 8 >GEX:2TR,#(Q,#DS,'AE>#,R9#$N:'1M M[1G];]HX]%_Q,>W62N0+VHH&5JE+J59I*UU)=;?[S20.L6;BS#$%[J^_]YR$ M!J[K51K5T*F5*,1^?M^?SN WRQIF*=/));1?,8R32+%J(;5!=TXQ\9DIQ(<@'Q>,I(^34]CS;M7O'EG4V %1!=49F/O$\I^-TW(Y'W*Y_ M=.P?>>3F,SFX"X-# WTQ"L*O-\.2ZLW=AT]7 6E9CO-'-W"\XB\7"7G1MJ:9.>.ND>B:.'"%EP>Q8QZVS :[ M?T;CL\&,:4JBE*J"Z?>MN_#2Z@&$YEJPLX%3?Y>P$QFOS@8QOR>%7@GVOC6C M:LHS2\O<[[JY[L-)![:W8);6@L5/I$[[VP0>.YG7YQ*9:2NA,RY6_KN0SUA!KMF" MW,H9S=ZURQ7X+ICBR;N^@2[XWPQ0@WB:+;5%!9\"%T!0<+WR4Q['+ . W]_T.FZW/W 0\&R';#1DCR 0 MF-IB;+)!9<&,+2=2Q+ 9#&_#J\NKX#R\&EV#5]^.[\ZO0Q*.B-N^V!,]D7WL_'Y/QB=!,.+S88K]D]=4_(Z)*$'X=[Q//X_/;#^?5P M;(W^_#3\2LZ#$'GLN&YGQTSNB6]NL!&FC,RSF*D"= =9-V6*358D8DKSA+.B M31*IB :H?*X@60 EF9 QBS!I_/[&.W'[Z(.X&*0T!\V3DRX^A9@+T6/A-QZ_ MRSAF];&&Y%Z00,:L36A!:"QS7 ?LQ9R"1K3RX'"V3:MZJU!PN1^E/M;/E-55$, M/B3P3#_2= *VF4@%=G_?J[(E2>L2 I!\X+Y]8_^#OS1 M@NJDY*8>?X6)8YH(<$J'O'!_'A.B6P:*Z@@0$TPR7T91ETE%5>\$Z[1WU( O': M\U'W#CJ(8SSJ-:I?HWH'4=W9_ZAF4!X3W,9P@L#+-.58[*%H%O,HK0,]H1S# M/E>LP! T197"I ;G@!\J($"+'&*R:)O82W@&,Q^N \;83!$8;@@U%V4$RYPI M0[18E^"'?@)PRAC.@A& %V@Z-*:?DA?[I8-V/WLQD#\H.Z^HM!4LL"7D.&R1 MJ%'B->C+9-I.F6CM?6I0<>0TOO>^A<[7JI/2LS)-R<<)$$]+C\91%9T5G+$* MO]-3^_1MF1!JG!6L5R6*=1!NA[:L0_@8LDM#T*U@;0S-#VR8+;E;")]5>15M5@;U\24 )/"9O7//WA%E>0!].X9 PA7,%C'%9/*54 MQ:68.W&D/<:K!=5O3TT MU&PJP5;UK5U4M=Q4,9))36(&,W4,_;JH7\5LC<[H1NOQ.9"S&2\*[#ZQ5?_Q MM5_OF4-X><\W*V\*#IH0AVU#NN932S+!42620%*9ET P%2B6P("01;@#$#1; MH20HKDQ*3@8.?ZS>-C7UR+5O\T*PMN&3NC;7I-L"/\C9;7 +V>W3E:U\9RS37C?OE:S;RG M._L'4$L#!!0 ( ,2%8E-!QH90:@8 *09 8 >GEX:2TR,#(Q,#DS M,'AE>#,R9#(N:'1M[1EI;]LV]*^\N5B; -;A(X$KN0%9Y!G)8YK N^CJ/20B M7BUIKB"6E"B$KIG*(!)%07*XHE(RSN&M9,F" KQV.QW7=P;N[?O+,;0 M#1-V#Z7:'RP0)(MLAU,6-4"23E1[)YJV@VJ,:=$!G.ALO"0P6,[BWI?*G+EI&3) M^#9X%;$E+>&:KN%6+$G^JFTA^%U2R=)7H<$NV6\42:-ZBFZ40SA;('$M:VCU M#ZSJDTW&YDQ!K^MVAU[Q5$SW> SU8DWVGI7(D#.U#3*6)#1'A)X.)[<1I<7E^-1=#F]QJB^G=V-KB.( MIM 9P)T[<\3CS :1UK&KN]WGUC(9Q*;>V)$&855GE!9HNVPZF94 MTOD68BH52QDMVY *"0JQBI7$8H&<1 HS&NNB\?)%Y]0/=0QJX#@C!5H>3GOZ M*=*U4$%(O5P1M(@2^]1UR%0D9D3. M24Y+9[KA= NC6.D5[:@VL!PR5D),"A*C&0WI')=3AJIHM%^W.=VTX3*/73C2 MMNWZH8&9WYWPN(T\B.&O"7W*Q9I3;%#!$UI^KYIW^^Y)';D,/9"KP*E@#QZ" M^EVM',1-U5$,/JL4A+?22UP MA3:HFJU*FHM?%/I0R'N=$#'A59$Q7D/YPG6&8>UH6]$ 0T:2(FPPK6Q:"==Q M#T787]]S[3\RJ7W4A% HN20\;-:]"M2HF3J 3#' R/^P(A+3F&_AEA9"8H[E M<($[H.,['W;5X+/% HJ1BUE-,8F7(9R+J>U9_S^HGR.KN\\]JBNTQULQCJ/[:3 M5VQ]A0"ZP1JG1R1BC'B-]C*5MFL+K?NI+NJ4/ME5F[I8=8H-E(*S M!%[XYM4TS$%R?P/#>Z4'YR1GE,-/+EP)(?5]@K'O0:'YHD[_JLQ_)U@>4ONO M>THWD?_83=]=]!RT&F>,IG"Q:T73ZL2G&]&-9 @L$/JPKN&C.!:K7*%@-?K_ MV7-UW[17C<]$O&\A!MNC:>1!%T*[/6XVV1*(I) +!0G%PT>" M@PVO[ZP/SA@Z>G;GC+%8+EE9ZC:M9YH_OQ\9?.5IQ5Z(+.V1ZJB)<=PVK&LY ME8"YGNEB@2REN2W'\4G2%">I/-8KB$'RK=9$JRM2*\G08X^,HWN6>N1^K'ES M4OOPB[8V]TF'"C_HV6OJV89J'&RJVX9U1A$HO&$C[2:.#%9D07>#K[6/:^QBLL;DB/W,Y&Z& M(?&GA<22D>@Y1LB@[C>-:_7]A6J:Z6)@(@/J5,_^WDQCK^[WAIH]T.Y_@@)% M=N:2DD^.,4! [@6K3TN#@=OM[_JBA?GF7&3_?S!_:)S]#E!+ 0(4 Q0 ( M ,2%8E,EL@D_VPP %-^ 1 " 0 !Z>7AI+3(P,C$P M.3,P+GAS9%!+ 0(4 Q0 ( ,2%8E-_RMSUX0T );% 5 M " 0H- !Z>7AI+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4 " #$A6)3 MZ%8XH?@@ !G$0( %0 @ $>&P >GEX:2TR,#(Q,#DS,%]D M968N>&UL4$L! A0#% @ Q(5B4\?VQ2TC3@ JW8$ !4 M ( !23P 'IY>&DM,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0 ( ,2%8E,E MZG5\L38 *KR P 5 " 9^* !Z>7AI+3(P,C$P.3,P7W!R M92YX;6Q02P$"% ,4 " #$A6)39!3?U"V& 0 /)A, %0 M@ &#P0 >GEX:2TR,#(Q,#DS,'@Q,'$N:'1M4$L! A0#% @ Q(5B4P"" MAK2=" !S$ !@ ( !XT<" 'IY>&DM,C R,3 Y,S!X97@S M,60Q+FAT;5!+ 0(4 Q0 ( ,2%8E/C+- BD0@ -PQ 8 M " ;90 @!Z>7AI+3(P,C$P.3,P>&5X,S%D,BYH=&U02P$"% ,4 " #$ MA6)3:.L&:;$& ![' & @ %]60( >GEX:2TR,#(Q,#DS M,'AE>#,R9#$N:'1M4$L! A0#% @ Q(5B4T'&AE!J!@ I!D !@ M ( !9& " 'IY>&DM,C R,3 Y,S!X97@S,F0R+FAT;5!+!08 .."@ * *8" $9P( ! end